NOVEL FAMILY OF PHEROMONE RECEPTORS

Abstract: The invention describes a multigene family encoding a collection of novel mammalian pheromone receptors. Nucleic acids encoding the pheromone receptor polypeptides, including fragments and biologically functional variants thereof are provided. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.

Description: NOVEL FAMILY OF PHEROMONE RECEPTORS Field of the Invention This invention relates to nucleic acids and encoded polypeptides which are part of a multigene family encoding a collection of novel mammalian pheromone receptors. The invention further provides representative nucleic acids and encoded polypeptides in this multigene family. The representative polypeptides are expressed in the murine and rat vomeronasal organ (VNO). Agents which bind the nucleic acids or polypeptides also are provided. The invention further relates to methods of using such nucleic acids and polypeptides in the diagnosis and/or treatment of disease, including the use of these molecules in controlling fertility and behavior in vertebrates and invertebrates. Background of the Invention Pheromones are intraspecific chemical signals found throughout the animal kingdom. They regulate populations of animals by inducing innate behaviors and stereotyped changes in physiology (Karlson and Luscher, Nature, 1959, 183:55-56; Wilson, Sci. Am., 1963, 208:100- 114; Sorensen, Chem. Sens., 1996, 21:245-256). Pheromones can serve as cues for overcrowding, impending danger, reproductive status, gender, or dominance. In rodents, a variety of pheromone effects have been reported. These include effects on estrus and the onset of puberty as well as the induction of mating and aggressive behaviors (Singer, A.G., J Steroid. Biochem. Molec. Biol, 1991, 39:627-632; Halpern, M., Ann. Rev. Neurosci., 1987 10:325-362; Wysocki, C.J., et al., In the Neurobiology of Taste and Smell, 1987, 125-150; Novotny et al., Chemical signals in Vertebrates, 1990, Vol. 5, eds. D.W. Macdonald et al., Oxford University Press). The detection of pheromones is mediated by the olfactory system. However, sensory neurons that detect pheromones are typically segregated from those that detect volatile odorants (Keverne, E.B., Trends Neurosci., 1983, 6:381-384; Halpern, M., Ann. Rev. Neurosci., 1987, 10:325-362; Wysocki, C.J., et al, In the Neurobiology of Taste and Smell, 1987, 125-150; Hildebrand, J.G., et al., Brain Res., 1997, 677:157-161). In mammals, sensory neurons in the nasal olfactory epithelium (OE) detect volatile odorants and some pheromones while those in an accessory olfactory organ, called the vomeronasal organ (VNO), are thought to be specialized to detect pheromones. The VNO is a tubular structure, at the base of the nasal septum, which is connected to the nasal cavity by a small duct. Signals from the OE are relayed through the olfactory bulb (OB) to the olfactory cortex, and then to multiple brain regions, including those involved in conscious perception. In contrast, signals from the VNO are conveyed through the accessory olfactory bulb (AOB) to the amygdala and hypothalamus, areas associated with the endocrine and behavioral responses induced by pheromones. Volatile odorants are detected in the OE by as many as 1000 different types of odorant receptors (ORs), which are differentially expressed by olfactory sensory neurons (Buck and Axel, Cell, 1991, 65:175-187; Levy, N.S., et al, J Steroid Biochem. Mol. Biol, 1991, 39:633-637, 1991; Nef, P., et al, Proc. Natl. Acad. Sci., 1992, 89:8948-8952; Strotman, J., et al., Neuroreport, 1992, 3:1053-1056; Ngai, J., et al., Cell, 1993, 72:667-680; Ressler, K.J., et al, Cell, 1993, 73:597-609; Vassar, R., et al, Cell, 1993, 74:309-318. The ORs are thought to couple to the G protein a subunit, Gα 0 | f , thereby initiating a cascade of transduction events which culminate in the generation of action potentials in the sensory axons (reviewed in Firestein, S., Curr.Opin. in Neurobiology, 1992, 2:444-448; Reed, R., Neuron, 1992, 8:205-209; Ronnett, G., et al., Trends Neurosci, 1992, 15:508-513). Current evidence suggests that each OR may recognize a particular molecular feature that can be shared by many odorants (Ressler, K., et al., Cell, 1994, 79:1245-1255; Vassar, R., et al., Cell, 1994, 79:981-991; Axel, R., Sci. Am., 1995, 1273:154-159; Buck, L., Annu. Rev. Neurosci., 1996, 19:517-544). This is consistent with a combinatorial coding model in which the identities of different odorants are encoded by different combinations of receptors, but each receptor serves as one component of the codes for many odorants. By contrast, very little is known about how pheromones are detected or encoded in the VNO. Although VNO neurons (VNs) resemble olfactory sensory neurons in the nose, only a rare VN expresses an OR gene. VNs also lack a number of other olfactory sensory transduction molecules, including the G protein a subunit,Gα 01f (Reed, R., Neuron, 1992, 8:205- 209), which is highly expressed in olfactory neurons (Dulac and Axel, Cell, 1995, 83:195-206; Berghard, A., et al, Proc. Natl. Acad. Sci. USA, 1996, 93:2365-2369; Wu, Y., et al, Biochem. Biopys. Res. Com., 1996, 220:900-904). Instead, VNs express high levels of two other G protein a subunits,Gα 0 and Gαi 2 (Dulac and Axel, Cell, 1995, 83:195-206; Halpern, M., Brain Res., 41995, 677:157-161; Berghard, A., et al, Proc. Natl. Acad. Sci. USA, 1996, 93:2365-2369) G ao and Gαi 2 are expressed in spatially-segregated subsets of VNs that form longitudinal zones in the VNO neuroepithelium. Interestingly, Dulac and Axel have identified a family of -100 candidate pheromones receptors ("VNRs") which appear to be expressed exclusively in the Gαi 2 subset (Dulac and Axel, Cell, 1995, 83:195-206). This invention differs from the state of the art in providing a novel family of mammalian pheromone receptors. Accordingly, the objects of the invention relate to providing compositions containing these novel receptors and their binding partners and methods for using such compositions to modulate pheromone receptor activity. Summary of the Invention The invention involves the discovery of a multigene family of mammalian pheromone receptors. In particular, the invention involves the cDNA cloning of multiple pheromone receptors from a murine VNO cDNA library and from a rat VNO cDNA library. Partial sequences of human homologs of these pheromone receptors also are provided. In general, the invention provides isolated nucleic acid molecules encoding the novel pheromone receptors, unique fragments of the isolated nucleic acid molecules, expression vectors containing the foregoing, and host cells transfected with the foregoing. The invention also provides isolated pheromone receptor polypeptides and agents which bind such polypeptides, including antibodies. The foregoing can be used in the diagnosis or treatment of conditions, including the control of fertility, that are characterized by the expression ofa pheromone receptor polypeptide. Methods for identifying pharmacological agents useful in the diagnosis or treatment of such conditions and methods for identifying additional members of this multigene family also are provided. Applicants have discovered that the pheromone receptors disclosed herein are expressed in the vomeronasal organ (VNO), particularly in Gα 0 protein expressing neurons. This is in contrast to the prior art VNO pheromone receptors which are expressed in neurons which express different G-coupled proteins (Gαi 2 -expressing neurons). Thus, the novel pheromone receptors disclosed herein are distinct from, and expressly exclude, the prior art VNO pheromone receptors which differ in primary structure, as well as in cell localization. Although Applicants do not intend the invention to be limited to a particular theory or mechanism, the amino acid sequence homology and structural organization of the pheromone receptor polypeptides to other well- known G-protein coupled receptors suggests that the pheromone receptors disclosed herein also are G-protein coupled. Thus, it is anticipated that the binding to the pheromone receptor of its cognate ligand (pheromone) will be accompanied by G-protein signal transduction, an event which can be measured using conventional screening assays, such as assays that measure changes in the intracellular concentrations of calcium and/or cyclic nucleotides (see, e.g., PCT publication no. WO 94/18959, entitled "Calcium Receptor- Active Molecules", inventors E. Nemeth et al.). According to one aspect of the invention, a family of pheromone receptor polypeptides is provided. Each polypeptide of the family shares amino acid sequence homology and structural organization with a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. Each polypeptide member of the receptor family contains, from amino terminus to carboxyl terminus, the following domains: (a) an amino-terminal extracellular domain containing from 30 to 600 amino acids; (b) a transmembrane region comprising: (i) seven non-contiguous transmembrane domains designated TM1, TM2, TM3, TM4, TM5, TM6 and TM7, (ii) three noncontiguous extracellular domains designated EC2, EC3 and EC4, and (iii) three non-contiguous intracellular domains designated ICl, IC2, and IC3, wherein the transmembrane domains, the extracellular domains and the intracellular domains are attached to one another from amino terminus to carboxyl terminus in the order TM1 -IC 1 -TM2-EC2-TM3- IC2-TM4-EC3-TM5-IC3- TM6-EC4-TM7, and wherein the transmembrane region has at least about 35% homology and a length approximately equal to a transmembrane region of a polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50; and (c) a carboxyl-terminal intracellular domain containing from 5 to 200 amino acids. Each polypeptide member of the family is expressed in a Gα 0 protein-expressing vomeronasal organ neuron or are expressed in another olfactory organ neuron in an animal which does not possess a vomeronasal organ. One skilled in the art can readily identify olfactory organs in animals which do not possess a vomeronasal organ. In general, the amino-terminal extracellular domains (NTDs) of the receptor family members share sequence homology to a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 50 to a lesser extent than that observed for the transmembrane region. The length of the extracellular domain can vary among members of the family. Accordingly, certain embodiments of the invention have extracellular domains that contain at least 50, 100, 200, 300, 400 or 500 amino acids. Preferably, the transmembrane region has greater than 40% homology with the corresponding region of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50, and more preferably, have even greater sequence homology (e.g., more than 50%), 60%, 70%, 80% or 90% homology). The length of the carboxyl-terminal intracellular domain can vary among members of the family. Accordingly, certain embodiments of the invention have carboxyl-terminal intracellular domains that contain at least between 5 and 50 amino acids. More preferably, carboxyl-terminal intracellular domains contain between 15 and 25 amino acids. According to another aspect of the invention, a method for identifying a nucleic acid encoding a pheromone receptor is provided. The method involves contacting a mixture of nucleic acid molecules (genomic library, cDNA library, genomic DNA, RNA, etc.) with at least one nucleic acid probe ofa nucleic acid selected from the group consisting of: (a) a nucleic acid molecule selected from the group consisting of SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55 that encodes a pheromone receptor polypeptide; (b) a unique fragment of (a); (c) a human homolog of (a) or (b); and (d) a set of degenerate primers of any of (a), (b) or (c); and identifying the sequences within the mixture that hybridize to the probe. Selected fragments of human homologs of a pheromone receptor are selected from the group consisting of SEQ ID NO. 51, 53, 54 and 55. In certain embodiments, the nucleic acid probe further includes a detectable label to facilitate identification of the sequence in the library which hybridizes to the probe. In certain embodiments, the probe is represented by a pair of degenerate polymerase chain reaction ("PCR") primers that amplify a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55. The meaning of "unique fragment" in reference to a nucleic acid is provided below. By "degenerate PCR primers that amplify a unique fragment" is meant degenerate primers which result in the amplification of a unique fragment following a polymerase chain reaction. According to this embodiment, the method for identifying a nucleic acid encoding a pheromone receptor polypeptide further involves subjecting a mixture of nucleic acids and the degenerate PCR primers to amplification conditions prior to identifying the sequences of the mixture that hybridize to the probe and that form part of the amplification reaction products. In some embodiments the pair of degenerate polymerase chain reaction primers is selected from a conserved sequence motif of a pheromone receptor polypeptide. A "conserved sequence motif can be determined using the side-by-side comparison of the amino acid sequences of the different pheromone receptor polypeptides of the invention. Exemplary conserved sequence motifs include regions selected from the group consisting of amino acids 191-397, amino acids 565-825, amino acids 637-825, amino acids 637-804, amino acids 619-784, of the polypeptide of, for example, SEQ ID NO. 2 (VR1). In preferred embodiments, the pair of degenerate polymerase chain reaction primers is selected from the group consisting of SEQ ID NOs. 60 and 61 , SEQ ID NOs. 62 and 63, SEQ ID NOs. 64 and 63, SEQ ID NOs. 64 and 65, and SEQ ID NOs. 66 and 67. According to yet another aspect of the invention, an isolated nucleic acid molecule is provided. The isolated nucleic acid molecule hybridizes under high or low stringency conditions to a molecule consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55. The invention further embraces nucleic acid molecules that differ from the foregoing isolated nucleic acid molecules in codon sequence due to the degeneracy of the genetic code. The invention also embraces complements of the foregoing nucleic acids. The pheromone receptors of the invention are expressed in the vomeronasal organ or, in an animal which lacks such an organ, are expressed in another olfactory organ. More particularly, the receptors of the invention are expressed in a Gα 0 protein-expressing vomeronasal organ neuron. Although not intending to be bound to a particular mechanism, it is believed that the receptors of the invention are G-protein coupled receptors. This is supported by Applicants' discovery that the receptors of the invention are expressed in Gα 0 protein-expressing vomeronasal organ neurons. The pheromone receptors of the invention bind to ligands (pheromones) which induce certain changes in receptor conformation. Methods for identifying ligands which bind to the pheromone receptors of the invention are provided below, e.g., by forming an affinity matrix containing immobilized receptor and using the matrix to isolate a cognate ligand from a complex mixture. The particular ligand bound by a particular receptor is dictated by the primary and secondary structure of the receptor. In certain embodiments, the immobilized pheromone receptor polypeptide is a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. According to another aspect of the invention, an isolated nucleic acid molecule that is a unique fragment of any of the foregoing isolated nucleic acid molecules is provided. In general, the isolated nucleic acid molecule consists of a unique fragment between 12 and 4000 nucleotides in length, and complements thereof, of any cDNA (SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55) encoding a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. Depending upon its intended use (e.g., probe, primer), the unique fragment can be between 12 and 2000, 1000, 500, 250, 100, 50 or 25 nucleotides in length. Preferably, the isolated nucleic acid molecule consists of between 12 and 35 contiguous nucleotides of the foregoing cDNAs encoding the pheromone receptor polypeptides, or complements of such nucleic acid molecules. More preferably, the unique fragment is at least 14, 15, 16, 17, 18, 20 or 22 contiguous nucleotides of the nucleic acid sequence of the foregoing cDNAs encoding the pheromone receptor polypeptides, or complements thereof. Particularly preferred isolated nucleic acid molecules are isolated fragments of the foregoing cDNAs which encode one or more of the following pheromone receptor polypeptide domains, alone or in combination (e.g., as fusion proteins): an amino-terminal extracellular domain, a transmembrane region, and a carboxy- terminal intracellular domain. In certain embodiments, the unique fragments are a pheromone receptor extracellular domain or a pheromone receptor intracellular domain coupled to at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) transmembrane domain. According to yet another aspect of the invention, an isolated nucleic acid molecule comprising a molecule having a sequence selected from the group consisting of SEQ ID NO. 51, 53, 54, 55, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92, that encodes a pheromone receptor polypeptide are provided. This aspect of the invention further embraces nucleic acid molecules that differ from these nucleic acid molecules in codon sequence due to the degeneracy of the genetic code, and diversity among pheromone receptors and complements of foregoing. According to still other aspects of the invention, an expression vector comprising any of the foregoing isolated nucleic acid molecules operably linked to a promoter and host cells transformed or transfected with the same also are provided. According to another aspect of the invention, an isolated polypeptide encoded by any of the above-described isolated nucleic acid molecules is provided. Preferably, the isolated polypeptide is a pheromone receptor polypeptide that has a pheromone receptor activity or an antigenic fragment thereof. As used herein, a pheromone receptor activity refers to the ability of the pheromone receptor to selectively bind to its cognate ligand (pheromone) and, optionally, upon binding, to induce signal transduction in a cell that expresses the pheromone receptor. In preferred embodiments, the isolated polypeptide comprises a pheromone receptor polypeptide having a sequence selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. According to yet other embodiments, the isolated polypeptide comprises a polypeptide encoded by a nucleic acid which hybridizes under high or low stringency conditions to the extracellular domain, transmembrane region and/or intracellular domain of a cDNA sequence selected from the group consisting of SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55 that encodes a pheromone receptor polypeptide or fragment thereof. Thus, the invention embraces portions of a pheromone receptor polypeptide that may include, for example, an amino-terminal extracellular domain or a carboxy- terminal intracellular domain coupled to 1, 2, 3, 4, 5, 6, or 7 transmembrane domains. Preferably, such polypeptides or fragments thereof are unique fragments and can function as, for example, antigens for making antibodies specific for pheromone receptor family members. Accordingly, the polypeptides of the invention can be used to isolate additional members of the pheromone receptor family or, alternatively, can be used to induce in vivo an immune response to a pheromone receptor, i.e., can be incorporated into a vaccine preparation. Such vaccine compositions are useful for controlling fertility or behavior in an animal by administering to the animal, an effective amount of the vaccine to elicit an immune response to the pheromone receptor. Thus, the invention embraces fragments or variants of the foregoing pheromone receptors which exhibit certain detectable activities, e.g., a ligand binding activity, an antigenicity activity. In certain embodiments, the isolated polypeptide is encoded by a cDNA selected from the group consisting of SEQ ID NO. 51, 53, 54, 55, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92, that encodes a pheromone receptor polypeptide or one or more of its domains. According to another aspect of the invention, there are provided isolated binding polypeptides which selectively bind a unique amino acid sequence of a pheromone receptor polypeptide or fragment thereof. The isolated binding polypeptide in certain embodiments binds to a polypeptide comprising the extracellular domain and/or 1, 2, 3, 4, 5, 6, or 7 transmembrane domains of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. The isolated polypeptide preferably binds to a polypeptide consisting of the amino- terminal extracellular domain and/or one or more portions of the transmembrane region of a pheromone receptor polypeptide sequence selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. In preferred embodiments, isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab) 2 , Fd and antibody fragments which include a CDR3 region which binds selectively to the unique sequences of the polypeptides of the invention). In the preferred embodiments, the isolated binding peptides do not bind to pheromone receptors that are expressed in vomeronasal organ neurons other than Gαo-protein-expressing neurons. The invention provides in yet other aspects, isolated nucleic acids or polypeptides of the invention that are: (a) immobilized to an insoluble support (an affinity matrix containing immobilized pheromone receptor polypeptide or a unique fragment thereof); (b) associated with, covalently coupled to, or encapsulated a drug delivery device (e.g., a microsphere) to effect controlled release of the isolated nucleic acid or polypeptide in vivo or in vitro; (c) covalently coupled to another isolated nucleic acid or protein to form a chimeric molecule; and/or (d) labeled with a detectable agent (e.g., a radiolabel, a fluorescent label). Thus, the invention provides chimeric molecules containing at least one first structural domain of one pheromone receptor polypeptide (e.g., an extracellular domain) coupled to a second structural domain (e.g., a transmembrane domain, such as TM1, TM2, etc.) of a different pheromone receptor polypeptide. The invention also provides a method for isolating a pheromone receptor by (1) contacting a composition containing a putative pheromone receptor of the above-described family with an affinity matrix containing immobilized binding polypeptide under conditions to permit the pheromone receptor to selectively bind to the immobilized binding polypeptide, and (2) isolating the polypeptides that bind to the affinity matrix. According to still another aspect of the invention, pharmaceutical compositions containing any of the foregoing compounds of the invention in a pharmaceutically acceptable carrier and methods of producing same by placing the compositions in the carrier also are provided. According to still another aspect of the invention, methods for modulating a pheromone receptor activity (e.g., a ligand binding activity, a signal transduction activity) in a cell (vertebrate or invertebrate) are provided. The cell can be located in vivo or in vitro and the methods can be used to down regulate (inhibit) or up regulate (stimulate) the pheromone receptor activity. For example, to inhibit a ligand binding activity, the cell is contacted with an inhibitor that can be an isolated binding polypeptide that binds to an extracellular portion of the receptor and, thereby, inhibits receptor binding to its cognate ligand. Such binding also can induce conformational changes in the receptor that alter the signal transduction activity of the receptor. The inhibitor can be an isolated antibody (or function equivalent thereof) which binds to an epitope located on an extracellular portion (such as EC2, EC3, EC4) of the pheromone receptor polypeptide, e.g., an amino-terminal extracellular domain or an "extracellular transmembrane region domain", i.e., an extracellular portion of the transmembrane region located between one or more transmembrane domains. Alternatively, the inhibitor can be an agent (e.g., an isolated competitive binding polypeptide) that inhibits receptor-ligand binding. For example, the inhibitor can be an isolated fragment of a pheromone receptor (preferably, a soluble fragment), which fragment contains a ligand (pheromone) binding site. Other inhibitors can be identified in screening assays which test the ability of a putative inhibitor to inhibit pheromone receptor- mediated signal transduction or which test the ability of the putative inhibitor to inhibit binding of a pheromone receptor to its known cognate ligand. Similarly, such screening assays can be used to identify molecules which stimulate pheromone receptor-mediated signal transduction. Exemplary molecules which stimulate transduction include the naturally-occurring ligands (e.g., isolated from a biological source (e.g., urine, vaginal fluid), as well as synthetic ligands obtained from a non-biological source (e.g., a combinatorial library). According to still another aspect of the invention, methods for inhibiting the binding of a pheromone having a binding domain to a pheromone receptor polypeptide having a ligand binding site that selectively binds to the binding domain are provided. The method involves contacting (in vivo or in vitro) the pheromone receptor polypeptide with an agent which binds to the ligand binding site under conditions to permit binding of the agent to the receptor. For example, the agent can be an isolated binding polypeptide that binds to the ligand binding site of the pheromone receptor. Thus, the agent can be an isolated antibody (or functionally equivalent fragment thereof) which selectively binds to the ligand binding site of the receptor. Alternatively, the agent can be a pheromone receptor antagonist, e.g., a molecule that mimics the structure of the naturally-occurring ligand but that does not mimic the function (stimulating the receptor) of the naturally-occurring ligand. Agents which inhibit ligand binding can be identified in screening assays which test the ability of a putative binding inhibitor to inhibit binding of a pheromone receptor to its cognate ligand (e.g., pheromone). Such molecules can be isolated from a biological source or from a non-biological source. According to another aspect of the invention, methods for modulating pheromone receptor-mediated signal transduction in a subject are provided. The methods involve administering to a subject in need of such treatment an agent that selectively binds to any of the above-described isolated nucleic acid molecules which encode a pheromone receptor or unique fragment thereof, or an expression product thereof, in an amount effective to modulate (down regulate or up regulate) pheromone receptor-mediated signal transduction in the subject. Exemplary agents include antisense nucleic acid molecules and binding polypeptides. Thus, according to yet another aspect of the invention, methods are provided for identifying lead compounds for an pharmacological agent useful in the diagnosis or treatment of a condition associated with pheromone receptor signal transduction activity or otherwise generally associated with binding of the receptor to its cognate ligand. Preferably, cells expressing intact pheromone receptor polypeptides or portions thereof are used in the screening assays for identifying lead compounds which modulate pheromone receptor-mediated ligand binding or signal transduction activity. Cells expressing these polypeptides, isolated pheromone receptor polypeptides and fragments of these polypeptides which contain the ligand binding site can be used in the screening assays for identifying lead compounds which modulate binding of the receptor to a known ligand. The screening methods involve forming a mixture of a pheromone receptor polypeptide (as noted above) or fragment thereof containing a ligand binding site; a molecule which is known to (1) interact with the foregoing receptor to effect pheromone receptor-mediated signal transduction or (2) bind to the ligand binding site of the receptor; and a candidate pharmacological agent. The mixture is incubated under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of pheromone receptor-ligand binding or receptor-mediated signal transduction by the known ligand. A test amount of the selective binding of the ligand by receptor or of the specific activation of signal transduction is determined. Detection of an increase in the foregoing activities in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases specific activation of pheromone receptor-mediated signal transduction or selective binding of the ligand by the ligand binding site of the receptor. Detection of a decrease in the foregoing activities in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which decreases specific activation of pheromone receptor-mediated signal transduction or selective binding of the ligand by the ligand binding site of the receptor. Pheromone receptor polypeptides that are useful in the screening assays, preferably, are those selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. Extracellular domains or portions thereof and portions of the transmembrane region, alone or coupled to one another, of these pheromone receptor polypeptides (indicated in the Examples) can be tested for their ability to inhibit receptor-ligand binding. These and other objects of the invention will be described in further detail in connection with the detailed description of the invention. All patents, patent publications, references and other information identified in this document are incorporated in their entirety herein by reference. Brief Description of the Drawings Figure 1 depicts a comparison of the deduced protein sequences encoded by VR cDNA clones. Figure 2 is a schematic comparison of ORs, VNRs, and Vrs. Figure 3 depicts a comparison of the deduced protein sequences encoded by the Go-VN cDNA clones. Brief Description of the Sequences SEQ ID NO. 1 is the nucleotide sequence of the mouse pheromone receptor VR1 cDNA (GenBank Accession No. AF011411). SEQ ID NO. 2 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR1 cDNA (GenBank Accession No. AF011411). SEQ ID NO. 3 is the nucleotide sequence of the mouse pheromone receptor VR2 cDNA (GenBank Accession No. AF011412). SEQ ID NO. 4 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR2 cDNA (GenBank Accession No. AF011412). SEQ ID NO. 5 is the nucleotide sequence of the mouse pheromone receptor VR3 cDNA (GenBank Accession No. AF011413). SEQ ID NO. 6 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR3 cDNA (GenBank Accession No. AFOl 1413). SEQ ID NO. 7 is the nucleotide sequence of the mouse pheromone receptor VR4 cDNA (GenBank Accession No. AFOl 1414). SEQ ID NO. 8 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR4 cDNA (GenBank Accession No. AFOl 1414). SEQ ID NO. 9 is the nucleotide sequence of the mouse pheromone receptor VR5 cDNA (GenBank Accession No. AFOl 1415). SEQ ID NO. 10 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR5 cDNA (GenBank Accession No. AFOl 1415). SEQ ID NO. 11 is the nucleotide sequence of the mouse pheromone receptor VR6 cDNA (GenBank Accession No. AFOl 1416). SEQ ID NO. 12 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR6 cDNA (GenBank Accession No. AFOl 1416). SEQ ID NO. 13 is the nucleotide sequence of the mouse pheromone receptor VR7 cDNA (GenBank Accession No. AFOl 1417). SEQ ID NO. 14 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR7 cDNA (GenBank Accession No. AFOl 1417). SEQ ID NO. 15 is the nucleotide sequence of the mouse pheromone receptor VR8 cDNA (GenBank Accession No. AFOl 1418). SEQ ID NO. 16 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR8 cDNA (GenBank Accession No. AFOl 1418). SEQ ID NO. 17 is the nucleotide sequence of the mouse pheromone receptor VR9 cDNA (GenBank Accession No. AFOl 1419). SEQ ID NO. 18 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VR9 cDNA (GenBank Accession No. AFOl 1419). SEQ ID NO. 19 is the nucleotide sequence of the mouse pheromone receptor VR10 cDNA (GenBank Accession No. AFOl 1420). SEQ ID NO. 20 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 0 cDNA (GenBank Accession No. AFO 11420). SEQ ID NO. 21 is the nucleotide sequence of the mouse pheromone receptor VRl 1 cDNA (GenBank Accession No. AFOl 1421). SEQ ID NO. 22 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 1 cDNA (GenBank Accession No. AFOl 1421). SEQ ID NO. 23 is the nucleotide sequence of the mouse pheromone receptor VRl 2 cDNA (GenBank Accession No. AFOl 1422). SEQ ID NO. 24 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 2 cDNA (GenBank Accession No. AFOl 1422). SEQ ID NO. 25 is the nucleotide sequence of the mouse pheromone receptor VRl 3 cDNA (GenBank Accession No. AFOl 1423). SEQ ID NO. 26 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 3 cDNA (GenBank Accession No. AFO 11423). SEQ ID NO. 27 is the nucleotide sequence of the mouse pheromone receptor VRl 4 cDNA (GenBank Accession No. AFOl 1424). SEQ ID NO. 28 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 4 cDNA (GenBank Accession No. AFOl 1424). SEQ ID NO. 29 is the nucleotide sequence of the mouse pheromone receptor VRl 5 cDNA (GenBank Accession No. AFOl 1425). SEQ ID NO. 30 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 5 cDNA (GenBank Accession No. AFOl 1425). SEQ ID NO. 31 is the nucleotide sequence of the mouse pheromone receptor VRl 6 cDNA (GenBank Accession No. AFOl 1426). SEQ ID NO. 32 is the predicted amino acid sequence of the polypeptide encoded by the mouse pheromone receptor VRl 6 cDNA (GenBank Accession No. AFOl 1426). SEQ ID NO. 33 is the nucleotide sequence of the rat pheromone receptor Go-VNl cDNA (GenBank Accession No. AF016178). SEQ ID NO. 34 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VNl cDNA (GenBank Accession No. AF016178). SEQ ID NO. 35 is the nucleotide sequence of the rat pheromone receptor Go-VN2 cDNA (GenBank Accession No. AF016179). SEQ ID NO. 36 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN2 cDNA (GenBank Accession No. AFO 16179). SEQ ID NO. 37 is the nucleotide sequence of the rat pheromone receptor Go-VN3 cDNA (GenBank Accession No. AFOl 6180). SEQ ID NO. 38 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN3 cDNA (GenBank Accession No. AFOl 6180). SEQ ID NO. 39 is the nucleotide sequence of the rat pheromone receptor Go-VN4 cDNA (GenBank Accession No. AF016181). SEQ ID NO. 40 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN4 cDNA (GenBank Accession No. AFOl 6181). SEQ ID NO. 41 is the nucleotide sequence of the rat pheromone receptor Go-VN5 cDNA (GenBank Accession No. AF016182). SEQ ID NO. 42 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN5 cDNA (GenBank Accession No. AF016182). SEQ ID NO. 43 is the nucleotide sequence of the rat pheromone receptor G0-VN6 cDNA (GenBank Accession No. AF016183). SEQ ID NO. 44 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor G0-VN6 cDNA (GenBank Accession No. AFOl 6183). SEQ ID NO. 45 is the nucleotide sequence of the rat pheromone receptor Go-VN7 cDNA (GenBank Accession No. AFOl 6184). SEQ ID NO. 46 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN7 cDNA (GenBank Accession No. AFOl 6184). SEQ ID NO. 47 is the nucleotide sequence of the rat pheromone receptor Go-VN13C cDNA (GenBank Accession No. AFO 16185). SEQ ID NO. 48 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN13C cDNA (GenBank Accession No. AF016185). SEQ ID NO. 49 is the nucleotide sequence of the rat pheromone receptor Go-VNl 3B cDNA (GenBank Accession No. AF016186). SEQ ID NO. 50 is the predicted amino acid sequence of the polypeptide encoded by the rat pheromone receptor Go-VN13B cDNA (GenBank Accession No. AF016186). SEQ ID NO. 51 is a partial nucleotide sequence of the human pheromone receptor hVRl. SEQ ID NO. 52 is the predicted amino acid sequence of the polypeptide encoded by the partial sequence of the human pheromone receptor hVRl . SEQ ID NO. 53 is a partial nucleotide sequence of the human pheromone receptor hVNOl. SEQ ID NO. 54 is a partial nucleotide sequence of the human pheromone receptor hVNO2. SEQ ID NO. 55 is a partial nucleotide sequence of the human pheromone receptor hVNO3. SEQ ID NO. 56 is the nucleotide sequence of primer AL 1. SEQ ID NO. 57 is the nucleotide sequence of primer AL3. SEQ ID NO. 58 is a fifty amino acid sequence of Go-VN13B (SEQ ID NO. 50) that is absent from Go-VN13C (SEQ ID NO. 48). SEQ ID NO. 59 is the amino acid sequence of a rat kidney extracellular calcium/ polyvalent cation-sensing receptor. SEQ ID NO. 60 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 61 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 62 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 63 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 64 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 65 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 66 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 67 is a degenerate oligonucleotide primer from a conserved VR domain. SEQ ID NO. 68 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl . SEQ ID NO. 69 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR2. SEQ ID NO. 70 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR3. SEQ ID NO. 71 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR4. SEQ ID NO. 72 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR5. SEQ ID NO. 73 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR6. SEQ ID NO. 74 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR7. SEQ ID NO. 75 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR8. SEQ ID NO. 76 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR9. SEQ ID NO. 77 is the nucleotide sequence of the coding region of the mouse pheromone receptor VR10. SEQ ID NO. 78 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl 1. SEQ ID NO. 79 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl 2. SEQ ID NO. 80 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl 3. SEQ ID NO. 81 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl 4. SEQ ID NO. 82 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl 5. SEQ ID NO. 83 is the nucleotide sequence of the coding region of the mouse pheromone receptor VRl 6. SEQ ID NO. 84 is the nucleotide sequence of the coding region of the rat pheromone receptor Go VN1. SEQ ID NO. 85 is the nucleotide sequence of the coding region of the rat pheromone receptor GoVN2. SEQ ID NO. 86 is the nucleotide sequence of the coding region of the rat pheromone receptor GoVN3. SEQ ID NO. 87 is the nucleotide sequence of the coding region of the rat pheromone receptor GoVN4. SEQ ID NO. 88 is the nucleotide sequence of the coding region of the rat pheromone receptor GoVN5. SEQ ID NO. 89 is the nucleotide sequence of the coding region of the rat pheromone receptor GoVN6. SEQ ID NO. 90 is the nucleotide sequence of the coding region of the rat pheromone receptor GoVN7. SEQ ID NO. 91 is the nucleotide sequence of the coding region of the rat pheromone receptor Go VN13C. SEQ ID NO. 92 is the nucleotide sequence of the coding region of the rat pheromone receptor Go VN13B. Detailed Description of the Invention The present invention in one aspect involves the cloning of cDNAs encoding several members of a multigene family of pheromone receptors. Complete cDNA sequences for selected murine and rat pheromone receptors are provided. Partial sequences of the human gene also are provided. The present invention also relates to the discovery that this family of pheromone receptors is expressed in a Gα 0 protein-expressing vomeronasal organ neurons ("Gφ + VNO") or in another olfactory organ neuron in an animal (preferably, a mammal and more preferably, a human) which lacks a vomeronasal organ. Throughout this description, the pheromone receptors of the invention alternatively are referred to as "pheromone receptors", "Gα 0 + VNO pheromone receptors" or, simply, "Gα 0 + VNO receptors". Analysis of the sequence homology between members of the receptor family by comparison to nucleic acid and protein databases established that the pheromone receptor family has several domains. These include, from amino terminus to carboxyl terminus: (a) an amino-terminal extracellular domain containing from 30 to 600 amino acids; (b) a transmembrane region comprising: (i) seven non-contiguous transmembrane domains designated TMl, TM2, TM3, TM4, TM5, TM6 and TM7, (ii) three non-contiguous extracellular domains designated EC2, EC3 and EC4, and (iii) three non-contiguous intracellular domains designated ICl, IC2, and IC3, wherein the transmembrane domains, the extracellular domains and the intracellular domains are attached to one another from amino terminus to carboxyl terminus in the order TMl -IC 1 -TM2-EC2-TM3- IC2-TM4-EC3-TM5-IC3-TM6-EC4-TM7, and wherein the transmembrane region has at least about 35% homology and a length approximately equal to a transmembrane region of a polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50; and (c) a carboxyl-terminal intracellular domain containing from 5 to 200 amino acids. Each polypeptide member of the family is expressed in a Gα 0 protein-expressing vomeronasal organ neuron or are expressed in another olfactory organ neuron in an animal which does not possess a vomeronasal organ. One skilled in the art can readily identify olfactory organs in animals which do not possess a vomeronasal organ. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (ftp://ncbi.nlm.nih.gov/pub/). Exemplary tools include the BLAST system. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). The structure of the Gα 0 + VNO pheromone receptors suggests that these receptors are members of the large G protein-coupled receptor superfamily (GPCR). Like other GPCRs, the Gα 0 + VNO pheromone receptors exhibit seven hydrophobic stretches ("hydrophobic domains") and are similar in structure to other types of GPCRs, the calcium sensing receptor (CSR Ser. ID No. 59) and the metabotropic glutamate receptors (mGluRs). The CSR and mGluRs are unusual among the GPCRs in that they have extremely long N-terminal extracellular domain (e.g., 557- 565 amino acids), a feature that is shared by the pheromone receptors of the invention. Despite this similarity, the receptors of the invention do not share substantial primary structure homology with the CSR and mGluRs. The receptors of the invention also are very different structurally from two other G-protein coupled receptors, the odorant receptors and Gαi 2 + vomeronasal receptors, which share none of the characteristic sequence motifs of the receptors of the invention and, moreover, which have very small (-12-28 amino acids) N-terminal extracellular domains. The receptors of the invention differ somewhat in amino acid sequence, with regions of relatively high sequence homology. Refer to Examples 1 and 2 for a discussion and illustration of the amino acid sequence homology for the murine and rat Gα 0 + VNO receptors, respectively. Other features of these members of the Gα 0 + VNO receptor family also are discussed and illustrated in the Examples. For example, signal sequences have been identified for several of the Gα 0 + VNO receptors disclosed in the Examples. Homologs and alleles of the pheromone receptor nucleic acids of the invention can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences (SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55) which code for Gα 0 + VNO pheromone receptors and which hybridize to a nucleic acid molecule consisting of the coding region of any one Gα 0 + VNO pheromone receptor selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52, under high or low stringency conditions. The term "high or low stringency conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, high stringency conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH 2 PO 4 (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. Low stringency conditions would be the same, but with a lower temperature (e.g., 55 °C). After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.2 x SSC/0.5% SDS at temperatures of up to 65°C. Additional conditions of varying stringency are provided in the Examples. There are other conditions, reagents, and so forth which can used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the Gα 0 + VNO pheromone receptor nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing. In general homologs and alleles typically will share at least 35% nucleotide identity and/or at least 50% amino acid identity to the cDNAs encoding a Gα 0 + VNO pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52, in some instances will share at least 50% nucleotide identity and/or at least 65%) amino acid identity and in still other instances will share at least 60% nucleotide identity and/or at least 75%> amino acid identity. Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention. As discussed above in the Summary of the invention, certain domains within the pheromone receptors may share even greater sequence homology to a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. In screening for Gα 0 + VNO pheromone receptor polypeptides, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, in vitro or in vivo, to incorporate a serine residue into an elongating Gα 0 + VNO pheromone receptor polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to,: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code. In addition, areas of high similarity among pheromone receptors may differ in amino acid sequences such that they share many, but not all, amino acids. Their nucleotide sequences all differ accordingly. The invention also provides isolated unique fragments of the cDNAs encoding a Gα 0 + VNO polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52, or complements of these sequences. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules outside of the Gα 0 + VNO pheromone receptor nucleic acids defined above. Unique fragments can be used as probes in Southern blot assays to identify such nucleic acids, or can be used as primers in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200 nucleotides or more are preferred for certain uses such as Southern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the Gα 0 + VNO pheromone receptor polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and as a competitive binding partner of the pheromones and/or other ligands which bind to the Gα 0 + VNO pheromone receptor polypeptides, for example, in therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of Gα 0 + VNO pheromone receptor nucleic acids and polypeptides, particularly for the insecticide and other fertility control purposes as described in greater detail below. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions ofa cDNA selected from the group consisting of SEQ ID NO. 51, 53, 54, 55, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92, that encodes a Gα 0 + VNO polypeptide, and its complement will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases long). Virtually any segment of the region of the cDNAs encoding the full length Gα 0 + VNO polypeptide or their complements, that is 18 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-Gα 0 + VNO pheromone receptor nucleic acids. A comparison of the sequence of the fragment to those on known data bases typically is all that is necessary, although in vitro confirmatory hybridization and sequencing analysis may be performed. As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a Gα 0 + VNO pheromone receptor polypeptide, to decrease a pheromone receptor activity (e.g., a ligand binding activity, a signal transduction activity). This is desirable in virtually any condition wherein a reduction in pheromone binding or induction of a behavior that is triggered by pheromone binding is desirable, including to control fertility and behavior in vertebrates and invertebrates. The compositions of the invention are particularly useful in, for example, controlling fertility in livestock and controlling reproduction in rodents or insects by interrupting the normal behaviors of rodents or insects that result in reproduction. As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the cDNA sequences of Examples 1 and 2 (SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55), or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., Nature Biotechnol. 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N- terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3 '-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., Cell Mol. Neurobiol. 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, Examples 1 and 2 disclose cDNA sequences (SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55), one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of these cDNAs. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to a cDNA sequence selected from the group consisting of SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation. In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors. In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness. The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides. The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding pheromone receptor polypeptides, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art. As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined. As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction ofa frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art. Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding pheromone receptor polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell. Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α, which stimulates efficiently transcription in vitro. The plasmid is described by Mishizuma and Nagata (Nuc. Acids Res. 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (Mol. Cell. Biol. 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for El and E3 proteins (J Clin. Invest. 90:626-630, 1992). The use of the adenovirus as an Adeno.PlA recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against PI A (Int. J. Cancer, 67:303-310, 1996). The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included. The invention also permits the construction of pheromone receptor gene "knock-outs" in cells and in animals, providing materials for studying certain aspects of pheromone receptor binding, signal transduction activity, or function. The invention also provides isolated polypeptides, which include a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52 and unique fragments of these pheromone receptor polypeptides. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies. A unique fragment of a pheromone receptor polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52 will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long). Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides (G-proteins) or molecules (e.g., a ligand) or fragments thereof, selective binding of nucleic acids or proteins, and enzymatic activity. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known data bases typically is all that is necessary. The invention embraces variants of the pheromone receptor polypeptides described above. As used herein, a "variant" of a pheromone receptor polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a pheromone receptor polypeptide. Modifications which create a pheromone receptor variant can be made to a pheromone receptor polypeptide 1) to reduce or eliminate an activity of a pheromone receptor polypeptide, such as a ligand binding activity or a signal transduction activity; 2) to enhance a property of a pheromone receptor polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; or 3) to provide a novel activity or property to a pheromone receptor polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety. Modifications to a pheromone receptor polypeptide are typically made to the nucleic acid which encodes the pheromone receptor polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition ofa linker molecule, addition ofa detectable moiety, such as biotin, addition ofa fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the pheromone receptor amino acid sequence. In general, variants include pheromone receptor polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a pheromone receptor polypeptide by eliminating proteolysis by proteases in an expression system. Mutations ofa nucleic acid which encode a pheromone receptor polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such a hairpins or loops, which can be deleterious to expression of the variant polypeptide. Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non- variant pheromone receptor polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., E. coli, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a pheromone receptor gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of pheromone receptor polypeptides can be tested by cloning the gene encoding the variant pheromone receptor polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant pheromone receptor polypeptide, and testing for a functional capability of the pheromone receptor polypeptides as disclosed herein. For example, the variant pheromone receptor polypeptide can be tested for a ligand binding activity, wherein a ligand to which the receptor binds is contacted with the variant receptor and the amount of ligand binding to the variant receptor is determined using conventional procedures to measure the binding of one molecule to another. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art. The skilled artisan will also realize that conservative amino acid substitutions may be made in pheromone receptor polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e, the variants retain the functional capabilities of the pheromone receptor polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel. et al., eds., John Wiley & Sons, Inc., New York. To a certain extent, the various members of the pheromone receptor family that are illustrated in the Examples represent exemplary functionally equivalent variants of the pheromone receptor polypeptides. Other functionally equivalent variants include conservative amino acid substitutions of the amino acids of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. Conservative amino-acid substitutions in the amino acid sequence of pheromone receptor polypeptides to produce functionally equivalent variants of pheromone receptor polypeptides typically are made by alteration of the nucleic acid encoding pheromone receptor polypeptides. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method described in Proc. Nat. Acad. Sci. U.S.A. 82: 488-492, 1985, or by chemical synthesis ofa gene encoding a pheromone receptor polypeptide. Where amino acid substitutions are made to a small unique fragment of a pheromone receptor polypeptide, such as a ligand binding site peptide, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of pheromone receptor polypeptides can be tested by cloning the gene encoding the altered pheromone receptor polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered pheromone receptor polypeptide, and testing for a functional capability of the pheromone receptor polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to a ligand to which the unaltered pheromone receptor is known to bind. The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the pheromone receptor polypeptides of the Examples. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated pheromone receptor molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating pheromone receptor polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography. The isolation of the pheromone receptor gene also makes it possible for the artisan to diagnose a disorder characterized by expression of pheromone receptor . These methods involve determining expression of the pheromone receptor gene, and/or pheromone receptor polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction as exemplified in the examples below, or assaying with labeled hybridization probes. The invention also makes it possible to isolate the naturally occurring ligands (pheromones) and other ligands that have a ligand binding domain, namely, by the binding of such molecules to the pheromone receptor polypeptides (or fragments thereof containing a ligand binding site). Binding of the receptors to a ligand can be accomplished by introducing into a biological system in which the proteins bind (e.g., a cell) a molecule that includes a binding domain (putative ligand) in an amount sufficient to detect the binding. The invention also provides agents such as binding polypeptides which bind to pheromone receptor polypeptides and/or to complexes of pheromone receptor polypeptides and their ligand binding partners. Such binding agents can be used, for example, in screening assays to detect the presence or absence of pheromone receptor polypeptides and complexes of pheromone receptor polypeptides and their ligand binding partners and in purification protocols to isolate pheromone receptor polypeptides and complexes of pheromone receptor polypeptides and their ligand binding partners. Such agents also can be used to inhibit the native activity of the pheromone receptor polypeptides or their ligand binding partners, for example, by binding to such polypeptides, or their binding partners or both. The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to pheromone receptor polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) 77ze Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab') 2 fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist ofa covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope- binding ability in isolation. Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FRl through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity. It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of nonspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies. Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab') 2 , Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab') 2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies. Thus, the invention involves polypeptides of numerous size and type that bind specifically to pheromone receptor polypeptides, and or complexes of both pheromone receptor polypeptides and their ligand binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties. Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. ml3, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the pheromone receptor polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the pheromone receptor polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the pheromone receptor polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the pheromone receptor polypeptides. Thus, the pheromone receptor polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the pheromone receptor polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of pheromone receptor and for other purposes that will be apparent to those of ordinary skill in the art. A pheromone receptor polypeptide, or a fragment which contains the ligand binding site, also can be used to isolate naturally-occurring ligands and other binding partners of the receptors of the invention. For example, an isolated pheromone receptor can be used to isolate ligands that bind to the receptor binding site by immobilizing a receptor (or fragment containing the ligand binding site) on a chromatographic media, such as polystyrene beads, or a filter, and using the immobilized polypeptide to isolate molecules that bind to this affinity matrix in accordance with standard procedures for affinity chromatography. It will also be recognized that the invention embraces the use of the pheromone receptor cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., E. coli), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are oocytes, mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be ofa wide variety of tissue types, and include primary cells and cell lines. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described supra, be operably linked to a promoter. When administered, the therapeutic compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents. The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences. 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response in the condition being treated, e.g., modifying fertility or pheromone-mediated behaviors that are related to reproduction or aggression. For example, this can involve the use of the compounds of the invention as pesticides to slow or halt insect or rodent behaviors that result in reproduction. Alternatively, this can involve the use of the compounds of the invention as agents for controlling fertility in animals (e.g., livestock, domestic animals), by providing compounds which inhibit or stimulate the behaviors in such animals that result in reproduction or agression. This can be monitored by routine methods, e.g., observing the behavior in the animal (vertebrate or invertebrate) recipient. The invention also contemplates gene therapy, e.g., to prepare an animal model for studying the conditions and behaviors (e.g., fertility, aggression) that are pheromone receptor- mediated. The procedure for performing ex vivo gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction in vitro ofa functional copy ofa gene into a cell(s) of a subject which contains a defective copy of the gene, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. In vivo gene therapy using vectors such as adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention. The invention further provides efficient methods of identifying pharmacological agents or lead compounds for agents active at the level of a pheromone receptor or pheromone receptor fragment modulatable cellular function. In particular, such functions include ligand binding activity. Generally, the screening methods involve assaying for activation of pheromone receptors or assaying for compounds which interfere with a pheromone receptor activity such as pheromone receptor binding to its cognate ligand. Such methods are adaptable to automated, high throughput screening of compounds. The target therapeutic indications for pharmacological agents detected by the screening methods that block pheromone receptor activity are limited only in that the target cellular function be subject to modulation by alteration of the formation of a complex comprising a pheromone receptor polypeptide or fragment thereof and one or more natural pheromone receptor ligands. Target indications include cellular processes modulated by pheromone receptor signal transduction following receptor-ligand binding. A wide variety of assays for pharmacological agents are provided, including, labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays, cell- based assays such as two- or three-hybrid screens, expression assays, activation of G-proteins, etc. For example, three-hybrid screens are used to rapidly examine the effect of transfected nucleic acids on the intracellular binding of pheromone receptor or pheromone receptor fragments to specific extracellular targets (e.g., ligands in biological samples, such as urine, vaginal fluid, or in combinatorial libraries) . Pheromone receptor fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. The assay can be used to screen putative ligands for their ability to bind to the receptor. Pheromone receptor polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced pheromone receptor polypeptides include chimeric proteins comprising a fusion of a pheromone receptor protein with another polypeptide. For example, a polypeptide fused to a pheromone receptor polypeptide or fragment may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling. In addition to the pheromone receptor, a screening assay mixture includes a binding partner for the receptor, e.g., a naturally occurring ligand that is capable of binding to the pheromone receptor or, alternatively, is comprised of an analog which mimics the pheromone receptor binding properties of the naturally occurring ligand for purposes of the assay. The screening assay mixture also comprises a candidate pharmacological agent (e.g., a putative receptor agonist or antagonist). Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides and or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated. Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily be modified through conventional chemical, physical, and biochemical means. Further, known pharmacological agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents. A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used. The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the pheromone receptor polypeptide specifically binds the cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40 °C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours. After incubation, the presence or absence of specific binding between the pheromone receptor polypeptide and one or more binding targets is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximum signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost. Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet. Detection may be effected in any convenient way for cell-based assays such as two- or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of Pheromone receptor polypeptide binding to a target molecule typically encodes a directly or indirectly detectable product, e.g., β-galactosidase activity, luciferase activity, and the like. A wide variety of cell based assays for G-protein coupled receptors could also be employed for detection of molecules that stimulate (agonsists) pheromone receptors or block (agonists) that stimulation by natural ligands or agonists. Pheromone receptor polypeptides or chimeric receptors composed only in-part of a pheromone receptor could be employed in these assays. The chimeric receptors might, for example, contain part of another G-protein coupled receptor such that binding ofa ligand to the pheromone receptor binding domain results in coupling to a particular G-protein where activation could be easily assayed. For cell free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc), or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a pheromone receptor binding partner (ligand), or incorporated into the structure of the binding partner. A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradioactive energy transfers, etc. or indirectly detected with antibody conjugates, strepavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art. The invention provides pheromone receptor -specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development, including the development of pesticides and other agents for controlling fertility and reproduction (or related behaviors) in animals. For example, pheromone receptor-specific pharmacological agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with improper utilization of a pathway involving pheromone receptor. Novel pheromone receptor-specific binding agents include pheromone receptor-specific antibodies and other natural intracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular binding agents identified in screens of chemical libraries and the like. In general, the specificity of pheromone receptor binding to a binding agent is shown by binding equilibrium constants. Targets which are capable of selectively binding a pheromone receptor polypeptide preferably have binding equilibrium constants of at least about IO 7 M "1 , more preferably at least about 10 8 M "1 , and most preferably at least about IO 9 M "1 . The wide variety of cell based and cell free assays may be used to demonstrate pheromone receptor - specific binding. Cell based assays include one, two and three hybrid screens, assays in which pheromone receptor -mediated transcription is inhibited or increased activation of G-proteins, etc. Cell free assays include pheromone receptor -protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind pheromone receptor polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA). Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced in vitro or in vivo in a host. Such techniques include transfection of nucleic acid-CaPO 4 precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids. Examples Example 1 Experimental Procedures Preparation and analysis of single cell cDNAs Male mouse (C57BL/6J) VNOs were minced, incubated in Trypsin-EDTA (Gibco- BRL/LTI, Rockville, Maryland), and triturated to obtain dissociated cells. The cells were centrifuged (1000 RPM, 5 min) and resuspended in phosphate buffered saline + 0.1% bovine serum albumin. Individual cells that appeared to be neurons were transferred to separate tubes with a microcapillary pipet. cDNAs were prepared from each cell and amplified according to Brady and Iscove (Methods in Enzymology, 1993, 225:611-621) with minor modifications. Briefly, cDNAs were prepared from the 3' ends of mRNAs by reverse transcription with an oligo (dT) primer, and a poly dA stretch was added to each cDNA with terminal transferase. The cDNAs were then amplified by PCR with one of two primers, ALl (ATTGGATCCAGGCCGCTCTGGACAA AATATGAA TTC(T) ( SEQ. ID. No. 56) (Dulac and Axel, Cell, 1995, 83:195-206 or AL3 (GGCACATGG ACGAAATCTTGGTACTCTTCAGAATTC(T), (SEQ. ID. No. 57) and Taq polymerase [Amplitaq LD ("ALD") or Amplitaq Stoffel Fragment ("ASF") (Perkin Elmer, Norwalk, CT )]. Aliquots of each cDNA sample were electrophoresed on agarose gels and blotted onto nylon membranes (Hybond N + , Amersham, Piscataway, NJ) (Ausubel, F., et al, Current Protocols in Molecular Biology, 1988, John Wiley & Sons NY, NY; Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989). The blots were hybridized at 55° or 70°C in Hyb Buffer (0.5M sodium phosphate buffer (pH7.3), 4% SDS, 1% bovine serum albumin (BSA)) with 32 P-labeled probes prepared by random priming (Prime-It II, Stratagene, La Jolla, CA). Construction and screening of single cell cDNA libraries An aliquot of cDNA sample VN14 was digested with Eco RI and gel-isolated fragments of 0.1-1.5 kb were cloned into λZapII Ausubel, F., et al, Current Protocols in Molecular Biology, 1988, John Wiley & Sons NY, NY; Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989). Two thousand library clones were plated at low density. Replica filter lifts were hybridized at 75°C (in Hyb Buffer containing 2μg/ml poly (dT)24 and 1 μg/ml of random dA-dT 20-mers) to 32 P- labeled probes (-2.5 x 10 8 CPM/μg; 5 x IO 6 CPM/ml) prepared by PCR of different single cell cDNA samples. Clones that hybridized to only a VN14 probe were isolated, and a probe prepared from the insert of each was hybridized to blots of selected single cell cDNAs. Clones that hybridized to only VN14 cDNAs were sequenced. Isolation and analysis of VR cDNA clones sci 53, one VN14 + VN2 " clone from the VN14 library, was used as probe to screen a mouse VNO cDNA library ('λVNO') (Berghard, A., et al., J Neurosci, 1996, 16:909-918) and a mouse genomic DNA library (Stratagene, La Jolla, CA) (70°C, Hyb buffer). Hybridizing clones were found only in the genomic library. A fragment containing 2kb upstream of sci 53 was isolated from one genomic clone (153G1) and used to screen IVNO (55°C, Hyb Buffer). The region (D10-TM7) of one clone (D10) that showed homology to TM7 of the CSR (SEQ ID NO. 59) was then used to screen IVNO (55°C, Hyb Buffer), yielding a variety of VR cDNA clones. Additional clones were obtained from IVNO using probes prepared from clones previously isolated, or from PCR products obtained by amplification of mouse genomic DNA or VNO cDNA with degenerate primers (Buck, L., et al., Cell, 1991, 65:175-187) matching conserved motifs in the VRs. Some PCR products were also cloned into pCR2.1 (Invitrogen, Carlsbad, CA) and sequenced. Analysis of VR mRNAs by RT-PCR Random-primed cDNA prepared from male or female C57BL/6J mouse VNO RNAs (or VR cDNA clones) were used in PCR reactions with degenerate primers (Buck and Axel, Cell 1991, 65:175-187) matching conserved VR motifs to amplify VR sequences corresponding to amino acids 33-772 in VRl (SEQ ID NO.2). Nested PCR was performed with a 1/1000 dilution of the first PCR reaction and primer pairs matching regions of putative exons 1 and 6 in specific VR cDNA clones. Blots prepared from size-fractionated, nested PCR products were hybridized (70°C, Hyb buffer containing lOOμg/ml herring sperm DNA (Sigma, St Louis, MO)) to probes prepared from the PCR products of the cDNA clones. Northern and Southern blots and genomic library screens Northern Blots: One μg of PolyA + RNA prepared from mouse VNO and OE, or purchased from Clontech (other tissue RNAs), was size fractionated on formaldehyde gels, and blotted (see above) (Berghard and Buck, J Neurosci, 1996, 16:909-918). The blot was hybridized (70°C, Hyb Buffer) with a 32 P-labeled probe prepared from the regions of cDNAs VRl , VR2, VR4, and VRl 5 corresponding to that encoding amino acids 33-772 in VRl (SEQ ID NO. 1). Southern Blots: 5 μg of genomic DNA prepared from C57BL6/J mouse liver was digested with Eco RI or Hind III, size fractionated, and blotted (Ressler et al, Cell, 1993, 73:597- 609). The blots were hybridized (70°C, Hyb buffer containing sperm DNA (see above)) to probes prepared from 3' untranslated segments of different VR cDNA clones [VR2 (nt.2607- 2961 of SEQ ID NO. 3), VR3 (nt. 2505-2907 of SEQ ID NO. 5), and VRl 5 (nt. 3239-3689 of SEQ ID NO. 29)]. A VR4 probe was also used, which gave the same results as highly related VRl 5 probe. Genomic library screens to determine VR gene number: A mouse genomic library was screened separately at 70°C or 55°C (see above) with different 32 P-labeled probes. Probe 1: a mix of segments of cDNAs VRl (SEQ ID NO. 1), VR2 (SEQ ID NO. 3), VR4 (SEQ ID NO. 7), and VRl 5 (SEQ ID NO. 29) encoding the region corresponding to amino acids 619-772 of VRl (SEQ ID NO. 2). Probes 2-6: Segments of VR genes obtained from mouse genomic DNA by PCR with degenerate primers matching conserved VR sequence motifs. The PCR segments corresponded to the following amino stretches in VRl (SEQ ID NO. 2): amino acids 191-397, 565-825, 637-825, 637-804, and 619-784. For example, degenerate oligonucleotide primer pairs used included: for amino acids 191-397: 5' primeι= (GCT)TI(CT)A(CT) CA(AG)(AG)TIGCI(AC)CIAA(AG)GA(CT)AC (SEQ ID NO. 60), 3' primer= G(CT)(AG)T(GT)IGCI(AG)(CT)I(AG)C(AG)T(AG)IACI(AG)C(AG)TT (SEQ ID NO. 61); for amino acids 565-825: 5' primer= (AC)(AG)ITG (CT)CCI(GT)AIIA(CT)(AC)A(AG)TA(CT)GCIAA (SEQ ID NO.62), 3' primer= GIC(GT)IA(CT)IA(AG)IATIA (CT)(AG)TAI(AC)(AT)(CT)TTIGGIAC (SEQ ID NO. 63); for amino acids 637-825: i' primer= ATI(AT)(GC)I (CT) TI(AG)TITT(CT)TG(CT)TT(CT)(CT)TITG (SEQ ID NO. 64), 3 i"' pprriimmeerr== GIC(GT)IA(CT)IA(AG)IATIA (CT)(AG)TAI(AC)(AT)(CT)TTIGGIAC (SEQ ID N JΠO. £ 6-3*V) for amino acids 637-804: 5' primer= ATI(AT)(GC)I(CT)TI(AG)TITT(CT)TG(CT)TT(CT)(CT)TITG (SEQ ID NO. 64), 3' primer= (AG)IATI(GC)(AT)(AG)AAIA(CT)(CT)TCIACI (AG)CIACCAT (SEQ ID NO. 65); and for amino acids 619-784: 5' primer= GA(CT)ACICCIATIGTIAA(AG)GCIAA(CT)AA (SEQ ID NO. 66), 3' primer= AAIGTIA(CT)CCAIACI(GC)(AT)(AG)CA(AG)AAIAC (SEQ ID NO. 67), wherein all primers are in a 5'-3' direction, Inosine. In situ hybridization In situ hybridization was performed according to Schaeren-Wiemers and Gerfin-Moser (Histochemistry, 1993, 100:431-440) with sequential 16 micron sections of male or female VNOs. Digoxigenin- labeled cRNA probes were prepared from the same 3' untranslated regions of VR cDNAs as used for the genomic Southern blots. Sections were counter-stained with Hoechst 33258, which labels nuclei. The numbers of G ao . or G ai2 -labeled cells (or cells labeled with VR probes) was determined by counting the number of nuclei in labeled regions. The total number of cells was considered to be the sum of G ao + and G ai2 + cells in adjacent sections. Chromosome mapping of VR genes Southern blots of genomic DNA from C57BL/6J and Mus spretus (Jackson Labs) digested with different restriction enzymes were prepared and probed with specific VR cDNA probes as described above. Southern blots of Eco RI, size fractionated genomic DNAs from 94 different backcross mice (M. spretus x (M. spretus x C57BL/6J)), were purchased from Jackson Labs. These blots were hybridized to probes prepared from 3' untranslated segments of the VR2 or VR4 (see above) cDNA at 70°C and washed (see above). Polymorphic bands were typed as either M. spretus or M. spretus/C57BL/6J. The data was sent to the Jackson Laboratory Backcross DNA Mapping Panel Resource for determination of the chromosomal locations of the polymorphic fragments. Additional information was obtained via internet from Jackson Laboratory Mouse Genome Informatics. Cloning of a gene differentially expressed in G ao + VNs Different members of the OR and VNR families are expressed in different neurons in the OE and G ai2 + zone of the VNO, respectively. It therefore appeared likely that the same would be true of sensory receptors expressed by G w + VNs. The differential screening of cDNA libraries with cDNA probes prepared from a few neurons can be used to identify genes expressed in one neuron, but not another (Buck, L., et al, Annu. Rev. Neurosci, 1996, 19:517-544). Using PCR, this can be accomplished with single cells (Brady, G., et al., Methods in Enzymology, 1993, 225:611-621; Dulac, C, et al., Cell, 1995, 83:195-206). To search for genes encoding receptors expressed by G ao + VNs, we looked for genes expressed in one G^ VN, but not another, using the PCR-based differential screening approach. In initial experiments, we isolated a series of mouse VNs, prepared cDNAs from the 3' ends of mRNAs present in each, and amplified the single-cell cDN A fragments by PCR. Many of the amplified, single-cell cDNA samples hybridized to an OMP probe, confirming their derivation from VNs (Berghard et al, Proc. Natl. Acad. Sci. USA, 1996, 93:2365-2369). With one exception, G ao and G ai2 probes hybridized to different OMP+ samples, allowing us to identify samples that were derived from G ao + VNs. We next prepared a library from one of the G m + single-cell cDNA samples (VN14), and isolated clones that hybridized to a probe prepared from VN14, but not to a probe prepared from another G ao + sample (VN2). We identified 3 VN14+VN2- clones, which differed in size, but were otherwise identical in sequence. None contained an open reading frame, which was not surprising since, in the method used, the amplified cDNAs are only -400-800 bp long, and are derived from the 3' ends of mRNAs (Brady and Iscove, Methods in Enzymology, 1993, 225:611- 621). We next hybridized one of the VN14+VN2- clones (sci 53) to the original panel of single-cell cDNAs. sci 53 hybridized to VN14, but not to any of the other cDNA samples. Consistent with this result, sci 53 hybridized to only a small percentage (-0.3%) of VNs in VNO tissue sections. Using sci 53 as probe, we were able to isolate a scl53+ clone from a mouse genomic library which contained -2 kb of DNA 5' to the sci 53 sequence. Using this 2kb fragment as probe, we isolated a matching clone (D10) from the VNO cDNA library. Sequence analysis showed that sci 53 and D10 were derived from the same gene, but that the D10 cDNA was truncated at the 3' end and did not contain the final 685 bp of sequence present in sci 53. Like sci 53, D10 hybridized to only a small percentage of VNs in VNO tissue sections. The 5' end of the D10 cDNA contained a short open reading frame, which encoded a protein fragment with homology to transmembrane domain 7 (TM7) of the calcium sensing receptor (CSR), a G protein-coupled receptor (GPCR) (Brown et al, Nature, 1993, 366:575-580). When the TM7-related region of D10 (D10-TM7) was hybridized at reduced stringency (55°C) to the original panel of single-cell cDNAs, it labeled many of the G m + samples, but none of G^ ones (except the one that was also G ao +, and was probably derived from two cells). Since D10 labeled only a small percentage of VNs in tissue sections under high stringency conditions, this suggested that many G ao + neurons express a gene related to D10, but not identical to it. A novel multigene family encoding VNO receptors Hybridization of D10-TM7 to the VNO cDNA library at reduced stringency yielded a number of related cDNA clones (e.g. VR1-VR3, SEQ ID NOs. 1-6). Additional related cDNAs were obtained by RT-PCR with degenerate primers (e.g. VR6-VR7, SEQ ID NOs. 11-14), or by screening the VNO cDNA library with a PCR product obtained from genomic DNA (e.g., VR4, VR5, SEQ ID NOs. 7-10). These cDNAs encode a novel family of proteins, which are members of the G protein- coupled receptor (GPCR) superfamily (Figure 1). Like other GPCRs, these VNO receptors (VRs) have 7 hydrophobic stretches that may serve as membrane spanning domains. Only 287 of 850 residues are identical in all of the molecules shown in Figurel, indicating that the family is diverse. The VRs are related to two other types of GPCR, the calcium sensing receptor (CSR) and the metabotropic glutamate receptors (mGluRs) (Tanabe, Y., et al., Neuron, 1992, 8:169- 179; Brown, E., et al., Nature, 1993, 366:575-580). The most highly related molecule is the CSR; for example, VRl is 31% identical to rat CSR (Riccardi et al., Proc. Natl. Acad. Sci. USA, 1995, 92:131-135), with the highest homology residing in the TM1-TM7 region (44%) (Figure 1). However, the VRs comprise a distinct family of receptors, which share novel sequence motifs, and are more related to one another than they are to other receptors. For example, two divergent VRs, VRl (SEQ ID NO. 1, 2) and VR4 (SEQ ID NO. 7, 8), are 70% identical in TM1- TM7, and 48% identical overall. The VRs are unusual among GPCRs in having an extremely long N-terminal extracellular domain (Figures 1 and 2). This feature is shared by the CSR and mGluRs, and by an unrelated class of GPCRs that includes several receptors for glycoprotein hormones (Segaloff, D., et al., Oxf Rev. Reprod. Biol, 1992, 14:141-168). Importantly, the VRs are very different from both ORs and VNRs, which are also GPCRs (Buck. L., et al., Cell, 1991 51:127-133; Dulac, C, et al., Cell, 1995, 83:195-206). VRs share none of the characteristic sequence motifs of ORs or VNRs. In addition, the size of the N-terminal extracellular domain of VRs (557-565 amino acids) far exceeds that of ORs and VNRs (-12-28 amino acids) (Figure 2). The VRs are most variable in the N-terminal domain (25% identical residues compared to 51% in TM1-TM7). In the structurally-related mGluRs, the ligand binding site is thought to reside in the large N- terminal domain (O'Hara et al., Neuron, 1993, 11 :41-52; Takahashi et al, J Biol. Chem., 1993, 268:19341-19345). If this is also true of VRs, the accentuated diversity of the N-terminal domain may reflect an ability to recognize diverse pheromonal ligands. Most of the VR cDNAs that we analyzed appeared to belong to one of three subfamilies of highly related molecules. For example, VRl (SEQ ID NOs. 1 , 2), VR2 (SEQ ID NOs. 3, 4), and VR3 (SEQ ID NOs. 5, 6) are very similar as are VR4 (SEQ ID NOs. 7, 8) and VR5 (SEQ ID NOs. 9, 10), and VR6 (SEQ ID NOs. 11, 12) and VR7 (SEQ ID NOs. 13, 14) (Figure 1). Nonetheless, our results indicate that all of these cDNAs were derived from different genes. First, all cDNAs were sequenced on both strands to rule out sequencing errors. Second, the RNA used for library construction and PCR came from an inbred mouse strain (C57BL/6J), so they cannot be allelic variants. Third, the error rates of reverse transcriptase (or Taq polymerase) cannot account for the extent to which the cDNAs differ. For example, VR4 (SEQ ID NOs. 7, 8) and VR5 (SEQ ID NOs. 9, 10) cDNAs are 99% identical in nucleotide sequence, but the reverse transcriptase used to prepare them has an error rate of only 3.6 x 10 5 /bp (Ji, J., et al., Biochemistry, ,1992, 31 :954-958). Variant forms of VR mRNA Many of the VRs we characterized lacked a segment of the N-terminal domain present in other VRs. Invariably, the missing segment corresponded to a region of the human CSR encoded by a single exon, or pair of exons (PoUak, M., et al., Cell, 1993, 73:1297-1303). We also found several different VR cDNAs that contained a stretch of noncoding sequence at a site corresponding to a CSR exon-intron boundary (e.g. VRl 5). This suggested that the exon-intron structure of VR genes resembles that of the CSR gene, and that variant forms of VR mRNAs might be generated by differential RNA splicing. Variant VR mRNAs could derive either from different genes, or from the same gene by alternative RNA splicing. Consistent with the latter possibility, two pairs of cDNAs that we sequenced VR8 (SEQ ID NOs. 15, 16) and VR9 (SEQ ID NOs. 17, 18), and VR10 (SEQ ID NOs. 19, 20) and VRl 1 (SEQ ID NOs. 21, 22) were identical in nucleotide sequence, but were missing different segments. However, when we used RT-PCR to amplify VNO mRNA sequences encoding 5 different VRs, we obtained one major PCR product in each case, regardless of whether the RNA used was from male or female mice. In 4 cases, the size of the major product corresponded to a complete VR, even though one of the cDNAs (but not the PCR product) contained an intron (#5). In one case, in which the cDNA lacked one exon (#2), the major PCR product was even smaller, and was found to lack two exons. Although PCR products of a smaller size were also seen in these experiments, they were much less abundant. These results suggest that different VR forms derive from different genes. Thus many VR genes may be expressed pseudogenes, which either lack one or more exons, or have mutations that prevent proper RNA splicing. We cannot exclude the possibility that some variant VRs are functional, however. For example, some truncated VRs that lack transmembrane domains could conceivably be secreted pheromone-binding proteins. Differential expression of VR genes in VNO neurons To investigate the tissue distribution of VR gene expression, we conducted Northern blot analyses in which size fractionated polyA + RNAs from different mouse tissues were hybridized to a mix of radiolabeled VR cDNAs. The mixed probe hybridized to VNO RNAs of -1.9-3.7 kb, with intense hybridization to RNAs of 2.8-3.5 kb. It did not hybridize to RNAs from a variety of other tissues, including olfactory epithelium and brain. This suggested that VR genes may be expressed exclusively in the VNO. We found two partial cDNAs that were highly related to VR cDNAs in the NCBI dbEST database, one from spleen and the other from 2-cell stage mouse embryos. However, when we hybridized the most highly related VR cDNAs (VR6 and VR7) to spleen sections, only one questionably-labeled cell was seen out of -1.4 x 10 6 cells with one VR probe, and none was seen with the other. The EST clones might be DNA contaminants, or be due to the widespread, but low level, misexpression of tissue specific genes (Sarkar, G., et al., Science, 1989, 244:331-334); nonetheless, we cannot exclude the possibility that VR genes are expressed at a low frequency in some other tissues. To examine the patterns of expression of different VR genes in the VNO, we conducted in situ hybridization experiments. Labeled segments of the 3' untranslated regions of three VR cDNAs were hybridized separately, or in combination, to sequential sections through the VNO. Probes prepared from G ao and G ai2 cDNAs were hybridized to adjacent sections to delineate the G ao + and G ai2 + zones of the VNO neuroepithelium. The G ^ , and G^ probes gave patterns of hybridization similar to those we had previously seen (Berghard, A., et al, J Neurosci, 1996, 16:909-918). The G ao probe hybridized to a wavy stripe of VNO neurons in the basal (lower) region of the VNO neuroepithleium, whereas the G ai2 probe hybridized to an adjacent stripe of neurons in the apical (upper) part of the neuroepithelium. The waviness of the two zones appears to be caused by the periodic presence of blood vessels near the base of the epithelium (Berghard, A., et al, J Neurosci, 1996, 16:909- 918). Approximately 57% of VNs were labeled by the G ai2 probe and 43% were labeled by the G ^ probe. The single layer of supporting cells located just beneath the epithelial surface was not labeled by either probe. Each of the VR probes hybridized to a small percentage (2.4-5.7%)) of VNs that appeared to be restricted to the basal, G ao + zone of the VNO neuroepithelium. Labeled neurons were scattered throughout the anterior-posterior and dorsal-ventral extent of the G ao + zone. Small clusters of labeled cells were somtimes seen, particularly with the VR2 probe The mixed probe labeled a larger percentage of VNs (10.6%) that was almost equal to the sum of the percentages labeled by its individual components (10.8%). Thus different G ao + neurons must express different VRs. No differences were seen in the patterns of hybridization obtained using VNOs from male and female mice, and no hybridization was observed in the nasal olfactory epithelium using either the mix of VR probes or a full-length VR cDNA probe (not shown). Subsequent analyses of the size of the VR gene family, and the number of VR genes recognized by the VR in situ hybridization probes, allowed us to estimate the number of VR genes expressed by individual neurons (see below). The size of the VR multigene family To investigate the size of the VR gene family, we hybridized several different mixed VR gene probes to a mouse genomic library, using high (70°C) or low (55°C) stringency conditions. A probe prepared from the membrane spanning regions (putative exon 6) of several different cDNA clones hybridized to 59 and 98 clones per haploid genome equivalent, at high and low stringency, respectively. To obtain probes that were potentially more diverse, we amplified internal segments of putative exon3 or 6 from genomic DNA by PCR with degenerate primers. At high stringency, these probes hybridized to 60-140 clones per haploid equivalent. These results indicate that there are as many as 140 VR genes in the mouse genome. The VR probes that we used for in situ hybridization each labeled a small percentage of neurons. To determine how many VR genes each probe recognized, we hybridized probes prepared from the same VR cDNA segments to Southern blots of C57BL/6J mouse genomic DNA which had been digested with Eco RI or Hind III. Each probe hybridized to a small number of restriction fragments. Given the small size of the probes (-350-450 bp), most of these fragments should represent at least one gene, provided that there are no introns in the region probed. Consistent with this assumption, the VR2 (SEQ ID NO. 3) probe hybridized to 7 different restriction fragments, as many as five of which could be accounted for by characterized VR cDNAs that were 91-98% identical to VR2 (SEQ ID NO. 3) in the region probed. Given the number of genes recognized by each VR probe and the percentage G M + neurons that hybridized to each, we estimate that each VR gene may be expressed in only -1.1-1.9% of G ao + VNs. Since there appear to be 60-140 VR genes in the mouse genome, this suggests that each G ao + VNO neuron may express only one, or at most a few, VR genes. Linkage of chromosomal clusters of VR and OR genes We previously found that there are clusters of OR genes at multiple chromosomal sites in the mouse genome (Sullivan, S., et al., Proc. Natl. Acad. Sci, 1996, 93:884-888). To investigate the chromosomal locations of VR genes, we used the Jackson Laboratory Backcross DNA Mapping Panel, which allows the mapping of mouse genes using interspecies mouse crosses. Probes prepared from the 3' untranslated regions of VR2 (SEQ ID NO. 3) or VR4 cDNAs were first hybridized to Southern blots of genomic DNAs from two mouse species, C57BL/6J and Mus spretus, which had been digested with different restriction enzymes. Eco RI digests showed a number of restriction length polymorphisms with both VR probes. The VR probes were then hybridized to Eco Rl-digested DNAs from a large panel of different backcross mice ((C57BL/6J x M. spretus) x M. spretus). The patterns of inheritance of the polymorphic fragments recognized by the two VR probes allowed us to assign chromosomal locations to approximately 9 VR genes. Using the VR4 (SEQ ID NO. 7) probe, we could follow the inheritance of 4 polymorphic restriction fragments. All of these cosegregated in the backcrosses, and mapped to the proximal end of chromosome 7 (near D7Bir5). Five restriction fragments were followed for the VR2 (SEQ ID NO. 3) probe. Again, all of the restriction fragments cosegregated, allowing us to map the VR2 (SEQ ID NO. 3) fragments to the distal end of chromosome 4 (near D4Birl). Given the resolution of the genetic mapping, the cosegregating fragments can be no more than 3.8 cM from one another. These results indicate that VR genes are located near the ends of at least two different mouse chromosomes. They also indicate that highly related VR genes are clustered at the same chromosomal locus, as previously seen in our studies and others (Ben-Arie et al, Human Molecular Genetics, 1994, 3:229-235.). The VR4 gene subfamily appears to be closely linked to one OR gene locus, (olfR5 ) (Sullivan, S., et al., Proc. Natl. Acad. Sci, 1996, 93:884-888). Although the VRs and ORs were mapped in different mouse crosses, the synaptotagmin-3 gene (Syt3 ) was mapped in both crosses, allowing an estimate of their relative positions. The OR locus mapped 15.05 cM proximal to Syt3 while the VR4 gene cluster mapped 14.89 cM proximal to Syt3. (Jackson Laboratory Mouse Genome Informatics), suggesting a close linkage between VR and OR genes at the proximal end of chromosome 7. Our previous studies indicate that multiple OR gene loci arose via a series of duplications of very large chromosomal domains that maintained linkages between OR genes and members of other gene families. These results therefore suggest that VR genes and OR genes might have been linked in a primitive ancestor. They also suggest the possibility that additional clusters of VR genes might be linked to other OR gene loci. Example 2 Experimental procedures Preparation of cDNA Libraries from Isolated VNO Neurons VNOs were dissected from adult (7- to 8-week-old) male Lewis rats (Sprague-Dawley). Single-cell cDNA synthesis and amplification were performed and checked according to Dulac and Axel (Ce/7,1995, 83:195-206). Southern blot analysis of single-cell cDNA was used to detect expression of tubulin, OMP, Go, and Gi 2α (Dulac and Axel, Cell, 1995, 83:195-206). Eighteen cDNAs showed strong hybridization with tubulin and OMP probes, indicating that they originated from mature neurons, and were selected for further study. Cells VN3 and VN13 exhibited high levels of Go expression, whereas VN10 showed presence of Gi 2α , indicating the origin of these cells from two distinct regions of the VNO neuroepithelium. VN13 single-cell cDNA library was prepared according to Dulac and Axel (Cell, 1995, 83:195-206). Differential Screening of Single-Cell Library Plaque-forming units (12 x 10 3 ) from the VN13 library were plated at low density, and duplicate filters (Hybond N + , Amersham) were hybridized with probes generated from VN 10 and VN13 single-cell cDNAs, following the procedure described in Dulac and Axel, Cell, 1995, 83 : 195-206. Ten phage plaques were detected that showed a positive signal unique to the VN13 probe. These plaques were purified, and the corresponding phage inserts were amplified by PCR, run on 1.5% agarose gel, blotted onto nylon filter, and hybridized with the VN10, VN3, and VN13 single-cell cDNA probes. Isolation and Analysis of Full-Length cDNA Clones A 425 bp clone, Go-VNl 3 A, present at the frequency of 0.1% in the VN13 single-cell cDNA library, was selected and in vivo excised to generate the pBlueScriptSK(-) phagemid. High stringency (65 °C) screening of a cDNA library prepared from female rat VNO (Dulac and Axel, Cell, 1995, 83:195-206) with the Go-VN13A cDNA probe led to the isolation of Go-VN13B (SEQ ID NO. 49) , presenting 90% sequence homology with Go-VN13A. Phages (7.2 x 10 5 ) of the female rat VNO library were further screened with the Go-VN13B (SEQ ID NO. 49) cDNA probe under low stringency conditions: hybridization was carried out at 55 °C for 24 hr, and the filters were washed three times at 55 °C for 30 min in 0.5x SSC and 0.5% SDS. A total of 75 positive phages were identified and the corresponding inserts were amplified by PCR and analyzed by Southern blot using the Go-VNl 3B (SEQ ID NO. 49) probe at both high (65 °C) and low (55 °C) stringency. This led to the identification of 22 cDNA clones with insert sizes longer than 3 kb. Among those, six distinct subfamilies were defined by absence of cross-hybridization under stringent conditions of hybridization and washing. Full-length clones (Go-VNl to Go-VNό, SEQ ID NOs. 33, 35, 37, 39, 41, 43), each representative of a subfamily, were selected for in vivo excision and sequenced. Go-VN13C (SEQ ID NO. 47) and Go-VN13B (SEQ ID NO. 49) are identical sequences differing by a 150 bp deletion in Go-VNl 3C (SEQ ID N O . 4 7 ) . T h i s s e q u e n c e e n c o d e s f o r NMDQCANCPEYQYANTEKNKCIQKGVIVLSYEDPLGMALALIAFCFSAFTV (SEQ ID NO. 58) in Go-VN13B (SEQ ID NO. 49) and is replaced by an M at position 552 in Go-VN13C (SEQ ID NO. 48). DNA Sequencing and Sequence Analysis DNA sequencing was performed using ABI Prism dye terminator cycle ready reaction (Perkin Elmer, Norwalk, CT ) according to manufacturer's protocol. Samples were run on an ABI Prism 310 Genetic Analyzer (Perkin Elmer, Norwalk, CT). Sequence homologies were determined using the BLAST system (NIH network service). Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis were obtained with the Mac Vector sequence analysis software (Oxford Molecular Group). In Situ Hybridization Analysis In situ hybridization was performed as described elsewhere (Schaeren-Wiemers, N., et al., Histochemistry, 1993, 100:431-440). VNOs were dissected from adult male (8- to 9-week-old), adult female (9- to 11 -week-old), and young (1 -week-old) rats. Tissues were embedded in Tissue-Tek OCT. Antisense and sense digoxigenin-labeled probes were generated from the full-length cDNAs encoding for Go, Gi 2o , Go-VN13B (SEQ ID NO. 49), and Go-VNl to G0-VN6 (SEQ ID NOs. 33, 35, 37, 39, 41, 43), as well as from the 3' untranslated regions of the Go-VNl to G0-VN6 clones. Imaging Processing and Statistical Analysis Digital photographs were captured with a Leitz DMRB microscope (Leica) coupled to a ProgRes3012 digital camera (Kontron Electronic) and further processed with the Photoshop (Adobe System) and Canvas (Deneba) software for Macintosh. The relative positions of cells exhibiting a positive signal by in situ hybridization were measured along the basal-apical axis using the NIH Image analysis software. The number of cells in hemiconcentric sections of 10% along this axis from the basal (value = 0) to the apical (value = 100) boundaries was determined. Average data for Go-VNl and Go-VN3 to G0-VN6 were obtained from six to eight VNO sections, corresponding to four individuals analyzed in two independent experiments. For Go-VN2, 14 VNO sections, corresponding to ten individuals and four independent experiments, were analyzed for each sex. Southern Blot Analysis of Rat Genomic DNA and Screening of Rat and Human Genomic Libraries Genomic DNA, prepared from Lewis rat (Sprague-Dawley) liver, was digested with the restriction enzymes EcoRI and BamHI, size fractionated on 0.8% agarose gels, and blotted onto nylon membrane (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989). Membranes were cross-linked under UV light, hybridized overnight at both high (68 °C) and low (55 °C) stringency in hybridization buffer, and washed as described above. 32 P-labeled probes were generated by random priming, using the following DNA templates: EcoRI-EcoRV, Notl-Nsil, EcoRI-Sall, Pstl-Ndel, Xbal-HincII, and EcoRI-Nsil fragments of Go-VNl to Go-VNό (SEQ ID NOs. 33, 35, 37, 39, 41, 43), respectively; a full-length (425 bp) insert of Go-VN13A; and a cDNA fragment including the seven transmembrane domains of Go-VN 13B (SEQ ID NO. 49). Plaque-forming units (3 x 10 5 ) from rat and human genomic libraries (Stratagene, La Jolla, CA) were screened at low stringency (55 °C) using a mix of 32 P-labeled probes prepared from fragments of Go-VNl to Go-VNό (SEQ ID NOs. 33, 35, 37, 39, 41, 43) encompassing the transmembrane domains 2 to 7. Results The VNO Neuroepithelium Expresses Two Independent Families of Pheromone Receptors We hypothesized the existence of two distinct families of genes encoding pheromone receptor genes that are selectively colocalized with either the Go protein in the basal half of the vomeronasal neuroepithelium or with the Gi 2tt protein in the apical region. For simplicity of nomenclature, and with the understanding that the cosegregation of distinct G-protein subunits with independent families of pheromone receptors is consistent but does not demonstrate a functional link, the family of genes encoding putative pheromone receptors that we have previously identified and that colocalize with Gi 2α will be named Gi 2α -VN, whereas the novel family of receptors coexpressed with Go and described in this study will be named Go-VN. In the absence of information concerning the nature of the Go-VN receptor molecules, we reiterated the cloning strategy that allowed us to identify a family of putative pheromone receptor genes expressed by Gi 2tt + neurons (Dulac and Axel, Cell, 1995, 83:195-206). This strategy was based on the assumption that individual neurons within the VNO are likely to express only one pheromone receptor gene and that transcripts encoding a given receptor represent between 1% and 0.1%) of a single-cell mRNA. Differential screening of cDNA libraries constructed from single- VNO neurons takes advantage of the fact that different cells express different receptors and thus provides an experimental solution to the problem of detecting a specific transcript in a heterogeneous population of neurons. In this attempt, we expected that differential screening of a cDNA library prepared from an isolated Go+, Gi 2α - VNO neuron would permit the isolation ofa class of pheromone receptor genes distinct from the Gi 2a -VN family of receptor genes. A cDNA library prepared from a Go+ neuron (VN13) was differentially hybridized with 32 P-labeled probes prepared from VN13 and from a second VNO neuron cDNA (VN10). A 425 bp cDNA (Go-VN 13 A) present at a frequency of 0.1% in the VN13-cDNA library showed selective hybridization with VN13 cell probe. Two cDNAs of longer size, Go-VNl 3B (SEQ ID NO. 49) and Go-VNl 3C (SEQ ID NO. 47), were subsequently isolated from a cDNA library prepared from dissected adult VNOs and showed 90% sequence similarity with Go-VN 13 A. Hybridization to VNO cross-sections with digoxigenin-labeled antisense RNA probe showed that expression of these transcripts is restricted to a small subpopulation of VNO neurons in a location consistent with the region of Go expression of the neuroepithelium. The sequence of Go-VN 13B (SEQ ID NO. 49) reveals a partial open reading frame that includes seven hydrophobic stretches of 20 amino acids in length. Go-VN 13B (SEQ ID NO.49) sequence does not share any resemblance with the odorant receptor genes nor with the family of putative pheromone receptor genes previously identified (see below). In addition, hybridization of Go-VN 13B DNA probe to genomic DNA identified two discrete bands at high stringency and 13 or more at lower stringency, revealing the existence ofa family of closely related genes in the rat genome. Taken together, these data indicate that we have isolated a novel multigene family encoding seven transmembrane domain receptors and expressed by subsets of VNO neurons from the basal half of the neuroepithelium. Sequences of a New Family of VNO Receptors Recombinant phages from a VNO cDNA library were screened at low stringency with the Go-VNl 3B (SEQ ID NO. 49) DNA probe. Six distinct gene subfamilies were isolated that showed no cross-hybridization under stringent conditions of hybridization and washing. cDNAs Go-VNl to G0-VN6, each representative ofa subfamily, were fully sequenced (SEQ ID Nos 33, 35, 37, 39, 41 and 43). In Go-VNl to Go-VN5 cDNAs (SEQ ID Nos 33, 35, 37, 39 and 41), the first methionine of the open reading frame was tentatively chosen as a start for protein translation, revealing large open reading frames ranging from 548 to 866 amino acids. A frame shift in the G0-VN6 (SEQ ID NO. 44) sequence (amino acid 532; indicated by slash bar in Fig. 3) indicated that this transcript is unable to generate a functional protein. Deduced Amino Acid Sequences of cDNAs from the Go-VN Family of Pheromone Receptors The deduced amino acid sequences of eight cDNAs belonging to the Go-VN family of putative pheromone receptors is shown in Figure 3. Predicted position of seven transmembrane domains is also indicated (I- VII). Amino acids common to at least five cDNAs are shaded. Amino acids common to the rat mGluRl and Ca2 + -sensing receptors are indicated by a star. Hydropathy analysis of the predicted Go-VN proteins with the Kyte-Doolittle algorithm identified a large hydrophilic N-terminal domain that ranges in size from 274 amino acids in Go-VNl (SEQ ID NO. 34) to 595 in Go-VN4 (SEQ ID NO. 40). This is preceded in cDNAs Go-VN4 (SEQ ID NO. 40), Go-VN7 (SEQ ID NO. 46), and Go-VNl 3C (SEQ ID NO. 50) by an initial hydrophobic 21 amino acid segment characteristic of eukaryotic signal sequences. A cluster of seven hydrophobic regions representing potential membrane-spanning helices and typical of the G protein-coupled receptor superfamily is followed by a short hydrophilic sequence that indicates a potential intracytoplasmic C-terminal domain. A database search indicated the presence of sequence motifs common to Ca2 + -sensing and metabotropic glutamate (mGluR) receptors (Houamed, K., et al., Science, 1991, 252:1318-1321; Masu, M., et al., Nature, 1991, 349:760-765; Brown, E., et al., Nature, 1993, 366:575-580 ; Pollak, M., et al., Cell, 1993 75 : 1297- 1303). Pairwise sequence alignments reveal 18% to 23%) sequence identity between the rat Ca2 + -sensing receptor and the most distant (Go-VN3, SEQ ID Nos.37, 38) and the closest (Go-VNl, SEQ ID NOs. 33, 34) Go-VN sequences, respectively. Sequences of rat mGluRl and Go-VN cDNAs appear more distantly related. Several localized regions showed a more pronounced degree of similarity, including a cysteine-rich sequence just preceding the first transmembrane domain (amino acid 206 to 260 in Go-VNl, SEQ ID NO. 34), the predicted transmembrane domains 2 to 7 with surrounding cytoplasmic and extracellular loops, and the relative position of 20 cysteines. The N-terminal and first transmembrane domains show little degree of homology. In mGluR and Ca2 + -sensing receptors, the second intracellular loop is involved in providing specificity for G-protein coupling (Gomeza, J., et al., J. Biol. Chem., 1996, 271:2199-2205), enabling different classes of mGluR receptors to activate phospholipase C or to inhibit adenylyl cyclase. In Go-VN, this domain is rich in basic residues, as expected for potential G-protein coupling, and shows closer resemblance to the class II and III mGluRs that were shown to couple to Go and Gi subunits. Overall, the six Go-VN sequences share between 42%o and 75% sequence identity. Regions of Go-VN proteins downstream of transmembrane domain 2 are nearly identical in all VNO receptor sequences. In contrast, N-terminal extracellular regions and first transmembrane domains are quite divergent. Anomalies in Go-VN cDNA Sequences: Two unusual features were observed in the sequence of some Go-VN cDNAs. In Go-VNl (SEQ ID NO. 33) and Go-VN3 (SEQ ID NO. 37) cDNAs, stretches of open reading frame can be found in the 5' extremity of the cDNAs that generate polypeptide sequences of 310 and and 152 amino acids, respectively, which are interrupted by a frameshift in Go-VNl and by an insertion of 500 nucleic acids in Go-VN3. The prospective receptor protein sequences indicated for Go-VNl (SEQ ID NO. 33) and Go-VN3 (SEQ ID NO. 37) (Fig. 3) start at the next available methionin and are therefore significantly shorter than those of other receptor cDNAs. Go-VN7 (SEQ ID NO. 45) and Go-VNl 3C (SEQ ID NO. 47) cDNAs show a similar deletion of 150 bp located at the exact same position in the sequence. Strikingly, the 150 bp deletion does not alter the open reading frame but generates a gap that encompasses 34 amino acids upstream of the first transmembrane domain and most of the first transmembrane domain itself. Hydropathy analysis of Go-VN7 (SEQ ID NO. 46) and Go-VNl 3C (SEQ ID NO. 48) protein sequences detects only a seven to eight amino acid long hydrophobic stretch that might not be long enough to replace the deleted transmembrane domain 1 and allow the appropriate folding of the protein. Except for the 150 bp gap, sequences of Go-VNl 3B (SEQ ID NO. 50) and Go-VNl 3C (SEQ ID NO. 48) are identical. This raises the question as to whether both transcripts might originate from alternative splicing of the same gene. Alternatively, they might be transcribed from independent genes that evolved from recent duplication and deletion events. Size of the Go-VN Family of Genes We investigated the size of the Go-VN family of receptors by hybridizing 32 P-labeled cDNA probes prepared from regions spanning the most divergent N-terminal half of the receptor protein to rat genomic DNA. Individual probes identify two to four discrete bands under stringent conditions of hybridization and washing. Under conditions of reduced stringency, each of the individual probes now generates a unique pattern of 12 to 20 bands, providing a direct illustration of the existence of a very large family of related genes. A direct estimate of the size of the Go-VN receptor gene family was obtained by low stringency screening ofa rat genomic library. PCR amplification on genomic DNA had indicated that receptor genes are devoid of introns in the region encompassing transmembrane domains 2 to 7, enabling us to deduce directly the number of genes present in the rat genome. A mix of 32 P-labeled DNA probes prepared from the six Go-VN cDNA fragments identified 110 positive clones per haploid genome, indicating that the family of Go-VN receptors may consist of 100 genes. Expression Pattern of Go-VN Receptors The pattern of expression of the Go-VN receptor genes was examined by in situ hybridization with digoxigenin-labeled RNA antisense probes. No signal was observed after hybridizing the mix of Go-VNl to G0-VN6 (SEQ ID NOs. 33, 35, 37, 39, 41 and 43) receptor probes to sections of muscle, testis, brain, or whole head. The adult olfactory epithelium was also consistently negative, although rare positive cells (one to three cells per section) were observed in the olfactory neuroepithelium of El 9 rat embryo. In contrast, strong signals were observed when antisense receptor RNA probes were hybridized to VNO neuroepithelium. In adults, each one of the Go-VN probes detects small subsets of VNO sensory neurons. When hybridization and washing were performed at lower temperature, the number of faintly labeled neurons increased, revealing cross- hybridization to more distant receptor genes. Under high stringency conditions, cDNA clones Go-VNl to G0-VN6 label 1.9%, 3.6%, 6.1%), 0.4%), 3.5%), and 1.3% of the VNO sensory neurons, respectively. Under the same experimental conditions, the mix of all six Go-VN RNA probes labels 19% of the cells. This number is similar to the sum of labeled neurons detected with the six individual Go-VN probes (17%), indicating that probes representing the six receptor subfamilies recognize distinct populations of VNO sensory neurons. Spatial Distribution of Go-VN Receptor Transcripts Positive neurons identified with each of the Go-VN probes were randomly distributed along the anteroposterior and dorso-ventral axis of the VNO neuroepithelium. Most RNA probes recognize cells that are preferentially localized in the most basal two-thirds of the neuroepithelium corresponding to the zone of Go expression. However, careful examination of adjacent cross-sections of vomeronasal neuroepithelium labeled with each of the Go-VN probes reveals a well-organized spatial distribution of receptor expression. Different receptors appear preferentially localized in radial zones that define a series of hemiconcentric rings of distinct diameters. This pattern is observed along the entire length of the VNO and is conserved in all animals analyzed. The Go-VN3 (SEQ ID NO. 37) probe, for example, recognizes a subset of neurons that are confined to the most basal third of the VNO neuroepithelium. In contrast, the Go-VNl (SEQ ID NO. 33), Go-VN4 (SEQ ID NO. 39), and Go-VN5 (SEQ ID NO. 41) RNA probes identify cells restricted to a hemiconcentric zone immediately apical to the area of Go-VN3 expression, whereas Go-VN2 identifies cells apposed to the apical layer of supporting cells. G0-VN6 in turn is found only in sparse cells immediately apposed to the basal membrane. This is best seen in a statistical representation of Go-VN receptor localization collected from VNO sections and multiple animals that shows a striking conservation of these patterns. Thus, transcription of Go-VN cDNAs appears restricted to one of three circumscribed areas of the VNO neuroepithelium in a manner quite reminiscent of the odorant receptor gene expression in four zones of the MOE (Ressler, K., et al., Cell, 1993, 73:597-609 ; Vassar, R., et al., Cell, 1993, 74:309-318). Although Go-VN3 (SEQ ID NO. 37) and G0-VN6 (SEQ ID NO. 43) transcripts show a clear segregation in the most basal region of the VNO neuroepithelium, the sequence anomalies found in both transcripts leave the functionality of this area of the neuroepithelium as an open question. Sexual Dimorphism in Receptor Distribution and Age-Related Changes To identify potential sexual dimorphism in Go-VN receptor expression, we systematically hybridized each probe to sections originating from adult male and female rat VNOs. All receptors were equally distributed in males and females with the striking exception of Go-VN2 (SEQ ID NO. 35). In females, Go-VN2 appears expressed in a large and centrally located region comprising one-third of the neuroepithelium. In sharp contrast, the same probe recognizes in males a cohort of cells in the most apical side of the neuroepithelium, closely apposed to the VNO lumen, and most likely intermingled with Gi 2α VNO sensory neurons. Such a difference in the Go-VN2 expression pattern in males and females might result from the expression of the same receptor gene in a different zone of the VNO epithelium or from a differential expression of two distinct but closely related genes of the Go-VN2 subfamily. In females, Go-VN2 generates a very intense hybridization signal to most positive neurons and a fainter staining on a second set of labeled cells. The population of faintly labeled cells was never detected in males, indicating the existence of a female-specific neuronal subpopulation expressing either a lower level of the Go-VN2 transcript or a female-specific receptor significantly different but still cross-hybridizing to the Go-VN2 probe. We followed the emergence of receptor expression and of the VNO zonal organization during development and postnatal stages preceding puberty. Go-VN receptor expression is first detected in the VNO of El 4 embryos. No significant difference is observed in the onset of expression of Gi 2α -VN and Go-VN classes of receptor genes. In agreement with data of Berghard and Buck, 1996 in mouse, segregation of Gi 2α and Go expression in the apical and basal areas of VNO neuroepithelium, respectively, is not apparent in the embryo and in 1 -week-old animals. In contrast, Gi 2a + cells appear randomly distributed in large clusters over the whole thickness of the neuroepithelium, intermingled with Go cells. At 4 weeks after birth, however, Gi 2α cells appear clearly localized in the apex of the epithelium. Similarly, in situ hybridization experiments with mixes of Go-VN and Gi 2a -VN receptor probes on sections of the VNOs dissected from late embryos and 1 -week-old animals show that the two cell populations are still intermingled at early postnatal stages. We observed that the zonal distribution of the two families of receptors slowly emerges during sexual maturation to reach the spatial distribution observed in adults. Preliminary data indicate that the sexual dimorphic expression pattern of Go-VN2 is undetectable at 6 weeks after birth. Thus, in contrast to the zones of olfactory receptor gene expression, which are already present in the olfactory epithelium at the earliest stages of receptor gene expression in the embryo (Sullivan, S., et al., Neuron, 1995, 15:779-789), the spatial organization of the VNO neuroepithelium as detected by G-protein and receptor gene expression emerges only in a late postnatal period and reaches its definitive pattern at sexual maturity. Expression of Go-VN Receptors Is Restricted to Go+ VNO Neurons The expression of some of the Go-VN receptors in neurons lining the VNO lumen in an area mainly occupied by Gi 2a + cells raises the obvious question as to whether the expression of this family of genes is strictly restricted to Go+ VNO neurons. Single-cell cDNA prepared from 23 individual VNO neurons was analyzed by Southern blots with probes representing the six divergent subfamilies of Go-VN receptors and was PCR amplified with degenerated primers based on conserved motifs between Go-VN receptor sequences. Both approaches confirmed that none of the 19 cell cDNAs prepared from Gi 2a + neurons contained any sequence of the Go-VN receptor family. In contrast, all four cDNAs generated from Gi 2α - cells contained a sequence related to the Go-VN receptors. PCR products generated with degenerated primers based on conserved motifs between Go-VN receptor sequences and obtained from the four Go+ cells were subcloned and sequenced. For each single-cell cDNA, the insert sequences from ten independent colonies were found to be identical. This set of data strongly suggests that Go-VN receptor genes are not expressed by Gi 2o + neurons and constitutes preliminary evidence for the expression of only one Go-VN receptor gene per neuron. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. All references disclosed herein are incorporated by reference in their entirety. A Sequence Listing is presented below and is followed by what is claimed. SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: PRESIDENT AND FELLOWS OF HARVARD COLLEGE (ii) TITLE OF THE INVENTION: NOVEL PHEROMONE RECEPTORS (iii) NUMBER OF SEQUENCES: 92 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Wolf, Greenfield & Sacks, P.C. (B) STREET: 600 Atlantic Avenue (C) CITY: Boston (D) STATE: MA (E) COUNTRY: U.S.A. (F) ZIP: 02210-2211 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ for Windows Version 2.0 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/051,284 (B) FILING DATE: 30-JUN-1997 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Plumer, Elizabeth R. (B) REGISTRATION NUMBER: 36,637 (C) REFERENCE/DOCKET NUMBER: H0498/7074 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 617-720-3500 (B) TELEFAX: 617-720-2441 (C) TELEX: (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3080 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 57...2606 (D) OTHER INFORMATION: VRl (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GTTTTTCTGC ATCAGAAACG GATTTCACAG CAGCTCCATC TCAGATCCTA GCAGAC ATG 59 Met 1 AAG CAG CTC TGC GCT TTC ACT ATT TCT TTG TTG TTT CTG AAG TTT TCT 107 Lys Gin Leu Cys Ala Phe Thr lie Ser Leu Leu Phe Leu Lys Phe Ser 5 10 15 CTC ATC CTG TGC TGT TTG ACT GAA CCA AGT TGC TTT TGG AGA ATA AGG 155 Leu lie Leu Cys Cys Leu Thr Glu Pro Ser Cys Phe Trp Arg lie Arg 20 25 30 AAT AGT GAA GAT AGT GAT GGA GAT TTA CAA AGG GAA TGT CAT TTT TAC 203 Asn Ser Glu Asp Ser Asp Gly Asp Leu Gin Arg Glu Cys His Phe Tyr 35 40 45 CTT TGG AAA ACT GAT GAA CCT ATT GAA GAT AGT TTT TAT AAT TAT GAT 251 Leu Trp Lys Thr Asp Glu Pro lie Glu Asp Ser Phe Tyr Asn Tyr Asp 50 55 60 65 TTA AGT TTT AGA ATT GCA GCA AGT GAA TAT GAG TTT CTT CTC GTA ATG 299 Leu Ser Phe Arg lie Ala Ala Ser Glu Tyr Glu Phe Leu Leu Val Met 70 75 80 TTT TTT GCT ATC GAT GAG ATC AAC AGG AAT CCT TAT CTT TTA CCC AAC 347 Phe Phe Ala lie Asp Glu lie Asn Arg Asn Pro Tyr Leu Leu Pro Asn 85 90 95 ATA ACT TTG ATG TTC TCC TTC ATT GGT GGA AAC TGT CAG GAT TTA TTG 395 lie Thr Leu Met Phe Ser Phe lie Gly Gly Asn Cys Gin Asp Leu Leu 100 105 110 AGA GTT ATG GAC CAA GCA TAT ACA CAA ATA AAT GGA CAT ATG AAT TTT 443 Arg Val Met Asp Gin Ala Tyr Thr Gin lie Asn Gly His Met Asn Phe 115 120 125 GTT AAT TAT TTC TGT TAT TTA GAT GAT TCA TGT GCC ATA GGT CTT ACA 491 Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala lie Gly Leu Thr 130 135 140 145 GGA CCA TCA TGG AAA ACT TCC TTA AAA CTG GCA ATG CAC TCT TCG ATG 539 Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu Ala Met His Ser Ser Met 150 155 160 CCA CTG GTT TTC TTT GGA CCA TTT AAT CCT AAC CTA CGC GAC CAT GAC 587 Pro Leu Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His Asp 165 170 175 CGG CTG CCC CAT GTC CAT CAG GTA GCC CCC AAG GAC ACA CAT TTG TCC 635 Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu Ser 180 185 190 CAT GGC ATG GTC TCC TTG ATG TTT CAC TTT AGA TGG ACT TGG ATA GGA 683 His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp lie Gly 195 200 205 CTG GTC ATC TCA GAT GAT GAC CAG GGT ATT CAG TTT CTC TCA GAT TTA 731 Leu Val lie Ser Asp Asp Asp Gin Gly lie Gin Phe Leu Ser Asp Leu 210 215 220 225 AGA GAA GAA AGC CAA AGG CAT GGG ATC TGT TTA GCT TTT GTT AAT ATG 779 Arg Glu Glu Ser Gin Arg His Gly lie Cys Leu Ala Phe Val Asn Met 230 235 240 ATC CCA GAA AAC ATG CAG ATA TAC ATG ACA AGG GCT ACA ATA TAT GAT 827 lie Pro Glu Asn Met Gin lie Tyr Met Thr Arg Ala Thr lie Tyr Asp 245 250 255 AAA CAC ATT ATG ACA TCT TCA GCA AAG GTT GTT ATC ATT TAT GGT GAA 875 Lys His He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly Glu 260 265 270 ATG AAC TCT ACT CTA GAA GCA AGC TTT AGA AGA TGG GAA GAG TTA GGT 923 Met Asn Ser Thr Leu Glu Ala Ser Phe Arg Arg Trp Glu Glu Leu Gly 275 280 285 GCT CGG AGA ATC TGG ATC ACA ACC TCA CAA TGG GAT GTC ATC ACA AAT 971 Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp Val He Thr Asn 290 295 300 305 AAA AAA GAC TTC ACC CTT AAT CTC TTC CAT GGG ATC ATC ACT TTT GAA 1019 Lys Lys Asp Phe Thr Leu Asn Leu Phe His Gly He He Thr Phe Glu 310 315 320 CAT CAT AGA TTT GAG ATT CCT AAA TTA AAT AAA TTC ATG CAA ACA ATG 1067 His His Arg Phe Glu He Pro Lys Leu Asn Lys Phe Met Gin Thr Met 325 330 335 AAC ACT GCC AAA TAC CCA GTA GAT ATT TCT CAT ACT ATA TTG GAG TGG 1115 Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He Leu Glu Trp 340 345 350 AAT TAT TTT AAT TGT TCA ATA TCT AAG AAC AGC ATT AGA ATG CAT CAT 1163 Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser He Arg Met His His 355 360 365 ATT ACA TTC AAC AAC ACC TTG GAA TGG ACA TCA CTG CAC AAC TAT GAT 1211 He Thr Phe Asn Asn Thr Leu Glu Trp Thr Ser Leu His Asn Tyr Asp 370 375 380 385 GTG GCG ATG AGT GAT GAA GGT TAC AAT TTG TAC AAT GCT GTT TAT GCT 1259 Val Ala Met Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala Val Tyr Ala 390 395 400 GTG GCC CAC ACC TAC CAT GAA TAC ATT TTT CAA CAA GTA GAG TCT CAG 1307 Val Ala His Thr Tyr His Glu Tyr He Phe Gin Gin Val Glu Ser Gin 405 410 415 AAA AAG GCA AAA CCC AAA AGA TAT TTC ACT GCT TGT CAG CAG GTG TCT 1355 Lys Lys Ala Lys Pro Lys Arg Tyr Phe Thr Ala Cys Gin Gin Val Ser 420 425 430 TCC TTG ATG AAA ACC AGG GTA TTT ACG AAC CCT GTT GGA GAA CTG GTG 1403 Ser Leu Met Lys Thr Arg Val Phe Thr Asn Pro Val Gly Glu Leu Val 435 440 445 AAC ATG AAG CAT AGG GAA AAT CAG TGT ACA GAG TAT GAT ATT TTC ATC 1451 Asn Met Lys His Arg Glu Asn Gin Cys Thr Glu Tyr Asp He Phe He 450 455 460 465 ATT TGG AAT TTT CCA CAA GGC CTT GGA TTA AAA GTG AAA ATA GGA AGC 1499 He Trp Asn Phe Pro Gin Gly Leu Gly Leu Lys Val Lys He Gly Ser 470 475 480 TAT TTA CCT TGT TTT CCA CAG AGA CAA AAA CTT CAT ATA TCT GAT GAT 1547 Tyr Leu Pro Cys Phe Pro Gin Arg Gin Lys Leu His He Ser Asp Asp 485 490 495 TTG GAA TGG GCC AAG GGA GGA ACA TCA CCT CAG GTT CCC TCC TCC GTG 1595 Leu Glu Trp Ala Lys Gly Gly Thr Ser Pro Gin Val Pro Ser Ser Val 500 505 510 TGT AGT GTG GCA TGT ACT GCT GGA TTC AGG AAA ATT TAT CAA AAA GAA 1643 Cys Ser Val Ala Cys Thr Ala Gly Phe Arg Lys He Tyr Gin Lys Glu 515 520 525 ACA GCA GAC TGC TGC TTT GAT TGT GTT CAG TGC CCA GAA AAT GAG ATT 1691 Thr Ala Asp Cys Cys Phe Asp Cys Val Gin Cys Pro Glu Asn Glu He 530 535 540 545 TCC AAC GAA ACA GAT ATG GAA CAG TGT GTG AGG TGT CCA GAT GAT AAG 1739 Ser Asn Glu Thr Asp Met Glu Gin Cys Val Arg Cys Pro Asp Asp Lys 550 555 560 TAT GCC AAC ATA GAG CAA ACC CAC TGC CTC TCA AGA GCT GTA TCA TTT 1787 Tyr Ala Asn He Glu Gin Thr His Cys Leu Ser Arg Ala Val Ser Phe 565 570 575 CTG GCT TAT GAA GAT TCA TTG GGG ATG GCT CTA GGC TGC ATG GCA CTG 1835 Leu Ala Tyr Glu Asp Ser Leu Gly Met Ala Leu Gly Cys Met Ala Leu 580 585 590 TCC TTC TCA GCC ATC ACA ATT CTA ATC CTC GTC ACA TTT GTG AAG TAC 1883 Ser Phe Ser Ala He Thr He Leu He Leu Val Thr Phe Val Lys Tyr 595 600 605 AAA GAT ACT CCC ACT GTG AAG GCC AAT AAC CGC ATT CTC AGC TAC ATC 1931 Lys Asp Thr Pro Thr Val Lys Ala Asn Asn Arg He Leu Ser Tyr He 610 615 620 625 CTG CTC ATC TCT CTC GTC TTC TGC TTT CTC TGC TCC CTG CTC TTC ATT 1979 Leu Leu He Ser Leu Val Phe Cys Phe Leu Cys Ser Leu Leu Phe He 630 635 640 GGA CCT CCC GAC CAG GTC ACC TGC ATC TTT CAG CAG ACC ACA TTT GGA 2027 Gly Pro Pro Asp Gin Val Thr Cys He Phe Gin Gin Thr Thr Phe Gly 645 650 655 GTA TTG TTC ACT GTG TCT GTT TCT ACA GTG TTG GCC AAA ACA ATA ACT 2075 Val Leu Phe Thr Val Ser Val Ser Thr Val Leu Ala Lys Thr He Thr 660 665 670 GTG GTC ATG GCT TTC AAG CTC ACT ACT CCA GGA AGA AGG ATG AGA GGG 2123 Val Val Met Ala Phe Lys Leu Thr Thr Pro Gly Arg Arg Met Arg Gly 675 680 685 ATG ATG ATG ACA GGG GCA CCT AAG TTG GTC ATT CCC ATT TGT ACC CTG 2171 Met Met Met Thr Gly Ala Pro Lys Leu Val He Pro He Cys Thr Leu 690 695 700 705 ATC CAA CTT GTT CTC TGT GGA ATC TGG TTG GTC ACA TCT CCT CCC TTT 2219 He Gin Leu Val Leu Cys Gly He Trp Leu Val Thr Ser Pro Pro Phe 710 715 720 ATT GAC AGA GAC ATA CAA TCT GAG CAT GGG AAG ATT GTC ATT CTT TGC 2267 He Asp Arg Asp He Gin Ser Glu His Gly Lys He Val He Leu Cys 725 730 735 AAT AAA GGC TCA GTC ATT GCC TTC CAC GTC GTC CTG GGA TAC TTG GGC 2315 Asn Lys Gly Ser Val He Ala Phe His Val Val Leu Gly Tyr Leu Gly 740 745 750 TCC TTG GCT CTG GGG AGC TTC ACG TTG GCT TTC CTG GCT AGG AAC CTT 2363 Ser Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Arg Asn Leu 755 760 765 CCT GAC ACA TTC AAT GAA GCC AAG TTC CTA ACT TTC AGC ATG CTG GTG . 2411 Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met Leu Val 770 775 780 785 TTC TGC AGT GTC TGG ATC ACC TTC CTC CCT GTC TAC CAC AGC ACC AGG 2459 Phe Cys Ser Val Trp He Thr Phe Leu Pro Val Tyr His Ser Thr Arg 790 795 800 GGG AGG GTC ATG GTG GTT GTG GAG GTT TTC TCC ATC TTG GCT TCT AGT 2507 Gly Arg Val Met Val Val Val Glu Val Phe Ser He Leu Ala Ser Ser 805 810 815 GCA GGG TTG CTA ATG TGT ATC TTT GTC CCA AAG TGT TAT GTT ATT TTA 2555 Ala Gly Leu Leu Met Cys He Phe Val Pro Lys Cys Tyr Val He Leu 820 825 830 ATT AGA CCA GAT TCA AAT TTT ATA AAG AAC CAC AAA GGT AAA TTG CTT 2603 He Arg Pro Asp Ser Asn Phe He Lys Asn His Lys Gly Lys Leu Leu 835 840 845 TAT TGAAACTTTC ATGGTATGAA AATGTTAGAT GATATTCAAC TTATCTTATT CTTCAT 2662 Tyr 850 CTTAATAAAA GCAGTACTTC ATCATATAAA AAATAAAGTA ATATACAGAT TTATACTTAC 2722 AAACTGGACA GCAAACATGA ATATGTTGAG AACTGGGATT CTCAATTGAG GAATGGCTAC 2782 CAATATTTTG ATCTGTGGTT TTGTGTTTAA GCCATGTACT TAATTAATGA TTAATATGAG 2842 GTTACCCTAC TGTCTTTGAA CAGCGCCACC TCTAGGCATG CTGTCCTTGA GTTATAAGAA 2902 AGGGTACTGC ATACACAATG GACATGAAGC CAGTAATCAA CATTATTCCA CTTGCTTTCA 2962 TGGAGTTCTT ACATCCAAGT TCATGCCTTG ACTTTATTCA ATGTTCTATG ACAAAGGTAG 3022 ATAAATAAAT AAACACTTTC CTCGTCGACG CGGCCGCGTC GACGTCGACG CGGCCGCG 3080 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 850 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Met Lys Gin Leu Cys Ala Phe Thr He Ser Leu Leu Phe Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Leu Thr Glu Pro Ser Cys Phe Trp Arg He 20 25 30 Arg Asn Ser Glu Asp Ser Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Trp Lys Thr Asp Glu Pro He Glu Asp Ser Phe Tyr Asn Tyr 50 55 60 Asp Leu Ser Phe Arg He Ala Ala Ser Glu Tyr Glu Phe Leu Leu Val 65 70 75 80 Met Phe Phe Ala He Asp Glu He Asn Arg Asn Pro Tyr Leu Leu Pro 85 90 95 Asn He Thr Leu Met Phe Ser Phe He Gly Gly Asn Cys Gin Asp Leu 100 105 110 Leu Arg Val Met Asp Gin Ala Tyr Thr Gin He Asn Gly His Met Asn 115 120 125 Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala He Gly Leu 130 135 140 Thr Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu Ala Met His Ser Ser 145 150 155 160 Met Pro Leu Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His 165 170 175 Asp Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu 180 185 190 Ser His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He 195 200 205 Gly Leu Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp 210 215 220 Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn 225 230 235 240 Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr 245 250 255 Asp Lys His He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly 260 265 270 Glu Met Asn Ser Thr Leu Glu Ala Ser Phe Arg Arg Trp Glu Glu Leu 275 280 285 Gly Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp Val He Thr 290 295 300 Asn Lys Lys Asp Phe Thr Leu Asn Leu Phe His Gly He He Thr Phe 305 310 315 320 Glu His His Arg Phe Glu He Pro Lys Leu Asn Lys Phe Met Gin Thr 325 330 335 Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He Leu Glu 340 345 350 Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser He Arg Met His 355 360 365 His He Thr Phe Asn Asn Thr Leu Glu Trp Thr Ser Leu His Asn Tyr 370 375 380 Asp Val Ala Met Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala Val Tyr 385 390 395 400 Ala Val Ala His Thr Tyr His Glu Tyr He Phe Gin Gin Val Glu Ser 405 410 415 Gin Lys Lys Ala Lys Pro Lys Arg Tyr Phe Thr Ala Cys Gin Gin Val 420 425 430 Ser Ser Leu Met Lys Thr Arg Val Phe Thr Asn Pro Val Gly Glu Leu 435 440 445 Val Asn Met Lys His Arg Glu Asn Gin Cys Thr Glu Tyr Asp He Phe 450 455 460 He He Trp Asn Phe Pro Gin Gly Leu Gly Leu Lys Val Lys He Gly 465 470 475 480 Ser Tyr Leu Pro Cys Phe Pro Gin Arg Gin Lys Leu His He Ser Asp 485 490 495 Asp Leu Glu Trp Ala Lys Gly Gly Thr Ser Pro Gin Val Pro Ser Ser 500 505 510 Val Cys Ser Val Ala Cys Thr Ala Gly Phe Arg Lys He Tyr Gin Lys 515 520 525 Glu Thr Ala Asp Cys Cys Phe Asp Cys Val Gin Cys Pro Glu Asn Glu 530 535 540 He Ser Asn Glu Thr Asp Met Glu Gin Cys Val Arg Cys Pro Asp Asp 545 550 555 560 Lys Tyr Ala Asn He Glu Gin Thr His Cys Leu Ser Arg Ala Val Ser 565 570 575 Phe Leu Ala Tyr Glu Asp Ser Leu Gly Met Ala Leu Gly Cys Met Ala 580 585 590 Leu Ser Phe Ser Ala He Thr He Leu He Leu Val Thr Phe Val Lys 595 600 605 Tyr Lys Asp Thr Pro Thr Val Lys Ala Asn Asn Arg He Leu Ser Tyr 610 615 620 He Leu Leu He Ser Leu Val Phe Cys Phe Leu Cys Ser Leu Leu Phe 625 630 635 640 He Gly Pro Pro Asp Gin Val Thr Cys He Phe Gin Gin Thr Thr Phe 645 650 655 Gly Val Leu Phe Thr Val Ser Val Ser Thr Val Leu Ala Lys Thr He 660 665 670 Thr Val Val Met Ala Phe Lys Leu Thr Thr Pro Gly Arg Arg Met Arg 675 680 685 Gly Met Met Met Thr Gly Ala Pro Lys Leu Val He Pro He Cys Thr 690 695 700 Leu He Gin Leu Val Leu Cys Gly He Trp Leu Val Thr Ser Pro Pro 705 710 715 720 Phe He Asp Arg Asp He Gin Ser Glu His Gly Lys He Val He Leu 725 730 735 Cys Asn Lys Gly Ser Val He Ala Phe His Val Val Leu Gly Tyr Leu 740 745 750 Gly Ser Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Arg Asn 755 760 765 Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met Leu 770 775 780 Val Phe Cys Ser Val Trp He Thr Phe Leu Pro Val Tyr His Ser Thr 785 790 795 800 Arg Gly Arg Val Met Val Val Val Glu Val Phe Ser He Leu Ala Ser 805 810 815 Ser Ala Gly Leu Leu Met Cys He Phe Val Pro Lys Cys Tyr Val He 820 825 830 Leu He Arg Pro Asp Ser Asn Phe He Lys Asn His Lys Gly Lys Leu 835 840 845 Leu Tyr 850 (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2961 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 86...2509 (D) OTHER INFORMATION: VR2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AGACACATCG GTGCAACTGT GTGTGTGATG TTTTTCTGCA TCAGAAACGG ATTTCACAGC 60 AGCTCCATCT CAGATCCTAG CAGAC ATG AAG CAG CTC TGC ACT TTC ACT ATT 112 Met Lys Gin Leu Cys Thr Phe Thr He 1 5 TCA TTG TTG TTT CTG AAG TTT TCT CTC ATC TTG TGC TGT TGG AGT GAA 160 Ser Leu Leu Phe Leu Lys Phe Ser Leu He Leu Cys Cys Trp Ser Glu 10 15 20 25 CCA AGC TGC TTT TGG AGG ATA AAG AAG AGT GAA GAT AAT GAT GGA GAT 208 Pro Ser Cys Phe Trp Arg He Lys Lys Ser Glu Asp Asn Asp Gly Asp 30 35 40 TTA CAA AGG GAG TGT CAT TTT TAC CTT TGG AAA ACT GAT GAA CCT ATT 256 Leu Gin Arg Glu Cys His Phe Tyr Leu Trp Lys Thr Asp Glu Pro He 45 50 55 GAA GAT AGT TTT TAT AAT TAT GAT TTA AGT TTT AGA ATT GCA GGA AGT 304 Glu Asp Ser Phe Tyr Asn Tyr Asp Leu Ser Phe Arg He Ala Gly Ser 60 65 70 GAA TAT GAG CTT CTT CTG GTA ATG TTT TTT GCT ACT GAT GAG ATC AAC 352 Glu Tyr Glu Leu Leu Leu Val Met Phe Phe Ala Thr Asp Glu He Asn 75 80 85 AAG AAT CCT TAT CTT TTA CCC AAC ATG AGT TTG ATG TTC TCC ATC ATT 400 Lys Asn Pro Tyr Leu Leu Pro Asn Met Ser Leu Met Phe Ser He He 90 95 100 105 GGT GGA AAC TGT CAT GAT TTA TTG AGA AGT CTG GAT CAA GAA TAT GCA 448 Gly Gly Asn Cys His Asp Leu Leu Arg Ser Leu Asp Gin Glu Tyr Ala 110 115 120 CAA ATA GAT GGA CAT ATG AAT TTT GTT AAT TAT TTC TGT TAT TTA GAT 496 Gin He Asp Gly His Met Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp 125 130 135 GAT TCA TGT GCC ACA GGC CTT ACA GGA CCA TCA TGG AAA ACA TCC TTA 544 Asp Ser Cys Ala Thr Gly Leu Thr Gly Pro Ser Trp Lys Thr Ser Leu 140 145 150 AAA CTG GCA ATG CAT TCT TCA ATG CCA CTG GTT TTC TTT GGA CCA TTT 592 Lys Leu Ala Met His Ser Ser Met Pro Leu Val Phe Phe Gly Pro Phe 155 160 165 AAT CCT AAC CTA CGC GAC CAT GAC CGG CTG CCC CAT GTC CAT CAG GTA 640 Asn Pro Asn Leu Arg Asp His Asp Arg Leu Pro His Val His Gin Val 170 175 180 185 GCC CCC AAG GAC ACA CAT TTG TCC CAT GGC ATG GTC TCC TTG ATG TTT 688 Ala Pro Lys Asp Thr His Leu Ser His Gly Met Val Ser Leu Met Phe 190 195 200 CAT TTT AGG TGG ACT TGG ATA GGA CTG GTC ATC TCA GAT GAT GAT CAG 736 His Phe Arg Trp Thr Trp He Gly Leu Val He Ser Asp Asp Asp Gin 205 210 215 GGT ATT CAG TTT CTC TCA GAT TTA AGA GAA GAA AGC CAA AGG CAT GGG 784 Gly He Gin Phe Leu Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly 220 225 230 ATC TGT TTG GCT TTT GTT AAT ATG ATC CCA GAA AAC ATG CAG ATA TAC 832 He Cys Leu Ala Phe Val Asn Met He Pro Glu Asn Met Gin He Tyr 235 240 245 ATG ACA AGG GCT ACA ATA TAT GAT ACA CAA ATT ATG ACA TCT TCA GCA 880 Met Thr Arg Ala Thr He Tyr Asp Thr Gin He Met Thr Ser Ser Ala 250 255 260 265 AAG GTT GTT ATC ATT TAT GGT GAC ATG AAC TCT ACT CTA GAA GCA AGC 928 Lys Val Val He He Tyr Gly Asp Met Asn Ser Thr Leu Glu Ala Ser 270 275 280 TTT AGA AGA TGG GAA GAG TTA GGT GCT CGG AGA ATC TGG ATC ACA ACC 976 Phe Arg Arg Trp Glu Glu Leu Gly Ala Arg Arg He Trp He Thr Thr 285 290 295 ACA CAA TGG GAT GTC ATC ACA AAT AAA AAA GAC TTC ACC CTT AAT CTC 1024 Thr Gin Trp Asp Val He Thr Asn Lys Lys Asp Phe Thr Leu Asn Leu 300 305 310 TTC CAT GGG ACT ATT ACT TTT GCA CAC CAC AAA GAT GAG ATT CCT AAA 1072 Phe His Gly Thr He Thr Phe Ala His His Lys Asp Glu He Pro Lys 315 320 325 TTT AGG AAT TTT ATG CAA ACA AAG AAA ACT GCC AAA TAC CTT GTA GAT 1120 Phe Arg Asn Phe Met Gin Thr Lys Lys Thr Ala Lys Tyr Leu Val Asp 330 335 340 345 ATT TCT CAT ACT ATT TTG GAG TGG AAT TAT TTT AAT TGT TCA ATC TCT 1168 Ile Ser His Thr He Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser 350 355 360 AAG AAC AGC AGT AAA ATG GGT CAT TTT ACA TTC AAC AAC ACA TTG CAA 1216 Lys Asn Ser Ser Lys Met Gly His Phe Thr Phe Asn Asn Thr Leu Gin 365 370 375 TGG ACA GCA CTG CAC AAC TAT GAT ATG GCC CTG AGC GAT GAA GGT TAC 1264 Trp Thr Ala Leu His Asn Tyr Asp Met Ala Leu Ser Asp Glu Gly Tyr 380 385 390 AAT TTG TAT AAT GCT GTT TAT GCT GTG GCC CAC ACC TAC CAT GAA TAC 1312 Asn Leu Tyr Asn Ala Val Tyr Ala Val Ala His Thr Tyr His Glu Tyr 395 400 405 ATT CTT CAA CAA GTA GAG TCT CAG AAA AAG GCA AAA CCC AAA AGA TAT 1360 He Leu Gin Gin Val Glu Ser Gin Lys Lys Ala Lys Pro Lys Arg Tyr 410 415 420 425 TTC ACT GCT TGT CAG CAG GTG TCT TCC TTG ATG AAA ACC AGG GTA TTT 1408 Phe Thr Ala Cys Gin Gin Val Ser Ser Leu Met Lys Thr Arg Val Phe 430 435 440 ATG AAC CCT GTT GGA GAA CTG GTG AAC ATG AAG CAT AGG GAA AAT CAG 1456 Met Asn Pro Val Gly Glu Leu Val Asn Met Lys His Arg Glu Asn Gin 445 450 455 TGT ACA GAG TAT GAT ATT TTC ATC ATT TGG AAT TTT CCA CAA GGC CTT 1504 Cys Thr Glu Tyr Asp He Phe He He Trp Asn Phe Pro Gin Gly Leu 460 465 470 GGA TTA AAA GTG AAA GTA GGA AGC TAT TTA CCT TGC TTT CCA AAG AGT 1552 Gly Leu Lys Val Lys Val Gly Ser Tyr Leu Pro Cys Phe Pro Lys Ser 475 480 485 CAA CAA CTT CAT ATA GCT GAT GAT TTG GAA TGG GCC ATG GGA GGA ACA 1600 Gin Gin Leu His He Ala Asp Asp Leu Glu Trp Ala Met Gly Gly Thr 490 495 500 505 TCA GTG GAT ATG GAA CAG TGT GTG AGA TGT CCA GAT AAT AAA TAT GCC 1648 Ser Val Asp Met Glu Gin Cys Val Arg Cys Pro Asp Asn Lys Tyr Ala 510 515 520 AAT TTA GAG CAA ACC CAC TGC CTC CAA AGA ACG GTG TCA TTT CTG GCT 1696 Asn Leu Glu Gin Thr His Cys Leu Gin Arg Thr Val Ser Phe Leu Ala 525 530 535 TAT GAA GAT CCA TTG GGG ATG GCT CTA GGC TGC ATG GCA CTG TCC TTC 1744 Tyr Glu Asp Pro Leu Gly Met Ala Leu Gly Cys Met Ala Leu Ser Phe 540 545 550 TCG GCC ATC ACA ATT CTA GTC CTC GTC ACA TTT GTG AAG TAC AAG GAT 1792 Ser Ala He Thr He Leu Val Leu Val Thr Phe Val Lys Tyr Lys Asp 555 560 565 ACT CCC ATT GTG AAG GCC AAT AAC CGC ATT CTC AGC TAC ATC CTG CTC 1840 Thr Pro He Val Lys Ala Asn Asn Arg He Leu Ser Tyr He Leu Leu 570 575 580 585 ATC TCT CTC GTC TTC TGC TTT CTC TGT TCC CTG CTC TTC ATT GGA CAT 1888 He Ser Leu Val Phe Cys Phe Leu Cys Ser Leu Leu Phe He Gly His 590 595 600 CCC GAC CAG GTC ACC TGC ATC TTG CAG CAG ACC ACA TTT GGA GTA TTG 1936 Pro Asp Gin Val Thr Cys He Leu Gin Gin Thr Thr Phe Gly Val Leu 605 610 615 TTC ACT GTG TCT GTT TCT ACA GTG TTG GCC AAA ACA ATA ACT GTG GTC 1984 Phe Thr Val Ser Val Ser Thr Val Leu Ala Lys Thr He Thr Val Val 620 625 630 ATG GCT TTC AAG CTC ACT ACT CCA GGA AGA AGG ATG AGA GGG ATG ATG 2032 Met Ala Phe Lys Leu Thr Thr Pro Gly Arg Arg Met Arg Gly Met Met 635 640 645 ATG ACA GGG GCA CCT AAG TTG GTC ATT CCC ATT TGT ACC CTG ATC CAA 2080 Met Thr Gly Ala Pro Lys Leu Val He Pro He Cys Thr Leu He Gin 650 655 660 665 CTT GTT CTC TGT GGA ATC TGG TTG GTC ACA TCT CCT CCC TTT ATT GAC 2128 Leu Val Leu Cys Gly He Trp Leu Val Thr Ser Pro Pro Phe He Asp 670 675 680 AGA GAT ATA CAA TCT GAA CAT GGG AAG ATT GTC ATT CTT TGC AAT AAA 2176 Arg Asp He Gin Ser Glu His Gly Lys He Val He Leu Cys Asn Lys 685 690 695 GGC TCT GTC GTT GCC TTC CAC GTC GTC CTG GGA TAC TTG GGC TCC TTG 2224 Gly Ser Val Val Ala Phe His Val Val Leu Gly Tyr Leu Gly Ser Leu 700 705 710 GCT CTG GGG AGC TTC ACT TTG GCT TTC TTG GCT AGG AAC CTT CCT GAC 2272 Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Arg Asn Leu Pro Asp 715 720 725 ACA TTC AAT GAA GCC AAG TTC CTA ACT TTC AGC ATG CTG GTG TTC TGC 2320 Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met Leu Val Phe Cys 730 735 740 745 AGT GTC TGG ATC ACC TTC CTC CCT GTC TAC CAC AGC ACC AGG GGG AAG 2368 Ser Val Trp He Thr Phe Leu Pro Val Tyr His Ser Thr Arg Gly Lys 750 755 760 GTC ATG GTG GTT GTG GAG GTT TTC TCC ATC TTG GCT TCT AGT GCA GGG 2416 Val Met Val Val Val Glu Val Phe Ser He Leu Ala Ser Ser Ala Gly 765 770 775 TTG CTA ATG TGT ATC TTT GTC CCA AAG TGT TAT GTT ATT TTA ATT AGA 2464 Leu Leu Met Cys He Phe Val Pro Lys Cys Tyr Val He Leu He Arg 780 785 790 CCA GAT TCA AAT TTT ATA CAG AAC CAC AAA GGT AAA TTG CTT TAT TGAAA 2514 Pro Asp Ser Asn Phe He Gin Asn His Lys Gly Lys Leu Leu Tyr 795 800 805 CTTTCATGGT ATGAAAATGT TAGATGATAT TCAACTTATC TTATTCTTCA TCTTAATAAA 2574 AGCAGTACTT CATCATATAA AAAATAAAGT AATATACAGA TTTATACTTA CAAACTGGAC 2634 AGCAAACATG AATATGTTGA GAACTGGGAT TCTCAATTGA GGAATGGCTA CCAATATTTT 2694 GATCTGTGGT TTTGTGTTTA AGCCATGTAC TTAATTAATG ATTAACATGA GGTTACCCTA 2754 CTGTCTTTGA ACAGCGCCAC CTCTAGGCAT GCTGTCCTTG AGTTATAAGA AAGGGTACTG 2814 CATACACAAT GGACATGAAG CCAGTAATCA ACATTATTCC ACTTGCTTTC ATGGAGTTCT 2874 TACTTCCAAG TTCATGCCTT GACTTTATTC AATGTTCTAT GACAAAGGTA GAATAAATAA 2934 ATAAACACTT TCCTCACAAA AAAAAAA 2961 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 808 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 : Met Lys Gin Leu Cys Thr Phe Thr He Ser Leu Leu Phe Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Trp Ser Glu Pro Ser Cys Phe Trp Arg He 20 25 30 Lys Lys Ser Glu Asp Asn Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Trp Lys Thr Asp Glu Pro He Glu Asp Ser Phe Tyr Asn Tyr 50 55 60 Asp Leu Ser Phe Arg He Ala Gly Ser Glu Tyr Glu Leu Leu Leu Val 65 70 75 80 Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu Leu Pro 85 90 95 Asn Met Ser Leu Met Phe Ser He He Gly Gly Asn Cys His Asp Leu 100 105 110 Leu Arg Ser Leu Asp Gin Glu Tyr Ala Gin He Asp Gly His Met Asn 115 120 125 Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala Thr Gly Leu 130 135 140 Thr Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu Ala Met His Ser Ser 145 150 155 160 Met Pro Leu Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His 165 170 175 Asp Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu 180 185 190 Ser His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He 195 200 205 Gly Leu Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp 210 215 220 Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn 225 230 235 240 Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr 245 250 255 Asp Thr Gin He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly 260 265 270 Asp Met Asn Ser Thr Leu Glu Ala Ser Phe Arg Arg Trp Glu Glu Leu 275 280 285 Gly Ala Arg Arg He Trp He Thr Thr Thr Gin Trp Asp Val He Thr 290 295 300 Asn Lys Lys Asp Phe Thr Leu Asn Leu Phe His Gly Thr He Thr Phe 305 310 315 320 Ala His His Lys Asp Glu He Pro Lys Phe Arg Asn Phe Met Gin Thr 325 330 335 Lys Lys Thr Ala Lys Tyr Leu Val Asp He Ser His Thr He Leu Glu 340 345 350 Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser Ser Lys Met Gly 355 360 365 His Phe Thr Phe Asn Asn Thr Leu Gin Trp Thr Ala Leu His Asn Tyr 370 375 380 Asp Met Ala Leu Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala Val Tyr 385 390 395 400 Ala Val Ala His Thr Tyr His Glu Tyr He Leu Gin Gin Val Glu Ser 405 410 415 Gin Lys Lys Ala Lys Pro Lys Arg Tyr Phe Thr Ala Cys Gin Gin Val 420 425 430 Ser Ser Leu Met Lys Thr Arg Val Phe Met Asn Pro Val Gly Glu Leu 435 440 445 Val Asn Met Lys His Arg Glu Asn Gin Cys Thr Glu Tyr Asp He Phe 450 455 460 Ile He Trp Asn Phe Pro Gin Gly Leu Gly Leu Lys Val Lys Val Gly 465 470 475 480 Ser Tyr Leu Pro Cys Phe Pro Lys Ser Gin Gin Leu His He Ala Asp 485 490 495 Asp Leu Glu Trp Ala Met Gly Gly Thr Ser Val Asp Met Glu Gin Cys 500 505 510 Val Arg Cys Pro Asp Asn Lys Tyr Ala Asn Leu Glu Gin Thr His Cys 515 520 525 Leu Gin Arg Thr Val Ser Phe Leu Ala Tyr Glu Asp Pro Leu Gly Met 530 535 540 Ala Leu Gly Cys Met Ala Leu Ser Phe Ser Ala He Thr He Leu Val 545 550 555 560 Leu Val Thr Phe Val Lys Tyr Lys Asp Thr Pro He Val Lys Ala Asn 565 570 575 Asn Arg He Leu Ser Tyr He Leu Leu He Ser Leu Val Phe Cys Phe 580 585 590 Leu Cys Ser Leu Leu Phe He Gly His Pro Asp Gin Val Thr Cys He 595 600 605 Leu Gin Gin Thr Thr Phe Gly Val Leu Phe Thr Val Ser Val Ser Thr 610 615 620 Val Leu Ala Lys Thr He Thr Val Val Met Ala Phe Lys Leu Thr Thr 625 630 635 640 Pro Gly Arg Arg Met Arg Gly Met Met Met Thr Gly Ala Pro Lys Leu 645 650 655 Val He Pro He Cys Thr Leu He Gin Leu Val Leu Cys Gly He Trp 660 665 670 Leu Val Thr Ser Pro Pro Phe He Asp Arg Asp He Gin Ser Glu His 675 680 685 Gly Lys He Val He Leu Cys Asn Lys Gly Ser Val Val Ala Phe His 690 695 700 Val Val Leu Gly Tyr Leu Gly Ser Leu Ala Leu Gly Ser Phe Thr Leu 705 710 715 720 Ala Phe Leu Ala Arg Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe 725 730 735 Leu Thr Phe Ser Met Leu Val Phe Cys Ser Val Trp He Thr Phe Leu 740 745 750 Pro Val Tyr His Ser Thr Arg Gly Lys Val Met Val Val Val Glu Val 755 760 765 Phe Ser He Leu Ala Ser Ser Ala Gly Leu Leu Met Cys He Phe Val 770 775 780 Pro Lys Cys Tyr Val He Leu He Arg Pro Asp Ser Asn Phe He Gin 785 790 795 800 Asn His Lys Gly Lys Leu Leu Tyr 805 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2907 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...2409 (D) OTHER INFORMATION: VR3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: CAT TTT TAC CTT GGG GCA GTT GAT AAA CCA ATT GAA GAT AAT TTT TAT 48 His Phe Tyr Leu Gly Ala Val Asp Lys Pro He Glu Asp Asn Phe Tyr 1 5 10 15 AAT TCA CTT TTA AAG TTT AGA ATT GCA GCA AGT GAA TAT GAG TTT CTT 96 Asn Ser Leu Leu Lys Phe Arg He Ala Ala Ser Glu Tyr Glu Phe Leu 20 25 30 CTG GTA ATG TTT TTT GCT ACT GAT GAG ATC AAC AAG AAT CCT TAT CTT 144 Leu Val Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu 35 40 45 TTA CCC AAC ATA ACT TTG ATG TTC TCC ATC ATT GGT GGA AAC TGT CAT 192 Leu Pro Asn He Thr Leu Met Phe Ser He He Gly Gly Asn Cys His 50 55 60 GAT TTA TTG AGA GGT TTG GAT CAA GCA TAT ACA CAA ATA AAT GGA CAT 240 Asp Leu Leu Arg Gly Leu Asp Gin Ala Tyr Thr Gin He Asn Gly His 65 70 75 80 ATG AAT TTT GTT AAT TAT TTC TGT TAT TTA GAT GAT TCA TGT GCC ATA 288 Met Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala He 85 90 95 GGT CTT ACA GGA CCA TCA TGG AAA ACA TCC TTA AAT CTG GCA ATG CAT 336 Gly Leu Thr Gly Pro Ser Trp Lys Thr Ser Leu Asn Leu Ala Met His 100 105 110 TCT TCA ATG CCA CTG GTT TTC TTT GGA TCA TTT AAT CCT AAC CTA CAT 384 Ser Ser Met Pro Leu Val Phe Phe Gly Ser Phe Asn Pro Asn Leu His 115 120 125 GAC CAT GAC CGG CTG CAC CAT GTC CAT CAA GTA GCC ACC AAG GAC ACA 432 Asp His Asp Arg Leu His His Val His Gin Val Ala Thr Lys Asp Thr 130 135 140 CAT TTG TCC CAT GGC ATT GTC TCC TTG ATG TTT CAT TTT AGA TGG ACT 480 His Leu Ser His Gly He Val Ser Leu Met Phe His Phe Arg Trp Thr 145 150 155 160 TGG ATA GGA CTG GTC ATC TCA GAT GAT GAC AAG GGT ATT CAG TTT CTC 528 Trp He Gly Leu Val He Ser Asp Asp Asp Lys Gly He Gin Phe Leu 165 170 175 TCA GAT TTA AGA GAA GAA AGC CAA AGG CAT GGG ATC TGT TTA GCT TTT 576 Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe 180 185 190 GTT AAT ATG ATC CCA GAA AAC ATG CAG ATA TAC ATG ACA AGG GCT ACA 624 Val Asn Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr 195 200 205 ATA TAT GAT AAA CAA ATT ATG ACG TCT TTA GCA AAA GTT GTT ATC ATT 672 He Tyr Asp Lys Gin He Met Thr Ser Leu Ala Lys Val Val He He 210 215 220 TAT GGT GAA ATG AAC TCT ACA CTA GAA GTA AGC TTT AGA AGA TGG GAA 720 Tyr Gly Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg Arg Trp Glu 225 230 235 240 AAT TTA GGT GCT CGG AGA ATC TGG ATC ACA ACC TCA CAA TGG GAT GTC 768 Asn Leu Gly Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp Val 245 250 255 ATC ACA AAT AAA AAA GAA TTC ACC CTT AAT CTC TTC CAT GGG ACT ATT 816 He Thr Asn Lys Lys Glu Phe Thr Leu Asn Leu Phe His Gly Thr He 260 265 270 ACT TTT GCA CAC CGC AGA TTT GAG ATT CCT AAA TTT AAA AAA TTT ATG 864 Thr Phe Ala His Arg Arg Phe Glu He Pro Lys Phe Lys Lys Phe Met 275 280 285 CAA ACA ATG AAC ACT GCC AAA TAC CCA GTA GAT ATT TCT CAT ACT ATA 912 Gin Thr Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He 290 295 300 TTG GAG TGG AAT TAT TTT AAT TGT TCA ATC TCT AAG AAC AGC AGT AAA 960 Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser Ser Lys 305 310 315 320 ATG GAT CAT ATT ACA TTC AAC AAC ACA TTG GAA TGG ACA GCA CTG CAC 1008 Met Asp His He Thr Phe Asn Asn Thr Leu Glu Trp Thr Ala Leu His 325 330 335 AAC TAT GAT ATG GTG ATG AGT GAT GAA GGT TAC AAT TTG TAT AAT GCT 1056 Asn Tyr Asp Met Val Met Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala 340 345 350 GTT TAT GCT GTG GCC CAC ACC TAC CAT GAA CAT ATT TTT CAA CAA GTA 1104 Val Tyr Ala Val Ala His Thr Tyr His Glu His He Phe Gin Gin Val 355 360 365 GAG TCT CAG AAA AAG GCA AAA CCC AAA AGA TTT TTC ACT GTT TGT CAG 1152 Glu Ser Gin Lys Lys Ala Lys Pro Lys Arg Phe Phe Thr Val Cys Gin 370 375 380 CAG GTG TCT TCC TTG ATG AAA ACC AGG GTA TTT ACT AAC CCT GTT GGA 1200 Gin Val Ser Ser Leu Met Lys Thr Arg Val Phe Thr Asn Pro Val Gly 385 390 395 400 GAA CTG GTG AAC ATG AAG CAT AGG GAA AAT CAG TGT ACA GAG TAT GAC 1248 Glu Leu Val Asn Met Lys His Arg Glu Asn Gin Cys Thr Glu Tyr Asp 405 410 415 ATT TTC CTC ATT TGG AAC TTT CCA CAA GGC CTT GGA TTA AAA GTG AAA 1296 He Phe Leu He Trp Asn Phe Pro Gin Gly Leu Gly Leu Lys Val Lys 420 425 430 ATA GGA AGC TAT TTA CCT TGT TTT CCA CAG AGA CAA GAA CTT CAT ATA 1344 He Gly Ser Tyr Leu Pro Cys Phe Pro Gin Arg Gin Glu Leu His He 435 440 445 TCT GAT GAT TTG GAA TGG GCC ATG GGA GGA ACA TCA GTG GTT CCC TCC 1392 Ser Asp Asp Leu Glu Trp Ala Met Gly Gly Thr Ser Val Val Pro Ser 450 455 460 TCT GTG TGT AGT GTG GCA TGT ACT GCA GGA TTC AGG AAA ATT CAT CAG 1440 Ser Val Cys Ser Val Ala Cys Thr Ala Gly Phe Arg Lys He His Gin 465 470 475 480 AAA GAA ACA GCA GAC TGC TGC TTT GAT TGT GTT CAG TGC CCA GAA AAT 1488 Lys Glu Thr Ala Asp Cys Cys Phe Asp Cys Val Gin Cys Pro Glu Asn 485 490 495 GAG GTT TCC AAT GAA ACA GAT ATG GAA CAG TGT GTG AAG TGT CCA TAT 1536 Glu Val Ser Asn Glu Thr Asp Met Glu Gin Cys Val Lys Cys Pro Tyr 500 505 510 GAT AAG TAT GCC AAC ATA GAG AAA ACC CAC TGC CTC TCA AGA GCT GTA 1584 Asp Lys Tyr Ala Asn He Glu Lys Thr His Cys Leu Ser Arg Ala Val 515 520 525 TCA TTT CTG GCT TAT GAA GAT CCA TTG GGG ATA GCT CTA GGC TGC ATA 1632 Ser Phe Leu Ala Tyr Glu Asp Pro Leu Gly He Ala Leu Gly Cys He 530 535 540 GCA CTG TCC TTC TCA GCC ATC ACA ATT CTA GTA CTA ATC ACA TTT TTG 1680 Ala Leu Ser Phe Ser Ala He Thr He Leu Val Leu He Thr Phe Leu 545 550 555 560 AAG TAC AAG GAT ACT CCC ATT GTG AAG GCC AAT AAC CGC ATT CTC AGC 1728 Lys Tyr Lys Asp Thr Pro He Val Lys Ala Asn Asn Arg He Leu Ser 565 570 575 TAC ATC CTG CTC ATC TCT CTA GTC TTC TGC TTT CTC TGC TCC CTG CTC 1776 Tyr He Leu Leu He Ser Leu Val Phe Cys Phe Leu Cys Ser Leu Leu 580 585 590 TTC ATT GGA CAT CCA AAC CAG GTC TCC TGC GTC TTG CAG CAG ACC ACA 1824 Phe He Gly His Pro Asn Gin Val Ser Cys Val Leu Gin Gin Thr Thr 595 600 605 TTT GGA GTA TTT TTC ACT GTG TCT GTT TCT ACA GTG TTG GCC AAA ACA 1872 Phe Gly Val Phe Phe Thr Val Ser Val Ser Thr Val Leu Ala Lys Thr 610 615 620 ATA ACT GTG GTC ATG GCT TTC AAG CTC ACT ACT CCA GGA AGA AGA ATG 1920 He Thr Val Val Met Ala Phe Lys Leu Thr Thr Pro Gly Arg Arg Met 625 630 635 640 AGA GAG ATG TTG GTA ACA GGG GCA CCT AAG TTG GTC ATT CCC ATT TGT 1968 Arg Glu Met Leu Val Thr Gly Ala Pro Lys Leu Val He Pro He Cys 645 650 655 ACC CTA ATC CAA TTT GTT CTC TGT GGA ATC TGG TTG ATA ACA TCT CCT 2016 Thr Leu He Gin Phe Val Leu Cys Gly He Trp Leu He Thr Ser Pro 660 665 670 CCA TTT ATT GAC AGA GAT ATA CAA TCT GAG CAT GGG AAG ATT GTC ATT 2064 Pro Phe He Asp Arg Asp He Gin Ser Glu His Gly Lys He Val He 675 680 685 CTT TGC AAT AAA GGC TCT GTC ATT GCC TTC CAT GTT GTC CTG GGA TAC 2112 Leu Cys Asn Lys Gly Ser Val He Ala Phe His Val Val Leu Gly Tyr 690 695 700 TTG GGC TCC TTG GCT CTG GGG AGC TTC ACT TTG GCT TTC TTG GCT AGG 2160 Leu Gly Ser Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Arg 705 710 715 720 AAC CTT CCT GAC ACA TTC AAT GAA GCC AAA TTC CTG ACT TTC AGC ATG 2208 Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met 725 730 735 CTG GTG TTC TGC AGT GTC TGG ATC ACC TTT CTC CCT GTC TAC CAT AGC 2256 Leu Val Phe Cys Ser Val Trp He Thr Phe Leu Pro Val Tyr His Ser 740 745 750 ACC AGG GGG AAG GTC ATG GTG GTT GTG GAG GTT TTC TCA ATC TTG GCT 2304 Thr Arg Gly Lys Val Met Val Val Val Glu Val Phe Ser He Leu Ala 755 760 765 TCT AGT GCA GGG TTG CTA ATG TGT ATC TTT GTC CCA AAG TGT TAT GTT 2352 Ser Ser Ala Gly Leu Leu Met Cys He Phe Val Pro Lys Cys Tyr Val 770 775 780 ATT TTA GTT AGA CCA GAT TCA AAT TTT ATA CGG AAG TAC AAA GAT AAA 2400 He Leu Val Arg Pro Asp Ser Asn Phe He Arg Lys Tyr Lys Asp Lys 785 790 795 800 TTT CGT TAT TGAAATATTC ATACTATGAA AATGTTAGAT TATACTCAAC ATATTTTTC 2458 Phe Arg Tyr TTTGTCTTAA CAAAAGTAGT ACTTAATCTT ATAAAAATTT AAATAATATA CAAATTTGAA 2518 CTTACAAACA GGACAGAACT GTCTATTGTA ATACCAATTA CAAAACTTTG GTGAAAAATG 2578 GTCTCATTCA TAAGGACACA ATTCTGAAGA TATTGAGAAC CAGGAATCTC AACTGCGGAA 2638 ACGCTACCAT CATCCTGACC TGTGGTTTTG TGTGTAAAGC ATGAACTTAA TTAATGATTA 2698 ATATAAGGTG ACCATACTGA CTGTGAACAC TACCATCTCT GGGCAAGTTG TTCTTGTAGT 2758 TGTAAGAAAA AGCTCTGAAG ACAACATGGA AGTAAAGCCA GTAATCACCA TTATCCCTCA 2818 TGCTTTCATG GAGTGGCTGC ATCCAATTTC ATGCCTTGGC TTCATTCAAT ATACTGTGAC 2878 CAAGGTACAT AAGTAAAGAA ACACTTTTC 2907 (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 803 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : His Phe Tyr Leu Gly Ala Val Asp Lys Pro He Glu Asp Asn Phe Tyr 1 5 10 15 Asn Ser Leu Leu Lys Phe Arg He Ala Ala Ser Glu Tyr Glu Phe Leu 20 25 30 Leu Val Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu 35 40 45 Leu Pro Asn He Thr Leu Met Phe Ser He He Gly Gly Asn Cys His 50 55 60 Asp Leu Leu Arg Gly Leu Asp Gin Ala Tyr Thr Gin He Asn Gly His 65 70 75 80 Met Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala He 85 90 95 Gly Leu Thr Gly Pro Ser Trp Lys Thr Ser Leu Asn Leu Ala Met His 100 105 110 Ser Ser Met Pro Leu Val Phe Phe Gly Ser Phe Asn Pro Asn Leu His 115 120 125 Asp His Asp Arg Leu His His Val His Gin Val Ala Thr Lys Asp Thr 130 135 140 His Leu Ser His Gly He Val Ser Leu Met Phe His Phe Arg Trp Thr 145 150 155 160 Trp He Gly Leu Val He Ser Asp Asp Asp Lys Gly He Gin Phe Leu 165 170 175 Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe 180 185 190 Val Asn Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr 195 200 205 He Tyr Asp Lys Gin He Met Thr Ser Leu Ala Lys Val Val He He 210 215 220 Tyr Gly Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg Arg Trp Glu 225 230 235 240 Asn Leu Gly Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp Val 245 250 255 He Thr Asn Lys Lys Glu Phe Thr Leu Asn Leu Phe His Gly Thr He 260 265 270 Thr Phe Ala His Arg Arg Phe Glu He Pro Lys Phe Lys Lys Phe Met 275 280 285 Gin Thr Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He 290 295 300 Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser Ser Lys 305 310 315 320 Met Asp His He Thr Phe Asn Asn Thr Leu Glu Trp Thr Ala Leu His 325 330 335 Asn Tyr Asp Met Val Met Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala 340 345 350 Val Tyr Ala Val Ala His Thr Tyr His Glu His He Phe Gin Gin Val 355 360 365 Glu Ser Gin Lys Lys Ala Lys Pro Lys Arg Phe Phe Thr Val Cys Gin 370 375 380 Gin Val Ser Ser Leu Met Lys Thr Arg Val Phe Thr Asn Pro Val Gly 385 390 395 400 Glu Leu Val Asn Met Lys His Arg Glu Asn Gin Cys Thr Glu Tyr Asp 405 410 415 He Phe Leu He Trp Asn Phe Pro Gin Gly Leu Gly Leu Lys Val Lys 420 425 430 He Gly Ser Tyr Leu Pro Cys Phe Pro Gin Arg Gin Glu Leu His He 435 440 445 Ser Asp Asp Leu Glu Trp Ala Met Gly Gly Thr Ser Val Val Pro Ser 450 455 460 Ser Val Cys Ser Val Ala Cys Thr Ala Gly Phe Arg Lys He His Gin 465 470 475 480 Lys Glu Thr Ala Asp Cys Cys Phe Asp Cys Val Gin Cys Pro Glu Asn 485 490 495 Glu Val Ser Asn Glu Thr Asp Met Glu Gin Cys Val Lys Cys Pro Tyr 500 505 510 Asp Lys Tyr Ala Asn He Glu Lys Thr His Cys Leu Ser Arg Ala Val 515 520 525 Ser Phe Leu Ala Tyr Glu Asp Pro Leu Gly He Ala Leu Gly Cys He 530 535 540 Ala Leu Ser Phe Ser Ala He Thr He Leu Val Leu He Thr Phe Leu 545 550 555 560 Lys Tyr Lys Asp Thr Pro He Val Lys Ala Asn Asn Arg He Leu Ser 565 570 575 Tyr He Leu Leu He Ser Leu Val Phe Cys Phe Leu Cys Ser Leu Leu 580 585 590 Phe He Gly His Pro Asn Gin Val Ser Cys Val Leu Gin Gin Thr Thr 595 600 605 Phe Gly Val Phe Phe Thr Val Ser Val Ser Thr Val Leu Ala Lys Thr 610 615 620 He Thr Val Val Met Ala Phe Lys Leu Thr Thr Pro Gly Arg Arg Met 625 630 635 640 Arg Glu Met Leu Val Thr Gly Ala Pro Lys Leu Val He Pro He Cys 645 650 655 Thr Leu He Gin Phe Val Leu Cys Gly He Trp Leu He Thr Ser Pro 660 665 670 Pro Phe He Asp Arg Asp He Gin Ser Glu His Gly Lys He Val He 675 680 685 Leu Cys Asn Lys Gly Ser Val He Ala Phe His Val Val Leu Gly Tyr 690 695 700 Leu Gly Ser Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Arg 705 710 715 720 Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met 725 730 735 Leu Val Phe Cys Ser Val Trp He Thr Phe Leu Pro Val Tyr His Ser 740 745 750 Thr Arg Gly Lys Val Met Val Val Val Glu Val Phe Ser He Leu Ala 755 760 765 Ser Ser Ala Gly Leu Leu Met Cys He Phe Val Pro Lys Cys Tyr Val 770 775 780 He Leu Val Arg Pro Asp Ser Asn Phe He Arg Lys Tyr Lys Asp Lys 785 790 795 800 Phe Arg Tyr (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3625 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 117...2672 (D) OTHER INFORMATION: VR4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : TGAATATGCA ATAAACCTCA CATTTGCACA AAGAAATAAA AGCTGGTAGA AATCTGATGT 60 GCTGATATGC ATGGCACTTC ACAATCCGCA CTGCCCAGGT TTAAGGCAGG AAAAAG ATG 119 Met 1 TTC ATT TTC ATG GGA GTC TTC TTC CTA CTT AAT ATT ACA CTT CTC ATG 167 Phe He Phe Met Gly Val Phe Phe Leu Leu Asn He Thr Leu Leu Met 5 10 15 GCC AAT TTC ATT GAT CCC AGG TGC TTT TGG AGA ATA AAT TTG GAT GAA 215 Ala Asn Phe He Asp Pro Arg Cys Phe Trp Arg He Asn Leu Asp Glu 20 25 30 ATA ACG GAT GAA TAT TTG GGA TTA TCT TGT GCT TTC ATC CTG GCA GCT 263 He Thr Asp Glu Tyr Leu Gly Leu Ser Cys Ala Phe He Leu Ala Ala 35 40 45 GTT CAG ACA CCC ATT GAA AAA GAT TAT TTC AAC ACG ACT CTT AAT TTT 311 Val Gin Thr Pro He Glu Lys Asp Tyr Phe Asn Thr Thr Leu Asn Phe 50 55 60 65 CTA AAA ACT ACT AAA AAC CAC AAA TAT GCT TTG GCA TTG GTG TTT GCA 359 Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Val Phe Ala 70 75 80 ATG GAT GAA ATC AAC AGA TAT CCT GAT CTT TTA CCA AAT ATG TCT TTG 407 Met Asp Glu He Asn Arg Tyr Pro Asp Leu Leu Pro Asn Met Ser Leu 85 90 95 ATT ATC AGA TAC TCT TTG GGC CAT TGT GAT GGA AAA ACT GTA ACA CCT 455 He He Arg Tyr Ser Leu Gly His Cys Asp Gly Lys Thr Val Thr Pro 100 105 110 ACA CCA TAT TTA TTT CAT AGA AAA AAG CAA AGC CCT ATT CCT AAT TAT 503 Thr Pro Tyr Leu Phe His Arg Lys Lys Gin Ser Pro He Pro Asn Tyr 115 120 125 TTC TGT AAT GAA GAG AGT ATG TGT TCA TTT CTG CTT TCA GGA CCC AAT 551 Phe Cys Asn Glu Glu Ser Met Cys Ser Phe Leu Leu Ser Gly Pro Asn 130 135 140 145 TGG GAT GAA TCT TTA AGT TTC TGG AAG TAC CTG GAC AGC TTC TTA TCT 599 Trp Asp Glu Ser Leu Ser Phe Trp Lys Tyr Leu Asp Ser Phe Leu Ser 150 155 160 CCA CGT ATC CTT CAG CTT TCC TAT GGA TCT TTC AGT TCC ATC TTC AGT 647 Pro Arg He Leu Gin Leu Ser Tyr Gly Ser Phe Ser Ser He Phe Ser 165 170 175 GAT GAT GAA CAA TAT CCC TAT CTC TAT CAG ATG GCC CCA AAA GAC ACA 695 Asp Asp Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Ala Pro Lys Asp Thr 180 185 190 TCT CTA GCA TTG GCA ATG GTC TCC TTC ATA CTT TAT TTG AAA TGG AAT 743 Ser Leu Ala Leu Ala Met Val Ser Phe He Leu Tyr Leu Lys Trp Asn 195 200 205 TGG ATT GGC CTT GTC ATC CCA GAT GAT GAT CAA GGA AAC CAA TTT CTT 791 Trp He Gly Leu Val He Pro Asp Asp Asp Gin Gly Asn Gin Phe Leu 210 215 220 225 TTA GAG TTG AAG AAA CAG AGT GAA AAC AAA GAA ATT TGC TTT GCC TTT 839 Leu Glu Leu Lys Lys Gin Ser Glu Asn Lys Glu He Cys Phe Ala Phe 230 235 240 GTG AAA ATG ATC TCT GTT GAT GAA GTT TCA TTT CCA CAA AAA ACT GAA 887 Val Lys Met He Ser Val Asp Glu Val Ser Phe Pro Gin Lys Thr Glu 245 250 255 ATA AAC TAC AAA CAA ATT GTG AAG TCA CTA ACA AAT GTT ATT ATC ATT 935 He Asn Tyr Lys Gin He Val Lys Ser Leu Thr Asn Val He He He 260 265 270 TAT GGA GAA ACA TAT AAT TTC ATT GAT TTG ATC TTC AGA ATG TGG GAA 983 Tyr Gly Glu Thr Tyr Asn Phe He Asp Leu He Phe Arg Met Trp Glu 275 280 285 CCT CCC ATT TTA CAG AGA ATA TGG ATC ACC ACA AAA CAA TTG AAT TTC 1031 Pro Pro He Leu Gin Arg He Trp He Thr Thr Lys Gin Leu Asn Phe 290 295 300 305 CCT ACC AGT AAG ACA GAC ATA AGT CAT GAC ACA TTC TAT GGA TCA CTT 1079 Pro Thr Ser Lys Thr Asp He Ser His Asp Thr Phe Tyr Gly Ser Leu 310 315 320 ACT TTT CTA CCC CAC CAT GGT GAG ATT TCT GGC TTT AAA AAT TTT GTA 1127 Thr Phe Leu Pro His His Gly Glu He Ser Gly Phe Lys Asn Phe Val 325 330 335 CAG ACA TGG TTC CAT CTC AGA AAC ACA GAT TTA TGT CTA GTA ATG CCA 1175 Gin Thr Trp Phe His Leu Arg Asn Thr Asp Leu Cys Leu Val Met Pro 340 345 350 GAG TGG AAA TAT ATT AAC TCT GAA GAC TCA GCA TCT AAT TGT AAA ATA 1223 Glu Trp Lys Tyr He Asn Ser Glu Asp Ser Ala Ser Asn Cys Lys He 355 360 365 CTT AAG AAC AGT TCA TCT GAT GCC TCA TTT GAT TGG CTA ATG GAA GAG 1271 Leu Lys Asn Ser Ser Ser Asp Ala Ser Phe Asp Trp Leu Met Glu Glu 370 375 380 385 AAG CTT GAC ATG GCC TTT AGT GAG AAT AGT CAT AAC ATA TAT AAT GCT 1319 Lys Leu Asp Met Ala Phe Ser Glu Asn Ser His Asn He Tyr Asn Ala 390 395 400 GTG CAT GCC ATA GCC CAT GCC CTC CAT GAG ATG AAT CTG CAA CAG GCT 1367 Val His Ala He Ala His Ala Leu His Glu Met Asn Leu Gin Gin Ala 405 410 415 GAT AAT CAG GCA ATA GAT AAT GGA AAA GGA GCC AGT TCT CAC TGC TTG 1415 Asp Asn Gin Ala He Asp Asn Gly Lys Gly Ala Ser Ser His Cys Leu 420 425 430 AAG GTA AAC TCC TTT CTA AGA AGG ACC TAC TTC ACT AAT CCT CTT GGG 1463 Lys Val Asn Ser Phe Leu Arg Arg Thr Tyr Phe Thr Asn Pro Leu Gly 435 440 445 GAC AAA GTG TTT ATG AAG CAA AGA GTA ATA ATG CAG GAT GAA TAT GAC 1511 Asp Lys Val Phe Met Lys Gin Arg Val He Met Gin Asp Glu Tyr Asp 450 455 460 465 ATT GTT CAC TTT GCG AAT CTC TCA CAA CAC CTT GGG ATT AAG ATG AAG 1559 He Val His Phe Ala Asn Leu Ser Gin His Leu Gly He Lys Met Lys 470 475 480 TTA GGA AAG TTC AGC CCA TAT TTA CCA CAT GGT CGA CAC TCT CAC TTA 1607 Leu Gly Lys Phe Ser Pro Tyr Leu Pro His Gly Arg His Ser His Leu 485 490 495 TAC GTA GAC ATG ATT GAG TTG GCC ACA GGA AGA AGA AAG ATG CCA TCC 1655 Tyr Val Asp Met He Glu Leu Ala Thr Gly Arg Arg Lys Met Pro Ser 500 505 510 TCT GTG TGC AGT GCA GAT TGT AGT CCT GGA TTC AGA AGA TTA TGG AAG 1703 Ser Val Cys Ser Ala Asp Cys Ser Pro Gly Phe Arg Arg Leu Trp Lys 515 520 525 GAG GGA ATG GCA GCC TGC TGT TTT GTT TGC AGC CCC TGC CCT GAA AAT 1751 Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser Pro Cys Pro Glu Asn 530 535 540 545 GAA ATT TCT AAT GAG ACA AAT ATG GAT CAA TGC GTG AAT TGT CCA GAA 1799 Glu He Ser Asn Glu Thr Asn Met Asp Gin Cys Val Asn Cys Pro Glu 550 555 560 TAC CAA TAT GCC AAC ACA GAA CAG AAC AAA TGT ATT CAG AAA GGT GTC 1847 Tyr Gin Tyr Ala Asn Thr Glu Gin Asn Lys Cys He Gin Lys Gly Val 565 570 575 ACC TTC CTA AGC TAT GAA GAC CCC TTG GGG ATG GCA CTT GCC TTA ATG 1895 Thr Phe Leu Ser Tyr Glu Asp Pro Leu Gly Met Ala Leu Ala Leu Met 580 585 590 GCC TTC TGC TTC TCT GCA TTC ACA GCT GTG GTA CTT TGT GTC TTT GTG 1943 Ala Phe Cys Phe Ser Ala Phe Thr Ala Val Val Leu Cys Val Phe Val 595 600 605 AAG CAC CAT GAC ACT CCT ATT GTG AAG GCC AAT AAC AGA AGC CTC AGC 1991 Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg Ser Leu Ser 610 615 620 625 TAT CTA TTA CTC ATG TCA CTC ATG TTC TGT TTT CTG TGC TCC TTT TTC 2039 Tyr Leu Leu Leu Met Ser Leu Met Phe Cys Phe Leu Cys Ser Phe Phe 630 635 640 TTC ATT GGC CTT CCA AAC AAA GTC ATC TGT GTC TTA CAG CAA ATC ACA 2087 Phe He Gly Leu Pro Asn Lys Val He Cys Val Leu Gin Gin He Thr 645 650 655 TTT GGA ATT GTA TTC ACT GTG GCT GTT TCC ACA GTT CTG GCC AAA ACA 2135 Phe Gly He Val Phe Thr Val Ala Val Ser Thr Val Leu Ala Lys Thr 660 665 670 GTC ACT GTG GTT CTA GCT TTC AAA GTC ACA GTC CCA GGA AGA AGA TTG 2183 Val Thr Val Val Leu Ala Phe Lys Val Thr Val Pro Gly Arg Arg Leu 675 680 685 AGA TAC TTC CTT GTA TCA GGG ACA CTA AAC TAC ATT ATT CCT ATA TGT, 2231 Arg Tyr Phe Leu Val Ser Gly Thr Leu Asn Tyr He He Pro He Cys 690 695 700 705 TCC CTA CTC CAA TGT GTT CTG TGT GCA ATC TGG CTA GCA GTC TCT CCT 2279 Ser Leu Leu Gin Cys Val Leu Cys Ala He Trp Leu Ala Val Ser Pro 710 715 720 CCC TTT GTT GAT ATT GAT GAA CAC TCT CAG CAT GGC CAC ATC ATC ATT 2327 Pro Phe Val Asp He Asp Glu His Ser Gin His Gly His He He He 725 730 735 GTG TGC AAC AAG GGC TCA GTT ACT GCA TTC TAC TGT GTC CTT GGA TAC 2375 Val Cys Asn Lys Gly Ser Val Thr Ala Phe Tyr Cys Val Leu Gly Tyr 740 745 750 TTG GCC TGC CTG GCA CTG GGA AGC TTC ACT TTG GCT TTC TTG GCC AAG 2423 Leu Ala Cys Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Lys 755 760 765 AAT CTG CCT GAT GCA TTC AAT GAA GCC AAG TTC TTG ACC TTC AGC ATG 2471 Asn Leu Pro Asp Ala Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met 770 775 780 785 CTA GTG TTC TGC AGT GTC TGG GTC ACC TTC CTC CCT GTG TAC CAT AGC 2519 Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His Ser 790 795 800 ACA AAG GGC AAA CAC ATG GTT GCT GTG GAG ATC TTC TCT ATC TTG GCA 2567 Thr Lys Gly Lys His Met Val Ala Val Glu He Phe Ser He Leu Ala 805 810 815 TCC AGT GCA GGG ATG CTT GGA TGT ATT TTT GTA CCC AAG ATT TAT ATC 2615 Ser Ser Ala Gly Met Leu Gly Cys He Phe Val Pro Lys He Tyr He 820 825 830 ATT TTA ATG AGA CCA GAG AGA AAT TCT ACC CAA AAG ATC AGA GAA AAA 2663 He Leu Met Arg Pro Glu Arg Asn Ser Thr Gin Lys He Arg Glu Lys 835 840 845 TCA TAT TTT TGAACAAATA TTTAGGAATT CTGTCAAATG TAAAGTTGGT ACATAACCA 2721 Ser Tyr Phe 850 CCAAATATTG GGTTATAGTG CATGTGTCTA GTTTTAGAAT CACTCTCACT GGTTGCTCTA 2781 GTGATAAAAG GAAGTATCAT ATCTACTGAA CTTCCGTACA GTGTCCATAA AATCTTGCAC 2841 TCATTCACTT TCTTCATTTT CTCTCAGAGA ACTAAACTCT CTAATTATTA CAATTTTATT 2901 CTTCGTTTTG AATTTCATGG AGATTGCCCT CTGGTAACTT CCAAAAAAAC GTTGATAAGG 2961 CAGTTTAATC CACCACTTTG TGTAGAAAAA ATGAGATCTA GGACAGACAG GGTTACACAT 3021 AGAAACCATC TACCAAATCA AATAATCAAT GAGAAACACA GACTAACTAA ATAATCAGCA 3081 AAGTTGAAAT CAGAACTTAT TTTCTGATTT CCAGTAAGAG CACACACAGA AGAAAATACT 3141 GACTTTTTTT TTCTTCTGTT CTTCAAGCTA CTGGCCAATA ATCTAAGGAG GAAATGTTCC 3201 TTTTCTGCTG TCAAATACAA ATATATTATA TCCAACAATG ATCAGAAGCC CAGGGATTCT 3261 GTGGCTGAAT TGGGAATATT TGGAAGAAGC TGAGGAGGAG GGTGACCAGC ATTCTCAACA 3321 AACCTGGACA AGCAAGATCT CTCAGACACT GAGCCTCTAA CCAGAGATCA TACACAAGCT 3381 GATGTGAAGC CCCCAACAAA TATGCACCAT AAGACTGCCT GGTCTAGCAT CAGTGGGAGA 3441 CACACCTAAC CCCAGAGAGA CTTAAGTCCC CAGGGATTGG GAAGTGCTGG GCATTGGGGA 3501 TGTAGGGATA TCATCTTGGA GATGGCAGAG GAGTTGTTAG ATGAGGAAGA GTCAGTGGGG 3561 CAAACCAGGA GGGGGATAAC TACTAGATTG TAACAAAAAT ATTGAGTAAT AATAAATTAA 3621 AAAA 3625 (2) INFORMATION FOR SEQ ID NO : 8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 852 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Phe He Phe Met Gly Val Phe Phe Leu Leu Asn He Thr Leu Leu 1 5 10 15 Met Ala Asn Phe He Asp Pro Arg Cys Phe Trp Arg He Asn Leu Asp 20 25 30 Glu He Thr Asp Glu Tyr Leu Gly Leu Ser Cys Ala Phe He Leu Ala 35 40 45 Ala Val Gin Thr Pro He Glu Lys Asp Tyr Phe Asn Thr Thr Leu Asn 50 55 60 Phe Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Val Phe 65 70 75 80 Ala Met Asp Glu He Asn Arg Tyr Pro Asp Leu Leu Pro Asn Met Ser 85 90 95 Leu He He Arg Tyr Ser Leu Gly His Cys Asp Gly Lys Thr Val Thr 100 105 110 Pro Thr Pro Tyr Leu Phe His Arg Lys Lys Gin Ser Pro He Pro Asn 115 120 125 Tyr Phe Cys Asn Glu Glu Ser Met Cys Ser Phe Leu Leu Ser Gly Pro 130 135 140 Asn Trp Asp Glu Ser Leu Ser Phe Trp Lys Tyr Leu Asp Ser Phe Leu 145 150 155 160 Ser Pro Arg He Leu Gin Leu Ser Tyr Gly Ser Phe Ser Ser He Phe 165 170 175 Ser Asp Asp Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Ala Pro Lys Asp 180 185 190 Thr Ser Leu Ala Leu Ala Met Val Ser Phe He Leu Tyr Leu Lys Trp 195 200 205 Asn Trp He Gly Leu Val He Pro Asp Asp Asp Gin Gly Asn Gin Phe 210 215 220 Leu Leu Glu Leu Lys Lys Gin Ser Glu Asn Lys Glu He Cys Phe Ala 225 230 235 240 Phe Val Lys Met He Ser Val Asp Glu Val Ser Phe Pro Gin Lys Thr 245 250 255 Glu He Asn Tyr Lys Gin He Val Lys Ser Leu Thr Asn Val He He 260 265 270 He Tyr Gly Glu Thr Tyr Asn Phe He Asp Leu He Phe Arg Met Trp 275 280 285 Glu Pro Pro He Leu Gin Arg He Trp He Thr Thr Lys Gin Leu Asn 290 295 300 Phe Pro Thr Ser Lys Thr Asp He Ser His Asp Thr Phe Tyr Gly Ser 305 310 315 320 Leu Thr Phe Leu Pro His His Gly Glu He Ser Gly Phe Lys Asn Phe 325 330 335 Val Gin Thr Trp Phe His Leu Arg Asn Thr Asp Leu Cys Leu Val Met 340 345 350 Pro Glu Trp Lys Tyr He Asn Ser Glu Asp Ser Ala Ser Asn Cys Lys 355 360 365 He Leu Lys Asn Ser Ser Ser Asp Ala Ser Phe Asp Trp Leu Met Glu 370 375 380 Glu Lys Leu Asp Met Ala Phe Ser Glu Asn Ser His Asn He Tyr Asn 385 390 395 400 Ala Val His Ala He Ala His Ala Leu His Glu Met Asn Leu Gin Gin 405 410 415 Ala Asp Asn Gin Ala He Asp Asn Gly Lys Gly Ala Ser Ser His Cys 420 425 430 Leu Lys Val Asn Ser Phe Leu Arg Arg Thr Tyr Phe Thr Asn Pro Leu 435 440 445 Gly Asp Lys Val Phe Met Lys Gin Arg Val He Met Gin Asp Glu Tyr 450 455 460 Asp He Val His Phe Ala Asn Leu Ser Gin His Leu Gly He Lys Met 465 470 475 480 Lys Leu Gly Lys Phe Ser Pro Tyr Leu Pro His Gly Arg His Ser His 485 490 495 Leu Tyr Val Asp Met He Glu Leu Ala Thr Gly Arg Arg Lys Met Pro 500 505 510 Ser Ser Val Cys Ser Ala Asp Cys Ser Pro Gly Phe Arg Arg Leu Trp 515 520 525 Lys Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser Pro Cys Pro Glu 530 535 540 Asn Glu He Ser Asn Glu Thr Asn Met Asp Gin Cys Val Asn Cys Pro 545 550 555 560 Glu Tyr Gin Tyr Ala Asn Thr Glu Gin Asn Lys Cys He Gin Lys Gly 565 570 575 Val Thr Phe Leu Ser Tyr Glu Asp Pro Leu Gly Met Ala Leu Ala Leu 580 585 590 Met Ala Phe Cys Phe Ser Ala Phe Thr Ala Val Val Leu Cys Val Phe 595 600 605 Val Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg Ser Leu 610 615 620 Ser Tyr Leu Leu Leu Met Ser Leu Met Phe Cys Phe Leu Cys Ser Phe 625 630 635 640 Phe Phe He Gly Leu Pro Asn Lys Val He Cys Val Leu Gin Gin He 645 650 655 Thr Phe Gly He Val Phe Thr Val Ala Val Ser Thr Val Leu Ala Lys 660 665 670 Thr Val Thr Val Val Leu Ala Phe Lys Val Thr Val Pro Gly Arg Arg 675 680 685 Leu Arg Tyr Phe Leu Val Ser Gly Thr Leu Asn Tyr He He Pro He 690 695 700 Cys Ser Leu Leu Gin Cys Val Leu Cys Ala He Trp Leu Ala Val Ser 705 710 715 720 Pro Pro Phe Val Asp He Asp Glu His Ser Gin His Gly His He He 725 730 735 He Val Cys Asn Lys Gly Ser Val Thr Ala Phe Tyr Cys Val Leu Gly 740 745 750 Tyr Leu Ala Cys Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala 755 760 765 Lys Asn Leu Pro Asp Ala Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser 770 775 780 Met Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His 785 790 795 800 Ser Thr Lys Gly Lys His Met Val Ala Val Glu He Phe Ser He Leu 805 810 815 Ala Ser Ser Ala Gly Met Leu Gly Cys He Phe Val Pro Lys He Tyr 820 825 830 He He Leu Met Arg Pro Glu Arg Asn Ser Thr Gin Lys He Arg Glu 835 840 845 Lys Ser Tyr Phe 850 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3125 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...2169 (D) OTHER INFORMATION: VR5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: ATC TGT AAT GAA GAG AGT ATG TGT TCA TTT CTG CTT TCA GGA CCC AAT 48 He Cys Asn Glu Glu Ser Met Cys Ser Phe Leu Leu Ser Gly Pro Asn 1 5 10 15 TGG GAT GAA TCT TTA AGT TTC TGG AAG TAC CTG GAC AGC TTC TTA TCT 96 Trp Asp Glu Ser Leu Ser Phe Trp Lys Tyr Leu Asp Ser Phe Leu Ser 20 25 30 CCA CAT ATC CTT CAG CTT TCC TAT GGA TCT TTC AGT TCC ATC TTC AGT 144 Pro His He Leu Gin Leu Ser Tyr Gly Ser Phe Ser Ser He Phe Ser 35 40 45 GAT GAT GAA CAA TAT CCC TAT CTC TAT CAG ATG GCC CCA AAG GAC ACA 192 Asp Asp Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Ala Pro Lys Asp Thr 50 55 60 TCT CTA GCA TTG GCA ATG GTC TCC TTC ATA CTT TAT TTG AAA TGG AAT 240 Ser Leu Ala Leu Ala Met Val Ser Phe He Leu Tyr Leu Lys Trp Asn 65 70 75 80 TGG ATT GGC CTT GTC ATC CCA GAT GAC GAT CAA GGA AAC CAA TTT CTT 288 Trp He Gly Leu Val He Pro Asp Asp Asp Gin Gly Asn Gin Phe Leu 85 90 95 TTA GAG TTG AAG AAA CAG AGT GAA AAC AAA GAA ATT TGC TTT GCC TTT 336 Leu Glu Leu Lys Lys Gin Ser Glu Asn Lys Glu He Cys Phe Ala Phe 100 105 110 GTG AAA ATG ATA TCT GTT GAT GAA GTT TCA TTT CCA CAA AAA ACT GAA 384 Val Lys Met He Ser Val Asp Glu Val Ser Phe Pro Gin Lys Thr Glu 115 120 125 ATA TAC TAC AAA CAA ATT GTG AAG TCA TTA ACA AAT GTT ATT ATC ATT 432 He Tyr Tyr Lys Gin He Val Lys Ser Leu Thr Asn Val He He He 130 135 140 TAT GGA GAA ACA TAT AAT TTC ATT GAT TTG ATC TTC AGA ATG TGG GAA 480 Tyr Gly Glu Thr Tyr Asn Phe He Asp Leu He Phe Arg Met Trp Glu 145 150 155 160 CCT CCC ATT TTA CAG AGA ATA TGG ATC ACC ACA AAA CAA TTG AAT TTC 528 Pro Pro He Leu Gin Arg He Trp He Thr Thr Lys Gin Leu Asn Phe 165 170 175 CCT ACC AGT AAG ACA GAC ATA AGT CAT GAC ACA TTC TAT GGA TCA CTT 576 Pro Thr Ser Lys Thr Asp He Ser His Asp Thr Phe Tyr Gly Ser Leu 180 185 190 ACT TTT CTA CCC CAC CAT GGT GAG ATT TCT GGC TTT AAA AAT TTT GTA 624 Thr Phe Leu Pro His His Gly Glu He Ser Gly Phe Lys Asn Phe Val 195 200 205 CAG ACA TGG TTC CAT CTC AGA AAC ACA GAT TTA TAT CTA GTA ATG CCA 672 Gin Thr Trp Phe His Leu Arg Asn Thr Asp Leu Tyr Leu Val Met Pro 210 215 220 GAG TGG AAA TAT ATT AAC TCT GAA GAC TCA GCA TCT AAT TGT AAA ATA 720 Glu Trp Lys Tyr He Asn Ser Glu Asp Ser Ala Ser Asn Cys Lys He 225 230 235 240 CTG AAG AAC AGT TCA TCT GAT GCC TCA TTT GAT TGG CTA ATG GAA CAG 768 Leu Lys Asn Ser Ser Ser Asp Ala Ser Phe Asp Trp Leu Met Glu Gin 245 250 255 AAG CTT GAC ATG GCC TTT AGT GAT AAT AGT CAT AAC ATA TAT AAT GTT 816 Lys Leu Asp Met Ala Phe Ser Asp Asn Ser His Asn He Tyr Asn Val 260 265 270 GTG CAT GCC ATA GCC CAT GCC CTC CAT GAG ATG AAT CTG CAA CAG GCT 864 Val His Ala He Ala His Ala Leu His Glu Met Asn Leu Gin Gin Ala 275 280 285 GAT AAT CAG GCA ATA GAT AAT GGA AAA GGA GCC AGT TCT CAC TGC TTG 912 Asp Asn Gin Ala He Asp Asn Gly Lys Gly Ala Ser Ser His Cys Leu 290 295 300 AAG GTA AAC TCC TTT CTA AGA AGG ACC TAC TTC ACT AAT CCT CTT GGG 960 Lys Val Asn Ser Phe Leu Arg Arg Thr Tyr Phe Thr Asn Pro Leu Gly 305 310 315 320 GAC AAA GTG TTT ATG AAG CAA AGA GTA ATA ATG CAG GAT GAA TAT GAC 1008 Asp Lys Val Phe Met Lys Gin Arg Val He Met Gin Asp Glu Tyr Asp 325 330 335 ATT GTT CAC TTT GCG AAT CTC TCA CAA CAC CTT GGG ATT AAG ATG AAG 1056 He Val His Phe Ala Asn Leu Ser Gin His Leu Gly He Lys Met Lys 340 345 350 TTA GGA AAG TTC AGC CCA TAT TTA CCA CAT GGT CGA CAC TCT CAC TTA 1104 Leu Gly Lys Phe Ser Pro Tyr Leu Pro His Gly Arg His Ser His Leu 355 360 365 TAC GTA GAC ATG ATT GAG TTG GCC ACA GGA AGA AGA AAG ATG CCA TCC 1152 Tyr Val Asp Met He Glu Leu Ala Thr Gly Arg Arg Lys Met Pro Ser 370 375 380 TCT GTG TGC AGT GCA GAT TGT AGT CCT GGA TTC AGA AGA TTA TGG AAG 1200 Ser Val Cys Ser Ala Asp Cys Ser Pro Gly Phe Arg Arg Leu Trp Lys 385 390 395 400 GAG GGA ATG GCA GCC TGC TGT TTT GTT TGC AGC CCC TGC CCT GAA AAT 1248 Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser Pro Cys Pro Glu Asn 405 410 415 GAA ATT TCT AAT GAG ACA AAT ATG GAT CAA TGC GTG AAT TGT CCA GAA 1296 Glu He Ser Asn Glu Thr Asn Met Asp Gin Cys Val Asn Cys Pro Glu 420 425 430 TAC CAA TAT GCC AAC ACA GAA CAG AAC AAA TGT ATT CAG AAA GGT GTC 1344 Tyr Gin Tyr Ala Asn Thr Glu Gin Asn Lys Cys He Gin Lys Gly Val 435 440 445 ACC TTC CTA AGC TAT GAA GAC CCC TTG GGG ATG GCA CTT GCC TTA ATG 1392 Thr Phe Leu Ser Tyr Glu Asp Pro Leu Gly Met Ala Leu Ala Leu Met 450 455 460 GCC TTC TGC TTC TCT GCA TTC ACA GCT GTG GTA CTT TGT GTC TTT GTG 1440 Ala Phe Cys Phe Ser Ala Phe Thr Ala Val Val Leu Cys Val Phe Val 465 470 475 480 AAG CAC CAT GAC ACT CCT ATT GTG AAG GCC AAT AAC AGA AGC CTC AGC 1488 Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg Ser Leu Ser 485 490 495 TAT CTA TTA CTC ATG TCA CTC ATG TTC TGT TTT CTG TGC TCC TTT TTC 1536 Tyr Leu Leu Leu Met Ser Leu Met Phe Cys Phe Leu Cys Ser Phe Phe 500 505 510 TTC ATT GGC CTT CCA AAC AAA GTC ATC TGT GTC TTA CAG CAG ATC ACA 1584 Phe He Gly Leu Pro Asn Lys Val He Cys Val Leu Gin Gin He Thr 515 520 525 TTT GGA ATT GTA TTT ACT GTA GCT GTT TCC ACA GTT CTG GCC AAA ACA 1632 Phe Gly He Val Phe Thr Val Ala Val Ser Thr Val Leu Ala Lys Thr 530 535 540 GTC ACT GTG GTT CTA GCT TTC AAA GTC ACA GAC CCA GGA AGA AGA TTG 1680 Val Thr Val Val Leu Ala Phe Lys Val Thr Asp Pro Gly Arg Arg Leu 545 550 555 560 AGA TAC TTC CTT GTA TCA GGG ACA CTA AAC TAC ATT ATT CCT ATA TGT 1728 Arg Tyr Phe Leu Val Ser Gly Thr Leu Asn Tyr He He Pro He Cys 565 570 575 TCC CTA CTC CAA TGT GTT CTG TGT GCA ATC TGG CTA GCA GTC TCT CCT 1776 Ser Leu Leu Gin Cys Val Leu Cys Ala He Trp Leu Ala Val Ser Pro 580 585 590 CCC TTT GTT GAT ATT GAT GAA CAC TCT CAG CAT GGC CAC ATC ATC ATT 1824 Pro Phe Val Asp He Asp Glu His Ser Gin His Gly His He He He 595 600 605 GTG TGC AAC AAG GGC TCA GTT ACT GCA TTC TAC TGT GTC CTT GGA TAC 1872 Val Cys Asn Lys Gly Ser Val Thr Ala Phe Tyr Cys Val Leu Gly Tyr 610 615 620 TTG GCC TGC CTG GCA CTG GGA AGC TTC ACT TTG GCT TTC TTG GCC AAG 1920 Leu Ala Cys Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Lys 625 630 635 640 AAT CTG CCT GAT GCA TTC AAT GAA GCC AAG TTC TTG ACC TTC AGC ATG 1968 Asn Leu Pro Asp Ala Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met 645 650 655 CTA GTG TTC TGC AGT GTC TGG GTC ACC TTC CTC CCT GTG TAC CAT AGC 2016 Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His Ser 660 665 670 ACA AAG GGC AAA CAC ATG GTT GCT GTG GAG ATC TTC TCC ATC TTG GCA 2064 Thr Lys Gly Lys His Met Val Ala Val Glu He Phe Ser He Leu Ala 675 680 685 TCC AGT GCA GGG ATG CTT GAA TGT ATT TTT GTA CCC AAG ATT TAT ATC 2112 Ser Ser Ala Gly Met Leu Glu Cys He Phe Val Pro Lys He Tyr He 690 695 700 ATT TTA ATG AGA CCA GAG AGA AAT TCT ACC CAA AAG ATC AGG GAA AAA 2160 He Leu Met Arg Pro Glu Arg Asn Ser Thr Gin Lys He Arg Glu Lys 705 710 715 720 TCA TAT TTC TGAACAAATA TTTAGGAATT CTGTCAAATG TAAAGTTGGT ACATAACCA 2218 Ser Tyr Phe CCAAATATTG GGTTATAGTG CATGTGTCTA GTTTTAGAAT CACTCTCACT GGTTGCTCTA 2278 GTGATAAAAG GAAGTATCAT ATCTACTGAA CTTATGTACA GTGTCCATAA AATCTTGCAC 2338 TCATTCACTT TCTTCATTTT CTCTCAGAGA ACTAAACTCT CTAATTATTA CAATTTTATT 2398 CTTCGTTTTG ATTTCATGGA GATTGCCCTC TGGTAACTTC CAAAAACCGT TGATAAGGCA 2458 GTTTAATCCA CCACTTTGTG TAGAAAAAAT GAGATCTAGG ACAGACAGGG TTACACATAG 2518 AAACCATCTA CCAAATCAAA TAATCAATGA GAAACACAGA CTAACTAAAT AATCAGCAAA 2578 GTTGAAATCA GAATTATTTT CTGATTTCCA GTAAGAGCAC ACACAGAAGA AAATACTGAC 2638 TTTTTTTTTC TTCTGTTCTT CAAGCTACTG GCCAATAATC TAAGGAGGAA ATGTTCCTTT 2698 TCTGCTGTCA AATACAAATA TATTATATCC AACAATGATC AGAAGCCCAG GGATTCTGTG 2758 GCTGAATTGG GAATATTTGG AAGAAGCTGA GGAGGAGGGT GACCAGCATT CTCAACAAAC 2818 CTGGACAAGC AAGATCTCTC AGACACTGAG CCTCTAACCA GAGATCATAC ACAAGCTGAT 2878 GTGAAGCCCC CAACAAATAT GCACCATAAG ACTGCCTGGT CTAGCATCAG TGGGAGACAC 2938 ACCTAACCCC AGAGAGACTT AAGTCCCCAG GGATTGGGAA GTGCTGGGCA TTGAGGATGT 2998 AGGGATATCA TCTTTGAGAT GGCAGAGGAG TTGTTAGATG AGGAAGAGTC AGGGGGGCAA 3058 ACCAGGAAGG GGATAACTAC TAGATTGTAA CAAAAATATT GAGTAATAAT AAATTAAAAA 3118 ATGAAAT 3125 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 723 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: He Cys Asn Glu Glu Ser Met Cys Ser Phe Leu Leu Ser Gly Pro Asn 1 5 10 15 Trp Asp Glu Ser Leu Ser Phe Trp Lys Tyr Leu Asp Ser Phe Leu Ser 20 25 30 Pro His He Leu Gin Leu Ser Tyr Gly Ser Phe Ser Ser He Phe Ser 35 40 45 Asp Asp Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Ala Pro Lys Asp Thr 50 55 60 Ser Leu Ala Leu Ala Met Val Ser Phe He Leu Tyr Leu Lys Trp Asn 65 70 75 80 Trp He Gly Leu Val He Pro Asp Asp Asp Gin Gly Asn Gin Phe Leu 85 90 95 Leu Glu Leu Lys Lys Gin Ser Glu Asn Lys Glu He Cys Phe Ala Phe 100 105 110 Val Lys Met He Ser Val Asp Glu Val Ser Phe Pro Gin Lys Thr Glu 115 120 125 He Tyr Tyr Lys Gin He Val Lys Ser Leu Thr Asn Val He He He 130 135 140 Tyr Gly Glu Thr Tyr Asn Phe He Asp Leu He Phe Arg Met Trp Glu 145 150 155 160 Pro Pro He Leu Gin Arg He Trp He Thr Thr Lys Gin Leu Asn Phe 165 170 175 Pro Thr Ser Lys Thr Asp He Ser His Asp Thr Phe Tyr Gly Ser Leu 180 185 190 Thr Phe Leu Pro His His Gly Glu He Ser Gly Phe Lys Asn Phe Val 195 200 205 Gin Thr Trp Phe His Leu Arg Asn Thr Asp Leu Tyr Leu Val Met Pro 210 215 220 Glu Trp Lys Tyr He Asn Ser Glu Asp Ser Ala Ser Asn Cys Lys He 225 230 235 240 Leu Lys Asn Ser Ser Ser Asp Ala Ser Phe Asp Trp Leu Met Glu Gin 245 250 255 Lys Leu Asp Met Ala Phe Ser Asp Asn Ser His Asn He Tyr Asn Val 260 265 270 Val His Ala He Ala His Ala Leu His Glu Met Asn Leu Gin Gin Ala 275 280 285 Asp Asn Gin Ala He Asp Asn Gly Lys Gly Ala Ser Ser His Cys Leu 290 295 300 Lys Val Asn Ser Phe Leu Arg Arg Thr Tyr Phe Thr Asn Pro Leu Gly 305 310 315 320 Asp Lys Val Phe Met Lys Gin Arg Val He Met Gin Asp Glu Tyr Asp 325 330 335 He Val His Phe Ala Asn Leu Ser Gin His Leu Gly He Lys Met Lys 340 345 350 Leu Gly Lys Phe Ser Pro Tyr Leu Pro His Gly Arg His Ser His Leu 355 360 365 Tyr Val Asp Met He Glu Leu Ala Thr Gly Arg Arg Lys Met Pro Ser 370 375 380 Ser Val Cys Ser Ala Asp Cys Ser Pro Gly Phe Arg Arg Leu Trp Lys 385 390 395 400 Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser Pro Cys Pro Glu Asn 405 410 415 Glu He Ser Asn Glu Thr Asn Met Asp Gin Cys Val Asn Cys Pro Glu 420 425 430 Tyr Gin Tyr Ala Asn Thr Glu Gin Asn Lys Cys He Gin Lys Gly Val 435 440 445 Thr Phe Leu Ser Tyr Glu Asp Pro Leu Gly Met Ala Leu Ala Leu Met 450 455 460 Ala Phe Cys Phe Ser Ala Phe Thr Ala Val Val Leu Cys Val Phe Val 465 470 475 480 Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg Ser Leu Ser 485 490 495 Tyr Leu Leu Leu Met Ser Leu Met Phe Cys Phe Leu Cys Ser Phe Phe 500 505 510 Phe He Gly Leu Pro Asn Lys Val He Cys Val Leu Gin Gin He Thr 515 520 525 Phe Gly He Val Phe Thr Val Ala Val Ser Thr Val Leu Ala Lys Thr 530 535 540 Val Thr Val Val Leu Ala Phe Lys Val Thr Asp Pro Gly Arg Arg Leu 545 550 555 560 Arg Tyr Phe Leu Val Ser Gly Thr Leu Asn Tyr He He Pro He Cys 565 570 575 Ser Leu Leu Gin Cys Val Leu Cys Ala He Trp Leu Ala Val Ser Pro 580 585 590 Pro Phe Val Asp He Asp Glu His Ser Gin His Gly His He He He 595 600 605 Val Cys Asn Lys Gly Ser Val Thr Ala Phe Tyr Cys Val Leu Gly Tyr 610 615 620 Leu Ala Cys Leu Ala Leu Gly Ser Phe Thr Leu Ala Phe Leu Ala Lys 625 630 635 640 Asn Leu Pro Asp Ala Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met 645 650 655 Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His Ser 660 665 670 Thr Lys Gly Lys His Met Val Ala Val Glu He Phe Ser He Leu Ala 675 680 685 Ser Ser Ala Gly Met Leu Glu Cys He Phe Val Pro Lys He Tyr He 690 695 700 He Leu Met Arg Pro Glu Arg Asn Ser Thr Gin Lys He Arg Glu Lys 705 710 715 720 Ser Tyr Phe (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1889 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GAATTCGGCT TCTGCACCAA ATGGCGACGA AAGACACATC TCTTTCACTT GCCATTGTTT 60 CTTTGATGGT TCATTTTAGG TGGTCTTGGG TTGGTCTAAT TCTCCCAGAT GACCACAAAG 120 GAAATAAAAT ACTATCAGAT TTTAGAAAGG AGATGGAAAG AAAAAGAATC TGTACGGCTT 180 TTGTAAAAAT GATTCCTGCC ACATGGACTT CATCTTTTGT CAAATTCTGG GAAAATATGG 240 ATGACACCAA CATAATAATT ATTTATGGTG ACATTGATTC TCTAGAAGGT CTAATGCGAA 300 ATATTGGGCA AAGGTTATTG ACATGGCATG TCTGGGTCAT GAACATTGAA CCCCATATTA 360 TTGAATATGA TAATTATTTC ATGTTAGATT CATTCCATGG AAGTTTAATT TTTAAGCACA 420 ATTATAGAGA GAATTTTGAG TTTACCAAAT TTATTCGAAC AGTTAATCCT AAAAAATACC 480 CAGAAGACAT TTATCTCCCT AAGATGTGGT ATTTGTTCTT CATGTGCTCA TTTTCTGATA 540 TTAATTGTCA AGTTTTGGAC AGCTGTCAAA CAAATGCTTC TTTGGATATG TTACCTAGTC 600 AGATATTTGA TGTGGTCATG AGTGAAGAGA GCACAAGTAT TTACAATGCT GTGTACGCTG 660 TGGCTCACAG CCTCCATGAG ATGAGACTTC AGCAACTTCA AACACAACCG TGTGAAAATG 720 AAGAAGGGAT GGAGTTCTTT CCATGGCAGC TTAATACTTT CCTGAAGGAT ATTGAGGTGA 780 GAGTCAACAG TTTAGACTGG AGACAGAGAA TAGATGCTGA ATATGACATT CTTAACCTCT 840 GGAATTTACC AAAGGGTCTT GGACTAAAAG TGAAAATAGG AAACTTTTAT GCAAATGCTC 900 CCCAGGGTCA ACAATTGTCT TTATCTGAAC AGATGATTCA ATGGCCAGAA ATATTTTCAG 960 AGATCCCTCA GTCGGTGTGC AGTGAGAGTT GTGGGCCTGG ATTCAGGAAA GTAACCCTGG 1020 AGAATAAGGC TATCTGCTGC TACAATTGTA CTCCCTGTGC AGACAATGAG ATTTCTAATG 1080 AGACAGATGT AGACCAGTGT GTGAAGTGTC CAGAGAGTCA TTATGCAAAT ACAGAGAAGA 1140 GCAACTGCTA TCAAAAGTCT GTGAGCTTTC TGGGCTATGA AGACCCTTTG GGGATGGCTC 1200 TAGCCAGCAT AGCTTTGTGC TTGTCTGCAC TAACTGCCTT TGTTATTGGC ATATTTGTGA 1260 AACACAAAGA CACTCCTATT GTTAAGGCCA ATAATCAAGC TCTGAGTTAC ACTTTGCTCA 1320 TCACACTCAA ATTCTGTTTC CTATGTTCTT TGAACTTCAT TGGTCAGCCC AACACAGTTG 1380 CCTGCATCCT TCAGCAGACC ACCTTTGCAG TTGCTTTCAC TATGGCTCTT GCCACTGTGT 1440 TGGCCAAAGC TATCACTGTG GTTCTTGCCT TTAAGGTCAG TTTTCCAGGG AGAATGGTAA 1500 GATGGCTAAT GATATCAAGG GGTCCAAACT ATATCATTCC TATCTGCACC CTGATCCAAC 1560 TTCTTCTTTG TGGAATATGG ATGGCAATAT CTCCACCATA CATTGACCAA GATGCTCATA 1620 TTGAACATGG TCACATCATC ATTTTGTGCA ACAAGGGCTC AGCTGTTGCC TTCCACTCTG 1680 TCCTGGGATA CCTCTGCTTC TTGGCCCTTG GGAGTTATAC CATGGCCTTC TTGTCAAGAA 1740 ATTTGCCTGA TACATTCAAC GAATCCAAAT TTATCTCACT AAGTATGCTG GTATTCTTCT 1800 GTGTCTGGAT CACCTTTCTT CCTGTCTACC ACAGCACTAA AGGGAAGGTC ATGGTCGCCG 1860 TCGAGGTCTT TTGCATCCAA GCCGAATTC 1889 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 604 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Ser Leu Ser Leu Ala He Val Ser Leu Met Val His Phe Arg Trp Ser 1 5 10 15 Trp Val Gly Leu He Leu Pro Asp Asp His Lys Gly Asn Lys He Leu 20 25 30 Ser Asp Phe Arg Lys Glu Met Glu Arg Lys Arg He Cys Thr Ala Phe 35 40 45 Val Lys Met He Pro Ala Thr Trp Thr Ser Ser Phe Val Lys Phe Trp 50 55 60 Glu Asn Met Asp Asp Thr Asn He He He He Tyr Gly Asp He Asp 65 70 75 80 Ser Leu Glu Gly Leu Met Arg Asn He Gly Gin Arg Leu Leu Thr Trp 85 90 95 His Val Trp Val Met Asn He Glu Pro His He He Glu Tyr Asp Asn 100 105 110 Tyr Phe Met Leu Asp Ser Phe His Gly Ser Leu He Phe Lys His Asn 115 120 125 Tyr Arg Glu Asn Phe Glu Phe Thr Lys Phe He Arg Thr Val Asn Pro 130 135 140 Lys Lys Tyr Pro Glu Asp He Tyr Leu Pro Lys Met Trp Tyr Leu Phe 145 150 155 160 Phe Met Cys Ser Phe Ser Asp He Asn Cys Gin Val Leu Asp Ser Cys 165 170 175 Gin Thr Asn Ala Ser Leu Asp Met Leu Pro Ser Gin He Phe Asp Val 180 185 190 Val Met Ser Glu Glu Ser Thr Ser He Tyr Asn Ala Val Tyr Ala Val 195 200 205 Ala His Ser Leu His Glu Met Arg Leu Gin Gin Leu Gin Thr Gin Pro 210 215 220 Cys Glu Asn Glu Glu Gly Met Glu Phe Phe Pro Trp Gin Leu Asn Thr 225 230 235 240 Phe Leu Lys Asp He Glu Val Arg Val Asn Ser Leu Asp Trp Arg Gin 245 250 255 Arg He Asp Ala Glu Tyr Asp He Leu Asn Leu Trp Asn Leu Pro Lys 260 265 270 Gly Leu Gly Leu Lys Val Lys He Gly Asn Phe Tyr Ala Asn Ala Pro 275 280 285 Gin Gly Gin Gin Leu Ser Leu Ser Glu Gin Met He Gin Trp Pro Glu 290 295 300 He Phe Ser Glu He Pro Gin Ser Val Cys Ser Glu Ser Cys Gly Pro 305 310 315 320 Gly Phe Arg Lys Val Thr Leu Glu Asn Lys Ala He Cys Cys Tyr Asn 325 330 335 Cys Thr Pro Cys Ala Asp Asn Glu He Ser Asn Glu Thr Asp Val Asp 340 345 350 Gin Cys Val Lys Cys Pro Glu Ser His Tyr Ala Asn Thr Glu Lys Ser 355 360 365 Asn Cys Tyr Gin Lys Ser Val Ser Phe Leu Gly Tyr Glu Asp Pro Leu 370 375 380 Gly Met Ala Leu Ala Ser He Ala Leu Cys Leu Ser Ala Leu Thr Ala 385 390 395 400 Phe Val He Gly He Phe Val Lys His Lys Asp Thr Pro He Val Lys 405 410 415 Ala Asn Asn Gin Ala Leu Ser Tyr Thr Leu Leu He Thr Leu Lys Phe 420 425 430 Cys Phe Leu Cys Ser Leu Asn Phe He Gly Gin Pro Asn Thr Val Ala 435 440 445 Cys He Leu Gin Gin Thr Thr Phe Ala Val Ala Phe Thr Met Ala Leu 450 455 460 Ala Thr Val Leu Ala Lys Ala He Thr Val Val Leu Ala Phe Lys Val 465 470 475 480 Ser Phe Pro Gly Arg Met Val Arg Trp Leu Met He Ser Arg Gly Pro 485 490 495 Asn Tyr He He Pro He Cys Thr Leu He Gin Leu Leu Leu Cys Gly 500 505 510 He Trp Met Ala He Ser Pro Pro Tyr He Asp Gin Asp Ala His He 515 520 525 Glu His Gly His He He He Leu Cys Asn Lys Gly Ser Ala Val Ala 530 535 540 Phe His Ser Val Leu Gly Tyr Leu Cys Phe Leu Ala Leu Gly Ser Tyr 545 550 555 560 Thr Met Ala Phe Leu Ser Arg Asn Leu Pro Asp Thr Phe Asn Glu Ser 565 570 575 Lys Phe He Ser Leu Ser Met Leu Val Phe Phe Cys Val Trp He Thr 580 585 590 Phe Leu Pro Val Tyr His Ser Thr Lys Gly Lys Val 595 600 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1889 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GAATTCGGCT TCTGCATCAA ATGGCGACGA AGGACACATC TCTTTCACTT GCCATTGTTT 60 CTTTGATGGT TCATTTTAGG TGGTCTTGGG TTGGTCTAAT TCTCCCAGAT GACCACAAAG 120 GAAATAAAAT ACTATCAGAT TTTAGAAAGG AGATGGAGAG AAAAAGAATC TGTACGGCTT 180 TTGTAAAAAT GATTCCTGCC ACATGGACTT CATCTTTTGT CAAATTCTGG GAAAATATGG 240 ATGACACCAA CATAATAATT ATTTATGGTG ACATTGATTC TCTAGAAGGT CCAATGCGAA 300 ATATTGGGCA AAGGTTATTG ACATGGCATG TCTGGGTCAT GAACATTGAA CCCCATATTA 360 TTGAATATGA TAATTATTTC ATGTTAGATT CATTCCATGG AAGTTTAATT TTTAAGCACA 420 ATTATAGAGA GAATTTTGAG TTTACCAAAT TTATTCGAAC AGTTAATCCT AAAAAATACC 480 CAGAAGACAT TTATCTCCCT AAGATGTGGT ATTTGTTCTT CATGTGCTCA TTTTCTGATA 540 TTAATTGTCA AGTTTTGGAC AGCTGTCAAA CAAATGCTTC TTTGGATATG TTACCTAGTC 600 AGATATTTGA TGTGGTCATG AGTGAAGAGA GCACAAGTAT TTACAATGCT GTGTACGCTG 660 TGGCTCACAG CCTCCATGAG ATGAGACTTC AGCAACTTCA AACACAACCG TGTGAAAATG 720 AAGAAGGGAT GGAGTTCTTT CCATGGCAGC TTAATACTTT CCTGAAGGAT ATTGAGGTGA 780 GAGTCAACAG TTTGGACTGG AGACAGAGAA TAGATGCTGA ATATGACATT CTTAACCTCT 840 GGAATTTACC AAAGGGTCTT GGACTAAAAG TGAAAATAGG AAACTTTTAT GCAAATGCTC 900 CCCAGGGTCA ACAATTGTCT TTATCTGAAC AGATGATTCA ATGGCCAGAA ATATTTTCAG 960 AAGTCCCTCA GTCTGTGTGC AGTGAGAGTT GTAGGCCTGG ATTCAGGAAA GTATCCCTGG 1020 ATGATAAGGC CATCTGCTGC TACAAGTGCA CTCCTTGTGC CGACAATGAG ATATCTAATG 1080 AGACAGATGT AGACCAGTGT GTGAAGTGTC CAGAGAGTCA TTATGCAAAT ACAGAGAAGA 1140 GCAACTGCTT CCCAAAATCT GTGAGCTTTC TGGCCTATGA AGACCCCTTG GGGATGGCTC 1200 TAGCCAGCAT AGCTTTGTGC TTATCTGCAC TCACTGTCTT TGTTATTGGC ATCTTTGTGA 1260 AAAACAGAGA CACTCCTATT GTCAAGGCCA ATAATCGGAC TCTAAGTTAC ATTTTGCTCA 1320 TCACACTCAC CTTTTGTTTC TTATGTTCTT TGAACTTCAT TGGTCAGCCC AACACAGCTG 1380 CCTGCATCCT TCAGCAGACC ACCTTTGCAG TTGCTTTCAC TATGGCTCTT GCCACTGTGT 1440 TGGCCAAAGC TATTACTGTA GTCCTTGCCT TTAAGATCAG TTTTCCAGGG AGAATGTTAA 1500 GGTGGCTAAT GATATCAAGG GGTCCAAGAT ACATCATTCC TATCTGCACA CTGATCCAGC 1560 TTCTTCTTTG TGGAATATGG ATGGCAACTT CTCCACCATT CATTGACCAA GATGTTAATA 1620 CTGAAGATGG ATACATCATC CTTTTGTGCA ACAAGGGCTC AGCTGTTGCC TTCCATTCAG 1680 TCCTGGGATA CCTCTGTTTC TTGGCCCTTG GGAGTTATAC CATGGCCTTC TTGTCTAGAA 1740 ATTTGCCTGA TACATTCAAT GAATCCAAAT TTCTGTCATT CAGTATGCTG GTGTTCTTCT 1800 GTGTCTGGGT CACCTTTCTT CCTGTCTACC ACAGCACTAA AGGGAAAGTT ATGGTCGTCG 1860 TCGAAGTCTT CTGCATCCAA GCCGAATTC 1889 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 604 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 14 : Ser Leu Ser Leu Ala He Val Ser Leu Met Val His Phe Arg Trp Ser 1 5 10 15 Trp Val Gly Leu He Leu Pro Asp Asp His Lys Gly Asn Lys He Leu 20 25 30 Ser Asp Phe Arg Lys Glu Met Glu Arg Lys Arg He Cys Thr Ala Phe 35 40 45 Val Lys Met He Pro Ala Thr Trp Thr Ser Ser Phe Val Lys Phe Trp 50 55 60 Glu Asn Met Asp Asp Thr Asn He He He He Tyr Gly Asp He Asp 65 70 75 80 Ser Leu Glu Gly Pro Met Arg Asn He Gly Gin Arg Leu Leu Thr Trp 85 90 95 His Val Trp Val Met Asn He Glu Pro His He He Glu Tyr Asp Asn 100 105 110 Tyr Phe Met Leu Asp Ser Phe His Gly Ser Leu He Phe Lys His Asn 115 120 125 Tyr Arg Glu Asn Phe Glu Phe Thr Lys Phe He Arg Thr Val Asn Pro 130 135 140 Lys Lys Tyr Pro Glu Asp He Tyr Leu Pro Lys Met Trp Tyr Leu Phe 145 150 155 160 Phe Met Cys Ser Phe Ser Asp He Asn Cys Gin Val Leu Asp Ser Cys 165 170 175 Gin Thr Asn Ala Ser Leu Asp Met Leu Pro Ser Gin He Phe Asp Val 180 185 190 Val Met Ser Glu Glu Ser Thr Ser He Tyr Asn Ala Val Tyr Ala Val 195 200 205 Ala His Ser Leu His Glu Met Arg Leu Gin Gin Leu Gin Thr Gin Pro 210 215 220 Cys Glu Asn Glu Glu Gly Met Glu Phe Phe Pro Trp Gin Leu Asn Thr 225 230 235 240 Phe Leu Lys Asp He Glu Val Arg Val Asn Ser Leu Asp Trp Arg Gin 245 250 255 Arg He Asp Ala Glu Tyr Asp He Leu Asn Leu Trp Asn Leu Pro Lys 260 265 270 Gly Leu Gly Leu Lys Val Lys He Gly Asn Phe Tyr Ala Asn Ala Pro 275 280 285 Gin Gly Gin Gin Leu Ser Leu Ser Glu Gin Met He Gin Trp Pro Glu 290 295 300 He Phe Ser Glu Val Pro Gin Ser Val Cys Ser Glu Ser Cys Arg Pro 305 310 315 320 Gly Phe Arg Lys Val Ser Leu Asp Asp Lys Ala He Cys Cys Tyr Lys 325 330 335 Cys Thr Pro Cys Ala Asp Asn Glu He Ser Asn Glu Thr Asp Val Asp 340 345 350 Gin Cys Val Lys Cys Pro Glu Ser His Tyr Ala Asn Thr Glu Lys Ser 355 360 365 Asn Cys Phe Pro Lys Ser Val Ser Phe Leu Ala Tyr Glu Asp Pro Leu 370 375 380 Gly Met Ala Leu Ala Ser He Ala Leu Cys Leu Ser Ala Leu Thr Val 385 390 395 400 Phe Val He Gly He Phe Val Lys Asn Arg Asp Thr Pro He Val Lys 405 410 415 Ala Asn Asn Arg Thr Leu Ser Tyr He Leu Leu He Thr Leu Thr Phe 420 425 430 Cys Phe Leu Cys Ser Leu Asn Phe He Gly Gin Pro Asn Thr Ala Ala 435 440 445 Cys He Leu Gin Gin Thr Thr Phe Ala Val Ala Phe Thr Met Ala Leu 450 455 460 Ala Thr Val Leu Ala Lys Ala He Thr Val Val Leu Ala Phe Lys He 465 470 475 480 Ser Phe Pro Gly Arg Met Leu Arg Trp Leu Met He Ser Arg Gly Pro 485 490 495 Arg Tyr He He Pro He Cys Thr Leu He Gin Leu Leu Leu Cys Gly 500 505 510 He Trp Met Ala Thr Ser Pro Pro Phe He Asp Gin Asp Val Asn Thr 515 520 525 Glu Asp Gly Tyr He He Leu Leu Cys Asn Lys Gly Ser Ala Val Ala 530 535 540 Phe His Ser Val Leu Gly Tyr Leu Cys Phe Leu Ala Leu Gly Ser Tyr 545 550 555 560 Thr Met Ala Phe Leu Ser Arg Asn Leu Pro Asp Thr Phe Asn Glu Ser 565 570 575 Lys Phe Leu Ser Phe Ser Met Leu Val Phe Phe Cys Val Trp Val Thr 580 585 590 Phe Leu Pro Val Tyr His Ser Thr Lys Gly Lys Val 595 600 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2561 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 80...349 (D) OTHER INFORMATION: VR8 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: ATAGGTGCAA CTGTGTGTGT GATGTTTTTC TACATCAGAA ACGGATTTCA CAACAGCTCC 60 ATCTTAGATC CTAGCAGAC ATG AAG AAG CTC TGT GCT TTC ACG ATT TCA TTG 112 Met Lys Lys Leu Cys Ala Phe Thr He Ser Leu 1 5 10 TTG TTT CTG AAG TTT TCT CTC ATC TTG TGC TGT TGG AGT GAA CCA AGT 160 Leu Phe Leu Lys Phe Ser Leu He Leu Cys Cys Trp Ser Glu Pro Ser 15 20 25 TGC TTT TGG AGG ATA AAG AAT AGT GAT GAT AAT GAC GGA GAT TTG CAA 208 Cys Phe Trp Arg He Lys Asn Ser Asp Asp Asn Asp Gly Asp Leu Gin 30 35 40 AGG GAA TGT CAT TTT TAC CTT GGG GCA GCT GAT ACA CCA GTT GAA GAT 256 Arg Glu Cys His Phe Tyr Leu Gly Ala Ala Asp Thr Pro Val Glu Asp 45 50 55 AAT TTT TAT AGT TCA CTT TTA AAA TTT AGG TTT TCT TTG GAC CAT TTA 304 Asn Phe Tyr Ser Ser Leu Leu Lys Phe Arg Phe Ser Leu Asp His Leu 60 65 70 75 ATC CTA ACC TAC GCG ACC ATG ACC GGC TGC CCC ATG TCC ATC AGG TAGCC 354 He Leu Thr Tyr Ala Thr Met Thr Gly Cys Pro Met Ser He Arg 80 85 90 CCCAAGGACA CACATTTGTC CCATGGCATG GTCTCCTTGA TGTTTCACTT TAGATGGACT 414 TGGATAGGAA TGGTCATCTC AGATGATGAC CAGGGTATTC AGTTTCTCTC AGATTTAAGA 474 GAAGAAAGCC AAAGGCATGG GATCTGTTTA GCTTTTGTTA ATATGATCCC AGAAAACATG 534 CAGATATACA TGACAAGGGC TACAATATAT GATCAACAAA TTATGACATC TTCAGCAAAG 594 GTTGTTATCA TTTATGGTGA AATGAACTCT ACTCTAGAAG TAAGCTTTAG AAGATGGGAA 654 GAGTTAGGTG CTCGGAGAAT CTGGATCACA ACCTCACAAT GGGATGTCAT CACAAATAAA 714 AAAGACTTCA CCCTTAATCT CTTCCATGGG ACTATCACTT TTGCACACCA CAGAGTTGAG 774 ATTCCTAAAT TAAATAAATT CATGCAAACA ATGAACACTG CCAAATACCC AGTAGATATT 834 TCTCATACTA TATTGGAGTG GAATTATTTT AATTGTTCAA TATCTAAGAA CAGCATTAGA 894 ATGCATCATA TTACATTCAA CAACACCTTG GAATGGACAT CACTGCACAA CTATGATATG 954 GCGATGAGTG ATGAAGGTTA CAGTTTATAT AATGCTGTTT ATGCTGTGGC CCACACCTAC 1014 CATGAATACA TTTTTCAACA AGTAGAGTCT CAGAAAAAGG CAAAACCCAA AAGATATTTC 1074 ACTGCTTGTC AGCAGCCTCA GGTTCCCTCC TCCGTGTGTA GTGTGGCATG TACTGCTGGA 1134 TTCAGGAAAA TTTATCAAAA AGAAACAGCA GACTGCTGCT TTGATTGTGT TCAGTGCCCA 1194 GAAAATGAGA TTTCCAACGA AACAGATATG GAACAGTGTG TGAGGTGTCC AGATGATAAG 1254 TATGCCAACA TAGAGCAAAC CCACTGCCTC TCAAGAGCTG TATCATTTCT GGCTTATGAA 1314 GATCCATTGG GGATGGCTCT AGGCTGCATG GCACTGTCCT TCTCGGCCAT CACAATTCTA 1374 GTCCTCGTCA CATTTGTGAA ACACAACGAT ACTCCCATTG TGAAGGCCAA TAACCGCATT 1434 CTCAGCTACA TCCTGCTCAT CTCTCTCGTC TTCTGCTTTC TCTGCTCCCT GCTCTTCATT 1494 GGACCTCCCG ACCAGGTCAC CTGCATCTTG CAGCAGACCA CATTTGGAGT ATTTTTCACT 1554 GTGTCTGTTT CTACAGTGTT GGCCAAAACA ATAACTGTGG TCATGGCTTT CAAGCTCACT 1614 ACTCCAGGAA GAAGGATGAG AGGGATGATG ATGACAGGGG CACCTAAGTT GGTCATTCCC 1674 ATTTGTACCC TGATCCAACT TGTTCTCTGT GGAATCTGGT TGGTCACATC TCCTCCCTTT 1734 ATTGACAGAG ATATACAATC TGAGCATGGG AAGATTGTCA TTCTTTGCAA TAAAGGCTCA 1794 GTCATTGCCT TCCACGTCGT CCTGGGATAC TTGGGCTCCT TGGCTCTGGG GAGCTTCACT 1854 TTGGCTTTCT TGGCTAGGAA CCTTCCTGAC ACATTCAATG AAGCCAAGTT CCTAACTTTC 1914 AGCATGCTGG TGTTCTGCAG TGTCTGGATC ACCTTCCTCC CTGTCTACCA CAGCACCAGG 1974 GGGAGGGTCA TGGTGGTTGT GGAGGTTTTC TCCATCTTGG CTTCTAGTGC AGGGTTGCTA 2034 ATGTGTATCT TTGTCCCAAA GTGTTATGTT ATTTTAATTA GACCAGATTC AAATATTATA 2094 AAGAAACATA AAGGTAAAGT GCTTAATTGA AACTTTCATG GTATGAAAAT GTTAGATGAT 2154 ATTCAACTTA TCTTATTCTT CATCTTAATA AAAGCAGTAC TTCATCATAT AAAAAATAAA 2214 GTAATATACA GATTTATACT TACAAACTGG ACAGCAAACA TGAATATGTT GAGAACTGGG 2274 ATTCTCAATT GAGGAATGGC TACCAACATT TTGATCTGTG GTTTTGTGTT TAAGCCATGC 2334 ACTTAATTAA TGATTAACAT GAGGTTACCC TACTGTCTGT GAACAGCGCC ACCTCTAGGC 2394 ATGCTGTCCT TGAGTTATAA GAAAGGGTAC TGCATACACA ATGGACATGA AGCCAGTAAT 2454 CAACATTATT CCACTTGCTT TCATGGAGTT CTTACTTCCA AGTTCATGCC TTGACTTTAT 2514 TCAATGTTCT ATGACAAAGG TAGATAAATA AATAAACACT TTTCCTC 2561 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 90 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 16 : Met Lys Lys Leu Cys Ala Phe Thr He Ser Leu Leu Phe Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Trp Ser Glu Pro Ser Cys Phe Trp Arg He 20 25 30 Lys Asn Ser Asp Asp Asn Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Gly Ala Ala Asp Thr Pro Val Glu Asp Asn Phe Tyr Ser Ser 50 55 60 Leu Leu Lys Phe Arg Phe Ser Leu Asp His Leu He Leu Thr Tyr Ala 65 70 75 80 Thr Met Thr Gly Cys Pro Met Ser He Arg 85 90 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2734 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 80...1387 (D) OTHER INFORMATION: VR9 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ATAGGTGCAA CTGTGTGTGT GATGTTTTTC TACATCAGAA ACGGATTTCA CAACAGCTCC 60 ATCTTAGATC CTAGCAGAC ATG AAG AAG CTC TGT GCT TTC ACG ATT TCA TTG 112 Met Lys Lys Leu Cys Ala Phe Thr He Ser Leu 1 5 10 TTG TTT CTG AAG TTT TCT CTC ATC TTG TGC TGT TGG AGT GAA CCA AGT 160 Leu Phe Leu Lys Phe Ser Leu He Leu Cys Cys Trp Ser Glu Pro Ser 15 20 25 TGC TTT TGG AGG ATA AAG AAT AGT GAT GAT AAT GAC GGA GAT TTG CAA 208 Cys Phe Trp Arg He Lys Asn Ser Asp Asp Asn Asp Gly Asp Leu Gin 30 35 40 AGG GAA TGT CAT TTT TAC CTT GGG GCA GCT GAT ACA CCA GTT GAA GAT 256 Arg Glu Cys His Phe Tyr Leu Gly Ala Ala Asp Thr Pro Val Glu Asp 45 50 55 AAT TTT TAT AGT TCA CTT TTA AAA TTT AGA ATT GCA GCA AGT GAA TAT 304 Asn Phe Tyr Ser Ser Leu Leu Lys Phe Arg He Ala Ala Ser Glu Tyr 60 65 70 75 GAG TTT CTT CTC GTA ATG TTT TTT GCT ATC GAT GAG ATC AAC AGG AAT 352 Glu Phe Leu Leu Val Met Phe Phe Ala He Asp Glu He Asn Arg Asn 80 85 90 CCT TAT CTT TTA CCC AAC ATA ACT TTG ATG TTC TCC TTC ATT GGT GGA 400 Pro Tyr Leu Leu Pro Asn He Thr Leu Met Phe Ser Phe He Gly Gly 95 100 105 AAC TGT CAG GAT TTA TTG AGA GTT ATG GAC CAA GCA TAT ACA CAA ATA 448 Asn Cys Gin Asp Leu Leu Arg Val Met Asp Gin Ala Tyr Thr Gin He 110 115 120 AAT GGA CAT ATG AAT TTT GTT AAT TAT TTC TGT TAT TTA GAT GAT TCA 496 Asn Gly His Met Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser 125 130 135 TGT GCC ATA GGT CTT ACA GGA CCA TCA TGG AAA ACT TCC TTA AAA CTG 544 Cys Ala He Gly Leu Thr Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu 140 145 150 155 GCA ATG CAC TCT TCG ATG CCA CTG GTT TTC TTT GGA CCA TTT AAT CCT 592 Ala Met His Ser Ser Met Pro Leu Val Phe Phe Gly Pro Phe Asn Pro 160 165 170 AAC CTA CGC GAC CAT GAC CGG CTG CCC CAT GTC CAT CAG GTA GCC CCC 640 Asn Leu Arg Asp His Asp Arg Leu Pro His Val His Gin Val Ala Pro 175 180 185 AAG GAC ACA CAT TTG TCC CAT GGC ATG GTC TCC TTG ATG TTT CAC TTT 688 Lys Asp Thr His Leu Ser His Gly Met Val Ser Leu Met Phe His Phe 190 195 200 AGA TGG ACT TGG ATA GGA ATG GTC ATC TCA GAT GAT GAC CAG GGT ATT 736 Arg Trp Thr Trp He Gly Met Val He Ser Asp Asp Asp Gin Gly He 205 210 215 CAG TTT CTC TCA GAT TTA AGA GAA GAA AGC CAA AGG CAT GGG ATC TGT 784 Gin Phe Leu Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly He Cys 220 225 230 235 TTA GCT TTT GTT AAT ATG ATC CCA GAA AAC ATG CAG ATA TAC ATG ACA 832 Leu Ala Phe Val Asn Met He Pro Glu Asn Met Gin He Tyr Met Thr 240 245 250 AGG GCT ACA ATA TAT GAT CAA CAA ATT ATG ACA TCT TCA GCA AAG GTT 880 Arg Ala Thr He Tyr Asp Gin Gin He Met Thr Ser Ser Ala Lys Val 255 260 265 GTT ATC ATT TAT GGT GAA ATG AAC TCT ACT CTA GAA GTA AGC TTT AGA 928 Val He He Tyr Gly Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg 270 275 280 AGA TGG GAA GAG TTA GGT GCT CGG AGA ATC TGG ATC ACA ACC TCA CAA 976 Arg Trp Glu Glu Leu Gly Ala Arg Arg He Trp He Thr Thr Ser Gin 285 290 295 TGG GAT GTC ATC ACA AAT AAA AAA GAC TTC ACC CTT AAT CTC TTC CAT 1024 Trp Asp Val He Thr Asn Lys Lys Asp Phe Thr Leu Asn Leu Phe His 300 305 310 315 GGG ACT ATC ACT TTT GCA CAC CAC AGA GTT GAG ATT CCT AAA TTA AAT 1072 Gly Thr He Thr Phe Ala His His Arg Val Glu He Pro Lys Leu Asn 320 325 330 AAA TTC ATG CAA ACA ATG AAC ACT GCC AAA TAC CCA GTA GAT ATT TCT 1120 Lys Phe Met Gin Thr Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser 335 340 345 CAT ACT ATA TTG GAG TGG AAT TAT TTT AAT TGT TCA ATA TCT AAG AAC 1168 His Thr He Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn 350 355 360 AGC ATT AGA ATG CAT CAT ATT ACA TTC AAC AAC ACC TTG GAA TGG ACA 1216 Ser He Arg Met His His He Thr Phe Asn Asn Thr Leu Glu Trp Thr 365 370 375 TCA CTG CAC AAC TAT GAT ATG GCG ATG AGT GAT GAA GGT TAC AGT TTA 1264 Ser Leu His Asn Tyr Asp Met Ala Met Ser Asp Glu Gly Tyr Ser Leu 380 385 390 395 TAT AAT GCT GTT TAT GCT GTG GCC CAC ACC TAC CAT GAA TAC ATT TTT 1312 Tyr Asn Ala Val Tyr Ala Val Ala His Thr Tyr His Glu Tyr He Phe 400 405 410 CAA CAA GTA GAG TCT CAG AAA AAG GCA AAA CCC AAA AGA TAT TTC ACT 1360 Gin Gin Val Glu Ser Gin Lys Lys Ala Lys Pro Lys Arg Tyr Phe Thr 415 420 425 GCT TGT CAG CAG ATA TGG AAC AGT GTG TGAGGTGTCC AGATGATAAG TATGCCA 1414 Ala Cys Gin Gin He Trp Asn Ser Val 430 435 ACATAGAGCA AACCCACTGC CTCTCAAGAG CTGTATCATT TCTGGCTTAT GAAGATCCAT 1474 TGGGGATGGC TCTAGGCTGC ATGGCACTGT CCTTCTCGGC CATCACAATT CTAGTCCTCG 1534 TCACATTTGT GAAACACAAC GATACTCCCA TTGTGAAGGC CAATAACCGC ATTCTCAGCT 1594 ACATCCTGCT CATCTCTCTC GTCTTCTGCT TTCTCTGCTC CCTGCTCTTC ATTGGACCTC 1654 CCGACCAGGT CACCTGCATC TTGCAGCAGA CCACATTTGG AGTATTTTTC ACTGTGTCTG 1714 TTTCTACAGT GTTGGCCAAA ACAATAACTG TGGTCATGGC TTTCAAGCTC ACTACTCCAG 1774 GAAGAAGGAT GAGAGGGATG ATGATGACAG GGGCACCTAA GTTGGTCATT CCCATTTGTA 1834 CCCTGATCCA ACTTGTTCTC TGTGGAATCT GGTTGGTCAC ATCTCCTCCC TTTATTGACA 1894 GAGATATACA ATCTGAGCAT GGGAAGATTG TCATTCTTTG CAATAAAGGC TCAGTCATTG 1954 CCTTCCACGT CGTCCTGGGA TACTTGGGCT CCTTGGCTCT GGGGAGCTTC ACTTTGGCTT 2014 TCTTGGCTAG GAACCTTCCT GACACATTCA ATGAAGCCAA GTTCCTAACT TTCAGCATGC 2074 TGGTGTTCTG CAGTGTCTGG ATCACCTTCC TCCCTGTCTA CCACAGCACC AGGGGGAGGG 2134 TCATGGTGGT TGTGGAGGTT TTCTCCATCT TGGCTTCTAG TGCAGGGTTG CTAATGTGTA 2194 TCTTTGTCCC AAAGTGTTAT GTTATTTTAA TTAGACCAGA TTCAAATATT ATAAAGAAAC 2254 ATAAAGGTAA AGTGCTTAAT TGAAACTTTC ATGGTATGAA AATGTTAGAT GATATTCAAC 2314 TTATCTTATT CTTCATCTTA AT AAAGCAG TACTTCATCA TATAAAAAAT AAAGTAATAT 2374 ACAGATTTAT ACTTACAAAC TGGACAGCAA ACATGAATAT GTTGAGAACT GGGATTCTCA 2434 ATTGAGGAAT GGCTACCAAC ATTTTGATCT GTGGTTTTGT GTTTAAGCCA TGCACTTAAT 2494 TAATGATTAA CATGAGGTTA CCCTACTGTC TGTGAACAGC GCCACCTCTA GGCATGCTGT 2554 CCTTGAGTTA TAAGAAAGGG TACTGCATAC ACAATGGACA TGAAGCCAGT AATCAACATT 2614 ATTCCACTTG CTTTCATGGA GTTCTTACTT CCAAGTTCAT GCCTTGACTT TATTCAATGT 2674 TCTATGACAA AGGTAGATAA ATAAATAAAC ACTTTCCTCA CAAAAAAAAA AAAAAAAAAA 2734 2734 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 436 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Met Lys Lys Leu Cys Ala Phe Thr He Ser Leu Leu Phe Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Trp Ser Glu Pro Ser Cys Phe Trp Arg He 20 25 30 Lys Asn Ser Asp Asp Asn Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Gly Ala Ala Asp Thr Pro Val Glu Asp Asn Phe Tyr Ser Ser 50 55 60 Leu Leu Lys Phe Arg He Ala Ala Ser Glu Tyr Glu Phe Leu Leu Val 65 70 75 80 Met Phe Phe Ala He Asp Glu He Asn Arg Asn Pro Tyr Leu Leu Pro 85 90 95 Asn He Thr Leu Met Phe Ser Phe He Gly Gly Asn Cys Gin Asp Leu 100 105 110 Leu Arg Val Met Asp Gin Ala Tyr Thr Gin He Asn Gly His Met Asn 115 120 125 Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala He Gly Leu 130 135 140 Thr Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu Ala Met His Ser Ser 145 150 155 160 Met Pro Leu Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His 165 170 175 Asp Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu 180 185 190 Ser His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He 195 200 205 Gly Met Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp 210 215 220 Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn 225 230 235 240 Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr 245 250 255 Asp Gin Gin He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly 260 265 270 Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg Arg Trp Glu Glu Leu 275 280 285 Gly Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp Val He Thr 290 295 300 Asn Lys Lys Asp Phe Thr Leu Asn Leu Phe His Gly Thr He Thr Phe 305 310 315 320 Ala His His Arg Val Glu He Pro Lys Leu Asn Lys Phe Met Gin Thr 325 330 335 Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He Leu Glu 340 345 350 Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser He Arg Met His 355 360 365 His He Thr Phe Asn Asn Thr Leu Glu Trp Thr Ser Leu His Asn Tyr 370 375 380 Asp Met Ala Met Ser Asp Glu Gly Tyr Ser Leu Tyr Asn Ala Val Tyr 385 390 395 400 Ala Val Ala His Thr Tyr His Glu Tyr He Phe Gin Gin Val Glu Ser 405 410 415 Gin Lys Lys Ala Lys Pro Lys Arg Tyr Phe Thr Ala Cys Gin Gin He 420 425 430 Trp Asn Ser Val 435 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2732 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 80...1375 (D) OTHER INFORMATION: VR10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: ATAGTTGTAA ATGTGTGTGT GATGTTTTTC TACATCAGAA ACGGATTTCA CAACAACTCC 60 ATCTTAGATC CTAGCAGAC ATG AAG AAG CTC TGT GCT TTC ACT ATT TCA TTT 112 Met Lys Lys Leu Cys Ala Phe Thr He Ser Phe 1 5 10 TTG TCT CTG AAG TTT TCT CTC ATC TTG TGC TGT TTG ACT GAA GCA AGT 160 Leu Ser Leu Lys Phe Ser Leu He Leu Cys Cys Leu Thr Glu Ala Ser 15 20 25 TGC TTT TGG AGG ATA AAG AAT AGT GAA GAT AGT GAT GGA GAT TTG CAA 208 Cys Phe Trp Arg He Lys Asn Ser Glu Asp Ser Asp Gly Asp Leu Gin 30 35 40 AGA GAA TGT CAT TTT TAC CTT TGG GTA ATT GAT AAA CCT ATT GAA GAT 256 Arg Glu Cys His Phe Tyr Leu Trp Val He Asp Lys Pro He Glu Asp 45 50 55 AAT TTT TAT AAT TCA GTT TTA AAT TTT AGA ATA TCA GCA AGT GAA TAT 304 Asn Phe Tyr Asn Ser Val Leu Asn Phe Arg He Ser Ala Ser Glu Tyr 60 65 70 75 GAG TTT CTT CTG GTA ATG TTT TTT GCT ACT GAT GAG ATC AAC AAG AAT 352 Glu Phe Leu Leu Val Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn 80 85 90 CCT TAT CTT TTA CCC AAC ATA ACT TTG ATA TTC AGC ATC GTT GGT GGT 400 Pro Tyr Leu Leu Pro Asn He Thr Leu He Phe Ser He Val Gly Gly 95 100 105 CAC TGT CAT GAT TTA TTG AGA GGT CTG GAT CAA TCA TAT ACA CAA ATA 448 His Cys His Asp Leu Leu Arg Gly Leu Asp Gin Ser Tyr Thr Gin He 110 115 120 AAT GGA CGT GTG AAT TTT GTT AAT TAT TTC TGT TAT TTA GAT GAT TCA 496 Asn Gly Arg Val Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser 125 130 135 TGT AAC ATA GGC CTT ACA GGA CCA TCA TGG AAA AAA TCC TTA AAA CTG 544 Cys Asn He Gly Leu Thr Gly Pro Ser Trp Lys Lys Ser Leu Lys Leu 140 145 150 155 GCA ATG GAT TCT TCA ATA CCA ATG GTT TTC TTT GGA CCA TTT AAT CCT 592 Ala Met Asp Ser Ser He Pro Met Val Phe Phe Gly Pro Phe Asn Pro 160 165 170 AAC CTA CGC GAC CAT GAC CGG CTG CCC CAT GTC CAT CAG GTA GCC CCC 640 Asn Leu Arg Asp His Asp Arg Leu Pro His Val His Gin Val Ala Pro 175 180 185 AAG GAC ACA CAT TTA TCC CAT GGC ATG GTC TCC TTG ATG TTT CAT TTT 688 Lys Asp Thr His Leu Ser His Gly Met Val Ser Leu Met Phe His Phe 190 195 200 AGA TGG ACT TGG ATA GGA CTG GTC ATC TCA GAT GAT GAC CAG GGT ATT 736 Arg Trp Thr Trp He Gly Leu Val He Ser Asp Asp Asp Gin Gly He 205 210 215 CAG TTT CTC TCA GAT TTA AGA GAA GAA AGC CAA AGG CAT GGG ATC TGT 784 Gin Phe Leu Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly He Cys 220 225 230 235 TTA GCT TTT GTT AAT ATG ATC CCA GAA AAC ATG CAG ATA TAC ATG ACA 832 Leu Ala Phe Val Asn Met He Pro Glu Asn Met Gin He Tyr Met Thr 240 245 250 AGG GCT ACA ATA TAT GAT AAA CAA ATT ATG ACA TCT TCA GCA AAG GTT 880 Arg Ala Thr He Tyr Asp Lys Gin He Met Thr Ser Ser Ala Lys Val 255 260 265 GTT ATC ATT TAT GGT GAA ATG AAC TCT ACT CTA GAA GTA AGC TTC AGA 928 Val He He Tyr Gly Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg 270 275 280 AGA TGG GAA GAT TTA GGT GCT CGG AGA ATC TGG ATC ACA ACC TCA CAA 976 Arg Trp Glu Asp Leu Gly Ala Arg Arg He Trp He Thr Thr Ser Gin 285 290 295 TGG GAT ATC ATA TTA AAT AAA AAA GAA TTC ACT CTT AAT CTC TTC CAT 1024 Trp Asp He He Leu Asn Lys Lys Glu Phe Thr Leu Asn Leu Phe His 300 305 310 315 GGC CCT ATC ACT TTT GCA CAC CAC AAA GTT GAG ATT CCT AAA TTA AGG 1072 Gly Pro He Thr Phe Ala His His Lys Val Glu He Pro Lys Leu Arg 320 325 330 AAT TTT ATG CAA ACA ATG AAC ACT GCC AAA TAC CCA GTA GAT ATT TCT 1120 Asn Phe Met Gin Thr Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser 335 340 345 CAT ACT ATA CTG GAG TGG AAT TAT TTT AAT TGT TCA ATC TCT AAG AAC 1168 His Thr He Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn 350 355 360 AGC AGT AAA ATG GAT CTT TTT ACA TCC AAC AAC ACA TTG GAA TGG ACA 1216 Ser Ser Lys Met Asp Leu Phe Thr Ser Asn Asn Thr Leu Glu Trp Thr 365 370 375 GCA CTG CAC AAC TAT GAT ATG GCC ATG AGT GAT GAA GGT TAC AAT TTG 1264 Ala Leu His Asn Tyr Asp Met Ala Met Ser Asp Glu Gly Tyr Asn Leu 380 385 390 395 TAT AAT GCT GTT TAT GTT GCG GCC CAC ACC TAC CAT GAA CAC ATT CTT 1312 Tyr Asn Ala Val Tyr Val Ala Ala His Thr Tyr His Glu His He Leu 400 405 410 CAA CAA GTA GAG TCT CAG AAA AAG GTA GAA CAC AAC AGA TAT TTC ACT 1360 Gin Gin Val Glu Ser Gin Lys Lys Val Glu His Asn Arg Tyr Phe Thr 415 420 425 GTT TGT CAG CAG ATA TAGAACAGTG TGTGAAATGT CCAGATGATA AGTATGCCAA C 1416 Val Cys Gin Gin He 430 ATAGAACAAA CCTACTGCCT CTCAAGAGCT GTATCATTTC TGGCTTTTGA AGAACCACTG 1476 GGGATGGCTC TAGGCTGCAT GGCACTATCC TTCTCGGCCA TCACAATTCT AGTACTAGTC 1536 ACATTTGTGA AGTACAAGAA TACTCCCATT GTGAAGGCCA ATAACCGCAT TCTCAGCTAC 1596 ATCCTGCTCA TCTCTCTAGT CTTCTGTTTT CTCTGCTCCC TGCTCTTCAT TGGACATCCT 1656 GACCAGGTCA CCTGCATCTT GCAGCAGACC ACATTTGGAG TATTTTTCAC TGTGTCTGTT 1716 TCTACAGTGT TGGCCAAAAC AATAACTGTG GTCATGGCTT TCAAGTTCAC TACTCCAGGA 1776 AGAAGGATGA GAGGGATGTT GGTAACAGGT GCACCTAAGT TGGTCATTCC CATTTGTACC 1836 CTAATCCAAC TTGTTCTCTG TGGAATCTGG TTGGTAACAT CTCCTCCATT TATTGACAGA 1896 GATATACAAT CTGAACATGG GAAGGTAGTC ATTCTTTGCA ATAAAGGCTC TGTCATTGCC 1956 TTCCACATTG TCCTGGGATA CTTGGGCTCC TTGGCTCTGG GGAGCTTCAC TTTGGCTTTC 2016 TTGGCTAGGA ACCTTCCTGA CACATTCAAT GAAGCCAAAT TCCTAACTTT CAGCATGCTG 2076 GTGTTCTGCA GTGTCTGGAT CACCTTCCTC CCTGTCTACC ACAGCACCAG GGGGAAGGTC 2136 ATGGTGGTTG TGGAGGTTTT CTCAATCTTG GCTTCTAGTG CAGGGTTGCT AATGTGTATC 2196 TTTGTCCCAA AGTGTTATGT TATTTTAGTT AGACCAGATT CAAATTTTAC AAAGAACCGC 2256 AAAGGTAAAT TGCTTTATTG AAATTTTCAT GGTATGAAAA TGTTAGATTA TATTCAACTT 2316 ATCTTATTCT TCATCTTAAC AAAAGTAGTA CTTCATCATA TAAAAAATTA AGTAATATAC 2376 AGATTTATAC TTACAAACTG GACAGCAAAC ATGAATATGT TTAGAACTGG GAATCTCAAT 2436 TGAGGAATGG GTATCATCAT TTTGACCTGT GGTTATGTGT TTAAGCCATG TGTTTAATTA 2496 ATGATTAACA TGAGGTTGCC CTACTGTCTG TGAACCATAC CACCTCTAGG CACACTGTCC 2556 TTGAGTTATA AGATAGGGTA CTGCATACAA AATGGACATG AAACCAGTAA TCAACATTAT 2616 CCCTCTTGCT TTCATGGAGT TCTTGCATCC AATTTCATGC CTTGACTTCA TTCAATGTAC 2676 TATGACAAAG GTACATAAAT AAATAAACAC TTTCCCCACC AAAAAAAAAA AAAAAA 2732 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 432 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: Met Lys Lys Leu Cys Ala Phe Thr He Ser Phe Leu Ser Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Leu Thr Glu Ala Ser Cys Phe Trp Arg He 20 25 30 Lys Asn Ser Glu Asp Ser Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Trp Val He Asp Lys Pro He Glu Asp Asn Phe Tyr Asn Ser 50 55 60 Val Leu Asn Phe Arg He Ser Ala Ser Glu Tyr Glu Phe Leu Leu Val 65 70 75 80 Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu Leu Pro 85 90 95 Asn He Thr Leu He Phe Ser He Val Gly Gly His Cys His Asp Leu 100 105 110 Leu Arg Gly Leu Asp Gin Ser Tyr Thr Gin He Asn Gly Arg Val Asn 115 120 125 Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Asn He Gly Leu 130 135 140 Thr Gly Pro Ser Trp Lys Lys Ser Leu Lys Leu Ala Met Asp Ser Ser 145 150 155 160 He Pro Met Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His 165 170 175 Asp Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu 180 185 190 Ser His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He 195 200 205 Gly Leu Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp 210 215 220 Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn 225 230 235 240 Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr 245 250 255 Asp Lys Gin He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly 260 265 270 Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg Arg Trp Glu Asp Leu 275 280 285 Gly Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp He He Leu 290 295 300 Asn Lys Lys Glu Phe Thr Leu Asn Leu Phe His Gly Pro He Thr Phe 305 310 315 320 Ala His His Lys Val Glu He Pro Lys Leu Arg Asn Phe Met Gin Thr 325 330 335 Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He Leu Glu 340 345 350 Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser Ser Lys Met Asp 355 360 365 Leu Phe Thr Ser Asn Asn Thr Leu Glu Trp Thr Ala Leu His Asn Tyr 370 375 380 Asp Met Ala Met Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala Val Tyr 385 390 395 400 Val Ala Ala His Thr Tyr His Glu His He Leu Gin Gin Val Glu Ser 405 410 415 Gin Lys Lys Val Glu His Asn Arg Tyr Phe Thr Val Cys Gin Gin He 420 425 430 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2962 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 81...1601 (D) OTHER INFORMATION: VR11 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: CATAGTTGTA AATGTGTGTG TGATGTTTTT CTACATCAGA AACGGATTTC ACAACAACTC 60 CATCTTAGAT CCTAGCAGAC ATG AAG AAG CTC TGT GCT TTC ACT ATT TCA 110 Met Lys Lys Leu Cys Ala Phe Thr He Ser 1 5 10 TTT TTG TCT CTG AAG TTT TCT CTC ATC TTG TGC TGT TTG ACT GAA GCA 158 Phe Leu Ser Leu Lys Phe Ser Leu He Leu Cys Cys Leu Thr Glu Ala 15 20 25 AGT TGC TTT TGG AGG ATA AAG AAT AGT GAA GAT AGT GAT GGA GAT TTG 206 Ser Cys Phe Trp Arg He Lys Asn Ser Glu Asp Ser Asp Gly Asp Leu 30 35 40 CAA AGA GAA TGT CAT TTT TAC CTT TGG GTA ATT GAT AAA CCT ATT GAA 254 Gin Arg Glu Cys His Phe Tyr Leu Trp Val He Asp Lys Pro He Glu 45 50 55 GAT AAT TTT TAT AAT TCA GTT TTA AAT TTT AGA ATA TCA GCA AGT GAA 302 Asp Asn Phe Tyr Asn Ser Val Leu Asn Phe Arg He Ser Ala Ser Glu 60 65 70 TAT GAG TTT CTT CTG GTA ATG TTT TTT GCT ACT GAT GAG ATC AAC AAG 350 Tyr Glu Phe Leu Leu Val Met Phe Phe Ala Thr Asp Glu He Asn Lys 75 80 85 90 AAT CCT TAT CTT TTA CCC AAC ATA ACT TTG ATA TTC AGC ATC GTT GGT 398 Asn Pro Tyr Leu Leu Pro Asn He Thr Leu He Phe Ser He Val Gly 95 100 105 GGT CAC TGT CAT GAT TTA TTG AGA GGT CTG GAT CAA TCA TAT ACA CAA 446 Gly His Cys His Asp Leu Leu Arg Gly Leu Asp Gin Ser Tyr Thr Gin 110 115 120 ATA AAT GGA CGT GTG AAT TTT GTT AAT TAT TTC TGT TAT TTA GAT GAT 494 He Asn Gly Arg Val Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp 125 130 135 TCA TGT AAC ATA GGC CTT ACA GGA CCA TCA TGG AAA AAA TCC TTA AAA 542 Ser Cys Asn He Gly Leu Thr Gly Pro Ser Trp Lys Lys Ser Leu Lys 140 145 150 CTG GCA ATG GAT TCT TCA ATA CCA ATG GTT TTC TTT GGA CCA TTT AAT 590 Leu Ala Met Asp Ser Ser He Pro Met Val Phe Phe Gly Pro Phe Asn 155 160 165 170 CCT AAC CTA CGC GAC CAT GAC CGG CTG CCC CAT GTC CAT CAG GTA GCC 638 Pro Asn Leu Arg Asp His Asp Arg Leu Pro His Val His Gin Val Ala 175 180 185 CCC AAG GAC ACA CAT TTA TCC CAT GGC ATG GTC TCC TTG ATG TTT CAT 686 Pro Lys Asp Thr His Leu Ser His Gly Met Val Ser Leu Met Phe His 190 195 200 TTT AGA TGG ACT TGG ATA GGA CTG GTC ATC TCA GAT GAT GAC CAG GGT 734 Phe Arg Trp Thr Trp He Gly Leu Val He Ser Asp Asp Asp Gin Gly 205 210 215 ATT CAG TTT CTC TCA GAT TTA AGA GAA GAA AGC CAA AGG CAT GGG ATC 782 He Gin Phe Leu Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly He 220 225 230 TGT TTA GCT TTT GTT AAT ATG ATC CCA GAA AAC ATG CAG ATA TAC ATG 830 Cys Leu Ala Phe Val Asn Met He Pro Glu Asn Met Gin He Tyr Met 235 240 245 250 ACA AGG GCT ACA ATA TAT GAT AAA CAA ATT ATG ACA TCT TCA GCA AAG 878 Thr Arg Ala Thr He Tyr Asp Lys Gin He Met Thr Ser Ser Ala Lys 255 260 265 GTT GTT ATC ATT TAT GGT GAA ATG AAC TCT ACT CTA GAA GTA AGC TTC 926 Val Val He He Tyr Gly Glu Met Asn Ser Thr Leu Glu Val Ser Phe 270 275 280 AGA AGA TGG GAA GAT TTA GGT GCT CGG AGA ATC TGG ATC ACA ACC TCA 974 Arg Arg Trp Glu Asp Leu Gly Ala Arg Arg He Trp He Thr Thr Ser 285 290 295 CAA TGG GAT ATC ATA TTA AAT AAA AAA GAA TTC ACT CTT AAT CTC TTC 1022 Gin Trp Asp He He Leu Asn Lys Lys Glu Phe Thr Leu Asn Leu Phe 300 305 310 CAT GGC CCT ATC ACT TTT GCA CAC CAC AAA GTT GAG ATT CCT AAA TTA 1070 His Gly Pro He Thr Phe Ala His His Lys Val Glu He Pro Lys Leu 315 320 325 330 AGG AAT TTT ATG CAA ACA ATG AAC ACT GCC AAA TAC CCA GTA GAT ATT 1118 Arg Asn Phe Met Gin Thr Met Asn Thr Ala Lys Tyr Pro Val Asp He 335 340 345 TCT CAT ACT ATA CTG GAG TGG AAT TAT TTT AAT TGT TCA ATC TCT AAG 1166 Ser His Thr He Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser Lys 350 355 360 AAC AGC AGT AAA ATG GAT CTT TTT ACA TCC AAC AAC ACA TTG GAA TGG 1214 Asn Ser Ser Lys Met Asp Leu Phe Thr Ser Asn Asn Thr Leu Glu Trp 365 370 375 ACA GCA CTG CAC AAC TAT GAT ATG GCC ATG AGT GAT GAA GGT TAC AAT 1262 Thr Ala Leu His Asn Tyr Asp Met Ala Met Ser Asp Glu Gly Tyr Asn 380 385 390 TTG TAT AAT GCT GTT TAT GTT GCG GCC CAC ACC TAC CAT GAA CAC ATT 1310 Leu Tyr Asn Ala Val Tyr Val Ala Ala His Thr Tyr His Glu His He 395 400 405 410 CTT CAA CAA GTA GAG TCT CAG AAA AAG GTA GAA CAC AAC AGA TAT TTC 1358 Leu Gin Gin Val Glu Ser Gin Lys Lys Val Glu His Asn Arg Tyr Phe 415 420 425 ACT GTT TGT CAG CAG GTA TCT TCC TTG ATG AAA ACC AGG GTA TTT ACG 1406 Thr Val Cys Gin Gin Val Ser Ser Leu Met Lys Thr Arg Val Phe Thr 430 435 440 AAC CCG GTT GGA GAA CTG GTG AAC ATG AAG CAT AGG GAA AAT CAG TGT 1454 Asn Pro Val Gly Glu Leu Val Asn Met Lys His Arg Glu Asn Gin Cys 445 450 455 ACA GAG TAT GAT ATT TTC ATC ATT TGG AAT TTT CCA CAA GGC CTT GGA 1502 Thr Glu Tyr Asp He Phe He He Trp Asn Phe Pro Gin Gly Leu Gly 460 465 470 TTA AAA TTG AAA ATA GGA AGC TAT ATA CCT TGT TTT CCA AAG AGT CAA 1550 Leu Lys Leu Lys He Gly Ser Tyr He Pro Cys Phe Pro Lys Ser Gin 475 480 485 490 CAA CTT CAT ATA TCT GAT GAT TTG GAA TGG GCC ATG GGA GGA ACA TCA 1598 Gin Leu His He Ser Asp Asp Leu Glu Trp Ala Met Gly Gly Thr Ser 495 500 505 ATA TAGAACAGTG TGTGAAATGT CCAGATGATA AGTATGCCAA CATAGAACAA ACCTAC 1657 He TGCCTCTCAA GAGCTGTATC ATTTCTGGCT TTTGAAGAAC CACTGGGGAT GGCTCTAGGC 1717 TGCATGGCAC TATCCTTCTC GGCCATCACA ATTCTAGTAC TAGTCACATT TGTGAAGTAC 1777 AAGAATACTC CCATTGTGAA GGCCAATAAC CGCATTCTCA GCTACATCCT GCTCATCTCT 1837 CTAGTCTTCT GTTTTCTCTG CTCCCTGCTC TTCATTGGAC ATCCTGACCA GGTCACCTGC 1897 ATCTTGCAGC AGACCACATT TGGAGTATTT TTCACTGTGT CTGTTTCTAC AGTGTTGGCC 1957 AAAACAATAA CTGTGGTCAT GGCTTTCAAG TTCACTACTC CAGGAAGAAG GATGAGAGGG 2017 ATGTTGGTAA CAGGTGCACC TAAGTTGGTC ATTCCCATTT GTACCCTAAT CCAACTTGTT 2077 CTCTGTGGAA TCTGGTTGGT AACATCTCCT CCATTTATTG ACAGAGATAT ACAATCTGAA 2137 CATGGGAAGG TAGTCATTCT TTGCAATAAA GGCTCTGTCA TTGCCTTCCA CATTGTCCTG 2197 GGATACTTGG GCTCCTTGGC TCTGGGGAGC TTCACTTTGG CTTTCTTGGC TAGGAACCTT 2257 CCTGACACAT TCAATGAAGC CAAATTCCTA ACTTTCAGCA TGCTGGTGTT CTGCAGTGTC 2317 TGGATCACCT TCCTCCCTGT CTACCACAGC ACCAGGGGGA AGGTCATGGT GGTTGTGGAG 2377 GTTTTCTCAA TCTTGGCTTC TAGTGCAGGG TTGCTAATGT GTATCTTTGT CCCAAAGTGT 2437 TATGTTATTT TAGTTAGACC AGATTCAAAT TTTACAAAGA ACCGCAAAGG TAAATTGCTT 2497 TATTGAAATT TTCATGGTAT GAAAATGTTA GATTATATTC AACTTATCTT ATTCTTCATC 2557 TTAACAAAAG TAGTACTTCA TCATATAAAA AATTAAGTAA TATACAGATT TATACTTACA 2617 AACTGGACAG CAAACATGAA TATGTTTAGA ACTGGGAATC TCAATTGAGG AATGGGTATC 2677 ATCATTTTGA CCTGTGGTTA TGTGTTTAAG CCATGTGTTT AATTAATGAT TAACATGAGG 2737 TTGCCCTACT GTCTGTGAAC CATACCACCT CTAGGCACAC TGTCCTTGAG TTATAAGATA 2797 GGGTACTGCA TACAAAATGG ACATGAAACC AGTAATCAAC ATTATCCCTC TTGCTTTCAT 2857 GGAGTTCTTG CATCCAATTT CATGCCTTGA CTTCATTCAA TGTACTATGA CAAAGGTACA 2917 TAAATAAATA AACACTTTCC CCACAAAAAA AAAAAAAAAA AAAAA 2962 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 507 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Met Lys Lys Leu Cys Ala Phe Thr He Ser Phe Leu Ser Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Leu Thr Glu Ala Ser Cys Phe Trp Arg He 20 25 30 Lys Asn Ser Glu Asp Ser Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Trp Val He Asp Lys Pro He Glu Asp Asn Phe Tyr Asn Ser 50 55 60 Val Leu Asn Phe Arg He Ser Ala Ser Glu Tyr Glu Phe Leu Leu Val 65 70 75 80 Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu Leu Pro 85 90 95 Asn He Thr Leu He Phe Ser He Val Gly Gly His Cys His Asp Leu 100 105 110 Leu Arg Gly Leu Asp Gin Ser Tyr Thr Gin He Asn Gly Arg Val Asn 115 120 125 Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Asn He Gly Leu 130 135 140 Thr Gly Pro Ser Trp Lys Lys Ser Leu Lys Leu Ala Met Asp Ser Ser 145 150 155 160 He Pro Met Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His 165 170 175 Asp Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu 180 185 190 Ser His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He 195 200 205 Gly Leu Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp 210 215 220 Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn 225 230 235 240 Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr 245 250 255 Asp Lys Gin He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly 260 265 270 Glu Met Asn Ser Thr Leu Glu Val Ser Phe Arg Arg Trp Glu Asp Leu 275 280 285 Gly Ala Arg Arg He Trp He Thr Thr Ser Gin Trp Asp He He Leu 290 295 300 Asn Lys Lys Glu Phe Thr Leu Asn Leu Phe His Gly Pro He Thr Phe 305 310 315 320 Ala His His Lys Val Glu He Pro Lys Leu Arg Asn Phe Met Gin Thr 325 330 335 Met Asn Thr Ala Lys Tyr Pro Val Asp He Ser His Thr He Leu Glu 340 345 350 Trp Asn Tyr Phe Asn Cys Ser He Ser Lys Asn Ser Ser Lys Met Asp 355 360 365 Leu Phe Thr Ser Asn Asn Thr Leu Glu Trp Thr Ala Leu His Asn Tyr 370 375 380 Asp Met Ala Met Ser Asp Glu Gly Tyr Asn Leu Tyr Asn Ala Val Tyr 385 390 395 400 Val Ala Ala His Thr Tyr His Glu His He Leu Gin Gin Val Glu Ser 405 410 415 Gin Lys Lys Val Glu His Asn Arg Tyr Phe Thr Val Cys Gin Gin Val 420 425 430 Ser Ser Leu Met Lys Thr Arg Val Phe Thr Asn Pro Val Gly Glu Leu 435 440 445 Val Asn Met Lys His Arg Glu Asn Gin Cys Thr Glu Tyr Asp He Phe 450 455 460 He He Trp Asn Phe Pro Gin Gly Leu Gly Leu Lys Leu Lys He Gly 465 470 475 480 Ser Tyr He Pro Cys Phe Pro Lys Ser Gin Gin Leu His He Ser Asp 485 490 495 Asp Leu Glu Trp Ala Met Gly Gly Thr Ser He 500 505 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2821 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 60...992 (D) OTHER INFORMATION: VR12 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GACGTTTTTC TGCATCAGAA ACGGATTTCA CAGCAGCTCC ATCTCAGATC CTAGCAGAC A 60 Me TGA AGC AGC TCT GCA CTT TCA CTA TTT CAT TGT TGT TTC TGA AGT TTT 108 t Lys Gin Leu Cys Thr Phe Thr He Ser Leu Leu Phe Leu Lys Phe Se 5 10 15 CTC TCA TCT TGT GCT GTT GGA GTG AAC CAA GCT GCT TTT GGA GGA TAA 156 r Leu He Leu Cys Cys Trp Ser Glu Pro Ser Cys Phe Trp Arg He Ly 20 25 30 AGA AGA GTG AAG ATA ATG ATG GAG ATT TAC AAA GGG AGT GTC ATT TTT 204 s Lys Ser Glu Asp Asn Asp Gly Asp Leu Gin Arg Glu Cys His Phe Ty 35 40 45 ACC TTT GGA AAA CTG ATG AAC CTA TTG AAG ATA GTT TTT ATA ATT ATG 252 r Leu Trp Lys Thr Asp Glu Pro He Glu Asp Ser Phe Tyr Asn Tyr As 50 55 60 6 ATT TAA GTT TTA GAA TTG CAG GAA GTG AAT ATG AGC TTC TTC TGG TAA 300 p Leu Ser Phe Arg He Ala Gly Ser Glu Tyr Glu Leu Leu Leu Val Me 70 75 80 TGT TTT TTG CTA CTG ATG AGA TCA ACA AGA ATC CTT ATC TTT TAC CCA 348 t Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu Leu Pro As 85 90 95 ACA TGA GTT TGA TGT TCT CCA TCA TTG GTG GAA ACT GTC ATG ATT TAT 396 n Met Ser Leu Met Phe Ser He He Gly Gly Asn Cys His Asp Leu Le 100 105 110 TGA GAA GTC TGG ATC AAG AAT ATG CAC AAA TAG ATG GAC ATA TGA ATT 444 u Arg Ser Leu Asp Gin Glu Tyr Ala Gin He Asp Gly His Met Asn Ph 115 120 125 TTG TTA ATT ATT TCT GTT ATT TAG ATG ATT CAT GTG CCA CAG GCC TTA 492 e Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala Thr Gly Leu Th 130 135 140 1 CAG GAC CAT CAT GGA AAA CAT CCT TAA AAC TGG CAA TGC ATT CTT CAA 540 r Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu Ala Met His Ser Ser Me 5 150 155 160 TGC CAC TGG TTT TCT TTG GAC CAT TTA ATC CTA ACC TAC GCG ACC ATG 588 t Pro Leu Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His As 165 170 175 ACC GGC TGC CCC ATG TCC ATC AGG TAG CCC CCA AGG ACA CAC ATT TGT 636 p Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu Se 180 185 190 CCC ATG GCA TGG TCT CCT TGA TGT TTC ATT TTA GGT GGA CTT GGA TAG 684 r His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He Gl 195 200 205 GAC TGG TCA TCT CAG ATG ATG ATC AGG GTA TTC AGT TTC TCT CAG ATT 732 y Leu Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp Le 210 215 220 2 TAA GAG AAG AAA GCC AAA GGC ATG GGA TCT GTT TGG CTT TTG TTA ATA 780 u Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn Me 5 230 235 240 TGA TCC CAG AAA ACA TGC AGA TAT ACA TGA CAA GGG CTA CAA TAT ATG 828 t He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr As 245 250 255 ATA CAC AAA TTA TGA CAT CTT CAG CAA AGG TTG TTA TCA TTT ATG GTG 876 p Thr Gin He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly As 260 265 270 ACA TGA ACT CTA CTC TAG AAG CAA GCT TTA GAA GAT GGG AAG AGT TAG 924 p Met Asn Ser Thr Leu Glu Ala Ser Phe Arg Arg Trp Glu Glu Leu Gl 275 280 285 GTG CTC GGA GAA TCT GGA TCA CAA CCA CAC AAT GGG ATG TCA TCA CAA 972 y Ala Arg Arg He Trp He Thr Thr Thr Gin Trp Asp Val He Thr As 290 295 300 3 ATA AAA AAA GAC TTC ACC CT TAATCTCTTC CATGGGACTA TTACTTTTGC ACACC 1027 n Lys Lys Arg Leu His Pro 5 310 ACAAAGATGA GATTCCTAAA TTTAGGAATT TTATGCAAAC AAAGAAAACT GCCAAATACC 1087 TTGTAGATAT TTCTCATACT ATTTTGGAGT GGAATTATTT TAATTGTTCA ATCTCTAAGA 1147 ACAGCAGTAA AATGGGTCAT TTTACATTCA ACAACACATT GCAATGGACA GCACTGCACA 1207 ACTATGATAT GGCCCTGAGC GATGAAGGTT ACAATTTGTA TAATGCTGTT TATGCTGTGG 1267 CCCACACCTA CCATGAATAC ATTCTTCAAC AAGTAGAGTC TCAGAAAAAG GCAAAACCCA 1327 AAAGATATTT CACTGCTTGT CAGCAGGTTC CCTCCTCTGT GTGTAGTGTG GCATGTACTG 1387 CAGGATTCAG GAAAATTCAT CAGAAAGAAA CGGCAGATTG CTGCTTTGAT TGTGTTCAGT 1447 GCCTAGAAAA TGAGGTTTCC AATGAAACAG ATATGGAACA GTGTGTGAGA TGTCCAGATA 1507 ATAAATATGC CAATTTAGAG CAAACCCACT GCCTCCAAAG AACGGTGTCA TTTCTGGCTT 1567 ATGAAGATCC ATTGGGGATG GCTCTAGGCT GCATGGCACT GTCCTTCTCG GCCATCACAA 1627 TTCTAGTCCT CGTCACATTT GTGAAGTACA AGGATACTCC CATTGTGAAG GCCAATAACC 1687 GCATTCTCAG CTACATCCTG CTCATCTCTC TCGTCTTCTG CTTTCTCTGT TCCCTGCTCT 1747 TCATTGGACA TCCCGACCAG GTCACCTGCA TCTTGCAGCA GACCACATTT GGAGTATTGT 1807 TCACTGTGTC TGTTTCTACA GTGTTGGCCA AAACAATAAC TGTGGTCATG GCTTTCAAGC 1867 TCACTACTCC AGGAAGAAGG ATGAGAGGGA TGATGATGAC AGGGGCACCT AAGTTGGTCA 1927 TTCCCATTTG TACCCTGATC CAACTTGTTC TCTGTGGAAT CTGGTTGGTC ACATCTCCTC 1987 CCTTTATTGA CAGAGATATA CAATCTGAAC ATGGGAAGAT TGTCATTCTT TGCAATAAAG 2047 GCTCTGTCGT TGCCTTCCAC GTCGTCCTGG GATACTTGGG CTCCTTGGCT CTGGGGAGCT 2107 TCACTTTGGC TTTCTTGGCT AGGAACCTTC CTGACACATT CAATGAAGCC AAGTTCCTAA 2167 CTTTCAGCAT GCTGGTGTTC TGCAGTGTCT GGATCACCTT CCTCCCTGTC TACCACAGCA 2227 CCAGGGGGAA GGTCATGGTG GTTGTGGAGG TTTTCTCCAT CTTGGCTTCT AGTGCAGGGT 2287 TGCTAATGTG TATCTTTGTC CCAAAGTGTT ATGTTATTTT AATTAGACCA GATTCAAATT 2347 TTATACAGAA CCACAAAGGT AAATTGCTTT ATTGAAACTT TCATGGTATG AAAATGTTAG 2407 ATGATATTCA ACTTATCTTA TTCTTCATCT TAATAAAAGC AGTACTTCAT CATATAAAAA 2467 ATAAAGTAAT ATACAGATTT ATACTTACAA ACTGGACAGC AAACATGAAT ATGTTGAGAA 2527 CTGGGATTCT CAATTGAGGA ATGGCTACCA ATATTTTGAT CTGTGGTTTT GTGTTTAAGC 2587 CATGTACTTA ATTAATGATT AACATGAGGT TACCCTACTG TCTTTGAACA GCGCCACCTC 2647 TAGGCATGCT GTCCTTGAGT TATAAGAAAG GGTACTGCAT ACACAATGGA CATGAAGCCA 2707 GTAATCAACA TTATTCCACT TGCTTTCATG GAGTTCTTAC TTCCAAGTTC ATGCCTTGAC 2767 TTTATTCAAT GTTCTATGAC AAAGGTAGAA TAAATAAATA AACACTTTCC TCAC 2821 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Met Lys Gin Leu Cys Thr Phe Thr He Ser Leu Leu Phe Leu Lys Phe 1 5 10 15 Ser Leu He Leu Cys Cys Trp Ser Glu Pro Ser Cys Phe Trp Arg He 20 25 30 Lys Lys Ser Glu Asp Asn Asp Gly Asp Leu Gin Arg Glu Cys His Phe 35 40 45 Tyr Leu Trp Lys Thr Asp Glu Pro He Glu Asp Ser Phe Tyr Asn Tyr 50 55 60 Asp Leu Ser Phe Arg He Ala Gly Ser Glu Tyr Glu Leu Leu Leu Val 65 70 75 80 Met Phe Phe Ala Thr Asp Glu He Asn Lys Asn Pro Tyr Leu Leu Pro 85 90 95 Asn Met Ser Leu Met Phe Ser He He Gly Gly Asn Cys His Asp Leu 100 105 110 Leu Arg Ser Leu Asp Gin Glu Tyr Ala Gin He Asp Gly His Met Asn 115 120 125 Phe Val Asn Tyr Phe Cys Tyr Leu Asp Asp Ser Cys Ala Thr Gly Leu 130 135 140 Thr Gly Pro Ser Trp Lys Thr Ser Leu Lys Leu Ala Met His Ser Ser 145 150 155 160 Met Pro Leu Val Phe Phe Gly Pro Phe Asn Pro Asn Leu Arg Asp His 165 170 175 Asp Arg Leu Pro His Val His Gin Val Ala Pro Lys Asp Thr His Leu 180 185 190 Ser His Gly Met Val Ser Leu Met Phe His Phe Arg Trp Thr Trp He 195 200 205 Gly Leu Val He Ser Asp Asp Asp Gin Gly He Gin Phe Leu Ser Asp 210 215 220 Leu Arg Glu Glu Ser Gin Arg His Gly He Cys Leu Ala Phe Val Asn 225 230 235 240 Met He Pro Glu Asn Met Gin He Tyr Met Thr Arg Ala Thr He Tyr 245 250 255 Asp Thr Gin He Met Thr Ser Ser Ala Lys Val Val He He Tyr Gly 260 265 270 Asp Met Asn Ser Thr Leu Glu Ala Ser Phe Arg Arg Trp Glu Glu Leu 275 280 285 Gly Ala Arg Arg He Trp He Thr Thr Thr Gin Trp Asp Val He Thr 290 295 300 Asn Lys Lys Arg Leu His Pro 305 310 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2773 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 3...1238 (D) OTHER INFORMATION: VR13 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: AA GCA AGT TGC TTT TGG CGG ATA AAG AAT AGT GAA GAT AAT GAT GGA 47 Ala Ser Cys Phe Trp Arg He Lys Asn Ser Glu Asp Asn Asp Gly 1 5 10 15 GAT TTG CAA AGG GAA TGT CAT TTT TAC CTT GGG GCA GTT GAT AAA CCA 95 Asp Leu Gin Arg Glu Cys His Phe Tyr Leu Gly Ala Val Asp Lys Pro 20 25 30 ATT GAA GAT AAT TTT TAT AAT TCA CTT TTA AAG TTT AGA ATT GCA GCA 143 He Glu Asp Asn Phe Tyr Asn Ser Leu Leu Lys Phe Arg He Ala Ala 35 40 45 AGT GAA TAT GAG TTT CTT CTG GTA ATG TTT TTT GCT ACT GAT GAG ATC 191 Ser Glu Tyr Glu Phe Leu Leu Val Met Phe Phe Ala Thr Asp Glu He 50 55 60 AAC AAG AAT CCT TAT CTT TTA CCC AAC ATA ACT TTG ATG TTC TCC ATC 239 Asn Lys Asn Pro Tyr Leu Leu Pro Asn He Thr Leu Met Phe Ser He 65 70 75 ATT GGT GGA AAC TGT CAT GAT TTA TTG AGA GGT TTG GAT CAA GCA TAT 287 He Gly Gly Asn Cys His Asp Leu Leu Arg Gly Leu Asp Gin Ala Tyr 80 85 90 95 ACA CAA ATA AAT GGA CAT ATG AAT TTT GTT AAT TAT TTC TGT TAT TTA 335 Thr Gin He Asn Gly His Met Asn Phe Val Asn Tyr Phe Cys Tyr Leu 100 105 110 GAT GAT TCA TGT GCC ATA GGT CTT ACA GGA CCA TCA TGG AAA ACA TCC 383 Asp Asp Ser Cys Ala He Gly Leu Thr Gly Pro Ser Trp Lys Thr Ser 115 120 125 TTA AAA CTG GCA ATG CAT TCT TCA ATG CCA CTG GTT TTC TTT GGA TCA 431 Leu Lys Leu Ala Met His Ser Ser Met Pro Leu Val Phe Phe Gly Ser 130 135 140 TTT AAT CCT AAC CTA CAT GAC CAT GAC CGG CTG CAC CAT GTC CAT CAA 479 Phe Asn Pro Asn Leu His Asp His Asp Arg Leu His His Val His Gin 145 150 155 GTA GCC ACC AAG GAC ACA CAT TTG TCC CAT GGC ATT GTC TCC TTG ATG 527 Val Ala Thr Lys Asp Thr His Leu Ser His Gly He Val Ser Leu Met 160 165 170 175 TTT CAT TTT AGA TGG ACT TGG ATA GGA CTG GTC ATC TCA GAT GAT GAC 575 Phe His Phe Arg Trp Thr Trp He Gly Leu Val He Ser Asp Asp Asp 180 185 190 AAG GGT ATT CAG TTT CTC TCA GAT TTA AGA GAA GAA AGC CAA AGG CAT 623 Lys Gly He Gin Phe Leu Ser Asp Leu Arg Glu Glu Ser Gin Arg His 195 200 205 GGG ATC TGT TTA GCT TTT GTT AAT ATG ATC CCA GAA AAC ATG CAG ATA 671 Gly He Cys Leu Ala Phe Val Asn Met He Pro Glu Asn Met Gin He 210 215 220 TAC ATG ACA AGG GCT ACA ATA TAT GAT AAA CAA ATT ATG ACG TCT TTA 719 Tyr Met Thr Arg Ala Thr He Tyr Asp Lys Gin He Met Thr Ser Leu 225 230 235 GCA AAA GTT GTT ATC ATT TAT GGT GAA ATG AAC TCT ACA CTA GAA GTA 767 Ala Lys Val Val He He Tyr Gly Glu Met Asn Ser Thr Leu Glu Val 240 245 250 255 AGC TTT AGA AGA TGG GAA AAT TTA GGT GCT CGG AGA ATC TGG ATC ACA 815 Ser Phe Arg Arg Trp Glu Asn Leu Gly Ala Arg Arg He Trp He Thr 260 265 270 ACC TCA CAA TGG GAT GTC ATC ACA AAT AAA AAA GAA TTC ACC CTT AAT 863 Thr Ser Gin Trp Asp Val He Thr Asn Lys Lys Glu Phe Thr Leu Asn 275 280 285 CTC TTC CAT GGG ACT ATT ACT TTT GCA CAC CGC AGA TTT GAG ATT CCT 911 Leu Phe His Gly Thr He Thr Phe Ala His Arg Arg Phe Glu He Pro 290 295 300 AAA TTT AAA AAA TTT ATG CAA ACA ATG AAC ACT GCC AAA TAC CCA GTA 959 Lys Phe Lys Lys Phe Met Gin Thr Met Asn Thr Ala Lys Tyr Pro Val 305 310 315 GAT ATT TCT CAT ACT ATA TTG GAG TGG AAT TAT TTT AAT TGT TCA ATC 1007 Asp He Ser His Thr He Leu Glu Trp Asn Tyr Phe Asn Cys Ser He 320 325 330 335 TCT AAG AAC AGC AGT AAA ATG GAT CAT ATT ACA TTC AAC AAC ACA TTG 1055 Ser Lys Asn Ser Ser Lys Met Asp His He Thr Phe Asn Asn Thr Leu 340 345 350 GAA TGG ACA GCA CTG CAC AAC TAT GAT ATG GTG ATG AGT GAT GAA GGT 1103 Glu Trp Thr Ala Leu His Asn Tyr Asp Met Val Met Ser Asp Glu Gly 355 360 365 TAC AAT TTG TAT AAT GCT GTT TAT GCT GTG GCC CAC ACC TAC CAT GAA 1151 Tyr Asn Leu Tyr Asn Ala Val Tyr Ala Val Ala His Thr Tyr His Glu 370 375 380 CAT ATT TTT CAA CAA GTA GAG TCT CAG AAA AAG GCA AAA CCC AAA AGA 1199 His He Phe Gin Gin Val Glu Ser Gin Lys Lys Ala Lys Pro Lys Arg 385 390 395 - I ll - TTT TTC ACT GTT TGT CAG CAG CAG ATA TGG AAC AGT GTG TGAAGTGTCC AT 1250 Phe Phe Thr Val Cys Gin Gin Gin He Trp Asn Ser Val 400 405 410 ATGATAAGTA TGCCAACATA GAGAAAACCC ACTGCCTCTC AAGAGCTGTA TCATTTCTGG 1310 CTTATGAAGA TCCATTGGGG ATAGCTCTAG GCTGCATAGC ACTGTCCTTC TCAGCCATCA 1370 CAATTCTAGT ACTAATCACA TTTTTGAAGT ACAAGGATAC TCCCATTGTG AAGGCCAATA 1430 ACCGCATTCT CAGCTACATC CTGCTCATCT CTCTAGTCTT CTGCTTTCTC TGCTCCCTGC 1490 TCTTCATTGG ACATCCAAAC CAGGTCTCCT GCGTCTTGCA GCAGACCACA TTTGGAGTAT 1550 TTTTCACTGT GTCTGTTTCT ACAGTGTTGG CCAAAACAAT AACTGTGGTC ATGGCTTTCA 1610 AGCTCACTAC TCCAGGAAGA AGAATGAGAG AGATGTTGGT AACAGGGGCA CCTAAGTTGG 1670 TCATTCCCAT TTGTACCCTA ATCCAATTTG TTCTCTGTGG AATCTGGTTG ATAACATCTC 1730 CTCCATTTAT TGACAGAGAT ATACAATCTG AGCATGGGAA GATTGTCATT CTTTGCAATA 1790 AAGGCTCTGT CATTGCCTTC CATGTTGTCC TGGGATACTT GGGCTCCTTG GCTCTGGGGA 1850 GCTTCACTTT GGCTTTCTTG GCTAGGAACC TTCCTGACAC ATTCAATGAA GCCAAATTCC 1910 TGACTTTCAG CATGCTGGTG TTCTGCAGTG TCTGGATCAC CTTTCTCCCT GTCTACCATA 1970 GCACCAGGGG GAAGGTCATG GTGGTTGTGG AGGTTTTCTC AATCTTGGCT TCTAGTGCAG 2030 GGTTGCTAAT GTGTATCTTT GTCCCAAAGT GTTATGTTAT TTTAGTTAGA CCAGATTCAA 2090 ATTTTATACG GAAGTACAAA GATAAATTTC GTTATTGAAA TATTCATACT ATGAAAATGT 2150 TAGATTATAC TCAACATATT TTTCTTTGTC TTAACAAAAG TAGTACTTAA TCTTATAAAA 2210 ATTTAAATAA TATACAAATT TGAACTTACA AACAGGACAG AACTGTCTAT TGTAATACCA 2270 ATTACAAAAC TTTGGTGAAA AATGGTCTCA TTCATAAGGA CACAATTCTG AAGATATTGA 2330 GAACCAGGAA TCTCAACTGC GGAAACGCTA CCATCATCCT GACCTGTGGT TTTGTGTGTA 2390 AAGCATGAAC TTAATTAATG ATTAATATAA GGTGACCATA CTGACTGTGA ACACTACCAT 2450 CTCTGGGCAA GTTGTTCTTG TAGTTGTAAG AAAAAGCTCT GAAGACAACA TGGAAGTAAA 2510 GCCAGTAATC ACCATTATCC CTCATGCTTT CATGGAGTGG CTGCATCCAA TTTCATGCCT 2570 TGGCTTCATT CAATATACTG TGACCAAGGT ACATAAGTAA AGAAACACTT TTCTTACAAG 2630 CTTCTTCTGA TCGTTGTGGG TTTTTTTGTT TTTTGTTTTT TGTTTTTTGT TTGTTTGTTT 2690 GTATTTTTAC ATCAACGGAA TTTAAAATAT CAACAAAATG GTAAATTGTT TCTGTTGAGA 2750 TTTAGAATAT CATCGATTCC TGA 2773 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 412 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: Ala Ser Cys Phe Trp Arg He Lys Asn Ser Glu Asp Asn Asp Gly Asp 1 5 10 15 Leu Gin Arg Glu Cys His Phe Tyr Leu Gly Ala Val Asp Lys Pro He 20 25 30 Glu Asp Asn Phe Tyr Asn Ser Leu Leu Lys Phe Arg He Ala Ala Ser 35 40 45 Glu Tyr Glu Phe Leu Leu Val Met Phe Phe Ala Thr Asp Glu He Asn 50 55 60 Lys Asn Pro Tyr Leu Leu Pro Asn He Thr Leu Met Phe Ser He He 65 70 75 80 Gly Gly Asn Cys His Asp Leu Leu Arg Gly Leu Asp Gin Ala Tyr Thr 85 90 95 Gin He Asn Gly His Met Asn Phe Val Asn Tyr Phe Cys Tyr Leu Asp 100 105 110 Asp Ser Cys Ala He Gly Leu Thr Gly Pro Ser Trp Lys Thr Ser Leu 115 120 125 Lys Leu Ala Met His Ser Ser Met Pro Leu Val Phe Phe Gly Ser Phe 130 135 140 Asn Pro Asn Leu His Asp His Asp Arg Leu His His Val His Gin Val 145 150 155 160 Ala Thr Lys Asp Thr His Leu Ser His Gly He Val Ser Leu Met Phe 165 170 175 His Phe Arg Trp Thr Trp He Gly Leu Val He Ser Asp Asp Asp Lys 180 185 190 Gly He Gin Phe Leu Ser Asp Leu Arg Glu Glu Ser Gin Arg His Gly 195 200 205 He Cys Leu Ala Phe Val Asn Met He Pro Glu Asn Met Gin He Tyr 210 215 220 Met Thr Arg Ala Thr He Tyr Asp Lys Gin He Met Thr Ser Leu Ala 225 230 235 240 Lys Val Val He He Tyr Gly Glu Met Asn Ser Thr Leu Glu Val Ser 245 250 255 Phe Arg Arg Trp Glu Asn Leu Gly Ala Arg Arg He Trp He Thr Thr 260 265 270 Ser Gin Trp Asp Val He Thr Asn Lys Lys Glu Phe Thr Leu Asn Leu 275 280 285 Phe His Gly Thr He Thr Phe Ala His Arg Arg Phe Glu He Pro Lys 290 295 300 Phe Lys Lys Phe Met Gin Thr Met Asn Thr Ala Lys Tyr Pro Val Asp 305 310 315 320 He Ser His Thr He Leu Glu Trp Asn Tyr Phe Asn Cys Ser He Ser 325 330 335 Lys Asn Ser Ser Lys Met Asp His He Thr Phe Asn Asn Thr Leu Glu 340 345 350 Trp Thr Ala Leu His Asn Tyr Asp Met Val Met Ser Asp Glu Gly Tyr 355 360 365 Asn Leu Tyr Asn Ala Val Tyr Ala Val Ala His Thr Tyr His Glu His 370 375 380 He Phe Gin Gin Val Glu Ser Gin Lys Lys Ala Lys Pro Lys Arg Phe 385 390 395 400 Phe Thr Val Cys Gin Gin Gin He Trp Asn Ser Val 405 410 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3108 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 116...2527 (D) OTHER INFORMATION: VR14 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: GAATATGCAA TAAACATCTC CTTTGCCTAA AGAAATAAAA GCTGGTAGAA ATCTGATGTG 60 CTGATATGCA TGGCACTTCA CAATCCACAC TGCCCAGGTT TAAGGCAGGA AAAAG ATG 118 Met 1 TTC ATT TTC ATG GAA GTC TTC TTC CTC CTT AAT ATT ACA CTT CTC ATG 166 Phe He Phe Met Glu Val Phe Phe Leu Leu Asn He Thr Leu Leu Met 5 10 15 GCC AAT TTC ATT GAT CCC AGG TGC TTT TGG AGA ATA AAT TTG GAT GAA 214 Ala Asn Phe He Asp Pro Arg Cys Phe Trp Arg He Asn Leu Asp Glu 20 25 30 ATA ATG GAT GAA TAT TTG GGA TTA TCT TGT GCT TTC ATC CTG GCA GCA 262 He Met Asp Glu Tyr Leu Gly Leu Ser Cys Ala Phe He Leu Ala Ala 35 40 45 GTT CAG ACA CCC ATT GAA AAT GAT TAT TTC AAC AAG ACT CTT AAT GTT 310 Val Gin Thr Pro He Glu Asn Asp Tyr Phe Asn Lys Thr Leu Asn Val 50 55 60 65 CTA AAA ACA ACT AAA AAC CAC AAA TAT GCT TTG GCA TTG GTG TTT GCA 358 Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Val Phe Ala 70 75 80 ATG GAT GAA ATC AAC AGA AAT CCT GAT CTT TTA CCA AAT ATG TCT TTG 406 Met Asp Glu He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser Leu 85 90 95 ATT ATA AGA TAC ACT TTG GGC CGT TGT GAT GGA AAA ACT GTA ATA CCT 454 He He Arg Tyr Thr Leu Gly Arg Cys Asp Gly Lys Thr Val He Pro 100 105 110 ACA CCA TAT TTA TTT CGT AAA AAA AAA GAA AGC CCT ATC CCT AAT TAT 502 Thr Pro Tyr Leu Phe Arg Lys Lys Lys Glu Ser Pro He Pro Asn Tyr 115 120 125 TTC TGT AAT GAA GAG ACT ATG TGT TCC TAT CTG CTT ACA GGA CCC CAT 550 Phe Cys Asn Glu Glu Thr Met Cys Ser Tyr Leu Leu Thr Gly Pro His 130 135 140 145 TGG GAG GTA TCT TTA GGT TTC TGG AAG CAC ATG AAC AGC TTC TTA TCT 598 Trp Glu Val Ser Leu Gly Phe Trp Lys His Met Asn Ser Phe Leu Ser 150 155 160 CCA CGT ATC CTT CAG CTT ACC TAT GGA CCT TTC CAC TCC ATC TTC AGT 646 Pro Arg He Leu Gin Leu Thr Tyr Gly Pro Phe His Ser He Phe Ser 165 170 175 GAT GAT GAA CAA TAT CCC TAT CTC TAT CAG ATG GCC CCA AAG GAC ACA 694 Asp Asp Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Ala Pro Lys Asp Thr 180 185 190 TCT CTA GCA TTG GCA ATG GTC TCC TTC ATA CTT TAC TTT AGC TGG AAC 742 Ser Leu Ala Leu Ala Met Val Ser Phe He Leu Tyr Phe Ser Trp Asn 195 200 205 TGG ATT GGC CTT GTC ATT CCA GAT GAT GAC CAA GGA AAC CAA TTT CTT 790 Trp He Gly Leu Val He Pro Asp Asp Asp Gin Gly Asn Gin Phe Leu 210 215 220 225 TTA GAG TTG AAG AAA CAG AGT GAA AAC AAG GAA ATT TGC TTT GCC TTT 838 Leu Glu Leu Lys Lys Gin Ser Glu Asn Lys Glu He Cys Phe Ala Phe 230 235 240 GTG AAA ATG ATC TCT GTT GAT GAT GTT TCA TTT CCA CAA AAT ACT GAA 886 Val Lys Met He Ser Val Asp Asp Val Ser Phe Pro Gin Asn Thr Glu 245 250 255 ATG TAC TAC AAC CAA ATT GTG ATG TCA TCC ACA AAT GTT ATT ATC ATT 934 Met Tyr Tyr Asn Gin He Val Met Ser Ser Thr Asn Val He He He 260 265 270 TAT GGA GAA ACA TAC AAT TTC ATT GAT TTG ATC TTC AGA ATG TGG GAA 982 Tyr Gly Glu Thr Tyr Asn Phe He Asp Leu He Phe Arg Met Trp Glu 275 280 285 CCT CCC ATT TTA CAG AGA ATA TGG ATC ACC ACA AAA CAA TTG AAT TTC 1030 Pro Pro He Leu Gin Arg He Trp He Thr Thr Lys Gin Leu Asn Phe 290 295 300 305 CCT ACC AGG AAA AAA GAC ATA AGT CAT GGC ACA TTC TAT GGA TCA CTT 1078 Pro Thr Arg Lys Lys Asp He Ser His Gly Thr Phe Tyr Gly Ser Leu 310 315 320 ACT TTT CTA CCC CAC CAT GGT GTG ATT TCT GGT TTT AAA AAT TTT GTA 1126 Thr Phe Leu Pro His His Gly Val He Ser Gly Phe Lys Asn Phe Val 325 330 335 CAG ACA TGG TTC CAT CTC AGA AAC ACA GAT TTA TAT CTA GTA ATG CAA 1174 Gin Thr Trp Phe His Leu Arg Asn Thr Asp Leu Tyr Leu Val Met Gin 340 345 350 GAG TGG AAA TAC TTT AAC TAT GAA GAC TCA GCA TCT ACC TGT AAA ATA 1222 Glu Trp Lys Tyr Phe Asn Tyr Glu Asp Ser Ala Ser Thr Cys Lys He 355 360 365 CTG AAG AAC AAT TCA TCT AAT GCC TCA TTT GAT TGG CTA ATG GAA CAG 1270 Leu Lys Asn Asn Ser Ser Asn Ala Ser Phe Asp Trp Leu Met Glu Gin 370 375 380 385 AAG TTT GAC ATG ACC TTT AGT GAG AAT AGT CAT AAC ATA TAC AAT GCT 1318 Lys Phe Asp Met Thr Phe Ser Glu Asn Ser His Asn He Tyr Asn Ala 390 395 400 GTG CAT GCC ATA GCC CAT GCC CTC CAT GAG ATG AAT CTG CAA CAG GCT 1366 Val His Ala He Ala His Ala Leu His Glu Met Asn Leu Gin Gin Ala 405 410 415 GAT AAT CAG GCA ATA GAC AAT GGG AAA AAG GAG CCC AGT TCC TCC CAC 1414 Asp Asn Gin Ala He Asp Asn Gly Lys Lys Glu Pro Ser Ser Ser His 420 425 430 TGC TTG AAG GTA AAC TCC TTT CTA AGA AGG ATT TAC TTC ACT AAT CCT 1462 Cys Leu Lys Val Asn Ser Phe Leu Arg Arg He Tyr Phe Thr Asn Pro 435 440 445 CCT GGG GAC AAA GTG TTT ATG AAG CAA AGA GTA ATA ATG CAC GAT GAA 1510 Pro Gly Asp Lys Val Phe Met Lys Gin Arg Val He Met His Asp Glu 450 455 460 465 TAT GAC ATT GTT CAC TTT GTG AAT CTC TCA CAA CAC CTT GGG ATT AAG 1558 Tyr Asp He Val His Phe Val Asn Leu Ser Gin His Leu Gly He Lys 470 475 480 ATG AAG TTA GGA AAG TTC AGC CCA TAT TTA CCA CAT GGT CGA CAC TCT 1606 Met Lys Leu Gly Lys Phe Ser Pro Tyr Leu Pro His Gly Arg His Ser 485 490 495 CAC TTA TAT GTA GAC AGG ATT GAG TTG GCC ACA GGA AGA AGA AAG ATG 1654 His Leu Tyr Val Asp Arg He Glu Leu Ala Thr Gly Arg Arg Lys Met 500 505 510 CCA TCC TCT GTG TGC AGT GCT GAT TGT AGT CCT GGA TTC AGA AGA TTA 1702 Pro Ser Ser Val Cys Ser Ala Asp Cys Ser Pro Gly Phe Arg Arg Leu 515 520 525 TGG AAG GAG GGA ATG GCA GCC TGC TGT TTT GTT TGC AGC CCC TGC CCT 1750 Trp Lys Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser Pro Cys Pro 530 535 540 545 GAA AAT GAA ATT TCT AAT GAG ACA ACT GTG GTA CTT TGT GTC TTT GTG 1798 Glu Asn Glu He Ser Asn Glu Thr Thr Val Val Leu Cys Val Phe Val 550 555 560 AAG CAT CAT GAC ACT CCT ATT GTG AAG GCC AAT AAC AGA AGC CTC AGC 1846 Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg Ser Leu Ser 565 570 575 TAC CTA TTA CTC ATG TCA CTC ATG TCC TGT TTT CTG TGC TCC TTT TTC 1894 Tyr Leu Leu Leu Met Ser Leu Met Ser Cys Phe Leu Cys Ser Phe Phe 580 585 590 TTC ATT GGC CTT CCA AAC AGA GCC ATC TGT GTC TTA CAG CAA ATC ACA 1942 Phe He Gly Leu Pro Asn Arg Ala He Cys Val Leu Gin Gin He Thr 595 600 605 TTT GGA ATT GTA TTC ACT ATG GCT GTT TCC ACA GTT CTG GCC AAA ACA 1990 Phe Gly He Val Phe Thr Met Ala Val Ser Thr Val Leu Ala Lys Thr 610 615 620 625 GTC ACT GTG GTT CTG GCT TTC AAA GTC ACA GAC CCA GGA AGA AGA TTG 2038 Val Thr Val Val Leu Ala Phe Lys Val Thr Asp Pro Gly Arg Arg Leu 630 635 640 AGA AAC TTC CTG GTA TCA GGA ACA CCC AAC TAC ATT ATT CCC ATA TGT 2086 Arg Asn Phe Leu Val Ser Gly Thr Pro Asn Tyr He He Pro He Cys 645 650 655 TCC CTA CTC CAA TGT GTT CTG TGT GCA ATC TGG CTA GCA GTT TCT CCT 2134 Ser Leu Leu Gin Cys Val Leu Cys Ala He Trp Leu Ala Val Ser Pro 660 665 670 CCC TTT GTT GAT ATT GAT GAA CAC ACT CTC CAT GGC CAC ATC ATC ATT 2182 Pro Phe Val Asp He Asp Glu His Thr Leu His Gly His He He He 675 680 685 GTG TGC AAC AAG GGC TCA GTT ACT GCA TTC TAC TGT ATC CTA GGA TAC 2230 Val Cys Asn Lys Gly Ser Val Thr Ala Phe Tyr Cys He Leu Gly Tyr 690 695 700 705 TTG GCC TGC CTG GCA CTT GGA AAC TTC TCT GTG GCT TTC TTG GCC AAG 2278 Leu Ala Cys Leu Ala Leu Gly Asn Phe Ser Val Ala Phe Leu Ala Lys 710 715 720 AAT CTG CCT GAC ACA TTC AAT GAA GCC AAG TTC TTG ACC TTC AGC ATG 2326 Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met 725 730 735 CTA GTG TTC TGT AGT GTC TGG GTC ACC TTC CTC CCT GTC TAC CAT AGC 2374 Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His Ser 740 745 750 ACC AAG GGC AAA CAC ATG GTT GCT GTG GAG ATC TTC TCC ATC TTG GCA 2422 Thr Lys Gly Lys His Met Val Ala Val Glu He Phe Ser He Leu Ala 755 760 765 TCC AGT GCT GGG ATC CTT GGA TGT ATA TTT GTA CCC AAG ATT TAT ATC 2470 Ser Ser Ala Gly He Leu Gly Cys He Phe Val Pro Lys He Tyr He 770 775 780 785 ATT TTA ATG AGA CCA GAG AGA AAT TCG ACC CAA AAG ATC AGG GAA AAA 2518 He Leu Met Arg Pro Glu Arg Asn Ser Thr Gin Lys He Arg Glu Lys 790 795 800 TCA TAT TTC TGAACAAATA TTTAGGAATT CTGTCAAATG TAAAGTTGGT ACATACCCA 2576 Ser Tyr Phe CCAAATATTG GGTTATAGTG CATGTGTCTA GTTTTAGAAT CACTCTCACT GGTTGCTCTA 2636 GTGATATCAG CAAGTATCAT ATCTACTGAA CTTCCCTACA GTGTCCATAA AATCTTGTAC 2696 TCATTCACTT TCTTCATTTT CTCTCAGAGA ACTAAACTCT CTAATTATTA CAATTTTATT 2756 CTTCATTTTG CTTTCATGGA GATTGCCCTC TGGTAACTTC CAAAAAATGT TGATAAGGCA 2816 GTTGAATCCA CCACTTTGTG TAGAAAAATG AGATCTAGGA AGACAGGGTT ACACATAAAA 2876 ACCATCTACC AAAATAAATA ATCAATGAGA AACACAGACT AACTAAATAA TCAGCAAAGA 2936 TGAAATCAGA ACATATTTTC TAATTTCCAG TAAGAGCACA CACATAAGAA AATACTTACT 2996 TTTTTCATCT GTTCTTCAAT CTACTGGCCA ATAGTCTAAG GAGGAAATGT TCCTTTTCTG 3056 CTGTCAAATA AAAATATATT ATATCCAAAA AAAAAAAAAA AAAAAAAAAA AA 3108 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 804 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: Met Phe He Phe Met Glu Val Phe Phe Leu Leu Asn He Thr Leu Leu 1 5 10 15 Met Ala Asn Phe He Asp Pro Arg Cys Phe Trp Arg He Asn Leu Asp 20 25 30 Glu He Met Asp Glu Tyr Leu Gly Leu Ser Cys Ala Phe He Leu Ala 35 40 45 Ala Val Gin Thr Pro He Glu Asn Asp Tyr Phe Asn Lys Thr Leu Asn 50 55 60 Val Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Val Phe 65 70 75 80 Ala Met Asp Glu He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser 85 90 95 Leu He He Arg Tyr Thr Leu Gly Arg Cys Asp Gly Lys Thr Val He 100 105 110 Pro Thr Pro Tyr Leu Phe Arg Lys Lys Lys Glu Ser Pro He Pro Asn 115 120 125 Tyr Phe Cys Asn Glu Glu Thr Met Cys Ser Tyr Leu Leu Thr Gly Pro 130 135 140 His Trp Glu Val Ser Leu Gly Phe Trp Lys His Met Asn Ser Phe Leu 145 150 155 160 Ser Pro Arg He Leu Gin Leu Thr Tyr Gly Pro Phe His Ser He Phe 165 170 175 Ser Asp Asp Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Ala Pro Lys Asp 180 185 190 Thr Ser Leu Ala Leu Ala Met Val Ser Phe He Leu Tyr Phe Ser Trp 195 200 205 Asn Trp He Gly Leu Val He Pro Asp Asp Asp Gin Gly Asn Gin Phe 210 215 220 Leu Leu Glu Leu Lys Lys Gin Ser Glu Asn Lys Glu He Cys Phe Ala 225 230 235 240 Phe Val Lys Met He Ser Val Asp Asp Val Ser Phe Pro Gin Asn Thr 245 250 255 Glu Met Tyr Tyr Asn Gin He Val Met Ser Ser Thr Asn Val He He 260 265 270 He Tyr Gly Glu Thr Tyr Asn Phe He Asp Leu He Phe Arg Met Trp 275 280 285 Glu Pro Pro He Leu Gin Arg He Trp He Thr Thr Lys Gin Leu Asn 290 295 300 Phe Pro Thr Arg Lys Lys Asp He Ser His Gly Thr Phe Tyr Gly Ser 305 310 315 320 Leu Thr Phe Leu Pro His His Gly Val He Ser Gly Phe Lys Asn Phe 325 330 335 Val Gin Thr Trp Phe His Leu Arg Asn Thr Asp Leu Tyr Leu Val Met 340 345 350 Gln Glu Trp Lys Tyr Phe Asn Tyr Glu Asp Ser Ala Ser Thr Cys Lys 355 360 365 He Leu Lys Asn Asn Ser Ser Asn Ala Ser Phe Asp Trp Leu Met Glu 370 375 380 Gin Lys Phe Asp Met Thr Phe Ser Glu Asn Ser His Asn He Tyr Asn 385 390 395 400 Ala Val His Ala He Ala His Ala Leu His Glu Met Asn Leu Gin Gin 405 410 415 Ala Asp Asn Gin Ala He Asp Asn Gly Lys Lys Glu Pro Ser Ser Ser 420 425 430 His Cys Leu Lys Val Asn Ser Phe Leu Arg Arg He Tyr Phe Thr Asn 435 440 445 Pro Pro Gly Asp Lys Val Phe Met Lys Gin Arg Val He Met His Asp 450 455 460 Glu Tyr Asp He Val His Phe Val Asn Leu Ser Gin His Leu Gly He 465 470 475 480 Lys Met Lys Leu Gly Lys Phe Ser Pro Tyr Leu Pro His Gly Arg His 485 490 495 Ser His Leu Tyr Val Asp Arg He Glu Leu Ala Thr Gly Arg Arg Lys 500 505 510 Met Pro Ser Ser Val Cys Ser Ala Asp Cys Ser Pro Gly Phe Arg Arg 515 520 525 Leu Trp Lys Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser Pro Cys 530 535 540 Pro Glu Asn Glu He Ser Asn Glu Thr Thr Val Val Leu Cys Val Phe 545 550 555 560 Val Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg Ser Leu 565 570 575 Ser Tyr Leu Leu Leu Met Ser Leu Met Ser Cys Phe Leu Cys Ser Phe 580 585 590 Phe Phe He Gly Leu Pro Asn Arg Ala He Cys Val Leu Gin Gin He 595 600 605 Thr Phe Gly He Val Phe Thr Met Ala Val Ser Thr Val Leu Ala Lys 610 615 620 Thr Val Thr Val Val Leu Ala Phe Lys Val Thr Asp Pro Gly Arg Arg 625 630 635 640 Leu Arg Asn Phe Leu Val Ser Gly Thr Pro Asn Tyr He He Pro He 645 650 655 Cys Ser Leu Leu Gin Cys Val Leu Cys Ala He Trp Leu Ala Val Ser 660 665 670 Pro Pro Phe Val Asp He Asp Glu His Thr Leu His Gly His He He 675 680 685 He Val Cys Asn Lys Gly Ser Val Thr Ala Phe Tyr Cys He Leu Gly 690 695 700 Tyr Leu Ala Cys Leu Ala Leu Gly Asn Phe Ser Val Ala Phe Leu Ala 705 710 715 720 Lys Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser 725 730 735 Met Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His 740 745 750 Ser Thr Lys Gly Lys His Met Val Ala Val Glu He Phe Ser He Leu 755 760 765 Ala Ser Ser Ala Gly He Leu Gly Cys He Phe Val Pro Lys He Tyr 770 775 780 He He Leu Met Arg Pro Glu Arg Asn Ser Thr Gin Lys He Arg Glu 785 790 795 800 Lys Ser Tyr Phe (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3689 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 39...419 (D) OTHER INFORMATION: VRl5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: TCAAAATCCG CACTGCCCAA GTTTAAGGCA GGAAAAAT ATG TTC ATT TTC ATG GGA 56 Met Phe He Phe Met Gly 1 5 GTC TTC TTC CTC CTT AAT ATT ACA CTT CTC ATG GCC AAT TTC ATT AAT 104 Val Phe Phe Leu Leu Asn He Thr Leu Leu Met Ala Asn Phe He Asn 10 15 20 CCC AGG TGC TTT TGG AGA ATA AAT TTG GAT GAA ATA ACG GAT GAA TAT 152 Pro Arg Cys Phe Trp Arg He Asn Leu Asp Glu He Thr Asp Glu Tyr 25 30 35 TTG GGA TTA TCT TGT ACT TTC ATC CTG GCG GCA GTT CAG ACA CCC ACT 200 Leu Gly Leu Ser Cys Thr Phe He Leu Ala Ala Val Gin Thr Pro Thr 40 45 50 GAA AAA GAT TAT TTC AAC AAG ACT CTT AAT GTT CTA AAA ACA ACT AAA 248 Glu Lys Asp Tyr Phe Asn Lys Thr Leu Asn Val Leu Lys Thr Thr Lys 55 60 65 70 AAC CAC AAA TAT GCT TTG GCA TTG GTG TTT GCA ATG GAT GAA ATC AAC 296 Asn His Lys Tyr Ala Leu Ala Leu Val Phe Ala Met Asp Glu He Asn 75 80 85 AGA AAT CCT GAT CTT TTA CCA AAT ATG TCT TTG ATT ATA AGA TAC ACT 344 Arg Asn Pro Asp Leu Leu Pro Asn Met Ser Leu He He Arg Tyr Thr 90 95 100 TTG GGC CTT TGT GAT GGA AAA ACT GTA ACA CCT ACA CCA TAT TTA TTT 392 Leu Gly Leu Cys Asp Gly Lys Thr Val Thr Pro Thr Pro Tyr Leu Phe 105 110 115 CAT AAA AAA AAA ACA AAG CCC TAT CCC TAATTATTTC TGTAATGAAG AGACTAT 446 His Lys Lys Lys Thr Lys Pro Tyr Pro 120 125 GTGTTCATTT CTGCTTTCAG GACCCAAGTG GGATGTATCT TTAAGTTTCT GGATGTACCT 506 GGACAGCTTC TTATCTCCGC GTATCCTTCA GCTTACCTAT GGACCTTTCC ATTCTATCTT 566 CAGTGATGAT GAACAATATC CCTATCTCTA TCAGATGGCC CCAAAGGACA CATCTCTAGC 626 ATTGGCAATG GTCTCCTTCA TACTTTATTT GAAATGGAAC TGGATTGGCC TTGTCATCCC 686 AGATGACGAT CAAGGAAACC AATTTCTTTT AGAGTTGAAG AAACAGAGTG AAAACAAGGA 746 AATTTGCTTT GCCTTTGTGA AAATGATCTC TGTTGATGAT ACTTCATTTC CACATAAAAC 806 TGAAATGGAC TACAACCAAA TTGTGATGTC ATCCACAAAT GTTATTATCA TTTATGGAGA 866 AACACGCAAT TTCATTTATT TGATCTTCAG AATGTGGGAA CCTCCCATTT TACAGAGAAT 926 ATGGATCACC ACAAAACAAT TGAATTTCCC TACCAGGAAG ACAGACATAA GTCATGGCAC 986 ATTCTATGGA TCACTTACTT TTCTACCCCA CCATGGTGAG ATTTCTGGCT TTAAAAAGTT 1046 TGTACAGACA TGGTTCCATG TCAGAAACAC AGATTTATAT TTAGTAATGC CAGAGTGGAA 1106 CTATTTTAAC TATGTAAGCT CAGCATCCAA TTGTAAAATA CTGAAGAACA ATTCATCTGA 1166 TGCCTCATTT GATTGGCTAA TGGAACAGAA GTTTGACATG ACCTTTAGTG AGAATAGTCA 1226 TAACATATAC AATGCTGTGC ATGCCATAGC CCATGCCCTC CATGAGATGA ATCTGCAACA 1286 GGCTGATAAT CAGGCAATAG GCAATGGAAA AGGAGCCAGT TCTCACTGCT TGAAGGTAAA 1346 CTCCTTTCTA AGAAGGACCT ACTTCACTAA TCCTCTTGGG GACAAAGTGT TTATGAAGCA 1406 AAGAGTAATA ATGCAGGATG AATATGATAT TATTCACTTT GGGAATCTCT CACAACACCT 1466 TGGGATTAAG ATGAAGTTAG GAAAGTTCAG CCCATATTTA CCACATGGTC GACACTCTCA 1526 CTTATATGTA GACATGATTG AGTTGGCCAC AGGAAGAAGA AAGATGCCAT CCTCTGTGTG 1586 CAGTGCAGAT TGTAGTCCTG GATTCAGAAG ATTGTGGAAG GAGGGAATGG CAGCCTGCTG 1646 TTTTGTTTGC AGCCCCTGCC CAGAAAATGA AATTTCTAAT GAGACAAGCT CCTCTCCATT 1706 TCATCCTTGC ATTCAGACAG GAACAATTAT GGGCTGGAGA TGTGACTATG GGATGGGAAT 1766 CCCATCACTC ACTTGATGTC CTGTCTTCCG GCTGGAGGTG GGCTCTTTAA GTTAACACTA 1826 TCTACTGTAG TACATTTCAT CTAAGGTCTC TGACCTCCCA AGTCTCTGGT GCATTTTGGT 1886 GGGTCCACCC ACCCTCCTAT TACCTGAAGT TGCCTGTTTA TATTCTTTTT GCTGGTCCTC 1946 AGAGATCGGT TCCCCTCTCA CCTGCCCACA CACCACAAAC CCCTTTCAAA TAACATCATA 2006 AATGATACAA TGAAGTTAAG TATACAAAGA ACAAATTGCT TGGTTTTATT TCATTTAAAT 2066 CTTTATGAAC TTTATGAATT GAAATCAATG CTCGGCAACA GCATCCTTCA CATTACATAT 2126 CAGCATCAAA GGCAGCATTG CAAGGCTTCT TTCATTACCC TTACTTGAAT TACCTTGACA 2186 ATAAAATTTC TGAAGCAGAC CTAACTAAGC TTTCCTTTGG AAATCAGATA TGGATCAATG 2246 TGTGAATTGT CCAGAATACC AATATGCCAA CACAGAACAG AACAAATGTA TTCAGAAAGG 2306 TGTCACCTTC CTAAGCTATG AAGACCCCTT GGGGATGGCA CTTGCCTTAA TGGCCTTCTG 2366 CTTCTCTGCA TTCACAGCTG TGGTACTTTG TGTCTTTGTG AAGCACCATG ACACTCCTAT 2426 TGTGAAGGCC AATAACAGAA GCCTCAGCTA CCTATTACTC ATGTCACTCA TGTTCTGTTT 2486 TCTGTGCTCC TTTTTCTTCA TTGGCCTTCC AAACAGAGCC ATCTGTGTCT TACAGCAAAT 2546 CACATTTGGA ATTGTATTCA CTGTGGCTGT TTCCACAGTT CTGGCCAAAA CAGTCACTGT 2606 GGTTCTGGCT TTCAAAGTCA CAGACCCAGG GAGAAGATTG AGAAACTTCC TGGTATCAGG 2666 GACACCCAAC TACATTATTC CCATATGTTC CCTACTCCAA TGTGTTCTGT GTGCAATCTG 2726 GCTAGCAGTT TCTCCTCCCT TTGTTGATAT TGATGAACAC ACTCTCCATG GCCATATCAT 2786 CATTGTGTGC AACAAGGGCT CAGATACTGC ATTCTACTGT ATCCTGGGAT ATTTGGCCTG 2846 CCTGGCACTT GGAAGCTTCT CTCTGGCTTT CTTGGCCAAG AATCTGCCTG ACACATTCAA 2906 TGAAGCCAAA TTCTTGACCT TCAGCATGCT AGTGTTCTGT AGTGTCTGGG TCACCTTCCT 2966 CCCTGTCTAC CATAGCACCA AGGGCAAACA CATGGTTGCT GTGGAGATCT TCTCCATCTT 3026 GGCATCCAGT GCAGGGATCC TTGGATGTAT TTTTGTACCC AAGATTTATA TCATTTTAAT 3086 GCGACCAGAG AGAAATTCTA CCCAAAAGAT CAGGGAAAAA TCATATTTCT GAACAAATAT 3146 TTAGGAATTC TGTCAAATGT AAAGTTGGTA CATACCCACC AAATATTGGG TTATAGTGCA 3206 TGTGTCTAGT TTTAGAATCA CTCTCACTGG TTGCTCTAGT GATATCAGGA AGTATCATAT 3266 CTACTGAACT TCCCTACAGT GTCCATAAAA TCTTGCACTC ATTCACTTTC TTCATTTTCT 3326 CTCAGAGAAC TAAACTCTCA ATTATTACAA TTTTATTCTT CATTTTGATT TCATGGAGAT 3386 GGCCCTCTGG TAACTGCCAA AAAATGTTGA TAAGGCAGTT GAATCCACCA CTTTGTGTAG 3446 AAAAATGAGA TCTAGGAAGA CAGGGTTACA CATAAAAACC ATCTACCAAA TCAAATAATC 3506 AATGAGAAAC ACAGACTAAC TAAATAATCA GCAAAGATGA AATCAGAACA TATTTTCTGA 3566 TTTCCAGTAA GAGCACACAC ATAAGAAAAT ACTTACTTTT TTCATCTGTT CTTCAATCTA 3626 CTGGCCAATA GTCTAAGGAG GAAATGTTCC TTTTCTGCTG TCAAATAAAA ATATATTATA 3686 TCC 3689 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 127 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: Met Phe He Phe Met Gly Val Phe Phe Leu Leu Asn He Thr Leu Leu 1 5 10 15 Met Ala Asn Phe He Asn Pro Arg Cys Phe Trp Arg He Asn Leu Asp 20 25 30 Glu He Thr Asp Glu Tyr Leu Gly Leu Ser Cys Thr Phe He Leu Ala 35 40 45 Ala Val Gin Thr Pro Thr Glu Lys Asp Tyr Phe Asn Lys Thr Leu Asn 50 55 60 Val Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Val Phe 65 70 75 80 Ala Met Asp Glu He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser 85 90 95 Leu He He Arg Tyr Thr Leu Gly Leu Cys Asp Gly Lys Thr Val Thr 100 105 110 Pro Thr Pro Tyr Leu Phe His Lys Lys Lys Thr Lys Pro Tyr Pro 115 120 125 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3896 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 36...263 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: ATTTCACAAC TTCTTGATCT TAGACCTTAG CAGAT ATG AAA AAC CTG TGT GTT 53 Met Lys Asn Leu Cys Val 1 5 TTC ACT CTT TCC TTT TTC CTC CTG GAG TTT TCT CTG ATC TTG TGC CAT 101 Phe Thr Leu Ser Phe Phe Leu Leu Glu Phe Ser Leu He Leu Cys His 10 15 20 TTG ACT GAA CCC ATT TGC TTT TGG AGG ATA AAT AAT AAT GAA GAT AAT 149 Leu Thr Glu Pro He Cys Phe Trp Arg He Asn Asn Asn Glu Asp Asn 25 30 35 GAT GGA GAT TTG AGA AGT GAC TGT GGT TTT TTC CTT GCA GCA GTT GAG 197 Asp Gly Asp Leu Arg Ser Asp Cys Gly Phe Phe Leu Ala Ala Val Glu 40 45 50 GGA CCT ACT GAC GAC TCT TAT AAT ATC TCT GAT CTT AGG TTT TCT TTG 245 Gly Pro Thr Asp Asp Ser Tyr Asn He Ser Asp Leu Arg Phe Ser Leu 55 60 65 70 GAC CAT TTA ATC CTA AGC TGAGTGACCA TGACCAGTTT CCCTATGTCC ATCAGGTA 301 Asp His Leu He Leu Ser 75 GCCACCAAGG ACACACGTTT GTCCCATGCA ATGGTCTCCT TGATGTTTCA TTTTACATGG 361 ATTTGGATAG GAATGGTCAT CTCAGATGAT GACCAGAGTA TTCAGTTTCT ATCAGACATG 421 AGAGAAGAAA TGCAAAGACA TGGAATCTGT TTAGCTTTTG TTAATATGAT CCCAGAAGAC 481 ATGCAGTTAT ATATGACAAG GGCTACAATA TATGATAAAC AAATTATGGA ATCAACAGCA 541 AAGGTTGTTA TGATTTATGG TGAAATGAAC TCTACCTTAG AAGTTAGCTT TAGAAGGTGG 601 GAAGATTTAA GTATAAGGAG AATCTGGATC ACAACCTCAC AATGGGACGT TATCACAAAT 661 AAAAATGATT TCAGCCTTGA TTTCTTCCAA GGGACTGTCA CTTTTGCACA CCATGTAGGT 721 GAAATTGCTA ACTTTAGGAA TTTCTTGCAA ACAATGAACA GTGAAAAATA CACAGTAAAC 781 ATTTCTGAGT CTAGACTGGG GTGGAATTAT TTTAATTGTT CCATCTCTAA GAACAGCAAT 841 AAAAAGGATC ATTTTACATT CAACAACACA TTGGAATGGA CAACACTGCA CAAATATGAC 901 ATGGTCCTAA GTGAGGAAGG CTACAATTTG TATAATGCTG TGTATGCTGT GGCCCACACC 961 TACCATGAAC TCGTTCTTCA ACAAGTAGAA TCTCAGCAAA TGACAGTACC CAAAGGAACA 1021 TTCACTGACT GTCAGCAGGT GTCTTCCATG CTGAAGTCCA GGATATTTAC TAACCCTGTT 1081 GGAGAACTGG TGAACATGAA GCATAGGGAA AATCAGTGTA CAGAGTATGA TATTTTCATC 1141 ATTTGGAATT TTCCACAAGG CCTTGGATTA AAAGTGAAAA TAGGAAGCTA TTTGCCTTGT 1201 TTCCAACAGA GCCAACAACT TCATATATCT GAAGATTTGG AGTGGGCCAC AGGAGGATCA 1261 TCAGTACCCC CCTCCCTGTG TAGTGTAACA TGTACTGCTG GATTCAGGAA AATTCATCAG 1321 AAACAAACAG CAGACTGCTG CTTTGATTGT GATCAGTGCC CAGAAAATGC AGTTTCCAAT 1381 GAAACAGAGA TATGCAATCT GAACATGGAA AGACCATCAT TATTTGCAAC AAAGGCTCAG 1441 TAATTGCCTT CCACTTTGTT CTCGGATACT TGGGTGCCTT GGCTCTGGGG AGCTTTACTG 1501 TGGCTTTCTT GGCTAGGAAC CTTCCTGACA GATTCAATGA AGCCAAATTC TTAACCTTCA 1561 GCATGCTGGT GTTCTGCAGT GTCTGGATCA CCTTCCTCCC TGTCTACCAC AGCACCCAGG 1621 GAACGGTCAT GGTGGTTGTG GAGGTTTTCT CCATCTTGGC TTCTAGTGCA GGCTTGCTAG 1681 GGTGTATCTT TCTCCCAAAA TGTTGTGTTT TATTACGTAT ACAAAATTCA AACTTTCTGC 1741 ATAAGTACAA ACATGAATTG CATTCTTGAT TCTTTAGTAA TTTAAAAATG CTAATCATAC 1801 TCAACTTATC TTTTTGCTTT GTCATAACAA AAGCACCACT AAATCATACA AAAAATTTAA 1861 GTAATATACA AATTTAGTAT TTACAATGTA GGGCAGCACA GCACTGCCTA ATGTAATGCC 1921 AATTATTGTT TTAGAGGTAA ATGGTCTTAT TCATGTGTAC ATAGATGTAA ACATTGAGAA 1981 TAGGGAATCT AACTTGATGA ATGGCTATCA ACACTTTGAC CTCTAGGTAT GTGTGTAAGC 2041 CATGTACCTA ATTTAATATG TAATAAGGTG AGCGTAACAT ATGTGAGAGT GCTACCTCTG 2101 GGCAGAAAGT TCTGGGAATT ATAAGAAAGA GGACTTCAAA GAGCACAGGC ATGAAGTCAA 2161 TAATCAGCAT TATTCCATGT GCTCTCATTG AGTGTCTGCA TCCACGTTCT TGTCTTGACT 2221 TCATTCTATT AACTGTGACT AAGGTACATA GGGAAATAGG ACTTTTCTCA CATGGTTCCT 2281 TTGACCATGG TGTTTTCTTA CAGCAACAGA CTCTAAGACA TCAGCAAAAT GTTAAATTGC 2341 CTTGGTTAGG ATTTGGAATA TCACAGATTA CTGATGCAAT AGAAGGCACT GATTTGAAAG 2401 AGAAAATAGA TTGAATACTA GGGGAGTGTG AGCATAGTTA CAGTGTTGCA TATTGTTGAT 2461 GGCCATCACA GAGGCCTGAG ATTTGTAATT GCTTCATAAT GTACTATGAA AATATTCAGA 2521 ATATCAGGTA ACATACTAAA AGAAGTACAA TATATGAAAA GGACAATGGG GTTCAGATTA 2581 TGCCTGCTCT ATAAGGCTCA TGAACTTCAT ATGAAAACAT ACCATTTCAA TATGAAATGA 2641 AGAAGTTTCA TTCAGGGAGA AAAATTGGTA GTGGAAAAAT TTACACACAA GACCTATATC 2701 ACAAGGAGAT CAGTGAAATC TTGGAATATA TAAGGCACTC TAGAAGAATG ACTTCAAAAA 2761 TGTTAGCAAA ATAGGAACAA CTAAGAATTA TTTGGTTTAA TATTACATAA TCAAAGATGT 2821 ACATACAAAC ACATGAACAT TATTATTTCT GGACGTCAGT TGCTGAAGGT CAGTGTCATT 2881 TTCTCTCAAA GTATTGTTTG TTGCTCTTAT TTTACTTGTT AATTTACAGT TTATTTTTGA 2941 TGGGATAATT TAATTGTTTT TTTCTTTATA TTTCCTGTCT CAAGAACACC ACTTGTAGCC 3001 CATCCATACA CTCCTAAAAT GCAAATGACC TATTATTTCA TTAATGCTTA ATGAATGCAT 3061 GCATGTATTT GTATATACAT ATACATTTTA AAGTATACAT TGTAGATACT ATGTAAAATT 3121 GCATGTTTTT ATGTTTTGAT GGCTCATTAT TTGGTAATAC CTGGCCAATA TTTGTTCCCT 3181 TCCCTGGCTA TGACAACCTC CTCCATTCCC TGATTTAAAG TTTCCTGTAA ATGGTTGTGT 3241 AGGGTAGAAG CTTTGAAAGC TTTCTTCCTT CCACGCTGCC ATGCACAGTG CAGTAATCCT 3301 TCTTCAGACC ATATTTTGTG TGTCATATTG GTAAAACTTC ATGGTCTACT TATGCTAGTT 3361 CTAGAAGATT TGTGTTCACA GCCAGTTTCC TCATCCTTTG ACTCACAAGA TCTTTTCCAC 3421 CATCTTCTTT ACGTTTCTCT GAGCCTTGGA TGAGGGAAAA TTTTGTAAGA GGATACATTG 3481 AATTGTTTCC TTCAACTACC TACTCTGGAA ATGACTATCA CACTATCACA ACATCTTTAA 3541 AAACAAGATG GAACTCCAAA ATCATTTTCT AAGGAAATAA ATGAAAATCT AAGTGTTCTT 3601 TTAATCTGGT TCATTGGAAT TTCCTGCATT TATCTGCCTG GGTGTATGTA ATCCCCCCCC 3661 CCCAGCCTGA AACCTGGCTG AACAGGTTTC ACTGTTAGCA CGAAGAGAGA ATCCGGGGTG 3721 GAGCCTTCCA CCCTATCATT CTGCCACTCC CACTGCTACT GCCTGCCGCC CAGCTGTTCC 3781 GGAGCTATCA CGTGGTCACC TGAAATTGGA CTCCAAGGAT GATTTGGAGG GAATGGGTGC 3841 CTTCCCCTTC TTCATAAACC AGTGTCTGGG AATAGTAAAA TTGAACTTTG ATCAG 3896 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 76 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Met Lys Asn Leu Cys Val Phe Thr Leu Ser Phe Phe Leu Leu Glu Phe 1 5 10 15 Ser Leu He Leu Cys His Leu Thr Glu Pro He Cys Phe Trp Arg He 20 25 30 Asn Asn Asn Glu Asp Asn Asp Gly Asp Leu Arg Ser Asp Cys Gly Phe 35 40 45 Phe Leu Ala Ala Val Glu Gly Pro Thr Asp Asp Ser Tyr Asn He Ser 50 55 60 Asp Leu Arg Phe Ser Leu Asp His Leu He Leu Ser 65 70 75 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2811 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 962...2605 (D) OTHER INFORMATION: GoVNl (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: GAAACGTCTA CTAATATGCT GTTCTCTTGG CTTTTTATCT CCTTGTTTCT ACAGATGCCA 60 ACTCTCATCT GGACCATTGC AACCCCTTCC TGCCTAACTG AATCAGGATA CCTCGTACAC 120 CAGGATGGAG CTGTGGTCAT TGGTGCATTT TTTCCTGTTT TAAAGTCCTT GCCTATAAGT 180 GAAATAATAG ATTGGAAAAC ATTATCTTTT GACACATACA ATTCTTTATG GATAAATGCA 240 CAAATGTACC AACTTGTTTT GGCCATGATA TTTGCGATCA ATGAGATCAA TGTGAAGTCC 300 CATATTTTAC CAAATACCTC TCTGGGACTT GAGATTTATA ATCTGCCATA TTTTGAACGG 360 AATATTCTGA GGAGTGCACT ATCTTGGCTC ACAGGCTTGA GCAAATTCAT TCCTAATTAC 420 ACCTGCAGAA AGGATAGCAA ATCAGCTGCT GCACTTACTG GAATATCACA GAAAACATCT 480 GAGACCTTTG GGACTTTGTT GGACATTTAC AAATTTCCTC AGCTTAATTT TGGGCCGTGT 540 GATCCTGTTC AGATAGGCAG AAACCAGTTT CCATCTGTGT ACCAGGTGGC CCCCAAAGAC 600 ACACCTCTGT TCTGTGGTAT CACCTCTTTG ATGCTTCATT TCAACTGGAC CTGGGTGGGA 660 CTGCTAATCA CAGATGACAA CAGAGGTTCT CAGTTTCTAT CAGAGTTAAG AAAGGAGCTG 720 GACAAGAATA AAATCTGCAT AGCCTTTGTG GAAACAGTAA TATTTTTTGG GGAATCATTG 780 CATTATATGC TAACCCACAA TCAGATGCAG ACTCTAGAGT CATCAGCAAA TGTGATTATA 840 GTTTATGGAC ATTTTGCTTT TCAATTAATT GTAATACAAA GTAAACACAG AAAGTATGAA 900 ATGAAAAAGA TTTGGGTCAT AACCTCAAAA TGGGTTGGCC AAAAAAATTG AACAATATAC 960 C ATG TTA GAA TTG GCC CAT GGC ACT CTG ACT TTC TCA CCC CAT CAT GGG 1009 Met Leu Glu Leu Ala His Gly Thr Leu Thr Phe Ser Pro His His Gly 1 5 10 15 GAG ATT TCT GAT TTC ACA AAT TTT ATG CAG GAA GTC ACC CCT ATC AAG 1057 Glu He Ser Asp Phe Thr Asn Phe Met Gin Glu Val Thr Pro He Lys 20 25 30 TAC CCA GAA GAC ATT TTT CTT CAC ATC TTG TGG AAC CAG TAT TTC AAT 1105 Tyr Pro Glu Asp He Phe Leu His He Leu Trp Asn Gin Tyr Phe Asn 35 40 45 TGT CCA CTT TTG CAT TCT GAG TGT AAA ATC TTT GAA AAC TGT ATA CCC 1153 Cys Pro Leu Leu His Ser Glu Cys Lys He Phe Glu Asn Cys He Pro 50 55 60 AAT GCC TCT TTG GAA TTG TTG CCA GGG GGT GTT TTT GAG CTG GTC ATG 1201 Asn Ala Ser Leu Glu Leu Leu Pro Gly Gly Val Phe Glu Leu Val Met 65 70 75 80 ACT GAA GAG AGT TAC AAT GTG TAC AAT GCT GTG TAT GCA GTG GCC CAC 1249 Thr Glu Glu Ser Tyr Asn Val Tyr Asn Ala Val Tyr Ala Val Ala His 85 90 95 AGT CTC CAT GAG AAG GCT CTC CAT CAA GTA GAA ATT CAA CCA CAG GAT 1297 Ser Leu His Glu Lys Ala Leu His Gin Val Glu He Gin Pro Gin Asp 100 105 110 AAT AAA GAT AGG ACT ATA TTA TTT CCT TGG CAG CTT CAC CCT TTT CTG 1345 Asn Lys Asp Arg Thr He Leu Phe Pro Trp Gin Leu His Pro Phe Leu 115 120 125 AAG AAC ATT CAG CTG ATA AAT TCT GTT GGT GAT CGT GTG ATT CTG GAC 1393 Lys Asn He Gin Leu He Asn Ser Val Gly Asp Arg Val He Leu Asp 130 135 140 TGG AAA AAG AAG ACG GAT ACA GAG TAT GAT ATT TCC AAT ATT TGG AAT 1441 Trp Lys Lys Lys Thr Asp Thr Glu Tyr Asp He Ser Asn He Trp Asn 145 150 155 160 TTC CCA ACA GGT CTT TCC TTA TTA GTG AAA GTG GGT ACA TTT GCT CCA 1489 Phe Pro Thr Gly Leu Ser Leu Leu Val Lys Val Gly Thr Phe Ala Pro 165 170 175 AGT GCT CCC AAG GGG GAA CAA CTT TCG ATA TCT GAA CAC ACA ATT AAC 1537 Ser Ala Pro Lys Gly Glu Gin Leu Ser He Ser Glu His Thr He Asn 180 185 190 TGG CCC ATA GGA TTT ACA GAG ATT CCA AAG TCT GTA TGC AGT GAG AGC 1585 Trp Pro He Gly Phe Thr Glu He Pro Lys Ser Val Cys Ser Glu Ser 195 200 205 TGC AGT CCT GGA CAC AGG AAA GTC ATC CTG GAG AGC AAG CCT GCC TGT 1633 Cys Ser Pro Gly His Arg Lys Val He Leu Glu Ser Lys Pro Ala Cys 210 215 220 TGC TTT GAC TGC ACT CCT TGC CCA GAT AAA GAG ATT TCC AAC GAG ACA 1681 Cys Phe Asp Cys Thr Pro Cys Pro Asp Lys Glu He Ser Asn Glu Thr 225 230 235 240 GAT GTG GGT CAG TGT GTG AAG TGT CCT GAA TCT CAT TAT GCA AAT ACA 1729 Asp Val Gly Gin Cys Val Lys Cys Pro Glu Ser His Tyr Ala Asn Thr 245 250 255 GAG AAG AGT CAC TGC CTG AAG AAG ACT ATG ACC TTT CTG GAT TAT AAT 1777 Glu Lys Ser His Cys Leu Lys Lys Thr Met Thr Phe Leu Asp Tyr Asn 260 265 270 GAT TCC TTG GGG ACG GGA CTC ACA CTC ATG TCT CTG GGA TTC TTT GTT 1825 Asp Ser Leu Gly Thr Gly Leu Thr Leu Met Ser Leu Gly Phe Phe Val 275 280 285 GTC ACA GGT CTT GTT ATT GGG GTT TTT ATA ATC CAC AGA AAC ACT CCA 1873 Val Thr Gly Leu Val He Gly Val Phe He He His Arg Asn Thr Pro 290 295 300 ATT GTG AAG GCC AAT AAT AGA TCT CTC AGT TAT ATC CTG CTC ATC ACT 1921 He Val Lys Ala Asn Asn Arg Ser Leu Ser Tyr He Leu Leu He Thr 305 310 315 320 CTC ACT CTC TGT TTC CTT TGT CCC TTG CTC TTC ATT GGG CTT CCA AAC 1969 Leu Thr Leu Cys Phe Leu Cys Pro Leu Leu Phe He Gly Leu Pro Asn 325 330 335 ACA GCC ACA TGT ATC CTA CAG CAG AAC TTG TTT GGA CTT CTC TTC ACT 2017 Thr Ala Thr Cys He Leu Gin Gin Asn Leu Phe Gly Leu Leu Phe Thr 340 345 350 GTG GCT CTA TCC ACA GTG TTG GCC AAA ACT ATC ACT GTA GTT ATG GCA 2065 Val Ala Leu Ser Thr Val Leu Ala Lys Thr He Thr Val Val Met Ala 355 360 365 TTC AAG ATT ACT GCT CCA GGA AGA AAG ACA AGA TGG TTG CTG ATA TTA 2113 Phe Lys He Thr Ala Pro Gly Arg Lys Thr Arg Trp Leu Leu He Leu 370 375 380 AGA GCC CCT CAG TTC ATC ATT CCA CTT TGT GCC CTG ATG CAA ATC CTT 2161 Arg Ala Pro Gin Phe He He Pro Leu Cys Ala Leu Met Gin He Leu 385 390 395 400 TTC TCT GGG ATA TGG CTG GGA ACA TCT CCT CCA TTT GTT GAC ATG GAT 2209 Phe Ser Gly He Trp Leu Gly Thr Ser Pro Pro Phe Val Asp Met Asp 405 410 415 GCT CAC TCT GAA CAT GGG CAC ATC ATC ATT CTA TGC AAC AAG GGC TCA 2257 Ala His Ser Glu His Gly His He He He Leu Cys Asn Lys Gly Ser 420 425 430 GCT ATT GGC TTC TAC TGT ACT CTG GCC TAC CTG GGA GTC ATG GCC TTT 2305 Ala He Gly Phe Tyr Cys Thr Leu Ala Tyr Leu Gly Val Met Ala Phe 435 440 445 GGT AGT TAC CTC TTG GCT TTC ATG TCC AGG AAT CTT CCT GAC ACA TTT 2353 Gly Ser Tyr Leu Leu Ala Phe Met Ser Arg Asn Leu Pro Asp Thr Phe 450 455 460 AAT GAA TCC AAG GCC CTG GCT TTC AGC ATG CTG ATG TTC TGC AGT GTC 2401 Asn Glu Ser Lys Ala Leu Ala Phe Ser Met Leu Met Phe Cys Ser Val 465 470 475 480 TGG GTC ACA TTC CTC CCT GTC TAC CAC AGC ACC ACT GGG AAG GTC AGG 2449 Trp Val Thr Phe Leu Pro Val Tyr His Ser Thr Thr Gly Lys Val Arg 485 490 495 GTG GCT ATG GAA ATG TTT TCT ATC TTG GCT TCC AGT GCA AGC ATT CTA 2497 Val Ala Met Glu Met Phe Ser He Leu Ala Ser Ser Ala Ser He Leu 500 505 510 ACC CTA ATC TTT GTC CCT AAG TGC TAC ATT GTT TTG TTC AGA CCA GAG 2545 Thr Leu He Phe Val Pro Lys Cys Tyr He Val Leu Phe Arg Pro Glu 515 520 525 AGG AAC ATA CTT CCT CTA AAC AGA GAA AAA AGA CAG CAT AGG AGT AAA 2593 Arg Asn He Leu Pro Leu Asn Arg Glu Lys Arg Gin His Arg Ser Lys 530 535 540 AAT TCT GAA ACA TAGCAGTCAA GACAAACATT GGCCTAGCAC AAAATGTCTG ATTGT 2650 Asn Ser Glu Thr 545 TGGCATTTCT CCTGCTATAT AAACAATTAG TCCTTTGACT TTGAGGACAG GATCACATGA 2710 GACAGACCGG TGATATTGCT TCAAATTATG TAAAATATGT GACATGGTTA TATTGACCAA 2770 TAAAATACTT GTTCTTGTAT GAAAAAAAAA AAAAAAAAAA A 2811 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 548 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: Met Leu Glu Leu Ala His Gly Thr Leu Thr Phe Ser Pro His His Gly 1 5 10 15 Glu He Ser Asp Phe Thr Asn Phe Met Gin Glu Val Thr Pro He Lys 20 25 30 Tyr- Pro Glu Asp He Phe Leu His He Leu Trp Asn Gin Tyr Phe Asn 35 40 45 Cys Pro Leu Leu His Ser Glu Cys Lys He Phe Glu Asn Cys He Pro 50 55 60 Asn Ala Ser Leu Glu Leu Leu Pro Gly Gly Val Phe Glu Leu Val Met 65 70 75 80 Thr Glu Glu Ser Tyr Asn Val Tyr Asn Ala Val Tyr Ala Val Ala His 85 90 95 Ser Leu His Glu Lys Ala Leu His Gin Val Glu He Gin Pro Gin Asp 100 105 110 Asn Lys Asp Arg Thr He Leu Phe Pro Trp Gin Leu His Pro Phe Leu 115 120 125 Lys Asn He Gin Leu He Asn Ser Val Gly Asp Arg Val He Leu Asp 130 135 140 Trp Lys Lys Lys Thr Asp Thr Glu Tyr Asp He Ser Asn He Trp Asn 145 150 155 160 Phe Pro Thr Gly Leu Ser Leu Leu Val Lys Val Gly Thr Phe Ala Pro 165 170 175 Ser Ala Pro Lys Gly Glu Gin Leu Ser He Ser Glu His Thr He Asn 180 185 190 Trp Pro He Gly Phe Thr Glu He Pro Lys Ser Val Cys Ser Glu Ser 195 200 205 Cys Ser Pro Gly His Arg Lys Val He Leu Glu Ser Lys Pro Ala Cys 210 215 220 Cys Phe Asp Cys Thr Pro Cys Pro Asp Lys Glu He Ser Asn Glu Thr 225 230 235 240 Asp Val Gly Gin Cys Val Lys Cys Pro Glu Ser His Tyr Ala Asn Thr 245 250 255 Glu Lys Ser His Cys Leu Lys Lys Thr Met Thr Phe Leu Asp Tyr Asn 260 265 270 Asp Ser Leu Gly Thr Gly Leu Thr Leu Met Ser Leu Gly Phe Phe Val 275 280 285 Val Thr Gly Leu Val He Gly Val Phe He He His Arg Asn Thr Pro 290 295 300 He Val Lys Ala Asn Asn Arg Ser Leu Ser Tyr He Leu Leu He Thr 305 310 315 320 Leu Thr Leu Cys Phe Leu Cys Pro Leu Leu Phe He Gly Leu Pro Asn 325 330 335 Thr Ala Thr Cys He Leu Gin Gin Asn Leu Phe Gly Leu Leu Phe Thr 340 345 350 Val Ala Leu Ser Thr Val Leu Ala Lys Thr He Thr Val Val Met Ala 355 360 365 Phe Lys He Thr Ala Pro Gly Arg Lys Thr Arg Trp Leu Leu He Leu 370 375 380 Arg Ala Pro Gin Phe He He Pro Leu Cys Ala Leu Met Gin He Leu 385 390 395 400 Phe Ser Gly He Trp Leu Gly Thr Ser Pro Pro Phe Val Asp Met Asp 405 410 415 Ala His Ser Glu His Gly His He He He Leu Cys Asn Lys Gly Ser 420 425 430 Ala He Gly Phe Tyr Cys Thr Leu Ala Tyr Leu Gly Val Met Ala Phe 435 440 445 Gly Ser Tyr Leu Leu Ala Phe Met Ser Arg Asn Leu Pro Asp Thr Phe 450 455 460 Asn Glu Ser Lys Ala Leu Ala Phe Ser Met Leu Met Phe Cys Ser Val 465 470 475 480 Trp Val Thr Phe Leu Pro Val Tyr His Ser Thr Thr Gly Lys Val Arg 485 490 495 Val Ala Met Glu Met Phe Ser He Leu Ala Ser Ser Ala Ser He Leu 500 505 510 Thr Leu He Phe Val Pro Lys Cys Tyr He Val Leu Phe Arg Pro Glu 515 520 525 Arg Asn He Leu Pro Leu Asn Arg Glu Lys Arg Gin His Arg Ser Lys 530 535 540 Asn Ser Glu Thr 545 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3584 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 273...2576 (D) OTHER INFORMATION: GoVN2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: CACACTGCCC AGGTTTAAGG CAGAAAGAAT ATGTTCATTT TGATGGTAGT ATTTTTCCTT 60 CTCCACCATC CACTTCTCAT GGCAAATTTC ATCGATCCCT GGTGCTTTTG GAGAACAAAT 120 TTGAATGAAG TCAAGGAAAA AAACTTGGAT ATAAATTGTG CCTTCATCCT TGGAGCAGTT 180 CAGTTGCCTA TGGAGAAAGA TATTTCAATG AGACTTTGAA TGTCCTAAAA ACAACTAAAA 240 ACAACAAATA TGCCTTGGCA TTAGCCTTTT CA ATG GAG GAA ATC AAC AGG AAC 293 Met Glu Glu He Asn Arg Asn 1 5 CCT GAT CTT TTA CCA AAT ATG TCT TTG GTT ATA AAA CAT ACT TTG AGC 341 Pro Asp Leu Leu Pro Asn Met Ser Leu Val He Lys His Thr Leu Ser 10 15 20 TAT TGT GAT GGA AAT ACT GCA GAC CAT ATA TTT AAA GAA AAA TTT TAT 389 Tyr Cys Asp Gly Asn Thr Ala Asp His He Phe Lys Glu Lys Phe Tyr 25 30 35 AAG CCT TTA CCT AAT TAT GTC TGT AAT GAA GAG ACT ATG TGT TCA TTT 437 Lys Pro Leu Pro Asn Tyr Val Cys Asn Glu Glu Thr Met Cys Ser Phe 40 45 50 55 ATG CTT ATA GGG CTG AAT TGG GTA TTG TCT CTA ACA CTT TTT AAA GAC 485 Met Leu He Gly Leu Asn Trp Val Leu Ser Leu Thr Leu Phe Lys Asp 60 65 70 TTG GAC ATC TTC TCA TTT CCA CGT TTC CTT CAA ATT TCC TAT GGA CCT 533 Leu Asp He Phe Ser Phe Pro Arg Phe Leu Gin He Ser Tyr Gly Pro 75 80 85 TTC CAT TCC ATC TTC AGT GAT AAT GAA CAA TTT CCA TAT CTC TAT CAG 581 Phe His Ser He Phe Ser Asp Asn Glu Gin Phe Pro Tyr Leu Tyr Gin 90 95 100 ATG ACC CCA AAG GAC ACA TCA CTA GCA TTG GCA ATT GTC TCC TTC TTA 629 Met Thr Pro Lys Asp Thr Ser Leu Ala Leu Ala He Val Ser Phe Leu 105 110 115 CTT TAC TTC AAT TGG AAC TGG GTT GGG CTT GTC ATC TCT GAT AAT GAT 677 Leu Tyr Phe Asn Trp Asn Trp Val Gly Leu Val He Ser Asp Asn Asp 120 125 130 135 GAA GGC AAT CAA TTT CTC TCA GAG TTG AAA AAA GAG ACC CAA AAC AAG 725 Glu Gly Asn Gin Phe Leu Ser Glu Leu Lys Lys Glu Thr Gin Asn Lys 140 145 150 GAA ATT TGC TTT GCC TTT GTT AAC ATG ATG TCA ATC CAT GAG CAT TCA 773 Glu He Cys Phe Ala Phe Val Asn Met Met Ser He His Glu His Ser 155 160 165 TCT TAT CAA AAA ACT GAA ATG TAC TAC AAT CAA ATA GTG ATG TCA TCA 821 Ser Tyr Gin Lys Thr Glu Met Tyr Tyr Asn Gin He Val Met Ser Ser 170 175 180 ACA AAT ATT ATT ATC ATT TAT GGG AAA ACA AAC AGT ATC ATT GAA TTG 869 Thr Asn He He He He Tyr Gly Lys Thr Asn Ser He He Glu Leu 185 190 195 AGC TTC AGA ATG TGG GTA TCT CCA GTT ATA CAG AGG ATT TGG GTC ACA 917 Ser Phe Arg Met Trp Val Ser Pro Val He Gin Arg He Trp Val Thr 200 205 210 215 AAC TCA GAG TTG GAT TTC CCG ACA AGT ATG AGA GAC TTC ACT CAT GGC 965 Asn Ser Glu Leu Asp Phe Pro Thr Ser Met Arg Asp Phe Thr His Gly 220 225 230 ACA TTC TAT GGG ACT CTG ACA TTT CTA CAC CAC CAT GGT GAG ATT TCT 1013 Thr Phe Tyr Gly Thr Leu Thr Phe Leu His His His Gly Glu He Ser 235 240 245 GGA TTT ACA AAT TTT TTC GAG ACA TGG GAC CAT CTC AGA AGC AGA GAT 1061 Gly Phe Thr Asn Phe Phe Glu Thr Trp Asp His Leu Arg Ser Arg Asp 250 255 260 TTA AAT CTA TTA ATA CCA GAG TGG AAG TAC TTT AGC TAT GAT GCC TCA 1109 Leu Asn Leu Leu He Pro Glu Trp Lys Tyr Phe Ser Tyr Asp Ala Ser 265 270 275 GGA TCT AAC TGT AAA ATA TTG AGG AAC TAT TCA TCC AAT GCC TCA TTG 1157 Gly Ser Asn Cys Lys He Leu Arg Asn Tyr Ser Ser Asn Ala Ser Leu 280 285 290 295 GAA TGG ATA ACA GAA CAG AAG TTT CAC ATG GCC TTT AAT GAT TAT AGT 1205 Glu Trp He Thr Glu Gin Lys Phe His Met Ala Phe Asn Asp Tyr Ser 300 305 310 CAT AGT ATA TAT AAT GCT GTG TAT GCC ATG GCC CAT GCC CTC CAT GAG 1253 His Ser He Tyr Asn Ala Val Tyr Ala Met Ala His Ala Leu His Glu 315 320 325 ACT AAT CTG CAA GAG GTT GAT AAT AAG GAA ATA AGA AAT GGG AAA GGA 1301 Thr Asn Leu Gin Glu Val Asp Asn Lys Glu He Arg Asn Gly Lys Gly 330 335 340 GCA AGT ACT CAC TGC TTG AAG GTA AAC TCA TTT CTC AGA AAG ACC CAC 1349 Ala Ser Thr His Cys Leu Lys Val Asn Ser Phe Leu Arg Lys Thr His 345 350 355 TTT ACT AAT TCT CAT GGA GAG AGA GTG ATT ATG AAA CAG AGA GTG AGA 1397 Phe Thr Asn Ser His Gly Glu Arg Val He Met Lys Gin Arg Val Arg 360 365 370 375 GTA CAG GAA GAC TAT GAC ATT GTT CAC ATT CAG AAT TTC TCA CAA CAC 1445 Val Gin Glu Asp Tyr Asp He Val His He Gin Asn Phe Ser Gin His 380 385 390 CTT CGG ATT AAG ATG AAG ATA GGA AAG TTC AGC CCA TAT TTT ACA CAT 1493 Leu Arg He Lys Met Lys He Gly Lys Phe Ser Pro Tyr Phe Thr His 395 400 405 GGT GGA CCC TTT CAC TTA TAT GAA GAC ATG ATT CAG TTG GCC ACA GGA 1541 Gly Gly Pro Phe His Leu Tyr Glu Asp Met He Gin Leu Ala Thr Gly 410 415 420 AGT AGA AAG ATG CCG TCC TCT GTG TGC AGT GCA GAT TGT AGT CCT GGA 1589 Ser Arg Lys Met Pro Ser Ser Val Cys Ser Ala Asp Cys Ser Pro Gly 425 430 435 TTC AGA AAA TCC TGG AAG GAG GGA ATG GCC CCC TGC TGT TTT ATT TGC 1637 Phe Arg Lys Ser Trp Lys Glu Gly Met Ala Pro Cys Cys Phe He Cys 440 445 450 455 AGC CTG TGC CCT GAA AAT GAA ATT TCT AAT GAG ACA AAT ATG GAT CAA 1685 Ser Leu Cys Pro Glu Asn Glu He Ser Asn Glu Thr Asn Met Asp Gin 460 465 470 TGT GTG AAT TGT CCA GAA TAC CAA TAT GCC AAC ACA GAA AAG AAC AAA 1733 Cys Val Asn Cys Pro Glu Tyr Gin Tyr Ala Asn Thr Glu Lys Asn Lys 475 480 485 TGC ATT CAG AAA GAC GTG ATT TTT CTA AGC TAT GAA GAC CCC TTG GGA 1781 Cys He Gin Lys Asp Val He Phe Leu Ser Tyr Glu Asp Pro Leu Gly 490 495 500 ATG GCT CTT GCC TTA ATT GCC TTC TGT TTG TCT GCA TTC ACA GCT GTG 1829 Met Ala Leu Ala Leu He Ala Phe Cys Leu Ser Ala Phe Thr Ala Val 505 510 515 GTA CTT TGG GTC TTT GTG AAG CAC CAT GAC ACT CCT ATT GTG AAG GCC 1877 Val Leu Trp Val Phe Val Lys His His Asp Thr Pro He Val Lys Ala 520 525 530 535 AAT AAC AGA ATC CTC AGC TAC ATA TTA ATC ATG TCA CTA ATG TTC TGT 1925 Asn Asn Arg He Leu Ser Tyr He Leu He Met Ser Leu Met Phe Cys 540 545 550 TTT CTC TGC TCC TTT TTC TTC ATT GGC CAT CCT AAC AGA GGT ACC TGT 1973 Phe Leu Cys Ser Phe Phe Phe He Gly His Pro Asn Arg Gly Thr Cys 555 560 565 ATC TTA CAG CAA ATC ACA TTT GGC ATT GTA TTC ACT GTG GCT GTT TCC 2021 He Leu Gin Gin He Thr Phe Gly He Val Phe Thr Val Ala Val Ser 570 575 580 ACA GTT CTG GCC AAA ACA ATC ACT GTC ATT CTT GCT TTC AAA CTC AGA 2069 Thr Val Leu Ala Lys Thr He Thr Val He Leu Ala Phe Lys Leu Arg 585 590 595 GAC CCA GGG AGA AGT TTA AGA AAC TTC CTG GTA TCT GGT GCA CCC AAC 2117 Asp Pro Gly Arg Ser Leu Arg Asn Phe Leu Val Ser Gly Ala Pro Asn 600 605 610 615 TAC ATT ATT CCT ATA TGT TCC TTA TTG CAA TGT ATT CTG TGT GCA ATT 2165 Tyr He He Pro He Cys Ser Leu Leu Gin Cys He Leu Cys Ala He 620 625 630 TGG CTA GCA GTT TCT CCT CCT TTT GTT GAT ATT GAT GAA CAT TCT GAG 2213 Trp Leu Ala Val Ser Pro Pro Phe Val Asp He Asp Glu His Ser Glu 635 640 645 CAT GGC CAC ATC ATG ATT GTG TGC AAC AAG GGC TCC ATT ATG GCA TTC 2261 His Gly His He Met He Val Cys Asn Lys Gly Ser He Met Ala Phe 650 655 660 TAC TGT GTC CTA GGA TAC TTG GCC TGC CTG GCG CTT GGA AGC TTC ACT 2309 Tyr Cys Val Leu Gly Tyr Leu Ala Cys Leu Ala Leu Gly Ser Phe Thr 665 670 675 ACA GCT TTC TTG GCA AAG AAT CTG CCA GAC ACA TTC AAC GAA GCC AAG 2357 Thr Ala Phe Leu Ala Lys Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys 680 685 690 695 TTC TTG ACC TTC AGC ATG CTA GTG TTC TGC AGT GTC TGG GTC ACC TTT 2405 Phe Leu Thr Phe Ser Met Leu Val Phe Cys Ser Val Trp Val Thr Phe 700 705 710 CTC CCT GTG TAC CAT AGC ACA AGG GGC AGG GTC ATG GTT GCT GTT GAG 2453 Leu Pro Val Tyr His Ser Thr Arg Gly Arg Val Met Val Ala Val Glu 715 720 725 ATC TTC TCT ATC TTG GCA TCC AGT GCA GGG ATG TTT GGA TGC ATC TTT 2501 He Phe Ser He Leu Ala Ser Ser Ala Gly Met Phe Gly Cys He Phe 730 735 740 GCA CCC AAA ATC TAC ATC ATA TTA ATG AAA CCA GAA AGA AAT TCT ATA 2549 Ala Pro Lys He Tyr He He Leu Met Lys Pro Glu Arg Asn Ser He 745 750 755 CAA AAG TTC AGG GAG AAA TCA TAT TTC TAAACAAATA TTTCAGGAAT TTAGTTG 2603 Gin Lys Phe Arg Glu Lys Ser Tyr Phe 760 765 AATATTAAGT TGGTATATAC CCACCAAATA TTTGGTTATT GTGCATGTAT AGAGTTTTAG 2663 AATCAGTCTT ACTGATTCCT CTATTGCTGT CTAGAGGTAT CTTATCTACC AGTCTTGCAT 2723 ACATTGTCCA TAAAATCTTG TACTCATTCA CTTCTTTAGT TTCCTCTGAG AAAACTAAAT 2783 TTCTCAAATT ATTACTAAAA TGTAATTCAA CATTATGCTT TCATGGATAT TTCCCCCTGG 2843 TTACATCAGA TAAATTTGAT AAGACAGCTG ATTTTGTTAC CTTATATAGA AGGTATATGA 2903 ATGTCCTGCC TTACAGGACA GAGAGGAATT ACACTTAGAA ACCGTCTATC AAGTCAAACA 2963 TTCAATCATA CTGAAAAATA AACTAAAGGA TCAACAGAGA TAAAAAGCAG AATACATTTT 3023 CTGTTTTCTA GTCGGAGCAT ATACATGACA GAATTCTGTT TTTATTTACA GTTGCTCTTC 3083 AAGGTTTTGG TCAATAGTCT AAGATGCAAA TGTTTTCTTT TTTTCTGATC TCAAAAAAAA 3143 TATTATAGCC AACAATTGAA AGAAGCCAGT GACCACTGTG TTTAAATTAG GAACTAGTTT 3203 GAGGATCCTG AGAAGGAGGG TGACTCATTG GAAGACCAGC AGTCTTATCT AACCTGAATA 3263 ACAAAGAATT TTCAGACACT GAGCCTCTAA CCGGGCAGCA TACACCAGTT GATATGAAGC 3323 CCCCAACATA TATGCAACAT AGGATGTCCT GGTCTGGCCT TGGTGAGAGA AGACACACCT 3383 AACCCCCAAG AGACATGATG CTCAAGGGAT TGGGAAGGTG TGGGAGTTGG GAAGGTGGGG 3443 ACTACTTCTT GATGCTGGGA AAGGAGATAT GGGGTGAGGA AGTGTCAGTG CTCAGACTGG 3503 GAAAGGGATA ATGAGTTCAC AGTAAAAAAA ATGTTAAAGA ATAAAAATCT AAAACAAAAT 3563 TAAAAAAAAA AAAAAAAAAA A 3584 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 768 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: Met Glu Glu He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser Leu 1 5 10 15 Val He Lys His Thr Leu Ser Tyr Cys Asp Gly Asn Thr Ala Asp His 20 25 30 He Phe Lys Glu Lys Phe Tyr Lys Pro Leu Pro Asn Tyr Val Cys Asn 35 40 45 Glu Glu Thr Met Cys Ser Phe Met Leu He Gly Leu Asn Trp Val Leu 50 55 60 Ser Leu Thr Leu Phe Lys Asp Leu Asp He Phe Ser Phe Pro Arg Phe 65 70 75 80 Leu Gin He Ser Tyr Gly Pro Phe His Ser He Phe Ser Asp Asn Glu 85 90 95 Gln Phe Pro Tyr Leu Tyr Gin Met Thr Pro Lys Asp Thr Ser Leu Ala 100 105 110 Leu Ala He Val Ser Phe Leu Leu Tyr Phe Asn Trp Asn Trp Val Gly 115 120 125 Leu Val He Ser Asp Asn Asp Glu Gly Asn Gin Phe Leu Ser Glu Leu 130 135 140 Lys Lys Glu Thr Gin Asn Lys Glu He Cys Phe Ala Phe Val Asn Met 145 150 155 160 Met Ser He His Glu His Ser Ser Tyr Gin Lys Thr Glu Met Tyr Tyr 165 170 175 Asn Gin He Val Met Ser Ser Thr Asn He He He He Tyr Gly Lys 180 185 190 Thr Asn Ser He He Glu Leu Ser Phe Arg Met Trp Val Ser Pro Val 195 200 205 He Gin Arg He Trp Val Thr Asn Ser Glu Leu Asp Phe Pro Thr Ser 210 215 220 Met Arg Asp Phe Thr His Gly Thr Phe Tyr Gly Thr Leu Thr Phe Leu 225 230 235 240 His His His Gly Glu He Ser Gly Phe Thr Asn Phe Phe Glu Thr Trp 245 250 255 Asp His Leu Arg Ser Arg Asp Leu Asn Leu Leu He Pro Glu Trp Lys 260 265 270 Tyr Phe Ser Tyr Asp Ala Ser Gly Ser Asn Cys Lys He Leu Arg Asn 275 280 285 Tyr Ser Ser Asn Ala Ser Leu Glu Trp He Thr Glu Gin Lys Phe His 290 295 300 Met Ala Phe Asn Asp Tyr Ser His Ser He Tyr Asn Ala Val Tyr Ala 305 310 315 320 Met Ala His Ala Leu His Glu Thr Asn Leu Gin Glu Val Asp Asn Lys 325 330 335 Glu He Arg Asn Gly Lys Gly Ala Ser Thr His Cys Leu Lys Val Asn 340 345 350 Ser Phe Leu Arg Lys Thr His Phe Thr Asn Ser His Gly Glu Arg Val 355 360 365 He Met Lys Gin Arg Val Arg Val Gin Glu Asp Tyr Asp He Val His 370 375 380 He Gin Asn Phe Ser Gin His Leu Arg He Lys Met Lys He Gly Lys 385 390 395 400 Phe Ser Pro Tyr Phe Thr His Gly Gly Pro Phe His Leu Tyr Glu Asp 405 410 415 Met He Gin Leu Ala Thr Gly Ser Arg Lys Met Pro Ser Ser Val Cys 420 425 430 Ser Ala Asp Cys Ser Pro Gly Phe Arg Lys Ser Trp Lys Glu Gly Met 435 440 445 Ala Pro Cys Cys Phe He Cys Ser Leu Cys Pro Glu Asn Glu He Ser 450 455 460 Asn Glu Thr Asn Met Asp Gin Cys Val Asn Cys Pro Glu Tyr Gin Tyr 465 470 475 480 Ala Asn Thr Glu Lys Asn Lys Cys He Gin Lys Asp Val He Phe Leu 485 490 495 Ser Tyr Glu Asp Pro Leu Gly Met Ala Leu Ala Leu He Ala Phe Cys 500 505 510 Leu Ser Ala Phe Thr Ala Val Val Leu Trp Val Phe Val Lys His His 515 520 525 Asp Thr Pro He Val Lys Ala Asn Asn Arg He Leu Ser Tyr He Leu 530 535 540 He Met Ser Leu Met Phe Cys Phe Leu Cys Ser Phe Phe Phe He Gly 545 550 555 560 His Pro Asn Arg Gly Thr Cys He Leu Gin Gin He Thr Phe Gly He 565 570 575 Val Phe Thr Val Ala Val Ser Thr Val Leu Ala Lys Thr He Thr Val 580 585 590 He Leu Ala Phe Lys Leu Arg Asp Pro Gly Arg Ser Leu Arg Asn Phe 595 600 605 Leu Val Ser Gly Ala Pro Asn Tyr He He Pro He Cys Ser Leu Leu 610 615 620 Gin Cys He Leu Cys Ala He Trp Leu Ala Val Ser Pro Pro Phe Val 625 630 635 640 Asp He Asp Glu His Ser Glu His Gly His He Met He Val Cys Asn 645 650 655 Lys Gly Ser He Met Ala Phe Tyr Cys Val Leu Gly Tyr Leu Ala Cys 660 665 670 Leu Ala Leu Gly Ser Phe Thr Thr Ala Phe Leu Ala Lys Asn Leu Pro 675 680 685 Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met Leu Val Phe 690 695 700 Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His Ser Thr Arg Gly 705 710 715 720 Arg Val Met Val Ala Val Glu He Phe Ser He Leu Ala Ser Ser Ala 725 730 735 Gly Met Phe Gly Cys He Phe Ala Pro Lys He Tyr He He Leu Met 740 745 750 Lys Pro Glu Arg Asn Ser He Gin Lys Phe Arg Glu Lys Ser Tyr Phe 755 760 765 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3578 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1181...3181 (D) OTHER INFORMATION: GoVN3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: CTATCTTGAA GAGTGCTTTT CTGTGTAACT TGCTTTGCTG CACGTTTACA AATTATTTTT 60 TCTTGGTGAA ATTACTAAGA TGTTCTCTTT TCTGTTTGCA ATTCTTGTCC TGAAGCTTTC 120 TTTTCCTTTG TGCAGTCCAA TTGACAACCG TTGTTTTTGG AGATTAAAAA CCAAGACATT 180 TTGGGAAGGA GACAAAGAAC TTGATTGCTT TTTTTTTATT TATACAAGGT TTGGTCATGT 240 AAAGAATGAA CAGTTCAGTG GGAATCTAGA CAAGCGGTTG ACATCTAAGA CTATCCACTT 300 GATTTTGACT CTTTATTTTG CCCTTGAAGA AATAAACAGG AACCCCCATA TTCTACCTAA 360 CATTTCACTG CTAGTTAAAA TTGAATGTGG GCTGCTAGAT GATTGGACAA TAAACAGTTT 420 ATCTTCTAAA AGAGAAAAAT ATCTTCCTAA CTACTACTGT ATAAATCAGA GAAGATATTT 480 AATTGTACTT ACAGGACCAA TGTGGTTAGC ATCTGTCATA GTTGGGCCAC TCCTATACAT 540 AACTAAGAGG CCAGAGATGG ATCAACTCAA CTCTTCTGGC TCAAATTCTT CCCTAAAGTC 600 ACTAATTGGA TATGGCTTTA CTCAGCTTCT CATTGATTTG CTTTGCTTGA ACAATCACTG 660 CCCATTTGTT TTAGTCTTCT GTCTCCTTTA TATTCTGGCT ACAACTGCCT CTACTGATGC 720 ACATTGAACT GCATGAACTC ACAAATTAAC TCAACACCAT TGCACTGCAT TCTTTGCACT 780 GAGTCTCAAA AGTCTGGTTT AACTCTTCTG CATTGAACTC AACTGACTAA TTAGAACTCA 840 GAAATCTGCA TCCCTCTGTC TCCTGAGTAC TTTGATTAAA GGTGTGTACT ATCACACCTG 900 CACCTAAACT TTTCTATACT AAAAATTTGC TTTATACTAG GCTGACCTTG AACTAAGTGA 960 TCTGCTTGCC TCTGTCTCCT GCCTTCCAAG GAATGCCTAT TTCCCAGCAG GATATTTTTT 1020 GCCTACAAGT CTTCAGATGT GATCCATTAA GTATAGTCAT GTTGCTGGAT TAAAATTCCT 1080 CTACAGATTT AATTTTCTGA TCCTGAGGCT AGTGAAACTT TACTATGGGC CATTTCACCC 1140 TCTCTTGAGC AACCAAGAAC TGTATCCATA TCTTTACCAA ATG GCT CCT AAG GAC 1195 Met Ala Pro Lys Asp 1 5 ACA TCT CTG GCA CTG GCC ATG GTT TCT TTG TTT GTC CAT TTC AGC TGG 1243 Thr Ser Leu Ala Leu Ala Met Val Ser Leu Phe Val His Phe Ser Trp 10 15 20 AAC TGG GTA GGA GCT GTT GTT TCA GAT GAT GAC CCA GGT TAT GAA TTT 1291 Asn Trp Val Gly Ala Val Val Ser Asp Asp Asp Pro Gly Tyr Glu Phe 25 30 35 ATC TTG GAA TTG AGA AGA GAA ATG CAA AGG AAC AAT TTT TGT TTA GCA 1339 He Leu Glu Leu Arg Arg Glu Met Gin Arg Asn Asn Phe Cys Leu Ala 40 45 50 TTT GTG AGT ATC ATT GTT AGT GAT GAC AAT TTA TTT CTG AAA AGG TAT 1387 Phe Val Ser He He Val Ser Asp Asp Asn Leu Phe Leu Lys Arg Tyr 55 60 65 AAT ATC TAT TAC AAC CAG ATC AAG ATG TCA TCA GCA AAA GTT GTT ATC 1435 Asn He Tyr Tyr Asn Gin He Lys Met Ser Ser Ala Lys Val Val He 70 75 80 85 ATT TAT GGA GAC AAA GAC TCT CCT CTA CAG GTG AAC TTT AGA CTA TGG 1483 He Tyr Gly Asp Lys Asp Ser Pro Leu Gin Val Asn Phe Arg Leu Trp 90 95 100 AAT TTA TTT GAT ATC CAA AGA ATC TGG GTC ACT ACT TCA CAG TGG GAT 1531 Asn Leu Phe Asp He Gin Arg He Trp Val Thr Thr Ser Gin Trp Asp 105 110 115 ATG ATC ATA AAT AAT GGA AAA TTC CTC CTT AAT TCC TTC TAT GGG ACT 1579 Met He He Asn Asn Gly Lys Phe Leu Leu Asn Ser Phe Tyr Gly Thr 120 125 130 CTC AGT TTT TCA CAT CAC TAT TCT GAA TTA TCT GGT TTT AAA ACA TTT 1627 Leu Ser Phe Ser His His Tyr Ser Glu Leu Ser Gly Phe Lys Thr Phe 135 140 145 ATC CAG ACA GCA TAC CCT TCA AAC TAC AGT GAT GAC TTT TCT CTT GGT 1675 He Gin Thr Ala Tyr Pro Ser Asn Tyr Ser Asp Asp Phe Ser Leu Gly 150 155 160 165 ATA TTA TGG TGG GTG TAT TTT AAT TGT TCT TTG TCA TTA TCT GAA TGT 1723 He Leu Trp Trp Val Tyr Phe Asn Cys Ser Leu Ser Leu Ser Glu Cys 170 175 180 AAG AAT CTG CAA AAT TGT CCA AAG GAA AAC ATA TTT AGA TGG TTA TAC 1771 Lys Asn Leu Gin Asn Cys Pro Lys Glu Asn He Phe Arg Trp Leu Tyr 185 190 195 AGG CAC CAT TTT GAA ATG TCT TTG AGT GAT ACT ACT TAT GAC CTA TAT 1819 Arg His His Phe Glu Met Ser Leu Ser Asp Thr Thr Tyr Asp Leu Tyr 200 205 210 AAT TCT ATG TAT GCT GTG GCT TAC ACA CTC CAA CAG ATG CTT CTG AAA 1867 Asn Ser Met Tyr Ala Val Ala Tyr Thr Leu Gin Gin Met Leu Leu Lys 215 220 225 CAA GCA GAT ACA TGG CAA ATA GAT GAT GGA AAA GAA CCA GAA TTT GAC 1915 Gin Ala Asp Thr Trp Gin He Asp Asp Gly Lys Glu Pro Glu Phe Asp 230 235 240 245 TCT TGG CAG ATG CTC TCT TTC CTG AGA AAT ATC CAA TTT ATA AAC CCT 1963 Ser Trp Gin Met Leu Ser Phe Leu Arg Asn He Gin Phe He Asn Pro 250 255 260 GTT GGT GAC AAA GTG AAC CTG AAT CAT GAA GAA AAA CTG GAT ACA AAG 2011 Val Gly Asp Lys Val Asn Leu Asn His Glu Glu Lys Leu Asp Thr Lys 265 270 275 TAT GAG ATT CAC CAG ACT TTG ACT TTT TTG CCA AAT CCT GTA TTT AAG 2059 Tyr Glu He His Gin Thr Leu Thr Phe Leu Pro Asn Pro Val Phe Lys 280 285 290 CTG AAA ATA GGA ACA TTT TCC CAA AAC TTA TCA CAT GGT CGA CAA TTA 2107 Leu Lys He Gly Thr Phe Ser Gin Asn Leu Ser His Gly Arg Gin Leu 295 300 305 TAT ATG TTG AAA GAA ATG ATA GAG TGG AAC ACA GGC CAC CAA CAG TCT 2155 Tyr Met Leu Lys Glu Met He Glu Trp Asn Thr Gly His Gin Gin Ser 310 315 320 325 CCA ACC TCA GTT TGC AGT ATT CCT TGT AGT CCA GGA TTC AGA AAA TCC 2203 Pro Thr Ser Val Cys Ser He Pro Cys Ser Pro Gly Phe Arg Lys Ser 330 335 340 CCT CAG CTG GGA AAG CCT GTT TGC TGT TTT GAT TGT ACA CCC TGC CCA 2251 Pro Gin Leu Gly Lys Pro Val Cys Cys Phe Asp Cys Thr Pro Cys Pro 345 350 355 GAA AAT GAA ATT TCC AAC ATG ACA AAC ATG AAT CAA TGT ATC AAG TGT 2299 Glu Asn Glu He Ser Asn Met Thr Asn Met Asn Gin Cys He Lys Cys 360 365 370 CTA AAT GAT CAG TAT GCC AAT CCT GGA GGA ACT CGC TGC CTC AAA AAA 2347 Leu Asn Asp Gin Tyr Ala Asn Pro Gly Gly Thr Arg Cys Leu Lys Lys 375 380 385 GTT ATT GTA TTC CTG GGT TAT GAA GAT CCA TTG GGA ATG TCT CTG GCT 2395 Val He Val Phe Leu Gly Tyr Glu Asp Pro Leu Gly Met Ser Leu Ala 390 395 400 405 ATC TTG GCT CTG TGC TTC TCT GCT CTC ACA GCT TTT GTA CTT AGT ATC 2443 He Leu Ala Leu Cys Phe Ser Ala Leu Thr Ala Phe Val Leu Ser He 410 415 420 TTT TTG AAG CAC CAA GAA ACA CCC ACT GTC AAG GCC AAT AAT AGA ACT 2491 Phe Leu Lys His Gin Glu Thr Pro Thr Val Lys Ala Asn Asn Arg Thr 425 430 435 CTC AGC TAT GTT CTA CTC ATC TCC CTC ATC TCT TGT TTT CTC TGC TCC 2539 Leu Ser Tyr Val Leu Leu He Ser Leu He Ser Cys Phe Leu Cys Ser 440 445 450 TTG CTC TTC ATT GGT CAT CCC AGC TTT ACC ACA TGT ATC ATG CAG CAG 2587 Leu Leu Phe He Gly His Pro Ser Phe Thr Thr Cys He Met Gin Gin 455 460 465 ACC ACA TTT GCT GTT GTG TTC ACT GTA GCT GCA TCT ACT GTC TTG GCC 2635 Thr Thr Phe Ala Val Val Phe Thr Val Ala Ala Ser Thr Val Leu Ala 470 475 480 485 AAA ACA ATT ATT GTA ATA TTG GCC TTC AAG GTT ACT AAT ACA AGT AGA 2683 Lys Thr He He Val He Leu Ala Phe Lys Val Thr Asn Thr Ser Arg 490 495 500 AAA ATG AGG TGG CTG CTG GTA TCA GGG GCA CCT AAA TTC ATC ATT CCA 2731 Lys Met Arg Trp Leu Leu Val Ser Gly Ala Pro Lys Phe He He Pro 505 510 515 ATT TGC ACA ATG ATT CAA CTG ATT CTC TGT GGA ATT TGG CTG GGT ACT 2779 He Cys Thr Met He Gin Leu He Leu Cys Gly He Trp Leu Gly Thr 520 525 530 TCT CCT CCA TTT GTT GAT GCT GAT GGA CAT GTT GAA AAA GGC CAC ATT 2827 Ser Pro Pro Phe Val Asp Ala Asp Gly His Val Glu Lys Gly His He 535 540 545 TTG ATT TTC TGT AAC AAA GGT TCA ATT CTT GCT TTC TAT TGT GTC CTG 2875 Leu He Phe Cys Asn Lys Gly Ser He Leu Ala Phe Tyr Cys Val Leu 550 555 560 565 GGA TAC TTA GTC TCC ATT GCC ATT GCA AGT TTC ACC CTT GCA TTC TTC 2923 Gly Tyr Leu Val Ser He Ala He Ala Ser Phe Thr Leu Ala Phe Phe 570 575 580 GCC AGA AAT CTG CCC GAC ACA TTC AAT GAA GCC AAG TTC CTA ACA TTC 2971 Ala Arg Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr Phe 585 590 595 AGT ATG CTA GTA TTT TGC AGT GTC TGG GTC ACC TTT CTT CCT GTC TAT 3019 Ser Met Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr 600 605 610 CAT AGC ACC AAG GGC AAG TCT ATG GTG GCT GTG GAA GTT TTC TGT ATA 3067 His Ser Thr Lys Gly Lys Ser Met Val Ala Val Glu Val Phe Cys He 615 620 625 TTG GCC TCT AGT GCA GGG CTG CTT TTT TGC ATC TTT GCA CCA AAG TGC 3115 Leu Ala Ser Ser Ala Gly Leu Leu Phe Cys He Phe Ala Pro Lys Cys 630 635 640 645 TTC ATT ATT TTG TTA AGA CCT GAG AAA AAA TCT TTT CAG AAG TTT CAG 3163 Phe He He Leu Leu Arg Pro Glu Lys Lys Ser Phe Gin Lys Phe Gin 650 655 660 AAT ATA CAT TCT AAA ATT TAAAACATTC ATTAAATTTT TCTGACACAC TTGCTAGA 3219 Asn He His Ser Lys He 665 CCAAACTTAT TCAGAAGACT CCACTGACAC TACTAGTTGA AATCAAATTT TAGATCCAAA 3279 CATGGAATTT GTTCCCAATA AAGAAAGGAA GCACTATGTA TTAGAATTTA AAAACACGTC 3339 TTAAATCTTG GTTCTCATAA ATCAAACTGT ATGATCAGTC ATTTCAATAA CTGTTTGCTG 3399 TATTTCTTAA TTTTATGCTT ATACTTGAAG AATGTAAAGA CTGGGAATTG GTTCTGAGTT 3459 TTATGAATTA ATTTCTAATT TTACTTTCCT TGGAAAAAAT GTCTAGTGTG TGTTGTTGTG 3519 CTCTATAATA AATAATTATG AGATAAATGC AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 3578 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 667 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: Met Ala Pro Lys Asp Thr Ser Leu Ala Leu Ala Met Val Ser Leu Phe 1 5 10 15 Val His Phe Ser Trp Asn Trp Val Gly Ala Val Val Ser Asp Asp Asp 20 25 30 Pro Gly Tyr Glu Phe He Leu Glu Leu Arg Arg Glu Met Gin Arg Asn 35 40 45 Asn Phe Cys Leu Ala Phe Val Ser He He Val Ser Asp Asp Asn Leu 50 55 60 Phe Leu Lys Arg Tyr Asn He Tyr Tyr Asn Gin He Lys Met Ser Ser 65 70 75 80 Ala- Lys Val Val He He Tyr Gly Asp Lys Asp Ser Pro Leu Gin Val . 85 90 95 Asn Phe Arg Leu Trp Asn Leu Phe Asp He Gin Arg He Trp Val Thr 100 105 110 Thr Ser Gin Trp Asp Met He He Asn Asn Gly Lys Phe Leu Leu Asn 115 120 125 Ser Phe Tyr Gly Thr Leu Ser Phe Ser His His Tyr Ser Glu Leu Ser 130 135 140 Gly Phe Lys Thr Phe He Gin Thr Ala Tyr Pro Ser Asn Tyr Ser Asp 145 150 155 160 Asp Phe Ser Leu Gly He Leu Trp Trp Val Tyr Phe Asn Cys Ser Leu 165 170 175 Ser Leu Ser Glu Cys Lys Asn Leu Gin Asn Cys Pro Lys Glu Asn He 180 185 190 Phe Arg Trp Leu Tyr Arg His His Phe Glu Met Ser Leu Ser Asp Thr 195 200 205 Thr Tyr Asp Leu Tyr Asn Ser Met Tyr Ala Val Ala Tyr Thr Leu Gin 210 215 220 Gin Met Leu Leu Lys Gin Ala Asp Thr Trp Gin He Asp Asp Gly Lys 225 230 235 240 Glu Pro Glu Phe Asp Ser Trp Gin Met Leu Ser Phe Leu Arg Asn He 245 250 255 Gin Phe He Asn Pro Val Gly Asp Lys Val Asn Leu Asn His Glu Glu 260 265 270 Lys Leu Asp Thr Lys Tyr Glu He His Gin Thr Leu Thr Phe Leu Pro 275 280 285 Asn Pro Val Phe Lys Leu Lys He Gly Thr Phe Ser Gin Asn Leu Ser 290 295 300 His Gly Arg Gin Leu Tyr Met Leu Lys Glu Met He Glu Trp Asn Thr 305 310 315 320 Gly His Gin Gin Ser Pro Thr Ser Val Cys Ser He Pro Cys Ser Pro 325 330 335 Gly Phe Arg Lys Ser Pro Gin Leu Gly Lys Pro Val Cys Cys Phe Asp 340 345 350 Cys Thr Pro Cys Pro Glu Asn Glu He Ser Asn Met Thr Asn Met Asn 355 360 365 Gin Cys He Lys Cys Leu Asn Asp Gin Tyr Ala Asn Pro Gly Gly Thr 370 375 380 Arg Cys Leu Lys Lys Val He Val Phe Leu Gly Tyr Glu Asp Pro Leu 385 390 395 400 Gly Met Ser Leu Ala He Leu Ala Leu Cys Phe Ser Ala Leu Thr Ala 405 410 415 Phe Val Leu Ser He Phe Leu Lys His Gin Glu Thr Pro Thr Val Lys 420 425 430 Ala Asn Asn Arg Thr Leu Ser Tyr Val Leu Leu He Ser Leu He Ser 435 440 445 Cys Phe Leu Cys Ser Leu Leu Phe He Gly His Pro Ser Phe Thr Thr 450 455 460 Cys He Met Gin Gin Thr Thr Phe Ala Val Val Phe Thr Val Ala Ala 465 470 475 480 Ser Thr Val Leu Ala Lys Thr He He Val He Leu Ala Phe Lys Val 485 490 495 Thr Asn Thr Ser Arg Lys Met Arg Trp Leu Leu Val Ser Gly Ala Pro 500 505 510 Lys Phe He He Pro He Cys Thr Met He Gin Leu He Leu Cys Gly 515 520 525 He Trp Leu Gly Thr Ser Pro Pro Phe Val Asp Ala Asp Gly His Val 530 535 540 Glu Lys Gly His He Leu He Phe Cys Asn Lys Gly Ser He Leu Ala 545 550 555 560 Phe Tyr Cys Val Leu Gly Tyr Leu Val Ser He Ala He Ala Ser Phe 565 570 575 Thr Leu Ala Phe Phe Ala Arg Asn Leu Pro Asp Thr Phe Asn Glu Ala 580 585 590 Lys Phe Leu Thr Phe Ser Met Leu Val Phe Cys Ser Val Trp Val Thr 595 600 605 Phe Leu Pro Val Tyr His Ser Thr Lys Gly Lys Ser Met Val Ala Val 610 615 620 Glu Val Phe Cys He Leu Ala Ser Ser Ala Gly Leu Leu Phe Cys He 625 630 635 640 Phe Ala Pro Lys Cys Phe He He Leu Leu Arg Pro Glu Lys Lys Ser 645 650 655 Phe Gin Lys Phe Gin Asn He His Ser Lys He 660 665 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4467 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 126...2723 (D) OTHER INFORMATION: GoVN4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: CAGGGATGAG GAAACACCTG TAGAAAAGGA AACCTGAATA CAGGTATAGC ATCTTCTTGG 60 CCAGTGTAGA AGATGGGGAT AATTGCTACC TGTTTGCTGA TCTGTGCAGC AATTAACTAC 120 CAATA ATG TCC AGG CTC AGA GCA GGA AAA AAT ATG CTC ACC TTC ATT TTA 170 Met Ser Arg Leu Arg Ala Gly Lys Asn Met Leu Thr Phe He Leu 1 5 10 15 CTC TTC TTT CTC CTG AAC ATT CCA CTT TTT GTG CCT AGT TTT ATT TAT 218 Leu Phe Phe Leu Leu Asn He Pro Leu Phe Val Pro Ser Phe He Tyr 20 25 30 CCC AGG TGC TTT TGG AGT ATG AAG AAG AAT GAA TAT CAG GAT AGA AAC 266 Pro Arg Cys Phe Trp Ser Met Lys Lys Asn Glu Tyr Gin Asp Arg Asn 35 40 45 CTG GGA ACA GGT TGT ATG TTC TTT ATT CTA GCA GTG CAA CAG CCT ATG 314 Leu Gly Thr Gly Cys Met Phe Phe He Leu Ala Val Gin Gin Pro Met 50 55 60 GAA AAA GAG TAT TTC AGT CAT ATT TCG AAT ATA CAA ACA CCT ACT GAA 362 Glu Lys Glu Tyr Phe Ser His He Ser Asn He Gin Thr Pro Thr Glu 65 70 75 AAC CAA AAG TAT CCT CTC ACC TTG GCT TTT TCC ATG AAT GAA ATC AAC 410 Asn Gin Lys Tyr Pro Leu Thr Leu Ala Phe Ser Met Asn Glu He Asn 80 85 90 95 AAC AAC CCT GAT CTT TTG CCA AAT ATG TCT TTA GCA TTT ACA TTC TCA 458 Asn Asn Pro Asp Leu Leu Pro Asn Met Ser Leu Ala Phe Thr Phe Ser 100 105 110 GAA TAT AGT TGT TAT TTG GAA TCC CAC CAC AAA AGA TTA TTT AAT TTT 506 Glu Tyr Ser Cys Tyr Leu Glu Ser His His Lys Arg Leu Phe Asn Phe 115 120 125 TCT TTA AAA AAT CAT GAA ATT CTC CCT AAT TTT ATC TGT ACA AAA GAC 554 Ser Leu Lys Asn His Glu He Leu Pro Asn Phe He Cys Thr Lys Asp 130 135 140 ATC AAG TGT GGA GTG GTA CTT ACC GGA CTT AGT TTG GTA ACA ACT GTG 602 He Lys Cys Gly Val Val Leu Thr Gly Leu Ser Leu Val Thr Thr Val 145 150 155 ACA CTT CAT ATA ATC CTA AAC AAT TTC ATA TTT CAG CAG TTC CGT CAG 650 Thr Leu His He He Leu Asn Asn Phe He Phe Gin Gin Phe Arg Gin 160 165 170 175 CTT ACT TAT GGA CAC TTT CAT CCT GCT CTG TGT GAT CAT GAA AAT TTT 698 Leu Thr Tyr Gly His Phe His Pro Ala Leu Cys Asp His Glu Asn Phe 180 185 190 CCT CAT CTA TAT CAG ATG GCC TCT GAT GAT ACA TCT CTA GCC CTT GCT 746 Pro His Leu Tyr Gin Met Ala Ser Asp Asp Thr Ser Leu Ala Leu Ala 195 200 205 CTC GTC TCC TTC ATA ATT CAT TTC AGT TGG AAC TGG ATA GGG TTG GCC 794 Leu Val Ser Phe He He His Phe Ser Trp Asn Trp He Gly Leu Ala 210 215 220 ATC TCA GAC AAT GAT CAA GGC ATA CAT TTT CTC TCT TAT TTG AGA AGA 842 He Ser Asp Asn Asp Gin Gly He His Phe Leu Ser Tyr Leu Arg Arg 225 230 235 GAG ATG GAA AAA AAT ACA GTC TGC TTT GCC TTT GTC AAC ATT ATT CCA 890 Glu Met Glu Lys Asn Thr Val Cys Phe Ala Phe Val Asn He He Pro 240 245 250 255 GTC AAT ATG AAT TTA TAC ATG TCA AGA GCT GAA GTG TAT TAC AGC CAA 938 Val Asn Met Asn Leu Tyr Met Ser Arg Ala Glu Val Tyr Tyr Ser Gin 260 265 270 GTT ATG ACA TCA TCC GCA AAT GTT GTT ATC ATT TAT GGT GAT ACA GGG 986 Val Met Thr Ser Ser Ala Asn Val Val He He Tyr Gly Asp Thr Gly 275 280 285 AAT ACG TTA GCT GTG AGC TTT AGA ATG TGG GAC TCT CTA GGT ATA CAG 1034 Asn Thr Leu Ala Val Ser Phe Arg Met Trp Asp Ser Leu Gly He Gin 290 295 300 AGA CTA TGG GTC ACC ACC TCA CAG TGG GAT GTC ACT CCT TTT AAG AAA 1082 Arg Leu Trp Val Thr Thr Ser Gin Trp Asp Val Thr Pro Phe Lys Lys 305 310 315 GAC TTC ACA TTT GAT AAT GGA TAT GGA ACT TTT GGT TTT GGA CAC CGC 1130 Asp Phe Thr Phe Asp Asn Gly Tyr Gly Thr Phe Gly Phe Gly His Arg 320 325 330 335 CAC AGT GAG ATT TCT GGT TTT AAA TAT TTT GTT CAG ACA TTG AAC CCT 1178 His Ser Glu He Ser Gly Phe Lys Tyr Phe Val Gin Thr Leu Asn Pro 340 345 350 TTC AAA TAC TCA GAT GAA TAT TTG GTA AAG CTG GAA TGG ATG TAT GTT 1226 Phe Lys Tyr Ser Asp Glu Tyr Leu Val Lys Leu Glu Trp Met Tyr Val 355 360 365 AAT TGT AAA ATC TTA GAA TAT AAC TGT AAG TCA CTG AAG AAC TGC TCC 1274 Asn Cys Lys He Leu Glu Tyr Asn Cys Lys Ser Leu Lys Asn Cys Ser 370 375 380 TTT AAT CAC TCA TTG GAA TGG CTA ATG ACA CAT ACT TTT GAC ATG GCC 1322 Phe Asn His Ser Leu Glu Trp Leu Met Thr His Thr Phe Asp Met Ala 385 390 395 ATT ATT GAA GGG AGT TAT GAA ATA TAC AAT GCT GTG TAT GCT TTT GCC 1370 Ile He Glu Gly Ser Tyr Glu He Tyr Asn Ala Val Tyr Ala Phe Ala 400 405 410 415 CAT GCA CTC CAT GAG ATG ACT CTT CAA AAT GTT GAT AAT GTT CTC CTT 1418 His Ala Leu His Glu Met Thr Leu Gin Asn Val Asp Asn Val Leu Leu 420 425 430 CCC AAT TAT GAA GAA CAA AAT TAT AAT TGC AAG ATG GTT TAT TCC TTT 1466 Pro Asn Tyr Glu Glu Gin Asn Tyr Asn Cys Lys Met Val Tyr Ser Phe 435 440 445 CTG AGC AAG ACT CAA TTC ACA AAT CCT GTT GGA GAC ACT GTG AAT ATG 1514 Leu Ser Lys Thr Gin Phe Thr Asn Pro Val Gly Asp Thr Val Asn Met 450 455 460 AAT CAA AGA AAC AAA CTG AAG GAA GAG TAC GAC ATT TTC TAC AAT TGG 1562 Asn Gin Arg Asn Lys Leu Lys Glu Glu Tyr Asp He Phe Tyr Asn Trp 465 470 475 AAT TTT CCA CAG GGA CTT GGA TTT AAA GTG AAA ATA GGA ATA TTT AGT 1610 Asn Phe Pro Gin Gly Leu Gly Phe Lys Val Lys He Gly He Phe Ser 480 485 490 495 CCA TAT TTT CCA AAA GGT CAA CAG CTT CAT TTA TCT GAA AAT CTG ATA 1658 Pro Tyr Phe Pro Lys Gly Gin Gin Leu His Leu Ser Glu Asn Leu He 500 505 510 GAG TGG TCC ACA GGA CGT ATA CAG ATG CCA ACC TCT GTG TGC AGT GCC 1706 Glu Trp Ser Thr Gly Arg He Gin Met Pro Thr Ser Val Cys Ser Ala 515 520 525 GAT TGT GGT CCT GGA TTT AGG AAA GTC TGG AAG AAT GGA ATG CCA GCC 1754 Asp Cys Gly Pro Gly Phe Arg Lys Val Trp Lys Asn Gly Met Pro Ala 530 535 540 TGT TGT TTT GAC TGC AGT CCC TGC CCA GAA AAT GAA ATT TCT AAT GAG 1802 Cys Cys Phe Asp Cys Ser Pro Cys Pro Glu Asn Glu He Ser Asn Glu 545 550 555 ACA AAT GTG GAA TTG TGT GTC CAG TGT CCA GAG GAC CAA TAT GCT AAC 1850 Thr Asn Val Glu Leu Cys Val Gin Cys Pro Glu Asp Gin Tyr Ala Asn 560 565 570 575 CAA GAG CAG AAT CAC TGC ATT CAC AAA GCT CGT ATC TTT CTC TCT TAT 1898 Gin Glu Gin Asn His Cys He His Lys Ala Arg He Phe Leu Ser Tyr 580 585 590 GAT GAA CCC TTG GGG ATG GCT CTT TCC TTA ATG GCC TTA TGC CTC GCT 1946 Asp Glu Pro Leu Gly Met Ala Leu Ser Leu Met Ala Leu Cys Leu Ala 595 600 605 GCA CTC ACA GTT GTG GTT CTT GGA GTC TTT GTG AAA CAT CAC AGA ACT 1994 Ala Leu Thr Val Val Val Leu Gly Val Phe Val Lys His His Arg Thr 610 615 620 CCC ATA GTT AAG GCC AAT AAC TGC ACT CTC ACC TAC ATC TTG CTC ATC 2042 Pro He Val Lys Ala Asn Asn Cys Thr Leu Thr Tyr He Leu Leu He 625 630 635 GCA CTC ATC TTT TGT TTC CTC TGC CCC TTG TTC TTC ATT GGC CAT CCA 2090 Ala Leu He Phe Cys Phe Leu Cys Pro Leu Phe Phe He Gly His Pro 640 645 650 655 AAC TCA GCT ACC TGC ATC CTT CAG CAA ATC ACA TTT GGA GTT GTG TTC 2138 Asn Ser Ala Thr Cys He Leu Gin Gin He Thr Phe Gly Val Val Phe 660 665 670 ACT GTG GCT ATT TCC ACT GTG TTG GCC AAA ACA ACC ACT GTC ATT CTG 2186 Thr Val Ala He Ser Thr Val Leu Ala Lys Thr Thr Thr Val He Leu 675 680 685 GCT TTC AGA GTC ACA GCC CCT CAT AGA ATG ATG AAG TAC TTT CTT GTT 2234 Ala Phe Arg Val Thr Ala Pro His Arg Met Met Lys Tyr Phe Leu Val 690 695 700 TCA AGG GCA TCT AAC TAC ATC ATT CCC ATT TGT ACT CTC ATT CAA ATT 2282 Ser Arg Ala Ser Asn Tyr He He Pro He Cys Thr Leu He Gin He 705 710 715 ATT GTA TGT GCC ATC TGG CTA GGA GCT TCT CCT CCT TCT GTT GAT ATT 2330 He Val Cys Ala He Trp Leu Gly Ala Ser Pro Pro Ser Val Asp He 720 725 730 735 GAT GCA CAG TCT GAG CAT GGT CAC ATC ATC ATT GCT TGC AAC AAG GGT 2378 Asp Ala Gin Ser Glu His Gly His He He He Ala Cys Asn Lys Gly 740 745 750 TCA GTC ACT GCT TTT TAC TGT GTC CTG GGA TAT CTG GCC TGC CTG GCC 2426 Ser Val Thr Ala Phe Tyr Cys Val Leu Gly Tyr Leu Ala Cys Leu Ala 755 760 765 TTT GTG AGC TTC ACC CTG GCT TTC CTT TCC AGA AAC CTG CCT GTC ACC 2474 Phe Val Ser Phe Thr Leu Ala Phe Leu Ser Arg Asn Leu Pro Val Thr 770 775 780 TTC AAT GAA GCC AAG TCC ATG ACA TTC AGC ATG CTG GTG TTC TGC AGT 2522 Phe Asn Glu Ala Lys Ser Met Thr Phe Ser Met Leu Val Phe Cys Ser 785 790 795 GTC TGG GTC ACT TTC CTA CCT GTT TAC CAT GGC ACC AAA GGC AAG GTT 2570 Val Trp Val Thr Phe Leu Pro Val Tyr His Gly Thr Lys Gly Lys Val 800 805 810 815 ATG GTG GCT GTT GAG ATC TTT TCC ACC TTG GCT TCT AGT GCA GGA ATG 2618 Met Val Ala Val Glu He Phe Ser Thr Leu Ala Ser Ser Ala Gly Met 820 825 830 TTG GGA TGC ATT TTT GCT CCA AAA TGC TAC ACA ATA CTG TTT AGA CCA 2666 Leu Gly Cys He Phe Ala Pro Lys Cys Tyr Thr He Leu Phe Arg Pro 835 840 845 GAC AGA AAT TCT CTT CAA ATG ATC AGG GAG AAG TCA TCT TCT CAT ACT 2714 Asp Arg Asn Ser Leu Gin Met He Arg Glu Lys Ser Ser Ser His Thr 850 855 860 CAC ATT TTA TAAAGTCTGA CTGACACAGG CATTGTTGGT TCATAATCAC CAAATATTC 2772 His He Leu 865 GATTACATTG CCATATCTAT TTTTAGAATG ACTGTCACTG TTCCCTTTGA TGATATTGCG 2832 TAGCAAGATC ATGTCTACTG AGGACTACCT TATCTCCTAT AATCTTCCAA CATTTTCTAC 2892 ATCAATCCTA CTCTTTTAGA GAAAGAGATA ATAGAATTTT AAACATTTTC AGAATTAGAG 2952 TTCTTCTAGG AACAGAGAAG AGAAAGAATT ATTTTTTCAA CAGGTTGATA GAATATCAGG 3012 AAAGGGGTTG AAGTCACAAC AATATAAATA AAGCCCTGCT CTTGTATAGG AACTTATGAA 3072 TACTCAATCC CACCAACTAC CATTAACAAC CACATGTAAC AAATGTTAAA AAGGATCAGA 3132 TGGTTTCTTA TTGTCTCCAA ATTTGCCTGA ACTTATTTAT GCACATAATG AGACACACAC 3192 ACACACACAC ACAAACACAC ACACAAATAC AAATTCCATA AAATTTTAAA AATATAGAAT 3252 ATTACAAAGA CTTAACACTG GCAATCTGCT CTTCAATGTT CATAATTACA GGAACTTACA 3312 GGAAAATATG GGACATAGGT AGAGATGACT GGGTTTATGT TAAGTCATTT TAAATAAGAA 3372 CCCTCAATTT TAAGTGTATC ATAAAAGACA CAGTTGTGAA ATTTTCAAGG ACAGCACTAC 3432 TTGTTGAAAT AATCTCCATC TGTGGAATTT ATAGGGTTTT GTGACAAAGA TCAGTTCTGA 3492 TATCAGAGAG TAAACTGAAG CAGGCAACCA TTAGTTGTCA GCACTGACAG CAGCTAATGG 3552 AGGTTGCTTC AGAAATCAAT TGAGGTTGAT TCTGGCAATG AGCAGTTAGA GAAGATAAAA 3612 AACAGGGAAA TCAAATATTC ACACACACAC ACACACACAC ACGTACACTC ACATGCACAA 3672 GCAAGTGCAT GCATGCAAAC CCACACAGAC TACTTGAAGC AAAGGCAAGG TCCAGCCACT 3732 TGAAACATAC AAATGTGTAC ATATAGACAG ACACAGACAA ACACATACAT ATCCACATGT 3792 TAAATGGCTG GAGCAATGTC AGCCAGCAGG CTCCATGTAT TTCACATATG TACATATATG 3852 CATGTAAATA AATATTCAGA TATACACATA TTCACATGTA CTGGTGGGTA GGTGGAATAA 3912 AGTTCCAAAA AACAGGCCCC AGGAATTTTA CACATAATGT ACAGACATAT ATAACACTAT 3972 TGGTGGAAGA ACAAGCTCCA ACATATTCAG GGAAGCATTG CATATACATA CATATAGATT 4032 TGATGGATGG AACAAAGTTC CAACAAATTC TCACATGAAC TTTATATATG TATATACATG 4092 AAAGGCAGCC TGGTTCCCAG TTGATCAGAG GTTTGAAAGC CCAGTGACCC TAAAAAAGAT 4152 GGTAGCCATT TAGCCTGATT CCCAGTAAAC CAGGCAAGTC ACTAGCCACA GCCCTCCATA 4212 GAATTTTGGC CATCAGTCAC TTAAGCCCAA CACCCTCCAC AGATTAAAGG AAGTGATTAC 4272 AGGTCACAGG GACTCAGAAC ACATTTCCAT TATGTGACAT AGTCAAAGAC TTGGAGACTT 4332 AGCCAATGAA CTTTCCTTCC CTGAAACTCC TCCCTGCAGG CCAACCTTGA AAAGAGGGGT 4392 ATGGTTTTAC TCATCTGCTT TCAGCCATGA CAATAAATGA CTTAAAACAA TGAAAAAAAA 4452 AAAAAAAAAA AAAAA 4467 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 866 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Met Ser Arg Leu Arg Ala Gly Lys Asn Met Leu Thr Phe He Leu Leu 1 5 10 15 Phe Phe Leu Leu Asn He Pro Leu Phe Val Pro Ser Phe He Tyr Pro 20 25 30 Arg Cys Phe Trp Ser Met Lys Lys Asn Glu Tyr Gin Asp Arg Asn Leu 35 40 45 Gly Thr Gly Cys Met Phe Phe He Leu Ala Val Gin Gin Pro Met Glu 50 55 60 Lys Glu Tyr Phe Ser His He Ser Asn He Gin Thr Pro Thr Glu Asn 65 70 75 80 Gin Lys Tyr Pro Leu Thr Leu Ala Phe Ser Met Asn Glu He Asn Asn 85 90 95 Asn Pro Asp Leu Leu Pro Asn Met Ser Leu Ala Phe Thr Phe Ser Glu 100 105 110 Tyr Ser Cys Tyr Leu Glu Ser His His Lys Arg Leu Phe Asn Phe Ser 115 120 125 Leu Lys Asn His Glu He Leu Pro Asn Phe He Cys Thr Lys Asp He 130 135 140 Lys Cys Gly Val Val Leu Thr Gly Leu Ser Leu Val Thr Thr Val Thr 145 150 155 160 Leu His He He Leu Asn Asn Phe He Phe Gin Gin Phe Arg Gin Leu 165 170 175 Thr Tyr Gly His Phe His Pro Ala Leu Cys Asp His Glu Asn Phe Pro 180 185 190 His Leu Tyr Gin Met Ala Ser Asp Asp Thr Ser Leu Ala Leu Ala Leu 195 200 205 Val Ser Phe He He His Phe Ser Trp Asn Trp He Gly Leu Ala He 210 215 220 Ser Asp Asn Asp Gin Gly He His Phe Leu Ser Tyr Leu Arg Arg Glu 225 230 235 240 Met Glu Lys Asn Thr Val Cys Phe Ala Phe Val Asn He He Pro Val 245 250 255 Asn Met Asn Leu Tyr Met Ser Arg Ala Glu Val Tyr Tyr Ser Gin Val 260 265 270 Met Thr Ser Ser Ala Asn Val Val He He Tyr Gly Asp Thr Gly Asn 275 280 285 Thr Leu Ala Val Ser Phe Arg Met Trp Asp Ser Leu Gly He Gin Arg 290 295 300 Leu Trp Val Thr Thr Ser Gin Trp Asp Val Thr Pro Phe Lys Lys Asp 305 310 315 320 Phe Thr Phe Asp Asn Gly Tyr Gly Thr Phe Gly Phe Gly His Arg His 325 330 335 Ser Glu He Ser Gly Phe Lys Tyr Phe Val Gin Thr Leu Asn Pro Phe 340 345 350 Lys Tyr Ser Asp Glu Tyr Leu Val Lys Leu Glu Trp Met Tyr Val Asn 355 360 365 Cys Lys He Leu Glu Tyr Asn Cys Lys Ser Leu Lys Asn Cys Ser Phe 370 375 380 Asn His Ser Leu Glu Trp Leu Met Thr His Thr Phe Asp Met Ala He 385 390 395 400 He Glu Gly Ser Tyr Glu He Tyr Asn Ala Val Tyr Ala Phe Ala His 405 410 415 Ala Leu His Glu Met Thr Leu Gin Asn Val Asp Asn Val Leu Leu Pro 420 425 430 Asn Tyr Glu Glu Gin Asn Tyr Asn Cys Lys Met Val Tyr Ser Phe Leu 435 440 445 Ser Lys Thr Gin Phe Thr Asn Pro Val Gly Asp Thr Val Asn Met Asn 450 455 460 Gin Arg Asn Lys Leu Lys Glu Glu Tyr Asp He Phe Tyr Asn Trp Asn 465 470 475 480 Phe Pro Gin Gly Leu Gly Phe Lys Val Lys He Gly He Phe Ser Pro 485 490 495 Tyr Phe Pro Lys Gly Gin Gin Leu His Leu Ser Glu Asn Leu He Glu 500 505 510 Trp Ser Thr Gly Arg He Gin Met Pro Thr Ser Val Cys Ser Ala Asp 515 520 525 Cys Gly Pro Gly Phe Arg Lys Val Trp Lys Asn Gly Met Pro Ala Cys 530 535 540 Cys Phe Asp Cys Ser Pro Cys Pro Glu Asn Glu He Ser Asn Glu Thr 545 550 555 560 Asn Val Glu Leu Cys Val Gin Cys Pro Glu Asp Gin Tyr Ala Asn Gin 565 570 575 Glu Gin Asn His Cys He His Lys Ala Arg He Phe Leu Ser Tyr Asp 580 585 590 Glu Pro Leu Gly Met Ala Leu Ser Leu Met Ala Leu Cys Leu Ala Ala 595 600 605 Leu Thr Val Val Val Leu Gly Val Phe Val Lys His His Arg Thr Pro 610 615 620 He Val Lys Ala Asn Asn Cys Thr Leu Thr Tyr He Leu Leu He Ala 625 630 635 640 Leu He Phe Cys Phe Leu Cys Pro Leu Phe Phe He Gly His Pro Asn 645 650 655 Ser Ala Thr Cys He Leu Gin Gin He Thr Phe Gly Val Val Phe Thr 660 665 670 Val Ala He Ser Thr Val Leu Ala Lys Thr Thr Thr Val He Leu Ala 675 680 685 Phe Arg Val Thr Ala Pro His Arg Met Met Lys Tyr Phe Leu Val Ser 690 695 700 Arg Ala Ser Asn Tyr He He Pro He Cys Thr Leu He Gin He He 705 710 715 720 Val Cys Ala He Trp Leu Gly Ala Ser Pro Pro Ser Val Asp He Asp 725 730 735 Ala Gin Ser Glu His Gly His He He He Ala Cys Asn Lys Gly Ser 740 745 750 Val Thr Ala Phe Tyr Cys Val Leu Gly Tyr Leu Ala Cys Leu Ala Phe 755 760 765 Val Ser Phe Thr Leu Ala Phe Leu Ser Arg Asn Leu Pro Val Thr Phe 770 775 780 Asn Glu Ala Lys Ser Met Thr Phe Ser Met Leu Val Phe Cys Ser Val 785 790 795 800 Trp Val Thr Phe Leu Pro Val Tyr His Gly Thr Lys Gly Lys Val Met 805 810 815 Val Ala Val Glu He Phe Ser Thr Leu Ala Ser Ser Ala Gly Met Leu 820 825 830 Gly Cys He Phe Ala Pro Lys Cys Tyr Thr He Leu Phe Arg Pro Asp 835 840 845 Arg Asn Ser Leu Gin Met He Arg Glu Lys Ser Ser Ser His Thr His 850 855 860 He Leu 865 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2916 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 299...2635 (D) OTHER INFORMATION: GoVN5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: CGGCACGAGT TCAACTAGTC ATGTTCAAGA AGGGGCAAAT ACTTTGTTAA TATGCTCTTC 60 GCTTGGACTT TTATCTCTTG CTTTCTGCAG ATTCCAATTA TTTTATGCTC CTACAGAAGC 120 AGCGAGTGCT TAGTCAAGAT GAATTATCGT TTAAAGGGGA AAGGAAATGT GGTGATTGTT 180 GGATTTTTCC CTGCTTTTGC TGTCTACCCC CTCAACAAAA CAATTGACTG GTGGATGCTT 240 AAATTCAGCA AAGAATTATG ATTGAGTTTA AGTTGAAGAG CTACCAGTAT ATTTGGCC AT 300 Met 1 GAG GTT TGC CAT TGA GGA AAT CAA CAG CAA TCC CCA TCT TTT ACC AAA 348 Arg Phe Ala He Glu Glu He Asn Ser Asn Pro His Leu Leu Pro Asn 5 10 15 CAC ATC CCT GGG ATT TGA GAT CAA TAA TGT CCC ACA CGG TCA GAG GTA 396 Thr Ser Leu Gly Phe Glu He Asn Asn Val Pro His Gly Gin Arg Tyr 20 25 30 CAC TCT GGT CAA ACT TTT TAG CTC ACT TTC AGG GTC TAA TTA TGA CAT 444 Thr Leu Val Lys Leu Phe Ser Ser Leu Ser Gly Ser Asn Tyr Asp He 35 40 45 TCC TAA CTA CAT AAG TGC AAG TGA GAG CAA TTC TGC TGC TGT ACT TAC 492 Pro Asn Tyr He Ser Ala Ser Glu Ser Asn Ser Ala Ala Val Leu Thr 50 55 60 65 AGG ACC ATC GTG GAC AAT ATC TGA ATG CGT AGG GAC ACT CCT GGA TCT 540 Gly Pro Ser Trp Thr He Ser Glu Cys Val Gly Thr Leu Leu Asp Leu 70 75 80 TTA CAA ATT TCC ACA GCT TAC TTT TGG GCC TTT TGA TAG TCT CCT GAG 588 Tyr Lys Phe Pro Gin Leu Thr Phe Gly Pro Phe Asp Ser Leu Leu Ser 85 90 95 TGA ACA AAG ACG GTT TTC TTC TCT GTA CCA AGT GGC CCC CAA AGA TAC 636 Glu Gin Arg Arg Phe Ser Ser Leu Tyr Gin Val Ala Pro Lys Asp Thr 100 105 110 ATT TCT GAC GCC TGG CAT TGT ATC TTT GAT GCT TCA TTT CCA CTG GAA 684 Phe Leu Thr Pro Gly He Val Ser Leu Met Leu His Phe His Trp Asn 115 120 125 CTG GGT GGG GTT ATT CAT CAT AGA TGA TGA CAA AGG TGC CCA GAC ACT 732 Trp Val Gly Leu Phe He He Asp Asp Asp Lys Gly Ala Gin Thr Leu 130 135 140 14 GTC AGA CTT GAG AAA TGA GAT GGA TAA AAA TGG AGT CTG CAC AGC ATT 780 Ser Asp Leu Arg Asn Glu Met Asp Lys Asn Gly Val Cys Thr Ala Phe 150 155 160 TGT AGA AAT GAT CCC AGT CAT CAA GGG TTC ATT TTT TAC CAA ATC CTG 828 Val Glu Met He Pro Val He Lys Gly Ser Phe Phe Thr Lys Ser Trp 165 170 175 GAA AAA TCA TGT GCA GAT CCT GGA ATC ATC ATC AAA TGT GAT TAT TAT 876 Lys Asn His Val Gin He Leu Glu Ser Ser Ser Asn Val He He He 180 185 190 TTA TGG GGA CTC TGA TTC TCT ATT AAG CTT AAT AGT AAA TAT TAA GCA 924 Tyr Gly Asp Ser Asp Ser Leu Leu Ser Leu He Val Asn He Lys Gin 195 200 205 GAA GTT GCT CAC ATG GAA AGT GTG GGT ACT GAT CTC ACA GTG GGA TGT 972 Lys Leu Leu Thr Trp Lys Val Trp Val Leu He Ser Gin Trp Asp Val 210 215 220 22 TTC TAA ATT TGA TGA TTA TTT CAT GGT AGA CTC ATT GCA TGG AGC TCT 1020 Ser Lys Phe Asp Asp Tyr Phe Met Val Asp Ser Leu His Gly Ala Leu 230 235 240 TAT TTT TTC ACA CCA TCG TGA GGA GAT TCC TAA TTT TAC AGA TTT TAT 1068 He Phe Ser His His Arg Glu Glu He Pro Asn Phe Thr Asp Phe Met 245 250 255 GCA GAA GTA CAA CCC TTC CAA GTA CCC GGA AGA CAC TTA TCT TCA TGT 1116 Gin Lys Tyr Asn Pro Ser Lys Tyr Pro Glu Asp Thr Tyr Leu His Val 260 265 270 ATT GTG GCA CAT GTA CTT CAA TTG CTC ATT TGT TAA GAA AGA TTG TAA 1164 Leu Trp His Met Tyr Phe Asn Cys Ser Phe Val Lys Lys Asp Cys Lys 275 280 285 AAT TGT GCA CAA CTG TTT GCC TAA TGC CTC CCT GGG GTT CTT GCC TGG 1212 He Val His Asn Cys Leu Pro Asn Ala Ser Leu Gly Phe Leu Pro Gly 290 295 300 30 GAA CAT ATT TGA CAT GGC CAT GAG TGA AGA GAG TTA CAA TGT ATA CAA 1260 Asn He Phe Asp Met Ala Met Ser Glu Glu Ser Tyr Asn Val Tyr Asn 310 315 320 TGC TGT GTA TGC TGT GGC CCA CAG TCT GCA TGA GAT GAT TCT CAA CCA 1308 Ala Val Tyr Ala Val Ala His Ser Leu His Glu Met He Leu Asn Gin 325 330 335 AGT ACA ATT TCA AAC TCA TGA AAA AGG AAA AAA GAT GGT ATT CTT TCC 1356 Val Gin Phe Gin Thr His Glu Lys Gly Lys Lys Met Val Phe Phe Pro 340 345 350 TTG GCA GCT TCA CCC CTT TCT AAG GGA AAG ACA ACT CAT CAA TCA GAA 1404 Trp Gin Leu His Pro Phe Leu Arg Glu Arg Gin Leu He Asn Gin Asn 355 360 365 TGG AGC GAA TGA AGA TCT GGA TTG TAC CAG GAA GTC ACA TGT AGA GTA 1452 Gly Ala Asn Glu Asp Leu Asp Cys Thr Arg Lys Ser His Val Glu Tyr 370 375 380 38 TGA CAT TCT CAA CTT TTG GAA TTT CCC AAA AGG TCT TGG GCT AAA TGT 1500 Asp He Leu Asn Phe Trp Asn Phe Pro Lys Gly Leu Gly Leu Asn Val 390 395 400 GAA AGT AGG AAC GTT TTC TCC AAG TGC TCC AAA GGA ACA GAA ACT GTC 1548 Lys Val Gly Thr Phe Ser Pro Ser Ala Pro Lys Glu Gin Lys Leu Ser 405 410 415 CAT ATC TTC TAA CAT GAT ACA GTG GGC CAC AGG GTC GAC AGA GAT TCC 1596 He Ser Ser Asn Met He Gin Trp Ala Thr Gly Ser Thr Glu He Pro 420 425 430 ACA GTC TGT ATG CAG TGA GAG CTG TCA TCC TGG ATT CAG GAA AAC CCA 1644 Gin Ser Val Cys Ser Glu Ser Cys His Pro Gly Phe Arg Lys Thr His 435 440 445 CCA GGA AGG CAG GGT TGC CTG TTG CTT TGA CTG CAT TCC TTG TCC AGA 1692 Gin Glu Gly Arg Val Ala Cys Cys Phe Asp Cys He Pro Cys Pro Glu 450 455 460 46 AAA TGA GAT CTC CAA TGA GAC AGA TGT GGA TCA GTG TGT GAA GTG TCC 1740 Asn Glu He Ser Asn Glu Thr Asp Val Asp Gin Cys Val Lys Cys Pro 470 475 480 AGA AAC TCA CTA TGC AAA CAT AGA GAA GAT CCA CTG CCT ACA GAA AAC 1788 Glu Thr His Tyr Ala Asn He Glu Lys He His Cys Leu Gin Lys Thr 485 490 495 TGT GAC ATT TCT GTA CTA TGA TGA CCC ATT GGG GAA GAC ACT TTG CTT 1836 Val Thr Phe Leu Tyr Tyr Asp Asp Pro Leu Gly Lys Thr Leu Cys Phe 500 505 510 CAT GTC CCT GGG TTT CTC CTC ACT CAC AGC TGC TGT TCT TGT GGT GTT 1884 Met Ser Leu Gly Phe Ser Ser Leu Thr Ala Ala Val Leu Val Val Phe 515 520 525 TCT GAA GAA CAG GGA CAC CCC CAT TGT CAA GGC CAA TAA CCT GGC TCT 1932 Leu Lys Asn Arg Asp Thr Pro He Val Lys Ala Asn Asn Leu Ala Leu 530 535 540 54 CAG TTA CAC CCT GCT CAT CAC TTT GAT GCT CTG TTT TCT CTG TCC CTT 1980 Ser Tyr Thr Leu Leu He Thr Leu Met Leu Cys Phe Leu Cys Pro Leu 550 555 560 GCT CTT CAT TGG CCG TCC CAG CAC AGC CTC CTG TAT CCT GCA GCA AAA 2028 Leu Phe He Gly Arg Pro Ser Thr Ala Ser Cys He Leu Gin Gin Asn 565 570 575 CAT TTT TGG GCT TCT GTT CAC TGT GGC TCT TTC CAC TGT GTT GGC CAA 2076 He Phe Gly Leu Leu Phe Thr Val Ala Leu Ser Thr Val Leu Ala Lys 580 585 590 AAC TAT CAC TGT GGT TAT AGC CTT CAA GAT CAC TTC TCC AGG AAG AAT 2124 Thr He Thr Val Val He Ala Phe Lys He Thr Ser Pro Gly Arg He 595 600 605 TAG AAG ATG GCT GCT GAT ATC AAG GGC CCC TAA TTT CAT TAT TCC CTT 2172 Arg Arg Trp Leu Leu He Ser Arg Ala Pro Asn Phe He He Pro Leu 610 615 620 62 ATG CAC CCT GCT CCA AGT TTT TCT ATC TGG AAT TTG GCT GAC AAC CTC . 2220 Cys Thr Leu Leu Gin Val Phe Leu Ser Gly He Trp Leu Thr Thr Ser 630 635 640 TCC TCC ATT TAT TGA TAA AGA TGC TCA CTC AGA ACA TGG ACA CAT CAT 2268 Pro Pro Phe He Asp Lys Asp Ala His Ser Glu His Gly His He He 645 650 655 CAT CAT TTG CAA TAA AGG CTC AGC TGT TGC TTT CCA TTG CAA CCT TGG 2316 He He Cys Asn Lys Gly Ser Ala Val Ala Phe His Cys Asn Leu Gly 660 665 670 ATA CCT GGG AGC ACT AGC CCT AGT GAG CTA CTT TAT GGC TTT CTT GTC 2364 Tyr Leu Gly Ala Leu Ala Leu Val Ser Tyr Phe Met Ala Phe Leu Ser 675 680 685 CAG AAA CCT ACC TGA CAC ATT CAA TGA AGC CAA GTT CCT GGC TTT CAG 2412 Arg Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Ala Phe Ser 690 695 700 70 CAT GCT GGT GTT CTG CAG TGT CTG GGT CAC CTT CCT CCC TGT CTA CCA 2460 Met Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr His 710 715 720 CAG CAC CAA GGG GAA GAA CAT GGT GGC TAT GGA AGT CTT CTC TAT CTT 2508 Ser Thr Lys Gly Lys Asn Met Val Ala Met Glu Val Phe Ser He Leu 725 730 735 GGC TTC CAG TAC ATC TCT CCT AGG CAT CAT CTT TGC CCC CAA GTG CTA 2556 Ala Ser Ser Thr Ser Leu Leu Gly He He Phe Ala Pro Lys Cys Tyr 740 745 750 CCT CAT ATT ATT AAG ACC AGA AAG GAA TTC ACT TAG CTA TAT CAG GGA 2604 Leu He Leu Leu Arg Pro Glu Arg Asn Ser Leu Ser Tyr He Arg Asp 755 760 765 CAA AAC ATA TGC TAA AAG CAT AAA ACC TTC T TAGCATCCTT ATGTGCCTCT T 2656 Lys Thr Tyr Ala Lys Ser He Lys Pro Ser 770 775 AAATTAAACA GCATCATTGA AGGCAATTGT TGTTCTTCAC TATCTGAACA CTCACATATA 2716 AAGTCATAAT TGTACATTTG ATCCAGGGGC TATTATTTCT TTAGTAGTCA TATATATGTA 2776 CCTAATGCTT TTTTCACATT AAAATATGTG CTGCATTTTT CGTCTTCCTC TTCTACTTAC 2836 TATTAGTTTT GTGCTATTGA TTTAACTTGC AATAAAATCC AAATTTCTGA GTTCTTCCAA 2896 AAAAAAAAAA AAAAAAAAAA 2916 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 779 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Met Arg Phe Ala He Glu Glu He Asn Ser Asn Pro His Leu Leu Pro 1 5 10 15 Asn Thr Ser Leu Gly Phe Glu He Asn Asn Val Pro His Gly Gin Arg 20 25 30 Tyr Thr Leu Val Lys Leu Phe Ser Ser Leu Ser Gly Ser Asn Tyr Asp 35 40 45 He Pro Asn Tyr He Ser Ala Ser Glu Ser Asn Ser Ala Ala Val Leu . 50 55 60 Thr Gly Pro Ser Trp Thr He Ser Glu Cys Val Gly Thr Leu Leu Asp 65 70 75 80 Leu Tyr Lys Phe Pro Gin Leu Thr Phe Gly Pro Phe Asp Ser Leu Leu 85 90 95 Ser Glu Gin Arg Arg Phe Ser Ser Leu Tyr Gin Val Ala Pro Lys Asp 100 105 110 Thr Phe Leu Thr Pro Gly He Val Ser Leu Met Leu His Phe His Trp 115 120 125 Asn Trp Val Gly Leu Phe He He Asp Asp Asp Lys Gly Ala Gin Thr 130 135 140 Leu Ser Asp Leu Arg Asn Glu Met Asp Lys Asn Gly Val Cys Thr Ala 145 150 155 160 Phe Val Glu Met He Pro Val He Lys Gly Ser Phe Phe Thr Lys Ser 165 170 175 Trp Lys Asn His Val Gin He Leu Glu Ser Ser Ser Asn Val He He 180 185 190 He Tyr Gly Asp Ser Asp Ser Leu Leu Ser Leu He Val Asn He Lys 195 200 205 Gin Lys Leu Leu Thr Trp Lys Val Trp Val Leu He Ser Gin Trp Asp 210 215 220 Val Ser Lys Phe Asp Asp Tyr Phe Met Val Asp Ser Leu His Gly Ala 225 230 235 240 Leu He Phe Ser His His Arg Glu Glu He Pro Asn Phe Thr Asp Phe 245 250 255 Met Gin Lys Tyr Asn Pro Ser Lys Tyr Pro Glu Asp Thr Tyr Leu His 260 265 270 Val Leu Trp His Met Tyr Phe Asn Cys Ser Phe Val Lys Lys Asp Cys 275 280 285 Lys He Val His Asn Cys Leu Pro Asn Ala Ser Leu Gly Phe Leu Pro 290 295 300 Gly Asn He Phe Asp Met Ala Met Ser Glu Glu Ser Tyr Asn Val Tyr 305 310 315 320 Asn Ala Val Tyr Ala Val Ala His Ser Leu His Glu Met He Leu Asn 325 330 335 Gin Val Gin Phe Gin Thr His Glu Lys Gly Lys Lys Met Val Phe Phe 340 345 350 Pro Trp Gin Leu His Pro Phe Leu Arg Glu Arg Gin Leu He Asn Gin 355 360 365 Asn Gly Ala Asn Glu Asp Leu Asp Cys Thr Arg Lys Ser His Val Glu 370 375 380 Tyr Asp He Leu Asn Phe Trp Asn Phe Pro Lys Gly Leu Gly Leu Asn 385 390 395 400 Val Lys Val Gly Thr Phe Ser Pro Ser Ala Pro Lys Glu Gin Lys Leu 405 410 415 Ser He Ser Ser Asn Met He Gin Trp Ala Thr Gly Ser Thr Glu He 420 425 430 Pro Gin Ser Val Cys Ser Glu Ser Cys His Pro Gly Phe Arg Lys Thr 435 440 445 His Gin Glu Gly Arg Val Ala Cys Cys Phe Asp Cys He Pro Cys Pro 450 455 460 Glu Asn Glu He Ser Asn Glu Thr Asp Val Asp Gin Cys Val Lys Cys 465 470 475 480 Pro Glu Thr His Tyr Ala Asn He Glu Lys He His Cys Leu Gin Lys 485 490 495 Thr Val Thr Phe Leu Tyr Tyr Asp Asp Pro Leu Gly Lys Thr Leu Cys 500 505 510 Phe Met Ser Leu Gly Phe Ser Ser Leu Thr Ala Ala Val Leu Val Val 515 520 525 Phe Leu Lys Asn Arg Asp Thr Pro He Val Lys Ala Asn Asn Leu Ala 530 535 540 Leu Ser Tyr Thr Leu Leu He Thr Leu Met Leu Cys Phe Leu Cys Pro 545 550 555 560 Leu Leu Phe He Gly Arg Pro Ser Thr Ala Ser Cys He Leu Gin Gin 565 570 575 Asn He Phe Gly Leu Leu Phe Thr Val Ala Leu Ser Thr Val Leu Ala 580 585 590 Lys Thr He Thr Val Val He Ala Phe Lys He Thr Ser Pro Gly Arg 595 600 605 He Arg Arg Trp Leu Leu He Ser Arg Ala Pro Asn Phe He He Pro 610 615 620 Leu Cys Thr Leu Leu Gin Val Phe Leu Ser Gly He Trp Leu Thr Thr 625 630 635 640 Ser Pro Pro Phe He Asp Lys Asp Ala His Ser Glu His Gly His He 645 650 655 He He He Cys Asn Lys Gly Ser Ala Val Ala Phe His Cys Asn Leu 660 665 670 Gly Tyr Leu Gly Ala Leu Ala Leu Val Ser Tyr Phe Met Ala Phe Leu 675 680 685 Ser Arg Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Ala Phe 690 695 700 Ser Met Leu Val Phe Cys Ser Val Trp Val Thr Phe Leu Pro Val Tyr 705 710 715 720 His Ser Thr Lys Gly Lys Asn Met Val Ala Met Glu Val Phe Ser He 725 730 735 Leu Ala Ser Ser Thr Ser Leu Leu Gly He He Phe Ala Pro Lys Cys 740 745 750 Tyr Leu He Leu Leu Arg Pro Glu Arg Asn Ser Leu Ser Tyr He Arg 755 760 765 Asp Lys Thr Tyr Ala Lys Ser He Lys Pro Ser 770 775 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3307 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 112...1761 (D) OTHER INFORMATION: G0VN6 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: TAAGGCAGGA AAAAATGTTC ATTTTGATGG AAGTCTTCTT CTTCTTCCTT AACATTCCAC 60 TGCTCATGGC AAATTTCATT GATCCCAAGT GCTTTTGGAG AGTAAATTTG A ATG AAG 117 Met Lys 1 TTA AGG GAT AAA GAC TTG AGC ATA ACT TGT TCC TTC ATC CTT GAA GCA 165 Leu Arg Asp Lys Asp Leu Ser He Thr Cys Ser Phe He Leu Glu Ala 5 10 15 GTT CAG ATG CCT ACG GAA AAC GAT TAT TTC AAC CAG ACT CTG AAT ATC 213 Val Gin Met Pro Thr Glu Asn Asp Tyr Phe Asn Gin Thr Leu Asn He 20 25 30 CTA AAA ACA ACA AAA AAC CAC AAA TAT GCT TTG GCA TTG GCC TTT TCA 261 Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Ala Phe Ser 35 40 45 50 ATT GAT GAA ATC AAC AGG AAT CCT GAT CTT TTA CCA AAT ATG TCT TTG 309 He Asp Glu He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser Leu 55 60 65 ATC ATA AAA TAC CCT TTG GGC CTT TGC GAT GGA CAA ACT ACA TTA CCT 357 He He Lys Tyr Pro Leu Gly Leu Cys Asp Gly Gin Thr Thr Leu Pro 70 75 80 ACA CCC TAT TTA TTT AAT GAA ATA TAT TTT AGG CCT ATC CCT AAT TAT 405 Thr Pro Tyr Leu Phe Asn Glu He Tyr Phe Arg Pro He Pro Asn Tyr 85 90 95 TTC TGT AAT GAA GAG ACT ATG TGT ACA TTT CTA CTT ACA GGA CCG CAT 453 Phe Cys Asn Glu Glu Thr Met Cys Thr Phe Leu Leu Thr Gly Pro His 100 105 110 TGG ATA ACA TCT TAT AGT TTC TGG ATA CAC TTG AAC ATC TTC TTA TCT 501 Trp He Thr Ser Tyr Ser Phe Trp He His Leu Asn He Phe Leu Ser 115 120 125 130 CCT AGT ATG AAC CCA AAG GAC ACA TCC CTA GCT TTG GCA ATG GTC TCC 549 Pro Ser Met Asn Pro Lys Asp Thr Ser Leu Ala Leu Ala Met Val Ser 135 140 145 TTC TTA CTT TAT TTC AAG TGG AAC TGG GTC GGC CTT GTC ATC TCA GAT 597 Phe Leu Leu Tyr Phe Lys Trp Asn Trp Val Gly Leu Val He Ser Asp 150 155 160 GAT GAT CAA GGC AAT CAA TTT CTC TCT GAG TTG AAA AAA GAG AGC AAA 645 Asp Asp Gin Gly Asn Gin Phe Leu Ser Glu Leu Lys Lys Glu Ser Lys 165 170 175 ATC AAG GAA ATT TGC TTT GCA TTT GTG AGC ATG CTG GCA ATC GAT GAG 693 He Lys Glu He Cys Phe Ala Phe Val Ser Met Leu Ala He Asp Glu 180 185 190 ATT TCA TTT TAT CAT AAA ACT GAA ATG TAC TAC AAC CAA ATT GTG ATG 741 He Ser Phe Tyr His Lys Thr Glu Met Tyr Tyr Asn Gin He Val Met 195 200 205 210 TCA TCC ACA AAC GTT ATT ATC ATT TAT GGG AAA ACA GAG AGT ATT ATT 789 Ser Ser Thr Asn Val He He He Tyr Gly Lys Thr Glu Ser He He 215 220 225 GAG TTG AGC TTC AGA ATG TGG GAA TCT CCA GTT ATC CAG AGA ATA TGG 837 Glu Leu Ser Phe Arg Met Trp Glu Ser Pro Val He Gin Arg He Trp 230 235 240 GTC ACC ACA AAA GAA ATG AAT TTC CCT ACC AGT AAG AGA GAT TTA ACT 885 Val Thr Thr Lys Glu Met Asn Phe Pro Thr Ser Lys Arg Asp Leu Thr 245 250 255 CAT GAC ACA TTC TAT GGG ACT CTT ACT TTT CTA CAC AGC CAT GGG GAG 933 His Asp Thr Phe Tyr Gly Thr Leu Thr Phe Leu His Ser His Gly Glu 260 265 270 ATT TCA GGC TTT AAA AAT TTT GTA CAG ACA TGG TAC CAT CTT AGA ATC 981 He Ser Gly Phe Lys Asn Phe Val Gin Thr Trp Tyr His Leu Arg He 275 280 285 290 ACT GAT TTG CAT CTA GTA ATG CCA GAG TGG AAA TAT TTT AAC TAT GAA 1029 Thr Asp Leu His Leu Val Met Pro Glu Trp Lys Tyr Phe Asn Tyr Glu 295 300 305 GCC TCA GCA TCT AAC TGT AAA ATA TTG AAG AAC TAT TCA TCC AGT GCC 1077 Ala Ser Ala Ser Asn Cys Lys He Leu Lys Asn Tyr Ser Ser Ser Ala 310 315 320 TCA TTG GAA TGG TTA ATG GAG CAG ACA TTT GAC ATG GTC TTT AGT GAT , 1125 Ser Leu Glu Trp Leu Met Glu Gin Thr Phe Asp Met Val Phe Ser Asp 325 330 335 GGA AGT CGG GAT ATA TAT AAT GCT GTA AAT GCC ATG GCC CAT GCA CTC 1173 Gly Ser Arg Asp He Tyr Asn Ala Val Asn Ala Met Ala His Ala Leu 340 345 350 CAT GAG ATG AAT CTG CAC CTG GTT GAT AAT CAG GCA ATA GAC AAT GGG 1221 His Glu Met Asn Leu His Leu Val Asp Asn Gin Ala He Asp Asn Gly 355 360 365 370 AAA GGA GCC AGT TCT CAC TGC TTT AAG ATA AAC TCC TTT CTC AGA AAG 1269 Lys Gly Ala Ser Ser His Cys Phe Lys He Asn Ser Phe Leu Arg Lys 375 380 385 ACC CAC TTC ACT AAT CCT CTT GGG GAC AGA GTG ATT ATG AAA GAG AGA 1317 Thr His Phe Thr Asn Pro Leu Gly Asp Arg Val He Met Lys Glu Arg 390 395 400 GAA ATA CTG CAA GAA GAC TAT AAC ATT TTT CAC ACT TGG AAT TTT TCT 1365 Glu He Leu Gin Glu Asp Tyr Asn He Phe His Thr Trp Asn Phe Ser 405 410 415 CAG CAC ATT GGT TTT AAG GTG AAG ATA GGA AAG TTC AGC CCA TAT TTT 1413 Gin His He Gly Phe Lys Val Lys He Gly Lys Phe Ser Pro Tyr Phe 420 425 430 CCA CAT GGC AGG CAC TTT CAC CTA TAT GTA GAC ATG ATT GAG TTG GCT 1461 Pro His Gly Arg His Phe His Leu Tyr Val Asp Met He Glu Leu Ala 435 440 445 450 ACA GGA AGT AGA AAG ATG CCA TCC TCT GTG TGC ACT GAA GAT TGT AGT 1509 Thr Gly Ser Arg Lys Met Pro Ser Ser Val Cys Thr Glu Asp Cys Ser 455 460 465 CCT GGA TAC AGA AGA TTC TGG AAG GAG GGA ATG GCA GCC TGC TGT TTT 1557 Pro Gly Tyr Arg Arg Phe Trp Lys Glu Gly Met Ala Ala Cys Cys Phe 470 475 480 GTT TGC AGT CCC TGC CCT GAA AAT GCA ATT TCT AAT GAG ACA AAT ATG 1605 Val Cys Ser Pro Cys Pro Glu Asn Ala He Ser Asn Glu Thr Asn Met 485 490 495 GAT CAG TGT GTG AAT TGT CCA GAA TAC CAA TAT GCC AAT ACA AAG CGG 1653 Asp Gin Cys Val Asn Cys Pro Glu Tyr Gin Tyr Ala Asn Thr Lys Arg 500 505 510 GAC AAA TGC ATT CAG AAA AAT GTG ATG TTT CTA AGC TAC AAA GAC CCC 1701 Asp Lys Cys He Gin Lys Asn Val Met Phe Leu Ser Tyr Lys Asp Pro 515 520 525 530 CTT GGG GAT GAC TCT TGC CTT CAT AGC CTT CTT TTT CTC TGC ATT AAC 1749 Leu Gly Asp Asp Ser Cys Leu His Ser Leu Leu Phe Leu Cys He Asn 535 540 545 AGC TGT TGT ACT TAGGGTCTTT GTGAAGCACC ATGACACTCC TATTGTGAAG GCCAA 1806 Ser Cys Cys Thr 550 TAACAGAATC CTCAGCTACC TATTAATCAC GTCTCTCTTG TTCTGTTTTC TCTGCTCATT 1866 TTTCTTCATT GGCCATCCTA ACAGAGCAAC CTGCATCTTA CAGCAAATCA CATTTGGAAT 1926 TGTATTCACT GTGGCTATTT CTACAATTTT GGCAAAAACA ATCACTGTGG TTCTGGCTTT 1986 CAAAGTCACA AACCCAGGAA GAAGGTTGAG AAACTTCCTA GTATTGGGTA CACTCAACTA 2046 CATTATCCCC ATATGTTCCC TGTTTCAATG TATTCTGTGT GCAATCTGGC TAGCAGTTTC 2106 TCCTCCCTTT GTTGATACTG ATGAACACAC TGAGTATGGC CACATCATCA TTGTGTGCAA 2166 CAAAGGCTCA GTAACTGCAT TCTACTGTGT CCTGGGATAC TTGGCCTGCT TGGCACTTGC 2226 AAGCTTCACT GTGGCTTTCT TGGCAAAGAA TCTGCCAGAC ACATTCAATG AAGCCAAGTT 2286 CTTGACCTTC AGCATGCTGG TGTTCTGCAG TGTCTGGGTC ACCTTCCTCC CTGTCTACCA 2346 CAGCACCAAG GGCAAGATCA TGGTTGCTGT GGAGATATTC TCCATTTTGG CATCCAGTGC 2406 AGGGATGCTT GGATGCATCT TTGCACCCAA GATTTACATC ATTTTAATGA GACCAGAGAG 2466 AAATGCTATC CAAAAGATCA GGGAGAAATC ATATTTCTGA ACAAATTATT TCAGAATTTC 2526 TATCAAATGT AAACATGGTA TATACCCATC AAATATTGTG TTACAGTGCA TGTATCTAGT 2586 TTTAGAATCA CTCTCACTGG TACCCCTAGT GATGTCTAGA AATATCATAT CTACCAATCT 2646 TGAATACATT GTCCATAAAA TCTTGTACAT ATTCACTAGC TTAGTTTCCT GTGGGAGAAC 2706 TAAAATTCTC AAATTATTAT TACAATTTTA TTCATAATTT TGCTCTCATG GCAAATCAGA 2766 ACTCATTTTC TAATTTCCAG TAACAACACA TACATGACAG AATACTGATT TTCAGCTATT 2826 CTTTAAGCTA TTGGCCAATA GACTAAGGTG GAAATGTTCT TTTTCTTTCT GAAACACAAA 2886 AATATTATAT CATATAATAC ACAGAAGTCA GGGACCCCTA TGGATGAATT AGGGAATAGT 2946 TGGAAGAAGC TGGCTGAGTA GAAGGGTGAC CCATAGGAAG ACCAGCAGTC TCACCTAACA 3006 AGGACAACCA AGATCTTGCT GACACTGAAT CACTTGCTAG GCAGTTGATT TGAGGCCCCT 3066 GACACATATC AAGCATAGGA CTACATTGGC TGGCCTCAGT GGGAGAAGAC AACCTAACCC 3126 CCTAGAGACT TGAGGCCCCA GGCTAAGGGG AGGTTGGGGG TTTTGAAAGT TGGGGATATT 3186 ATCTTGGAGT TGGGGAGGGG TATGGGATGA AGAAGAGTCA GGAGGCAGGT GCTGGTTGGA 3246 GTATAATGAC TGGACTGTAA ATAAAAGACT AACAACCAAA AATAAATAAA ATAACTTAAA 3306 A 3307 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 550 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: Met Lys Leu Arg Asp Lys Asp Leu Ser He Thr Cys Ser Phe He Leu 1 5 10 15 Glu Ala Val Gin Met Pro Thr Glu Asn Asp Tyr Phe Asn Gin Thr Leu 20 25 30 Asn He Leu Lys Thr Thr Lys Asn His Lys Tyr Ala Leu Ala Leu Ala 35 40 45 Phe Ser He Asp Glu He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met 50 55 60 Ser Leu He He Lys Tyr Pro Leu Gly Leu Cys Asp Gly Gin Thr Thr 65 70 75 80 Leu Pro Thr Pro Tyr Leu Phe Asn Glu He Tyr Phe Arg Pro He Pro 85 90 95 Asn Tyr Phe Cys Asn Glu Glu Thr Met Cys Thr Phe Leu Leu Thr Gly 100 105 110 Pro His Trp He Thr Ser Tyr Ser Phe Trp He His Leu Asn He Phe 115 120 125 Leu Ser Pro Ser Met Asn Pro Lys Asp Thr Ser Leu Ala Leu Ala Met 130 135 140 Val Ser Phe Leu Leu Tyr Phe Lys Trp Asn Trp Val Gly Leu Val He 145 150 155 160 Ser Asp Asp Asp Gin Gly Asn Gin Phe Leu Ser Glu Leu Lys Lys Glu 165 170 175 Ser Lys He Lys Glu He Cys Phe Ala Phe Val Ser Met Leu Ala He 180 185 190 Asp Glu He Ser Phe Tyr His Lys Thr Glu Met Tyr Tyr Asn Gin He 195 200 205 Val Met Ser Ser Thr Asn Val He He He Tyr Gly Lys Thr Glu Ser 210 215 220 He He Glu Leu Ser Phe Arg Met Trp Glu Ser Pro Val He Gin Arg 225 230 235 240 He Trp Val Thr Thr Lys Glu Met Asn Phe Pro Thr Ser Lys Arg Asp 245 250 255 Leu Thr His Asp Thr Phe Tyr Gly Thr Leu Thr Phe Leu His Ser His 260 265 270 Gly Glu He Ser Gly Phe Lys Asn Phe Val Gin Thr Trp Tyr His Leu 275 280 285 Arg He Thr Asp Leu His Leu Val Met Pro Glu Trp Lys Tyr Phe Asn 290 295 300 Tyr Glu Ala Ser Ala Ser Asn Cys Lys He Leu Lys Asn Tyr Ser Ser 305 310 315 320 Ser Ala Ser Leu Glu Trp Leu Met Glu Gin Thr Phe Asp Met Val Phe 325 330 335 Ser Asp Gly Ser Arg Asp He Tyr Asn Ala Val Asn Ala Met Ala His 340 345 350 Ala Leu His Glu Met Asn Leu His Leu Val Asp Asn Gin Ala He Asp 355 360 365 Asn Gly Lys Gly Ala Ser Ser His Cys Phe Lys He Asn Ser Phe Leu 370 375 380 Arg Lys Thr His Phe Thr Asn Pro Leu Gly Asp Arg Val He Met Lys 385 390 395 400 Glu Arg Glu He Leu Gin Glu Asp Tyr Asn He Phe His Thr Trp Asn 405 410 415 Phe Ser Gin His He Gly Phe Lys Val Lys He Gly Lys Phe Ser Pro 420 425 430 Tyr Phe Pro His Gly Arg His Phe His Leu Tyr Val Asp Met He Glu 435 440 445 Leu Ala Thr Gly Ser Arg Lys Met Pro Ser Ser Val Cys Thr Glu Asp 450 455 460 Cys Ser Pro Gly Tyr Arg Arg Phe Trp Lys Glu Gly Met Ala Ala Cys 465 470 475 480 Cys Phe Val Cys Ser Pro Cys Pro Glu Asn Ala He Ser Asn Glu Thr 485 490 495 Asn Met Asp Gin Cys Val Asn Cys Pro Glu Tyr Gin Tyr Ala Asn Thr 500 505 510 Lys Arg Asp Lys Cys He Gin Lys Asn Val Met Phe Leu Ser Tyr Lys 515 520 525 Asp Pro Leu Gly Asp Asp Ser Cys Leu His Ser Leu Leu Phe Leu Cys 530 535 540 He Asn Ser Cys Cys Thr 545 550 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3938 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 46...2424 (D) OTHER INFORMATION: GoVN7 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: CGGCACGAGC CCAGGTTTAA GGCTGGAAAA AATATGTTCA TTTTG ATG ATA GTA TTC 57 Met He Val Phe 1 TTT CTC CTC AAC ATT CCA CTT CTC ATG GCA AAT TCC GTT GAT CCC AGG 105 Phe Leu Leu Asn He Pro Leu Leu Met Ala Asn Ser Val Asp Pro Arg 5 10 15 20 TGC TTT TGG AAA ATA AAT TTG AAT GAA GTC AAG GAT ATA GAT TTA GAT 153 Cys Phe Trp Lys He Asn Leu Asn Glu Val Lys Asp He Asp Leu Asp 25 30 35 ACA AGT TGT TAC TTC ATC CTT GAG GCA GTT CAG TTG CCT ATG GAG AAA 201 Thr Ser Cys Tyr Phe He Leu Glu Ala Val Gin Leu Pro Met Glu Lys 40 45 50 GAT TAT TTC AAC CAG ACT CTG AAT GTC CTA AAA ACA ACC AAA TAC AAC 249 Asp Tyr Phe Asn Gin Thr Leu Asn Val Leu Lys Thr Thr Lys Tyr Asn 55 60 65 AGA TAT GCA TTG GCA TTA GCC TTT ACA ATG GAT GAA ATA AAC AGG AAT 297 Arg Tyr Ala Leu Ala Leu Ala Phe Thr Met Asp Glu He Asn Arg Asn 70 75 80 CCT CAT ATT TTA CCA AAC ATG TCT TTG ATT ATA AAA CAT ACA TTG GGC 345 Pro His He Leu Pro Asn Met Ser Leu He He Lys His Thr Leu Gly 85 90 95 100 CAC TGT GAT GGA AAT ATC CCA CTC CGC TTA CTT AAT CAA ATA TTT TAT 393 His Cys Asp Gly Asn He Pro Leu Arg Leu Leu Asn Gin He Phe Tyr 105 110 115 ATG CCT TTT CCT AAT TAT GGC TGT AAT GAA GAG ACT ATG TGT TCA TTT 441 Met Pro Phe Pro Asn Tyr Gly Cys Asn Glu Glu Thr Met Cys Ser Phe 120 125 130 ATG CTT ATG GGA CCG AAT TTG TGG CCA TCT GTA GAT TTT TTC ATT CAC 489 Met Leu Met Gly Pro Asn Leu Trp Pro Ser Val Asp Phe Phe He His 135 140 145 TTG AAC ATC TTA TTT CCT CAT TTC CTT CAG ATT TCC TTC GGA CCT TTC 537 Leu Asn He Leu Phe Pro His Phe Leu Gin He Ser Phe Gly Pro Phe 150 155 160 CAT TCC ATT TTC AGT GAT AAT GAA CAA TTT CCT TAT ATC TAT CAG ATG 585 His Ser He Phe Ser Asp Asn Glu Gin Phe Pro Tyr He Tyr Gin Met 165 170 175 180 ACC CCA AAG GAT ACA TCA CTA GCA TTG GCA ATG GTC TCT TTC ATA CTT 633 Thr Pro Lys Asp Thr Ser Leu Ala Leu Ala Met Val Ser Phe He Leu 185 190 195 TAC TTC AAC TGG AAC TGG GTT GGT CTT GTC CTC TCA GAT AAT GAT GAA 681 Tyr Phe Asn Trp Asn Trp Val Gly Leu Val Leu Ser Asp Asn Asp Glu 200 205 210 GGC AAT CAA TTT CTC ACA GAG TTG AAA AAA GAG ACC CAC AAC ACG GAA 729 Gly Asn Gin Phe Leu Thr Glu Leu Lys Lys Glu Thr His Asn Thr Glu 215 220 225 ATA TGC TTT GCC TTT GTG AAC ATG ATG GCA ATC AAT GAG AAT TCA TCC 777 He Cys Phe Ala Phe Val Asn Met Met Ala He Asn Glu Asn Ser Ser 230 235 240 ATG AAA AAA ACT GAC ATG TAC TAC AAC CAA ATT GTG ATG TCA ACC GCA 825 Met Lys Lys Thr Asp Met Tyr Tyr Asn Gin He Val Met Ser Thr Ala 245 250 255 260 AAT GTT ATT ATC ATT TAT GGG GAA CGA CCC AGT ATT ATT GAA CTG TGT 873 Asn Val He He He Tyr Gly Glu Arg Pro Ser He He Glu Leu Cys 265 270 275 TTC AGA ACA TGG ACA TCT CCA GTC ATA CAG AGG ATA TGG GTT ACC AAA 921 Phe Arg Thr Trp Thr Ser Pro Val He Gin Arg He Trp Val Thr Lys 280 285 290 TCA GAG TTG TAT TTC CCA ACA AGT AAG AGA GAC TTA AGT CAT GGA ACA 969 Ser Glu Leu Tyr Phe Pro Thr Ser Lys Arg Asp Leu Ser His Gly Thr 295 300 305 TTC TAT GGA ACT CTA GCA TTT CAA CAA CAC CAT GAT GTG ATT TCT GGA 1017 Phe Tyr Gly Thr Leu Ala Phe Gin Gin His His Asp Val He Ser Gly 310 315 320 TTT AAA AAT TTT GTA CAG ACA TGG TAC CAT CTC AAA AGC ATG GAT TTA 1065 Phe Lys Asn Phe Val Gin Thr Trp Tyr His Leu Lys Ser Met Asp Leu 325 330 335 340 TAT TTA TTA AAG CCA GAG TGG GGT TTC TTT GAA TAT GAA ACC TCA GCA 1113 Tyr Leu Leu Lys Pro Glu Trp Gly Phe Phe Glu Tyr Glu Thr Ser Ala 345 350 355 TCT TAC TGT AAA ATA CTG ATG AGT AAT TCA TCG AAT GTC TCA TTG GAA 1161 Ser Tyr Cys Lys He Leu Met Ser Asn Ser Ser Asn Val Ser Leu Glu 360 365 370 TGG CTA ATG GAA CAG AAG TTT GAC ATA GCC TTT AAT GAC AAT AGT CAT 1209 Trp Leu Met Glu Gin Lys Phe Asp He Ala Phe Asn Asp Asn Ser His 375 380 385 AGT ATA TAC AAT GCT GTG TAC GCC ATG GCC CAT GCT CTC CAT GAA AAG 1257 Ser He Tyr Asn Ala Val Tyr Ala Met Ala His Ala Leu His Glu Lys 390 395 400 AAT CTG AAA CAA ATT GAT AAT CAG GAA ATC AGC TAT GGC AAA GGA GCA 1305 Asn Leu Lys Gin He Asp Asn Gin Glu He Ser Tyr Gly Lys Gly Ala 405 410 415 420 AGT ACT CAC TGC TTG AAG TTA CAC TCA TTT TTG AGA ACG ATC CAC TTC 1353 Ser Thr His Cys Leu Lys Leu His Ser Phe Leu Arg Thr He His Phe 425 430 435 ACC AAT CCT TTT GGG GAG AGA GTG ATT ATG AAA GAG AGA GTA AGA GTG 1401 Thr Asn Pro Phe Gly Glu Arg Val He Met Lys Glu Arg Val Arg Val 440 445 450 CAG GAA GAC TAT GAC ATT GTT CAC CTG CAG AAC TGC TCA CAA CAC CTT 1449 Gin Glu Asp Tyr Asp He Val His Leu Gin Asn Cys Ser Gin His Leu 455 460 465 AGG ATT AAG GTG AAG ATA GGG CAG TTC AGC CCA TAT TTT CCA CAT GGT 1497 Arg He Lys Val Lys He Gly Gin Phe Ser Pro Tyr Phe Pro His Gly 470 475 480 GGA CAA TTT CAC TTA TAT GAA GAC ATG ATT GAT TTG GCC ACA GGA AGT 1545 Gly Gin Phe His Leu Tyr Glu Asp Met He Asp Leu Ala Thr Gly Ser 485 490 495 500 AGA AAG ATG CCT TTA TCT ATG TGT AGT GCA GAT TGT CGT CCT GGA TAC 1593 Arg Lys Met Pro Leu Ser Met Cys Ser Ala Asp Cys Arg Pro Gly Tyr 505 510 515 AGA AAA TTC TGG AAG GAG GGA ATG GCA GCC TGC TGT TTT GTT TGC AGT 1641 Arg Lys Phe Trp Lys Glu Gly Met Ala Ala Cys Cys Phe Val Cys Ser 520 525 530 CCC TGT CCA GAC AAT GAA ATT TCT AAT GAA ACA ACT GTG GTA CTT TGG 1689 Pro Cys Pro Asp Asn Glu He Ser Asn Glu Thr Thr Val Val Leu Trp 535 540 545 GTC TTT GTG AAG CAC CAT GAC ACT CCT ATT GTG AAG GCC AAT AAC AGA 1737 Val Phe Val Lys His His Asp Thr Pro He Val Lys Ala Asn Asn Arg 550 555 560 ATC CTC AGC TAC ATA TTA ATC ATG TCA CTC ATG TTC TGC TTT CTG TGC 1785 He Leu Ser Tyr He Leu He Met Ser Leu Met Phe Cys Phe Leu Cys 565 570 575 580 TCC TTT TTC TTC ATT GGC CAT CCT AAC AGA GGT ACC TGT ATC TTA CAG 1833 Ser Phe Phe Phe He Gly His Pro Asn Arg Gly Thr Cys He Leu Gin 585 590 595 CAA ATC ACA TTT GGA ATT GTA TTC ACT GTG GCT GTT TCC ACA GTT CTG 1881 Gin He Thr Phe Gly He Val Phe Thr Val Ala Val Ser Thr Val Leu 600 605 610 GCC AAA ACA ATC ACT GTG CTT CTG GCT TTT CAA GTC ACA GAC ACA GGA 1929 Ala Lys Thr He Thr Val Leu Leu Ala Phe Gin Val Thr Asp Thr Gly 615 620 625 AGA AAG TTA AGA AAC TTC CTG GTA TCG GGG ACA CCC AAC TAC ATT ATT 1977 Arg Lys Leu Arg Asn Phe Leu Val Ser Gly Thr Pro Asn Tyr He He 630 635 640 CCC ATA TGT TCC CTG TTG CAA TGC ACT CTG TGT GCA ATT TGG CTA GCA 2025 Pro He Cys Ser Leu Leu Gin Cys Thr Leu Cys Ala He Trp Leu Ala 645 650 655 660 GTT TCT CCA CCA TTT GTT GAT ATC GAT GAA CAT TCT GAG CAT GGT CAC 2073 Val Ser Pro Pro Phe Val Asp He Asp Glu His Ser Glu His Gly His 665 670 675 ATC ATA ATT GTG TGC AAC AAG GGA TCT GTT ATG GCA TTC TAC TGT GTC 2121 He He He Val Cys Asn Lys Gly Ser Val Met Ala Phe Tyr Cys Val 680 685 690 CTG GGA TAT TTG GCC TTC CTG GCC CTT GGA AGT TTC ACG ATG GCT TTC 2169 Leu Gly Tyr Leu Ala Phe Leu Ala Leu Gly Ser Phe Thr Met Ala Phe 695 700 705 TTG GCA AAG AAT CTG CCT GAC ACA TTC AAT GAA GCC AAG TTC TTG ACC 2217 Leu Ala Lys Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu Thr 710 715 720 TTC AGC ATG CTA GTG TTC TGC AGT GTC TGG ATC ACG TTC CTT CCT GTC 2265 Phe Ser Met Leu Val Phe Cys Ser Val Trp He Thr Phe Leu Pro Val 725 730 735 740 TAC CAT AGC ACC AAG GGC AGA GTC ATG GTT GCT GTT GAA ATT TTC TCC 2313 Tyr His Ser Thr Lys Gly Arg Val Met Val Ala Val Glu He Phe Ser 745 750 755 ATT TTG ACA TCC AGT GCA GGG ATG CTT GGA TGC GTC TTT GCA CCC AAA 2361 He Leu Thr Ser Ser Ala Gly Met Leu Gly Cys Val Phe Ala Pro Lys 760 765 770 ATT TAC ATC ATT TTA ATG AAA CCA GAG AGA ATT CTA TCC AAA AGA CAG 2409 He Tyr He He Leu Met Lys Pro Glu Arg He Leu Ser Lys Arg Gin 775 780 785 GAG AAA TCA CGT TTC TAAACAGATA TTTTAGAAAT TCTGTCAAAT GTACAGTTGT T 2465 Glu Lys Ser Arg Phe 790 ATATACCCAC CAAATATTTG GTTACAGTGC ATAAATCTAG TTTTAGAACT CTCACTAGTT 2525 CCTCTAATGA TATCTAGAAA TATTGTATCT ACCAATCTTA CATTCATTAT CCATAAAATC 2585 CTGCACTCAT TCACTTGTTT GTTCTACTCT GTGAGAAATA TAATTCCCAA TGTAGTATTA 2645 AATTTTTTCT AAAAATTTTG CTTTAATTGA CATTTTTTCC CTTATAACTT CAAGTACATT 2705 TGATAAGGCA TTTGAATCTA TAACCTTTTA TACAATAAGA TCCAGGACAG ACAGGATTAC 2765 ACATAGAAAC CGTCTATCGA ATCAAACAAT CAATCAGACT AAAAAACAAA GAATCAACAA 2825 AGATAACATC AGAATACATT ATCTGATTTC CAGTAGAAGC ACATATGTGA CAGAATACTG 2885 TCTGTTTTTA TAGTTCCTCT TCAAGCTATT GTATTGGTCA GCAGTCTAAG GTAGAAGTTT 2945 TTTTGTCACA AACACAAAAA TATTGTATCC AACAATGGAC AGAATCCAGT GAGCACCCTG 3005 TTCAAATTTG GAGATAGTTG GAATATCATG AAAAAGAGGG TGACCCATAA GAATACCAGC 3065 ATTCTCAACT AACCTGGACA ACCACGAATT TGAGCTGCTG ACCAGGCAGC ATACATAAGC 3125 TGATATGAGG CTCCCAGCAC AGATGCAACA TAGGGCTGCC TGGTCTGGCC TCAGTGGAAG 3185 AAGACACATT TAAACCACAA GAGACAGGAG TCACAAGGGA TTGGGAAGGT GTGATGGTTT 3245 GCATATGCTT GGCTCAGGAA GTGGCACTAT TAGAAGGTGT AGACTTGATG GAGGAATTTG 3305 TCACTGTAGG GGTGGGCTTG GAGATCCACC TCATAGCTGC CTGGGGATGC TCAGTCTGTT 3365 CCTGGCTTCC TTCAGGTGAA GATATAGAAC TCAGATCCTC CTTCACCAAG CCTGCCTGGA 3425 TGCTGTGATG CTGCCATGCT CCGACCTTGA TGATAATGGA CTGAACCTCT GAACATGTAA 3485 GCTGGCTCCA ATTAAAGGTT GTCCTTTATA AAACTTCCAT TGATCACAGT GTCTGTACAT 3545 AGCAATAAGA CCCAAACTAA GACAGAAGGT GTGTGGATTG GGGAAGTGGG GATTTCCTCT 3605 TGGAGGTGGG GAAGTAGTCA AAGATTAAAT TGGGAAGGGG ATAATGAGTA CACCGTAAAA 3665 AGTATTAAAG AATAAAATAC TAAAAAATTA ATTAAATAGG ATTGTGAATA TATTAACATG 3725 CTATTATATT ATAGTTCTGG AAGGGATAGG TAAAACTCCT GATGGTGGTT TGTACCTAAT 3785 TTTTCTTAGA GCTTGCCCTT TGTATTCAGT TGTGATTGAA ATCCTGGGCT CACAAAATTC 3845 TAGTACTATG GATATGGAGG CAGATACTTT GATTACGCTG CTTCCTAGAA ATAAATTTTC 3905 CAAAAACCAA AAAAAAAAAA AAAAAAAAAA AAA 3938 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 793 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: Met He Val Phe Phe Leu Leu Asn He Pro Leu Leu Met Ala Asn Ser 1 5 10 15 Val Asp Pro Arg Cys Phe Trp Lys He Asn Leu Asn Glu Val Lys Asp 20 25 30 He Asp Leu Asp Thr Ser Cys Tyr Phe He Leu Glu Ala Val Gin Leu 35 40 45 Pro Met Glu Lys Asp Tyr Phe Asn Gin Thr Leu Asn Val Leu Lys Thr 50 55 60 Thr Lys Tyr Asn Arg Tyr Ala Leu Ala Leu Ala Phe Thr Met Asp Glu 65 70 75 80 He Asn Arg Asn Pro His He Leu Pro Asn Met Ser Leu He He Lys 85 90 95 His Thr Leu Gly His Cys Asp Gly Asn He Pro Leu Arg Leu Leu Asn 100 105 110 Gin He Phe Tyr Met Pro Phe Pro Asn Tyr Gly Cys Asn Glu Glu Thr 115 120 125 Met Cys Ser Phe Met Leu Met Gly Pro Asn Leu Trp Pro Ser Val Asp 130 135 140 Phe Phe He His Leu Asn He Leu Phe Pro His Phe Leu Gin He Ser 145 150 155 160 Phe Gly Pro Phe His Ser He Phe Ser Asp Asn Glu Gin Phe Pro Tyr 165 170 175 He Tyr Gin Met Thr Pro Lys Asp Thr Ser Leu Ala Leu Ala Met Val 180 185 190 Ser Phe He Leu Tyr Phe Asn Trp Asn Trp Val Gly Leu Val Leu Ser 195 200 205 Asp Asn Asp Glu Gly Asn Gin Phe Leu Thr Glu Leu Lys Lys Glu Thr 210 215 220 His Asn Thr Glu He Cys Phe Ala Phe Val Asn Met Met Ala He Asn 225 230 235 240 Glu Asn Ser Ser Met Lys Lys Thr Asp Met Tyr Tyr Asn Gin He Val 245 250 255 Met Ser Thr Ala Asn Val He He He Tyr Gly Glu Arg Pro Ser He 260 265 270 He Glu Leu Cys Phe Arg Thr Trp Thr Ser Pro Val He Gin Arg He 275 280 285 Trp Val Thr Lys Ser Glu Leu Tyr Phe Pro Thr Ser Lys Arg Asp Leu 290 295 300 Ser His Gly Thr Phe Tyr Gly Thr Leu Ala Phe Gin Gin His His Asp 305 310 315 320 Val He Ser Gly Phe Lys Asn Phe Val Gin Thr Trp Tyr His Leu Lys 325 330 335 Ser Met Asp Leu Tyr Leu Leu Lys Pro Glu Trp Gly Phe Phe Glu Tyr 340 345 350 Glu Thr Ser Ala Ser Tyr Cys Lys He Leu Met Ser Asn Ser Ser Asn 355 360 365 Val Ser Leu Glu Trp Leu Met Glu Gin Lys Phe Asp He Ala Phe Asn 370 375 380 Asp Asn Ser His Ser He Tyr Asn Ala Val Tyr Ala Met Ala His Ala 385 390 395 400 Leu His Glu Lys Asn Leu Lys Gin He Asp Asn Gin Glu He Ser Tyr 405 410 415 Gly Lys Gly Ala Ser Thr His Cys Leu Lys Leu His Ser Phe Leu Arg 420 425 430 Thr He His Phe Thr Asn Pro Phe Gly Glu Arg Val He Met Lys Glu 435 440 445 Arg Val Arg Val Gin Glu Asp Tyr Asp He Val His Leu Gin Asn Cys 450 455 460 Ser Gin His Leu Arg He Lys Val Lys He Gly Gin Phe Ser Pro Tyr 465 470 475 480 Phe Pro His Gly Gly Gin Phe His Leu Tyr Glu Asp Met He Asp Leu 485 490 495 Ala Thr Gly Ser Arg Lys Met Pro Leu Ser Met Cys Ser Ala Asp Cys 500 505 510 Arg Pro Gly Tyr Arg Lys Phe Trp Lys Glu Gly Met Ala Ala Cys Cys 515 520 525 Phe Val Cys Ser Pro Cys Pro Asp Asn Glu He Ser Asn Glu Thr Thr 530 535 540 Val Val Leu Trp Val Phe Val Lys His His Asp Thr Pro He Val Lys 545 550 555 560 Ala Asn Asn Arg He Leu Ser Tyr He Leu He Met Ser Leu Met Phe 565 570 575 Cys Phe Leu Cys Ser Phe Phe Phe He Gly His Pro Asn Arg Gly Thr 580 585 590 Cys He Leu Gin Gin He Thr Phe Gly He Val Phe Thr Val Ala Val 595 600 605 Ser Thr Val Leu Ala Lys Thr He Thr Val Leu Leu Ala Phe Gin Val 610 615 620 Thr Asp Thr Gly Arg Lys Leu Arg Asn Phe Leu Val Ser Gly Thr Pro 625 630 635 640 Asn Tyr He He Pro He Cys Ser Leu Leu Gin Cys Thr Leu Cys Ala 645 650 655 He Trp Leu Ala Val Ser Pro Pro Phe Val Asp He Asp Glu His Ser 660 665 670 Glu His Gly His He He He Val Cys Asn Lys Gly Ser Val Met Ala 675 680 685 Phe Tyr Cys Val Leu Gly Tyr Leu Ala Phe Leu Ala Leu Gly Ser Phe 690 695 700 Thr Met Ala Phe Leu Ala Lys Asn Leu Pro Asp Thr Phe Asn Glu Ala 705 710 715 720 Lys Phe Leu Thr Phe Ser Met Leu Val Phe Cys Ser Val Trp He Thr 725 730 735 Phe Leu Pro Val Tyr His Ser Thr Lys Gly Arg Val Met Val Ala Val 740 745 750 Glu He Phe Ser He Leu Thr Ser Ser Ala Gly Met Leu Gly Cys Val 755 760 765 Phe Ala Pro Lys He Tyr He He Leu Met Lys Pro Glu Arg He Leu 770 775 780 Ser Lys Arg Gin Glu Lys Ser Arg Phe 785 790 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3359 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 59...2452 (D) OTHER INFORMATION: GoVN13C (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: CGGCACGAGC ACAGTCCACT CTGTCAGGGT TTAAGGCAGG AAAAACATGC TCATTTTG AT 60 Met 1 GGT AAT ATT CTT CCT TCT CAA CAT TCC ATT TCT CCT GGC AAA TTT CAT 108 Val He Phe Phe Leu Leu Asn He Pro Phe Leu Leu Ala Asn Phe Met 5 10 15 GGA TCC CAG ATG CTT TTG GAA AAT AAA TTT GAA TGA AAT CAA GGA TGA 156 Asp Pro Arg Cys Phe Trp Lys He Asn Leu Asn Glu He Lys Asp Glu 20 25 30 AGT CCT TGG GAT GAC TTG TTC CTT CAT CCT TGA AAC AGT TCA GAA GAC 204 Val Leu Gly Met Thr Cys Ser Phe He Leu Glu Thr Val Gin Lys Thr 35 40 45 TAT GGA CAA AGA TTA TTT CAA CCA GAC TCT GAA TGT CCT AAA TAC AAC 252 Met Asp Lys Asp Tyr Phe Asn Gin Thr Leu Asn Val Leu Asn Thr Thr 50 55 60 65 TAC AAA CCA CAA ATA TGC CTT GGC ATT GGC CTT TAC AGT GGA TGA AAT 300 Thr Asn His Lys Tyr Ala Leu Ala Leu Ala Phe Thr Val Asp Glu He 70 75 80 CAA CAG GAA TCC TGA TCT TTT ACC AAA TAT GTC TCT GAT TAT AAA ATA 348 Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser Leu He He Lys Tyr 85 90 95 CAA TTT GGG TCA TTG TGA TGG AAA AAC TGT AAC AAC TCT ATC CGA TTT 396 Asn Leu Gly His Cys Asp Gly Lys Thr Val Thr Thr Leu Ser Asp Leu 100 105 110 ATT TAA TCC AAA TAA TCA TCT CCA TTT CCC CAA TTA TTT ATG TAA TGA 444 Phe Asn Pro Asn Asn His Leu His Phe Pro Asn Tyr Leu Cys Asn Glu 115 120 125 AGG GAT TAT GTG TTT GGT TCT GCT TAC AGG ACC ACA TTG GAG AGC ATC 492 Gly He Met Cys Leu Val Leu Leu Thr Gly Pro His Trp Arg Ala Ser 130 135 140 14 TTT ATA TCT CTG GAT ATC CGT GTA TGT CTA CCT GTC TCC ACA TTT CCT 540 Leu Tyr Leu Trp He Ser Val Tyr Val Tyr Leu Ser Pro His Phe Leu 150 155 160 TCA GCT TTC CTA TGG ACC TTT CTA CTC CAT CTT CAG TGA TAA TGA ACA 588 Gin Leu Ser Tyr Gly Pro Phe Tyr Ser He Phe Ser Asp Asn Glu Gin 165 170 175 ATA TCC TTA TCT CTA TCA GAT GGG CCC AAA GGA CTC ATC ACT AGC ATT 636 Tyr Pro Tyr Leu Tyr Gin Met Gly Pro Lys Asp Ser Ser Leu Ala Leu 180 185 190 GGC AAT GGT CTC CTT CAT AAT TTA CTT CAA GTG GAA CTG GGT TGG GCT 684 Ala Met Val Ser Phe He He Tyr Phe Lys Trp Asn Trp Val Gly Leu 195 200 205 ATT TAT CTC AGA TGA TGA TCA AGG CAA TCA ATT TCT CTC AGA GTT GAA 732 Phe He Ser Asp Asp Asp Gin Gly Asn Gin Phe Leu Ser Glu Leu Lys 210 215 220 22 AAA AGA GAG CCA AAC CAA GGA TAT TTG CTT TGC CTT TGT GAA CAT GAT 780 Lys Glu Ser Gin Thr Lys Asp He Cys Phe Ala Phe Val Asn Met He 230 235 240 ATC AGT CAG TGA TGT TTC ATA CTA TCA TAA AAC TGA AAT GTA CTA CAA 828 Ser Val Ser Asp Val Ser Tyr Tyr His Lys Thr Glu Met Tyr Tyr Asn 245 250 255 CCA AAT TGT GAT GTC ATC CAC AAA GGT TAT TAT CAT TTA TGG GGA AAC 876 Gin He Val Met Ser Ser Thr Lys Val He He He Tyr Gly Glu Thr 260 265 270 AAA CAG TAT TAT TGA ATT GAG CTT CAG AAT GTG GTC ATC TCC AGT TAA 924 Asn Ser He He Glu Leu Ser Phe Arg Met Trp Ser Ser Pro Val Lys 275 280 285 ACA GAG AAT ATG GGT CAC CAC AAA ACA ATT TGA TTG CCC TAC CAG TAA 972 Gin Arg He Trp Val Thr Thr Lys Gin Phe Asp Cys Pro Thr Ser Lys 290 295 300 30 GAG AGA CTT AAC TCA TGG CAC ATT CTA TGG GAC CCT TAC ATT TCT ACA 1020 Arg Asp Leu Thr His Gly Thr Phe Tyr Gly Thr Leu Thr Phe Leu His 310 315 320 CCA CTA TGG TGA GAT TTC TGG CTT TAA AAA TTT TGT ACA GAC ACG GTA 1068 His Tyr Gly Glu He Ser Gly Phe Lys Asn Phe Val Gin Thr Arg Tyr 325 330 335 CAA TCT CAG AAG CAC AGA TTT ATA TCT AGT AAT GCC AGA GTG GAA ATA 1116 Asn Leu Arg Ser Thr Asp Leu Tyr Leu Val Met Pro Glu Trp Lys Tyr 340 345 350 TTT TAA CTA TGA AGC CTC AGC ATC TAA CTG TAA AAT ACT GAG AAA CTA 1164 Phe Asn Tyr Glu Ala Ser Ala Ser Asn Cys Lys He Leu Arg Asn Tyr 355 360 365 TTT ATC CAA TAT CTC ACT GGA ATG GCT AAT GGA ACA GAA ATT TGA CAT 1212 Leu Ser Asn He Ser Leu Glu Trp Leu Met Glu Gin Lys Phe Asp Met 370 375 380 38 GTC ATT TAG TGA TTA TAG TCA CAA CAT ATA CAA TGC TGT ATA TGC CAT 1260 Ser Phe Ser Asp Tyr Ser His Asn He Tyr Asn Ala Val Tyr Ala He 390 395 400 TGC TCA TGC ACT CCA TGA GAA GAA TCT GCA AGA AGT TGA AAA TCA GGC 1308 Ala His Ala Leu His Glu Lys Asn Leu Gin Glu Val Glu Asn Gin Ala 405 410 415 AAT AAA CAA TGC GAA AGG AGA AAA TAC TCA CTG CTT GAA GCT AAA CTC 1356 He Asn Asn Ala Lys Gly Glu Asn Thr His Cys Leu Lys Leu Asn Ser 420 425 430 ATT TCT GAG AAA GAC CCA CTT CAC TAA TTC TCT TGG GAA CAG AGT AAT 1404 Phe Leu Arg Lys Thr His Phe Thr Asn Ser Leu Gly Asn Arg Val He 435 440 445 TAT GAA ACA GAG AGA AGT AGT GCA TGG AGA CTA TAA TAT TGT TCA CAT 1452 Met Lys Gin Arg Glu Val Val His Gly Asp Tyr Asn He Val His Met 450 455 460 46 GTG GAA TTT CTC ACA ACG CCT TGG GAT TAA GGT GAA GAT AGG ACA ATT 1500 Trp Asn Phe Ser Gin Arg Leu Gly He Lys Val Lys He Gly Gin Phe 470 475 480 CAG CCC ACA TTT TCC ACA GGG TCA ACA GTT ACA CTT ATA TGT AGA CAT 1548 Ser Pro His Phe Pro Gin Gly Gin Gin Leu His Leu Tyr Val Asp Met 485 490 495 GAC TGA GTT GGC TAC AGG AAG TAG AAA GAT GCC ATC CTC AGT GTG CAG 1596 Thr Glu Leu Ala Thr Gly Ser Arg Lys Met Pro Ser Ser Val Cys Ser 500 505 510 TGC AGA TTG CCA TCC TGG ATT CAG AAG AAT CTG GAA GGA GGA AAT GGC 1644 Ala Asp Cys His Pro Gly Phe Arg Arg He Trp Lys Glu Glu Met Ala 515 520 525 AGC CTG CTG TTT TGT TTG CAA CCC CTG CCC TGA AAA TGA AAT TTC TAA 1692 Ala Cys Cys Phe Val Cys Asn Pro Cys Pro Glu Asn Glu He Ser Asn 530 535 540 54 TGA GAC GAT GGT GGT ATT TTG GGT CTT CGT GAA GCA CCA TGA CAC TCC 1740 Glu Thr Met Val Val Phe Trp Val Phe Val Lys His His Asp Thr Pro 550 555 560 TAT TGT GAA GGC CAA TAA CAG AAT CCT CAG CTA CCT ATT AAT CGT GTC 1788 He Val Lys Ala Asn Asn Arg He Leu Ser Tyr Leu Leu He Val Ser 565 570 575 ACT CAT GTT CTG TTT TCT GTG CTC CTT TTT CTT CAT TGG CTA TCC TAA 1836 Leu Met Phe Cys Phe Leu Cys Ser Phe Phe Phe He Gly Tyr Pro Asn 580 585 590 CAG AGC AAC CTG TAT CTT ACA GCA AAT CAC ATT TGG AAT CTT CTT TAC 1884 Arg Ala Thr Cys He Leu Gin Gin He Thr Phe Gly He Phe Phe Thr 595 600 605 TGT GGC TAT TTC CAC AGT TCT GGC CAA AAC AAT CAC TGT GGT TCT GGC 1932 Val Ala He Ser Thr Val Leu Ala Lys Thr He Thr Val Val Leu Ala 610 615 620 62 TTT CAA AGT CAC AGA CCC AGG AAG ACA ATT AAG AAT CTT TTT GGT ATC 1980 Phe Lys Val Thr Asp Pro Gly Arg Gin Leu Arg He Phe Leu Val Ser 630 635 640 GGG GAC ACC CAA CTA CAT TAT TCC CAT ATG TTC CCT ATT GCA ATG TAT 2028 Gly Thr Pro Asn Tyr He He Pro He Cys Ser Leu Leu Gin Cys He 645 650 655 TCT GTG TGC AAT CTG GCT AGC AGT TTC TCC TCC CTT TGT TGA TAT TGA 2076 Leu Cys Ala He Trp Leu Ala Val Ser Pro Pro Phe Val Asp He Asp 660 665 670 TGA ACA CTC TGA GCA TGG CCA CAT CAT CAT TGT GTG CAA CAA GGG CTC 2124 Glu His Ser Glu His Gly His He He He Val Cys Asn Lys Gly Ser 675 680 685 CAT TAC TGC ATT CTA CTG TGT CCT GGG ATA CTT GGC CTG CCT GGC CTT 2172 He Thr Ala Phe Tyr Cys Val Leu Gly Tyr Leu Ala Cys Leu Ala Phe 690 695 700 70 TGG AAG CTT CAC TAT AGC TTT CTT GGC AAA GAA CCT GCC TGA CAC ATT 2220 Gly Ser Phe Thr He Ala Phe Leu Ala Lys Asn Leu Pro Asp Thr Phe 710 715 720 CAA CGA AGC CAA GTT CTT GAC CTT CAG CAT GCT AGT GTT CTG CGC TGT 2268 Asn Glu Ala Lys Phe Leu Thr Phe Ser Met Leu Val Phe Cys Ala Val 725 730 735 CTG GGT CAC CTT CCT CCC TGT CTA CCA TAG CAC CAA GGG CAA GGT CAT 2316 Trp Val Thr Phe Leu Pro Val Tyr His Ser Thr Lys Gly Lys Val Met 740 745 750 GGT TGC TGT GGA GAT CTT CTC CAT CTT GGC ATC TAG TGC AGG GAT GCT 2364 Val Ala Val Glu He Phe Ser He Leu Ala Ser Ser Ala Gly Met Leu 755 760 765 GGG ATG CAT CTT TGC ACC CAA AGT TTA CAT CAT TTT AAT GAG ACC AGA 2412 Gly Cys He Phe Ala Pro Lys Val Tyr He He Leu Met Arg Pro Asp 770 775 780 78 CAG AAA TTC GAT CCA CAA AAT CAG GGA GAA ATC ATA TTT C TGAAAAGGTA 2462 Arg Asn Ser He His Lys He Arg Glu Lys Ser Tyr Phe 790 795 TTTCAGGAAT TCTGTCAAAT GTAAAGTTGA TACATACACC CCAAATATTT AGTTACAGAG 2522 CATATATCTA GTTTTAGAAT CACTCTCACT GGTTCCTCTA GTTAAGCATA GAAGTACCAT 2582 ATGTACTGAT CTTGCATATG TTGTCTATAA AATCTTACAA TCATTCATTT GCTTAGTATC 2642 TTCTGGAAGA AGTAAAATTT TCAAATAACT AGTACAATTT TATTCATTAT TTTGCTTTCA 2702 TGAGGATTTC CCCCTGGTAA CTTCAAATAA ATTTTATAAG TCAGTTGAAT ATATAACCTT 2762 ACATAGAAAG TGAGTTCTAG GACAGACAGG GATTATACAT AGAAACAAAC TAACTAAAAA 2822 TCAACAAAGA TGAAATCAGA ACACATTTTC TTATTTCCAG TAGGAACACA TACTTGACAG 2882 AATACTGTCT TTTTTTCAGC TGCTCTTTAA GATATTGGCC AATAGTCTAA GCTGAAAATG 2942 TTCTTTATCT ACTCTCAAAT ACAAAAATAT TATATCCAAC AATGGACAGA ATCTGAGAAC 3002 TCCTGTGGTT GAGTTAGGGA ATAGTTGGAA GATACTGAGA AGGAGGTGAC CCATAGGAAT 3062 ACAAAGCAGT CTCAACTAAC CTGGACAACC AAGGTCCCTC AGACACTGAG CCACTAACAA 3122 GTCAGCCTAC TCCAGCTGTT ATGAGGCCCC CAAAACATAT GCAACATAGG ATTGCCTGGT 3182 CCAGCCTCAG CAAGAGAATA CACACCTAAC CACAGAGAGA CTTCCCCAAG GGATTGGGGA 3242 GGTCTGGGGT TTGGAGAGTT GCGGATTGTC CCTTGATGAT TGGAAGGAGG TATTGGATGA 3302 GAATGAATCA GGGGGAAGAC TAGGAAGGGG ATAATGATGG AACTGTAAAA AAAAAAA 3359 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 798 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: Met Val He Phe Phe Leu Leu Asn He Pro Phe Leu Leu Ala Asn Phe 1 5 10 15 Met Asp Pro Arg Cys Phe Trp Lys He Asn Leu Asn Glu He Lys Asp 20 25 30 Glu Val Leu Gly Met Thr Cys Ser Phe He Leu Glu Thr Val Gin Lys 35 40 45 Thr Met Asp Lys Asp Tyr Phe Asn Gin Thr Leu Asn Val Leu Asn Thr 50 55 60 Thr Thr Asn His Lys Tyr Ala Leu Ala Leu Ala Phe Thr Val Asp Glu 65 70 75 80 He Asn Arg Asn Pro Asp Leu Leu Pro Asn Met Ser Leu He He Lys 85 90 95 Tyr Asn Leu Gly His Cys Asp Gly Lys Thr Val Thr Thr Leu Ser Asp 100 105 110 Leu Phe Asn Pro Asn Asn His Leu His Phe Pro Asn Tyr Leu Cys Asn 115 120 125 Glu Gly He Met Cys Leu Val Leu Leu Thr Gly Pro His Trp Arg Ala 130 135 140 Ser Leu Tyr Leu Trp He Ser Val Tyr Val Tyr Leu Ser Pro His Phe 145 150 155 160 Leu Gin Leu Ser Tyr Gly Pro Phe Tyr Ser He Phe Ser Asp Asn Glu 165 170 175 Gin Tyr Pro Tyr Leu Tyr Gin Met Gly Pro Lys Asp Ser Ser Leu Ala 180 185 190 Leu Ala Met Val Ser Phe He He Tyr Phe Lys Trp Asn Trp Val Gly 195 200 205 Leu Phe He Ser Asp Asp Asp Gin Gly Asn Gin Phe Leu Ser Glu Leu 210 215 220 Lys Lys Glu Ser Gin Thr Lys Asp He Cys Phe Ala Phe Val Asn Met 225 230 235 240 He Ser Val Ser Asp Val Ser Tyr Tyr His Lys Thr Glu Met Tyr Tyr 245 250 255 Asn Gin He Val Met Ser Ser Thr Lys Val He He He Tyr Gly Glu 260 265 270 Thr Asn Ser He He Glu Leu Ser Phe Arg Met Trp Ser Ser Pro Val 275 280 285 Lys Gin Arg He Trp Val Thr Thr Lys Gin Phe Asp Cys Pro Thr Ser 290 295 300 Lys Arg Asp Leu Thr His Gly Thr Phe Tyr Gly Thr Leu Thr Phe Leu 305 310 315 320 His His Tyr Gly Glu He Ser Gly Phe Lys Asn Phe Val Gin Thr Arg 325 330 335 Tyr Asn Leu Arg Ser Thr Asp Leu Tyr Leu Val Met Pro Glu Trp Lys 340 345 350 Tyr Phe Asn Tyr Glu Ala Ser Ala Ser Asn Cys Lys He Leu Arg Asn 355 360 365 Tyr Leu Ser Asn He Ser Leu Glu Trp Leu Met Glu Gin Lys Phe Asp 370 375 380 Met Ser Phe Ser Asp Tyr Ser His Asn He Tyr Asn Ala Val Tyr Ala 385 390 395 400 He Ala His Ala Leu His Glu Lys Asn Leu Gin Glu Val Glu Asn Gin 405 410 415 Ala He Asn Asn Ala Lys Gly Glu Asn Thr His Cys Leu Lys Leu Asn 420 425 430 Ser Phe Leu Arg Lys Thr His Phe Thr Asn Ser Leu Gly Asn Arg Val 435 440 445 He Met Lys Gin Arg Glu Val Val His Gly Asp Tyr Asn He Val His 450 455 460 Met Trp Asn Phe Ser Gin Arg Leu Gly He Lys Val Lys He Gly Gin 465 470 475 480 Phe Ser Pro His Phe Pro Gin Gly Gin Gin Leu His Leu Tyr Val Asp 485 490 495 Met Thr Glu Leu Ala Thr Gly Ser Arg Lys Met Pro Ser Ser Val Cys 500 505 510 Ser Ala Asp Cys His Pro Gly Phe Arg Arg He Trp Lys Glu Glu Met 515 520 525 Ala Ala Cys Cys Phe Val Cys Asn Pro Cys Pro Glu Asn Glu He Ser 530 535 540 Asn Glu Thr Met Val Val Phe Trp Val Phe Val Lys His His Asp Thr 545 550 555 560 Pro He Val Lys Ala Asn Asn Arg He Leu Ser Tyr Leu Leu He Val 565 570 575 Ser Leu Met Phe Cys Phe Leu Cys Ser Phe Phe Phe He Gly Tyr Pro 580 585 590 Asn Arg Ala Thr Cys He Leu Gin Gin He Thr Phe Gly He Phe Phe 595 600 605 Thr Val Ala He Ser Thr Val Leu Ala Lys Thr He Thr Val Val Leu 610 615 620 Ala Phe Lys Val Thr Asp Pro Gly Arg Gin Leu Arg He Phe Leu Val 625 630 635 640 Ser Gly Thr Pro Asn Tyr He He Pro He Cys Ser Leu Leu Gin Cys 645 650 655 He Leu Cys Ala He Trp Leu Ala Val Ser Pro Pro Phe Val Asp He 660 665 670 Asp Glu His Ser Glu His Gly His He He He Val Cys Asn Lys Gly 675 680 685 Ser He Thr Ala Phe Tyr Cys Val Leu Gly Tyr Leu Ala Cys Leu Ala 690 695 700 Phe Gly Ser Phe Thr He Ala Phe Leu Ala Lys Asn Leu Pro Asp Thr 705 710 715 720 Phe Asn Glu Ala Lys Phe Leu Thr Phe Ser Met Leu Val Phe Cys Ala 725 730 735 Val Trp Val Thr Phe Leu Pro Val Tyr His Ser Thr Lys Gly Lys Val 740 745 750 Met Val Ala Val Glu He Phe Ser He Leu Ala Ser Ser Ala Gly Met 755 760 765 Leu Gly Cys He Phe Ala Pro Lys Val Tyr He He Leu Met Arg Pro 770 775 780 Asp Arg Asn Ser He His Lys He Arg Glu Lys Ser Tyr Phe 785 790 795 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3012 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 3...2087 (D) OTHER INFORMATION: GOVN13B (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: AT GTC TAC CTG TCT CCA CAT TTC CTT CAG CTT TCC TAT GGA CCT TTC 47 Val Tyr Leu Ser Pro His Phe Leu Gin Leu Ser Tyr Gly Pro Phe 1 5 10 15 TAC TCC ATC TTC AGT GAT AAT GAA CAA TAT CCT TAT CTC TAT CAG ATG 95 Tyr Ser He Phe Ser Asp Asn Glu Gin Tyr Pro Tyr Leu Tyr Gin Met 20 25 30 GGC CCA AAG GAC TCA TCA CTA GCA TTG GCA ATG GTC TCC TTC ATA ATT 143 Gly Pro Lys Asp Ser Ser Leu Ala Leu Ala Met Val Ser Phe He He 35 40 45 TAC TTC AAG TGG AAC TGG GTT GGG CTA TTT ATC TCA GAT GAT GAT CAA 191 Tyr Phe Lys Trp Asn Trp Val Gly Leu Phe He Ser Asp Asp Asp Gin 50 55 60 GGC AAT CAA TTT CTC TCA GAG TTG AAA AAA GAG AGC CAA ACC AAG GAT 239 Gly Asn Gin Phe Leu Ser Glu Leu Lys Lys Glu Ser Gin Thr Lys Asp 65 70 75 ATT TGC TTT GCC TTT GTG AAC ATG ATA TCA GTC AGT GAT GTT TCA TAC 287 He Cys Phe Ala Phe Val Asn Met He Ser Val Ser Asp Val Ser Tyr 80 85 90 95 TAT CAT AAA ACT GAA ATG TAC TAC AAC CAA ATT GTG ATG TCA TCC ACA 335 Tyr His Lys Thr Glu Met Tyr Tyr Asn Gin He Val Met Ser Ser Thr 100 105 110 AAG GTT ATT ATC ATT TAT GGG GAA ACA AAC AGT ATT ATT GAA TTG AGC 383 Lys Val He He He Tyr Gly Glu Thr Asn Ser He He Glu Leu Ser 115 120 125 TTC AGA ATG TGG TCA TCT CCA GTT AAA CAG AGA ATA TGG GTC ACC ACA 431 Phe Arg Met Trp Ser Ser Pro Val Lys Gin Arg He Trp Val Thr Thr 130 135 140 AAA CAA TTT GAT TGC CCT ACC AGT AAG AGA GAC TTA ACT CAT GGC ACA 479 Lys Gin Phe Asp Cys Pro Thr Ser Lys Arg Asp Leu Thr His Gly Thr 145 150 155 TTC TAT GGG ACC CTT ACA TTT CTA CAC CAC TAT GGT GAG ATT TCT GGC 527 Phe Tyr Gly Thr Leu Thr Phe Leu His His Tyr Gly Glu He Ser Gly 160 165 170 175 TTT AAA AAT TTT GTA CAG ACA CGG TAC AAT CTC AGA AGC ACA GAT TTA 575 Phe Lys Asn Phe Val Gin Thr Arg Tyr Asn Leu Arg Ser Thr Asp Leu 180 185 190 TAT CTA GTA ATG CCA GAG TGG AAA TAT TTT AAC TAT GAA GCC TCA GCA 623 Tyr Leu Val Met Pro Glu Trp Lys Tyr Phe Asn Tyr Glu Ala Ser Ala 195 200 205 TCT AAC TGT AAA ATA CTG AGA AAC TAT TTA TCC AAT ATC TCA CTG GAA 671 Ser Asn Cys Lys He Leu Arg Asn Tyr Leu Ser Asn He Ser Leu Glu 210 215 220 TGG CTA ATG GAA CAG AAA TTT GAC ATG TCA TTT AGT GAT TAT AGT CAC 719 Trp Leu Met Glu Gin Lys Phe Asp Met Ser Phe Ser Asp Tyr Ser His 225 230 235 AAC ATA TAC AAT GCT GTA TAT GCC ATT GCT CAT GCA CTC CAT GAG AAA 767 Asn He Tyr Asn Ala Val Tyr Ala He Ala His Ala Leu His Glu Lys 240 245 250 255 GAT CTG CAA GAA TTT GAA AAT CAG GCA ATA AAC AAT GCG AAA GGA GAA 815 Asp Leu Gin Glu Phe Glu Asn Gin Ala He Asn Asn Ala Lys Gly Glu 260 265 270 AAT ACT CAC TGC TTG AAG CTA AAC TCA TTT CTG AGA AAG ACC CAC TTC 863 Asn Thr His Cys Leu Lys Leu Asn Ser Phe Leu Arg Lys Thr His Phe 275 280 285 ACT AAT TCT CTT GGG AAC AGA GTA ATT ATG AAA CAG AGA GAA GTA GTG 911 Thr Asn Ser Leu Gly Asn Arg Val He Met Lys Gin Arg Glu Val Val 290 295 300 CAT GGA GAC TAT AAT ATT GTT CAC ATG TGG AAT TTC TCA CAA CGC CTT 959 His Gly Asp Tyr Asn He Val His Met Trp Asn Phe Ser Gin Arg Leu 305 310 315 GGG ATT AAG GTG AAG ATA GGA CAA TTC AGC CCA CAT TTT CCA CAG GGT 1007 Gly He Lys Val Lys He Gly Gin Phe Ser Pro His Phe Pro Gin Gly 320 325 330 335 CAA CAG TTA CAC TTA TAT GTA GAC ATG ACT GAG TTG GCT ACA GGA AGT 1055 Gin Gin Leu His Leu Tyr Val Asp Met Thr Glu Leu Ala Thr Gly Ser 340 345 350 AGA AAG ATG CCA TCC TCA GTG TGC AGT GCA GAT TGC CAT CCT GGA TTC 1103 Arg Lys Met Pro Ser Ser Val Cys Ser Ala Asp Cys His Pro Gly Phe 355 360 365 AGA AGA ATC TGG AAG GAG GAA ATG GCA GCC TGC TGT TTT GTT TGC AAC 1151 Arg Arg He Trp Lys Glu Glu Met Ala Ala Cys Cys Phe Val Cys Asn 370 375 380 CCC TGC CCT GAA AAT GAA ATT TCT AAT GAG ACG AAT ATG GAT CAG TGT 1199 Pro Cys Pro Glu Asn Glu He Ser Asn Glu Thr Asn Met Asp Gin Cys 385 390 395 GCG AAT TGT CCA GAA TAC CAG TAT GCC AAC ACA GAA AAG AAC AAA TGC 1247 Ala Asn Cys Pro Glu Tyr Gin Tyr Ala Asn Thr Glu Lys Asn Lys Cys 400 405 410 415 ATC CAG AAA GGT GTG ATT GTT CTA AGC TAT GAA GAC CCC TTG GGG ATG 1295 He Gin Lys Gly Val He Val Leu Ser Tyr Glu Asp Pro Leu Gly Met 420 425 430 GCT CTT GCC TTA ATA GCA TTC TGT TTC TCT GCA TTC ACA GTG GTG GTA 1343 Ala Leu Ala Leu He Ala Phe Cys Phe Ser Ala Phe Thr Val Val Val 435 440 445 TTT TGG GTC TTC GTG AAG CAC CAT GAC ACT CCT ATT GTG AAG GCC AAT 1391 Phe Trp Val Phe Val Lys His His Asp Thr Pro He Val Lys Ala Asn 450 455 460 AAC AGA ATC CTC AGC TAC CTA TTA ATC GTG TCA CTC ATG TTC TGT TTT 1439 Asn Arg He Leu Ser Tyr Leu Leu He Val Ser Leu Met Phe Cys Phe 465 470 475 CTG TGC TCC TTT TTC TTC ATT GGC TAT CCT AAC AGA GCA ACC TGT ATC 1487 Leu Cys Ser Phe Phe Phe He Gly Tyr Pro Asn Arg Ala Thr Cys He 480 485 490 495 TTA CAG CAA ATC ACA TTT GGA ATC TTC TTT ACT GTG GCT ATT TCC ACA 1535 Leu Gin Gin He Thr Phe Gly He Phe Phe Thr Val Ala He Ser Thr 500 505 510 GTT CTG GCC AAA ACA ATC ACT GTG GTT CTG GCT TTC AAA GTC ACA GAC 1583 Val Leu Ala Lys Thr He Thr Val Val Leu Ala Phe Lys Val Thr Asp 515 520 525 CCA GGA AGA CAA TTA AGA ATC TTT TTG GTA TCG GGG ACA CCC AAC TAC 1631 Pro Gly Arg Gin Leu Arg He Phe Leu Val Ser Gly Thr Pro Asn Tyr 530 535 540 ATT ATT CCC ATA TGT TCC CTA TTG CAA TGT ATT CTG TGT GCA ATC TGG 1679 He He Pro He Cys Ser Leu Leu Gin Cys He Leu Cys Ala He Trp 545 550 555 CTA GCA GTT TCT CCT CCC TTT GTT GAT ATT GAT GAA CAC TCT GAG CAT 1727 Leu Ala Val Ser Pro Pro Phe Val Asp He Asp Glu His Ser Glu His 560 565 570 575 GGC CAC ATC ATC ATT GTG TGC AAC AAG GGC TCC ATT ACT GCA TTC TAC 1775 Gly His He He He Val Cys Asn Lys Gly Ser He Thr Ala Phe Tyr 580 585 590 TGT GTC CTG GGA TAC TTG GCC TGC CTG GCC TTT GGA AGC TTC ACT ATA 1823 Cys Val Leu Gly Tyr Leu Ala Cys Leu Ala Phe Gly Ser Phe Thr He 595 600 605 GCT TTC TTG GCA AAG AAC CTG CCT GAC ACA TTC AAC GAA GCC AAG TTC 1871 Ala Phe Leu Ala Lys Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe 610 615 620 TTG ACC TTC AGC ATG CTA GTG TTC TGC GCT GTC TGG GTC ACC TTC CTC 1919 Leu Thr Phe Ser Met Leu Val Phe Cys Ala Val Trp Val Thr Phe Leu 625 630 635 CCT GTC TAC CAT AGC ACC AAG GGC AAG GTC ATG GTT GCT GTG GAG ATC 1967 Pro Val Tyr His Ser Thr Lys Gly Lys Val Met Val Ala Val Glu He 640 645 650 655 TTC TCC ATC TTG GCA TCT AGT GCA GGG ATG CTG GGA TGC ATC TTT GCA 2015 Phe Ser He Leu Ala Ser Ser Ala Gly Met Leu Gly Cys He Phe Ala 660 665 670 CCC AAA GTT TAC ATC ATT TTA ATG AGA CCA GAC AGA AAT TCG ATC CAC 2063 Pro Lys Val Tyr He He Leu Met Arg Pro Asp Arg Asn Ser He His 675 680 685 AAA ATC AGG GAG AAA TCA TAT TTC TGAAAAGGTA TTTCAGGAAT TCTGTCAAAT 2117 Lys He Arg Glu Lys Ser Tyr Phe 690 695 GTAAAGTTGA TACATACACC CCAAATATTT AGTTACAGAG CATATATCTA GTTTTAGAAT 2177 CACTCTCACT GGTTCCTCTA GTTATGCATA GAAGTACCAT ATGTACTGAT CTTGCATATG 2237 TTGTCTATAA AATCTTACAA TCATTCATTT GCTTAGTATC TTCTGGAAGA AGTAAAATTT 2297 TCAAATAACT AGTACAATTT TATTCATTAT TTTGCTTTCA TGAGGATTTC CCCCTGGTAA 2357 CTTCAAATAA ATTTTATAAG TCAGTTGAAT ATATAACCTT ACATAGAAAG TGAGTTCTAG 2417 GACAGACAGG GATTATACAT AGAAACAAAC TAACTAAAAA TCAACAAAGA TGAAATCAGA 2477 ACACATTTTC TTATTTCCAG TAGGAACACA TACTTGACAG AATACTGTCT TTTTTTCAGC 2537 TGCTCTTTAA GATATTGGCC AATAGTCTAA GCTGAAAATG TTCTTTATCT ACTCTCAAAT 2597 ACAAAAATAT TATATCCAAC AATGGACAGA ATCTGAGAAC TCCTGTGGTT GAGTTAGGGA 2657 ATAGTTGGAA GATACTGAGA AGGAGGGTGA CCCATAGGAA TACAAAGCAG TCTCAACTAA 2717 CCTGGACAAC CAAGGTCCCT CAGACACTGA GCCACTAACA AGTCAGCCTA CTCCAGCTGT 2777 TATGAGGCCC CCAAAACATA TGCAACATAG GATTGCCTGG TCCAGCCTCA GCAAGAGAAT 2837 ACACACCTAA CCACAGAGAG ACTTCCCCAA GGGATTGGGG AGGTCTGGGG TTTGGAGAGT 2897 TGCGGATTGT CCCTTGATGA TTGGAAGGAG GTATTGGATG AGAATGAATC AGGGGGAAGA 2957 CTAGGAAGGG GATAATGATG GAACTGTAAA AAAAATTAAA AAAAAAAAAA AAAAA 3012 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 695 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: Val Tyr Leu Ser Pro His Phe Leu Gin Leu Ser Tyr Gly Pro Phe Tyr 1 5 10 15 - looser He Phe Ser Asp Asn Glu Gin Tyr Pro Tyr Leu Tyr Gin Met Gly 20 25 30 Pro Lys Asp Ser Ser Leu Ala Leu Ala Met Val Ser Phe He He Tyr 35 40 45 Phe Lys Trp Asn Trp Val Gly Leu Phe He Ser Asp Asp Asp Gin Gly 50 55 60 Asn Gin Phe Leu Ser Glu Leu Lys Lys Glu Ser Gin Thr Lys Asp He 65 70 75 80 Cys Phe Ala Phe Val Asn Met He Ser Val Ser Asp Val Ser Tyr Tyr 85 90 95 His Lys Thr Glu Met Tyr Tyr Asn Gin He Val Met Ser Ser Thr Lys 100 105 110 Val He He He Tyr Gly Glu Thr Asn Ser He He Glu Leu Ser Phe 115 120 125 Arg Met Trp Ser Ser Pro Val Lys Gin Arg He Trp Val Thr Thr Lys 130 135 140 Gin Phe Asp Cys Pro Thr Ser Lys Arg Asp Leu Thr His Gly Thr Phe 145 150 155 160 Tyr Gly Thr Leu Thr Phe Leu His His Tyr Gly Glu He Ser Gly Phe 165 170 175 Lys Asn Phe Val Gin Thr Arg Tyr Asn Leu Arg Ser Thr Asp Leu Tyr 180 185 190 Leu Val Met Pro Glu Trp Lys Tyr Phe Asn Tyr Glu Ala Ser Ala Ser 195 200 205 Asn Cys Lys He Leu Arg Asn Tyr Leu Ser Asn He Ser Leu Glu Trp 210 215 220 Leu Met Glu Gin Lys Phe Asp Met Ser Phe Ser Asp Tyr Ser His Asn 225 230 235 240 He Tyr Asn Ala Val Tyr Ala He Ala His Ala Leu His Glu Lys Asp 245 250 255 Leu Gin Glu Phe Glu Asn Gin Ala He Asn Asn Ala Lys Gly Glu Asn 260 265 270 Thr His Cys Leu Lys Leu Asn Ser Phe Leu Arg Lys Thr His Phe Thr 275 280 285 Asn Ser Leu Gly Asn Arg Val He Met Lys Gin Arg Glu Val Val His 290 295 300 Gly Asp Tyr Asn He Val His Met Trp Asn Phe Ser Gin Arg Leu Gly 305 310 315 320 He Lys Val Lys He Gly Gin Phe Ser Pro His Phe Pro Gin Gly Gin 325 330 335 Gin Leu His Leu Tyr Val Asp Met Thr Glu Leu Ala Thr Gly Ser Arg 340 345 350 Lys Met Pro Ser Ser Val Cys Ser Ala Asp Cys His Pro Gly Phe Arg 355 360 365 Arg He Trp Lys Glu Glu Met Ala Ala Cys Cys Phe Val Cys Asn Pro 370 375 380 Cys Pro Glu Asn Glu He Ser Asn Glu Thr Asn Met Asp Gin Cys Ala 385 390 395 400 Asn Cys Pro Glu Tyr Gin Tyr Ala Asn Thr Glu Lys Asn Lys Cys He 405 410 415 Gin Lys Gly Val He Val Leu Ser Tyr Glu Asp Pro Leu Gly Met Ala 420 425 430 Leu Ala Leu He Ala Phe Cys Phe Ser Ala Phe Thr Val Val Val Phe 435 440 445 Trp Val Phe Val Lys His His Asp Thr Pro He Val Lys Ala Asn Asn 450 455 460 Arg He Leu Ser Tyr Leu Leu He Val Ser Leu Met Phe Cys Phe Leu 465 470 475 480 Cys Ser Phe Phe Phe He Gly Tyr Pro Asn Arg Ala Thr Cys He Leu 485 490 495 Gin Gin He Thr Phe Gly He Phe Phe Thr Val Ala He Ser Thr Val 500 505 510 Leu Ala Lys Thr He Thr Val Val Leu Ala Phe Lys Val Thr Asp Pro 515 520 525 Gly Arg Gin Leu Arg He Phe Leu Val Ser Gly Thr Pro Asn Tyr He 530 535 540 He Pro He Cys Ser Leu Leu Gin Cys He Leu Cys Ala He Trp Leu 545 550 555 560 Ala Val Ser Pro Pro Phe Val Asp He Asp Glu His Ser Glu His Gly 565 570 575 His He He He Val Cys Asn Lys Gly Ser He Thr Ala Phe Tyr Cys 580 585 590 Val Leu Gly Tyr Leu Ala Cys Leu Ala Phe Gly Ser Phe Thr He Ala 595 600 605 Phe Leu Ala Lys Asn Leu Pro Asp Thr Phe Asn Glu Ala Lys Phe Leu 610 615 620 Thr Phe Ser Met Leu Val Phe Cys Ala Val Trp Val Thr Phe Leu Pro 625 630 635 640 Val Tyr His Ser Thr Lys Gly Lys Val Met Val Ala Val Glu He Phe 645 650 655 Ser He Leu Ala Ser Ser Ala Gly Met Leu Gly Cys He Phe Ala Pro 660 665 670 Lys Val Tyr He He Leu Met Arg Pro Asp Arg Asn Ser He His Lys 675 680 685 He Arg Glu Lys Ser Tyr Phe 690 695 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 435 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: CAGACTCTGA GCTACACCCT CCTTGTCTCC CTCACACTCT GCTTTCTCTC TTCCTCGCTC 60 TTCATCGGCC GCCCCAGCCC TGCCACCTGC CTCCTCTCAC AGACCACCTT TGCAGCTGTG 120 TTCACAGTGG CTGTGTTTTT CTGCAGGGCC TTCCAGGCTA TAAGGCCAGA AAGCAGGATC 180 CGAAAGTGGA TGGGTCCCCA AAAAACAAAT TCTGTTGTCT TCCTTTGCTC CTTTACCCAA 240 GTGACCCTCT GTGGAATCTG GCTGGGGACA GAGCCTCCCT TCGTAAACAA GGACCCTCAG 300 TTCATGCCTG GCTACATCAT TATCCAGTGT AATGAGGGCT CCGTCACTGC CTTCTACTCT 360 GTCTTGGGCT ACTTGGGCTT CTTGGTTTTA GGGTCCCTTG CTGTAGCCTT TCTGGCAAGG 420 AACCTGCCTG ATGCT 435 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 145 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: Gin Thr Leu Ser Tyr Thr Leu Leu Val Ser Leu Thr Leu Cys Phe Leu 1 5 10 15 Ser Ser Ser Leu Phe He Gly Arg Pro Ser Pro Ala Thr Cys Leu Leu 20 25 30 Ser Gin Thr Thr Phe Ala Ala Val Phe Thr Val Ala Val Phe Phe Cys 35 40 45 Arg Ala Phe Gin Ala He Arg Pro Glu Ser Arg He Arg Lys Trp Met 50 55 60 Gly Pro Gin Lys Thr Asn Ser Val Val Phe Leu Cys Ser Phe Thr Gin 65 70 75 80 Val Thr Leu Cys Gly He Trp Leu Gly Thr Glu Pro Pro Phe Val Asn 85 90 95 Lys Asp Pro Gin Phe Met Pro Gly Tyr He He He Gin Cys Asn Glu 100 105 110 Gly Ser Val Thr Ala Phe Tyr Ser Val Leu Gly Tyr Leu Gly Phe Leu 115 120 125 Val Leu Gly Ser Leu Ala Val Ala Phe Leu Ala Arg Asn Leu Pro Asp 130 135 140 Ala 145 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 474 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: CCCATTGTGA AGGCTAATAA CCAGACTCTG AGCTACACCC TCCTTGTCTC CCTCACACTC 60 TGCTTTCTCT CTTCCTCGCT CTTCATCGGC CGCCCCAGCC CTGCCACCTG CCTCCTCTCA 120 CAGACCACCT TTGCAGCTGT GTTCACAGTG GCTGTGTTTT CTGCAGGGCC TTCCAGGCTA 180 TAAGGCCAGA AAGCAGGATC CGAAAGTGGA TGGGTCCCCA AAAAACAAAT TCTGTTGTCT 240 TCCTTTGCTC CTTTACCCAA GTGACCCTCT GTGGAATCTG GCTGGGGACA GAGCCTCCCT 300 TCGTAAACAA GGACCCTCAG TTCATGCCTG GCTACATCAT TATCCAGTGT AATGAGGGCT 360 CCGTCACTGC CTTCTACTCT GTCTTGGGCT ACTTGGGCTT CTTGGTTTTA GGGTCCCTTG 420 CTGTAGCCTT TCTGGCAAGG AACCCGCCAG ATACGTTCAA TGAGGCCAAG TTAA 474 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 338 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: ACTCCCATTG TGAAGGCCAA CAACTGCCAG CTCAGCTATC TCCTGCTGTC CTCCTTGGCC 60 CTCAGCTTCC TCTGCCCCTT CATGTTCATT GGCCACCCAG ACCCCATCAC TTGTGCTGTG 120 CACNAGGCAG ATTTTGGGGT CACCTTCATG GTCTGCACAT CCACTGTGCT GGCCAAGACC 180 ATCGTGGTGG TGGCAGCCTT CCATGCCACC CAGGCAGACA CTCAGCTTAG GGGGTGGGCG 240 GGGACAGTCC TCCTCAGCAC CATCCTCACT GTTCCCTGAC CCAGGCAGCC TTGTGTGCAC 300 TCTGGGTGAC CAGATGGCCC CCTCAGCCTG TAAAATCT 338 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 182 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: AACCTNCCCG ATACNTTCAA TGAAGCCAAG TTCTTGATGT TCAGCATGCT GATGTTATGT 60 ACTGTTTGAA TTACCTTCCA TACTGTGTAA CATAGCACCA AAGGGAAGGT CATGGTTGCC 120 TTGGAAATAT TCTCCACCTT GACTTCCAGT GCTGAGTGCT AGGNTGTATC TTCGCNCCAA 180 AA 182 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: ATTGGATCCA GGCCGCTCTG GACAAAATAT GAATTCT 37 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: GGCACATGGA CGAAATCTTG GTACTCTTCA GAATTCT 37 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: Asn Met Asp Gin Cys Ala Asn Cys Pro Glu Tyr Gin Tyr Ala Asn Thr 1 5 10 15 Glu Lys Asn Lys Cys He Gin Lys Gly Val He Val Leu Ser Tyr Glu 20 25 30 Asp Pro Leu Gly Met Ala Leu Ala Leu He Ala Phe Cys Phe Ser Ala 35 40 45 Phe Thr Val 50 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1079 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: Met Ala Ser Tyr Ser Cys Cys Leu Ala Leu Leu Ala Leu Ala Trp His 1 5 10 15 Ser Ser Ala Tyr Gly Pro Asp Gin Arg Ala Gin Lys Lys Gly Asp He 20 25 30 He Leu Gly Gly Leu Phe Pro He His Phe Gly Val Ala Ala Lys Asp 35 40 45 Gin Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys He Arg Tyr Asn 50 55 60 Phe Arg Gly Phe Arg Trp Leu Gin Ala Met He Phe Ala He Glu Glu 65 70 75 80 He Asn Ser Ser Pro Ser Leu Leu Pro Asn Met Thr Leu Gly Tyr Arg 85 90 95 He Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu 100 105 110 Ser Phe Val Ala Gin Asn Lys He Asp Ser Leu Asn Leu Asp Glu Phe 115 120 125 Cys Asn Cys Ser Glu His He Pro Ser Thr He Ala Val Val Gly Ala 130 135 140 Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe 145 150 155 160 Tyr He Pro Gin Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn 165 170 175 Lys Asn Gin Tyr Lys Ser Phe Leu Arg Thr He Pro Asn Asp Glu His 180 185 190 Gin Ala Thr Ala Met Ala Asp He He Glu Tyr Phe Arg Trp Asn Trp 195 200 205 Val Gly Thr He Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly He Glu 210 215 220 Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp He Cys He Asp Phe Ser 225 230 235 240 Glu Leu He Ser Gin Tyr Ser Asp Glu Glu Glu He Gin Gin Val Val 245 250 255 Glu Val He Gin Asn Ser Thr Ala Lys Val He Val Val Phe Ser Ser 260 265 270 Gly Pro Asp Leu Glu Pro Leu He Lys Glu He Val Arg Arg Asn He 275 280 285 Thr Gly Arg He Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu 290 295 300 He Ala Met Pro Glu Tyr Phe His Val Val Gly Gly Thr He Gly Phe 305 310 315 320 Gly Leu Lys Ala Gly Gin He Pro Gly Phe Arg Glu Phe Leu Gin Lys 325 330 335 Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp 340 345 350 Glu Glu Thr Phe Asn Cys His Leu Gin Glu Gly Ala Lys Gly Pro Leu 355 360 365 Pro Val Asp Thr Phe Val Arg Ser His Glu Glu Gly Gly Asn Arg Leu 370 375 380 Leu Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn 385 390 395 400 He Asn Ser Val Glu Thr Pro Tyr Met Asp Tyr Glu His Leu Arg He 405 410 415 Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser He Ala His Ala Leu Gin 420 425 430 Asp He Tyr Thr Cys Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser 435 440 445 Cys Ala Asp He Lys Lys Val Glu Ala Trp Gin Val Leu Lys His Leu 450 455 460 Arg His Leu Asn Phe Thr Asn Asn Met Gly Glu Gin Val Thr Phe Asp 465 470 475 480 Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser He He Asn Trp His Leu 485 490 495 Ser Pro Glu Asp Gly Ser He Val Phe Lys Glu Val Gly Tyr Tyr Asn 500 505 510 Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe He Asn Glu Glu Lys He 515 520 525 Leu Trp Ser Gly Phe Ser Arg Glu Val Pro Phe Ser Asn Cys Ser Arg 530 535 540 Asp Cys Gin Ala Gly Thr Arg Lys Gly He He Glu Gly Glu Pro Thr 545 550 555 560 Cys Cys Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr Ser Gly Glu 565 570 575 Thr Asp Ala Ser Ala Cys Asp Lys Cys Pro Asp Asp Phe Trp Ser Asn 580 585 590 Glu Asn His Thr Ser Cys He Ala Lys Glu He Glu Phe Leu Ala Trp 595 600 605 Thr Glu Pro Phe Gly He Ala Leu Thr Leu Phe Ala Val Leu Gly He 610 615 620 Phe Leu Thr Ala Phe Val Leu Gly Val Phe He Lys Phe Arg Asn Thr 625 630 635 640 Pro He Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu Leu Leu Phe 645 650 655 Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe He Gly Glu Pro 660 665 670 Gin Asp Trp Thr Cys Arg Leu Arg Gin Pro Ala Phe Gly He Ser Phe 675 680 685 Val Leu Cys He Ser Cys He Leu Val Lys Thr Asn Arg Val Leu Leu 690 695 700 Val Phe Glu Ala Lys He Pro Thr Ser Phe His Arg Lys Trp Trp Gly 705 710 715 720 Leu Asn Leu Gin Phe Leu Leu Val Phe Leu Cys Thr Phe Met Gin He 725 730 735 Leu He Cys He He Trp Leu Tyr Thr Ala Pro Pro Ser Ser Tyr Arg 740 745 750 Asn His Glu Leu Glu Asp Glu He He Phe He Thr Cys His Glu Gly 755 760 765 Ser Leu Met Ala Leu Gly Ser Leu He Gly Tyr Thr Cys Leu Leu Ala 770 775 780 Ala He Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu Pro Glu Asn 785 790 795 800 Phe Asn Glu Ala Lys Phe He Thr Phe Ser Met Leu He Phe Phe He 805 810 815 Val Trp He Ser Phe He Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe 820 825 830 Val Ser Ala Val Glu Val He Ala He Leu Ala Ala Ser Phe Gly Leu 835 840 845 Leu Ala Cys He Phe Phe Asn Lys Val Tyr He He Leu Phe Lys Pro 850 855 860 Ser Arg Asn Thr He Glu Glu Val Arg Ser Ser Thr Ala Ala His Ala 865 870 875 880 Phe Lys Val Ala Ala Arg Ala Thr Leu Arg Arg Pro Asn He Ser Arg 885 890 895 Lys Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser He Pro Ser Ser 900 905 910 Ser He Ser Ser Lys Ser Asn Ser Glu Asp Arg Phe Pro Gin Pro Glu 915 920 925 Arg Gin Lys Gin Gin Gin Pro Leu Ser Leu Thr Gin Gin Glu Gin Gin 930 935 940 Gin Gin Pro Leu Thr Leu His Pro Gin Gin Gin Gin Gin Pro Gin Gin 945 950 955 960 Pro Arg Cys Lys Gin Lys Val He Phe Gly Ser Gly Thr Val Thr Phe 965 970 975 Ser Leu Ser Phe Asp Glu Pro Gin Lys Asn Ala Met Ala His Arg Asn 980 985 990 Ser Met Arg Gin Asn Ser Leu Glu Ala Gin Arg Ser Asn Asp Thr Leu 995 1000 1005 Gly Arg His Gin Ala Leu Leu Pro Leu Gin Cys Ala Asp Ala Asp Ser 1010 1015 1020 Glu Met Thr He Gin Glu Thr Gly Leu Gin Gly Pro Met Val Gly Asp 025 1030 1035 1040 His Gin Pro Glu Met Glu Ser Ser Asp Glu Met Ser Pro Ala Leu Val 1045 1050 1055 Met Ser Thr Ser Arg Ser Phe Val He Ser Gly Gly Gly Ser Ser Val 1060 1065 1070 Thr Glu Asn Val Leu His Ser 1075 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 3...3 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 12...12 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 15...15 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 18...18 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: BTNYAYCARR TNGCNMCNAA RGAYAC 26 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 6...6 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 9...9 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 12...12 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 18...18 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 21...21 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: GYRTKNGCNR YNRCRTRNAC NRCRTT 26 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 3...3 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 9...9 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 12...12 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 13...13 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 24...24 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: MRNTGYCCNK ANNAYMARTA YGCNAA 26 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 2...2 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 5...5 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 8...8 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 11...11 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 14...14 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 20...20 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 26...26 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 29...29 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: GNCKNAYNAR NATNAYRTAN MWYTTNGGNA C 31 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 3...3 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 6...6 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 9...9 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 12...12 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 16...16 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 24...24 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: ATNWSNYTNR TNTTYNGYTT YYTNTG 26 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 2...2 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 5...5 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 11...11 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 17...17 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 20...20 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 23...23 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: RNATNSWRAA NAYYTCNACN RCNACCAT 28 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 6...6 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 9...9 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 12...12 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 15...15 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 21...21 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: GAYACNCCNA TNGTNAARGC NAAYAA 26 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 3...3 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 6...6 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 12...12 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 15...15 (D) OTHER INFORMATION: Inosine (A) NAME/KEY: Modified Base (B) LOCATION: 24...24 (D) OTHER INFORMATION: Inosine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: AANGTNAYCC ANACNSWRCA RAANAC 26 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2550 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: ATGAAGCAGC TCTGCGCTTT CACTATTTCT TTGTTGTTTC TGAAGTTTTC TCTCATCCTG 60 TGCTGTTTGA CTGAACCAAG TTGCTTTTGG AGAATAAGGA ATAGTGAAGA TAGTGATGGA 120 GATTTACAAA GGGAATGTCA TTTTTACCTT TGGAAAACTG ATGAACCTAT TGAAGATAGT 180 TTTTATAATT ATGATTTAAG TTTTAGAATT GCAGCAAGTG AATATGAGTT TCTTCTCGTA 240 ATGTTTTTTG CTATCGATGA GATCAACAGG AATCCTTATC TTTTACCCAA CATAACTTTG 300 ATGTTCTCCT TCATTGGTGG AAACTGTCAG GATTTATTGA GAGTTATGGA CCAAGCATAT 360 ACACAAATAA ATGGACATAT GAATTTTGTT AATTATTTCT GTTATTTAGA TGATTCATGT 420 GCCATAGGTC TTACAGGACC ATCATGGAAA ACTTCCTTAA AACTGGCAAT GCACTCTTCG 480 ATGCCACTGG TTTTCTTTGG ACCATTTAAT CCTAACCTAC GCGACCATGA CCGGCTGCCC 540 CATGTCCATC AGGTAGCCCC CAAGGACACA CATTTGTCCC ATGGCATGGT CTCCTTGATG 600 TTTCACTTTA GATGGACTTG GATAGGACTG GTCATCTCAG ATGATGACCA GGGTATTCAG 660 TTTCTCTCAG ATTTAAGAGA AGAAAGCCAA AGGCATGGGA TCTGTTTAGC TTTTGTTAAT 720 ATGATCCCAG AAAACATGCA GATATACATG ACAAGGGCTA CAATATATGA TAAACACATT 780 ATGACATCTT CAGCAAAGGT TGTTATCATT TATGGTGAAA TGAACTCTAC TCTAGAAGCA 840 AGCTTTAGAA GATGGGAAGA GTTAGGTGCT CGGAGAATCT GGATCACAAC CTCACAATGG 900 GATGTCATCA CAAATAAAAA AGACTTCACC CTTAATCTCT TCCATGGGAT CATCACTTTT 960 GAACATCATA GATTTGAGAT TCCTAAATTA AATAAATTCA TGCAAACAAT GAACACTGCC 1020 AAATACCCAG TAGATATTTC TCATACTATA TTGGAGTGGA ATTATTTTAA TTGTTCAATA 1080 TCTAAGAACA GCATTAGAAT GCATCATATT ACATTCAACA ACACCTTGGA ATGGACATCA 1140 CTGCACAACT ATGATGTGGC GATGAGTGAT GAAGGTTACA ATTTGTACAA TGCTGTTTAT 1200 GCTGTGGCCC ACACCTACCA TGAATACATT TTTCAACAAG TAGAGTCTCA GAAAAAGGCA 1260 AAACCCAAAA GATATTTCAC TGCTTGTCAG CAGGTGTCTT CCTTGATGAA AACCAGGGTA 1320 TTTACGAACC CTGTTGGAGA ACTGGTGAAC ATGAAGCATA GGGAAAATCA GTGTACAGAG 1380 TATGATATTT TCATCATTTG GAATTTTCCA CAAGGCCTTG GATTAAAAGT GAAAATAGGA 1440 AGCTATTTAC CTTGTTTTCC ACAGAGACAA AAACTTCATA TATCTGATGA TTTGGAATGG 1500 GCCAAGGGAG GAACATCACC TCAGGTTCCC TCCTCCGTGT GTAGTGTGGC ATGTACTGCT 1560 GGATTCAGGA AAATTTATCA AAAAGAAACA GCAGACTGCT GCTTTGATTG TGTTCAGTGC 1620 CCAGAAAATG AGATTTCCAA CGAAACAGAT ATGGAACAGT GTGTGAGGTG TCCAGATGAT 1680 AAGTATGCCA ACATAGAGCA AACCCACTGC CTCTCAAGAG CTGTATCATT TCTGGCTTAT 1740 GAAGATTCAT TGGGGATGGC TCTAGGCTGC ATGGCACTGT CCTTCTCAGC CATCACAATT 1800 CTAATCCTCG TCACATTTGT GAAGTACAAA GATACTCCCA CTGTGAAGGC CAATAACCGC 1860 ATTCTCAGCT ACATCCTGCT CATCTCTCTC GTCTTCTGCT TTCTCTGCTC CCTGCTCTTC 1920 ATTGGACCTC CCGACCAGGT CACCTGCATC TTTCAGCAGA CCACATTTGG AGTATTGTTC 1980 ACTGTGTCTG TTTCTACAGT GTTGGCCAAA ACAATAACTG TGGTCATGGC TTTCAAGCTC 2040 ACTACTCCAG GAAGAAGGAT GAGAGGGATG ATGATGACAG GGGCACCTAA GTTGGTCATT 2100 CCCATTTGTA CCCTGATCCA ACTTGTTCTC TGTGGAATCT GGTTGGTCAC ATCTCCTCCC 2160 TTTATTGACA GAGACATACA ATCTGAGCAT GGGAAGATTG TCATTCTTTG CAATAAAGGC 2220 TCAGTCATTG CCTTCCACGT CGTCCTGGGA TACTTGGGCT CCTTGGCTCT GGGGAGCTTC 2280 ACGTTGGCTT TCCTGGCTAG GAACCTTCCT GACACATTCA ATGAAGCCAA GTTCCTAACT 2340 TTCAGCATGC TGGTGTTCTG CAGTGTCTGG ATCACCTTCC TCCCTGTCTA CCACAGCACC 2400 AGGGGGAGGG TCATGGTGGT TGTGGAGGTT TTCTCCATCT TGGCTTCTAG TGCAGGGTTG 2460 CTAATGTGTA TCTTTGTCCC AAAGTGTTAT GTTATTTTAA TTAGACCAGA TTCAAATTTT 2520 ATAAAGAACC ACAAAGGTAA ATTGCTTTAT 2550 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2424 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: ATGAAGCAGC TCTGCACTTT CACTATTTCA TTGTTGTTTC TGAAGTTTTC TCTCATCTTG 60 TGCTGTTGGA GTGAACCAAG CTGCTTTTGG AGGATAAAGA AGAGTGAAGA TAATGATGGA 120 GATTTACAAA GGGAGTGTCA TTTTTACCTT TGGAAAACTG ATGAACCTAT TGAAGATAGT 180 TTTTATAATT ATGATTTAAG TTTTAGAATT GCAGGAAGTG AATATGAGCT TCTTCTGGTA 240 ATGTTTTTTG CTACTGATGA GATCAACAAG AATCCTTATC TTTTACCCAA CATGAGTTTG 300 ATGTTCTCCA TCATTGGTGG AAACTGTCAT GATTTATTGA GAAGTCTGGA TCAAGAATAT 360 GCACAAATAG ATGGACATAT GAATTTTGTT AATTATTTCT GTTATTTAGA TGATTCATGT 420 GCCACAGGCC TTACAGGACC ATCATGGAAA ACATCCTTAA AACTGGCAAT GCATTCTTCA 480 ATGCCACTGG TTTTCTTTGG ACCATTTAAT CCTAACCTAC GCGACCATGA CCGGCTGCCC 540 CATGTCCATC AGGTAGCCCC CAAGGACACA CATTTGTCCC ATGGCATGGT CTCCTTGATG 600 TTTCATTTTA GGTGGACTTG GATAGGACTG GTCATCTCAG ATGATGATCA GGGTATTCAG 660 TTTCTCTCAG ATTTAAGAGA AGAAAGCCAA AGGCATGGGA TCTGTTTGGC TTTTGTTAAT 720 ATGATCCCAG AAAACATGCA GATATACATG ACAAGGGCTA CAATATATGA TACACAAATT 780 ATGACATCTT CAGCAAAGGT TGTTATCATT TATGGTGACA TGAACTCTAC TCTAGAAGCA 840 AGCTTTAGAA GATGGGAAGA GTTAGGTGCT CGGAGAATCT GGATCACAAC CACACAATGG 900 GATGTCATCA CAAATAAAAA AGACTTCACC CTTAATCTCT TCCATGGGAC TATTACTTTT 960 GCACACCACA AAGATGAGAT TCCTAAATTT AGGAATTTTA TGCAAACAAA GAAAACTGCC 1020 AAATACCTTG TAGATATTTC TCATACTATT TTGGAGTGGA ATTATTTTAA TTGTTCAATC 1080 TCTAAGAACA GCAGTAAAAT GGGTCATTTT ACATTCAACA ACACATTGCA ATGGACAGCA 1140 CTGCACAACT ATGATATGGC CCTGAGCGAT GAAGGTTACA ATTTGTATAA TGCTGTTTAT 1200 GCTGTGGCCC ACACCTACCA TGAATACATT CTTCAACAAG TAGAGTCTCA GAAAAAGGCA 1260 AAACCCAAAA GATATTTCAC TGCTTGTCAG CAGGTGTCTT CCTTGATGAA AACCAGGGTA 1320 TTTATGAACC CTGTTGGAGA ACTGGTGAAC ATGAAGCATA GGGAAAATCA GTGTACAGAG 1380 TATGATATTT TCATCATTTG GAATTTTCCA CAAGGCCTTG GATTAAAAGT GAAAGTAGGA 1440 AGCTATTTAC CTTGCTTTCC AAAGAGTCAA CAACTTCATA TAGCTGATGA TTTGGAATGG 1500 GCCATGGGAG GAACATCAGT GGATATGGAA CAGTGTGTGA GATGTCCAGA TAATAAATAT 1560 GCCAATTTAG AGCAAACCCA CTGCCTCCAA AGAACGGTGT CATTTCTGGC TTATGAAGAT 1620 CCATTGGGGA TGGCTCTAGG CTGCATGGCA CTGTCCTTCT CGGCCATCAC AATTCTAGTC 1680 CTCGTCACAT TTGTGAAGTA CAAGGATACT CCCATTGTGA AGGCCAATAA CCGCATTCTC 1740 AGCTACATCC TGCTCATCTC TCTCGTCTTC TGCTTTCTCT GTTCCCTGCT CTTCATTGGA 1800 CATCCCGACC AGGTCACCTG CATCTTGCAG CAGACCACAT TTGGAGTATT GTTCACTGTG 1860 TCTGTTTCTA CAGTGTTGGC CAAAACAATA ACTGTGGTCA TGGCTTTCAA GCTCACTACT 1920 CCAGGAAGAA GGATGAGAGG GATGATGATG ACAGGGGCAC CTAAGTTGGT CATTCCCATT 1980 TGTACCCTGA TCCAACTTGT TCTCTGTGGA ATCTGGTTGG TCACATCTCC TCCCTTTATT 2040 GACAGAGATA TACAATCTGA ACATGGGAAG ATTGTCATTC TTTGCAATAA AGGCTCTGTC 2100 GTTGCCTTCC ACGTCGTCCT GGGATACTTG GGCTCCTTGG CTCTGGGGAG CTTCACTTTG 2160 GCTTTCTTGG CTAGGAACCT TCCTGACACA TTCAATGAAG CCAAGTTCCT AACTTTCAGC 2220 ATGCTGGTGT TCTGCAGTGT CTGGATCACC TTCCTCCCTG TCTACCACAG CACCAGGGGG 2280 AAGGTCATGG TGGTTGTGGA GGTTTTCTCC ATCTTGGCTT CTAGTGCAGG GTTGCTAATG 2340 TGTATCTTTG TCCCAAAGTG TTATGTTATT TTAATTAGAC CAGATTCAAA TTTTATACAG 2400 AACCACAAAG GTAAATTGCT TTAT 2424 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2409 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: CATTTTTACC TTGGGGCAGT TGATAAACCA ATTGAAGATA ATTTTTATAA TTCACTTTTA 60 AAGTTTAGAA TTGCAGCAAG TGAATATGAG TTTCTTCTGG TAATGTTTTT TGCTACTGAT 120 GAGATCAACA AGAATCCTTA TCTTTTACCC AACATAACTT TGATGTTCTC CATCATTGGT 180 GGAAACTGTC ATGATTTATT GAGAGGTTTG GATCAAGCAT ATACACAAAT AAATGGACAT 240 ATGAATTTTG TTAATTATTT CTGTTATTTA GATGATTCAT GTGCCATAGG TCTTACAGGA 300 CCATCATGGA AAACATCCTT AAATCTGGCA ATGCATTCTT CAATGCCACT GGTTTTCTTT 360 GGATCATTTA ATCCTAACCT ACATGACCAT GACCGGCTGC ACCATGTCCA TCAAGTAGCC 420 ACCAAGGACA CACATTTGTC CCATGGCATT GTCTCCTTGA TGTTTCATTT TAGATGGACT 480 TGGATAGGAC TGGTCATCTC AGATGATGAC AAGGGTATTC AGTTTCTCTC AGATTTAAGA 540 GAAGAAAGCC AAAGGCATGG GATCTGTTTA GCTTTTGTTA ATATGATCCC AGAAAACATG 600 CAGATATACA TGACAAGGGC TACAATATAT GATAAACAAA TTATGACGTC TTTAGCAAAA 660 GTTGTTATCA TTTATGGTGA AATGAACTCT ACACTAGAAG TAAGCTTTAG AAGATGGGAA 720 AATTTAGGTG CTCGGAGAAT CTGGATCACA ACCTCACAAT GGGATGTCAT CACAAATAAA 780 AAAGAATTCA CCCTTAATCT CTTCCATGGG ACTATTACTT TTGCACACCG CAGATTTGAG 840 ATTCCTAAAT TTAAAAAATT TATGCAAACA ATGAACACTG CCAAATACCC AGTAGATATT 900 TCTCATACTA TATTGGAGTG GAATTATTTT AATTGTTCAA TCTCTAAGAA CAGCAGTAAA 960 ATGGATCATA TTACATTCAA CAACACATTG GAATGGACAG CACTGCACAA CTATGATATG 1020 GTGATGAGTG ATGAAGGTTA CAATTTGTAT AATGCTGTTT ATGCTGTGGC CCACACCTAC 1080 CATGAACATA TTTTTCAACA AGTAGAGTCT CAGAAAAAGG CAAAACCCAA AAGATTTTTC 1140 ACTGTTTGTC AGCAGGTGTC TTCCTTGATG AAAACCAGGG TATTTACTAA CCCTGTTGGA 1200 GAACTGGTGA ACATGAAGCA TAGGGAAAAT CAGTGTACAG AGTATGACAT TTTCCTCATT 1260 TGGAACTTTC CACAAGGCCT TGGATTAAAA GTGAAAATAG GAAGCTATTT ACCTTGTTTT 1320 CCACAGAGAC AAGAACTTCA TATATCTGAT GATTTGGAAT GGGCCATGGG AGGAACATCA 1380 GTGGTTCCCT CCTCTGTGTG TAGTGTGGCA TGTACTGCAG GATTCAGGAA AATTCATCAG 1440 AAAGAAACAG CAGACTGCTG CTTTGATTGT GTTCAGTGCC CAGAAAATGA GGTTTCCAAT 1500 GAAACAGATA TGGAACAGTG TGTGAAGTGT CCATATGATA AGTATGCCAA CATAGAGAAA 1560 ACCCACTGCC TCTCAAGAGC TGTATCATTT CTGGCTTATG AAGATCCATT GGGGATAGCT 1620 CTAGGCTGCA TAGCACTGTC CTTCTCAGCC ATCACAATTC TAGTACTAAT CACATTTTTG 1680 AAGTACAAGG ATACTCCCAT TGTGAAGGCC AATAACCGCA TTCTCAGCTA CATCCTGCTC 1740 ATCTCTCTAG TCTTCTGCTT TCTCTGCTCC CTGCTCTTCA TTGGACATCC AAACCAGGTC 1800 TCCTGCGTCT TGCAGCAGAC CACATTTGGA GTATTTTTCA CTGTGTCTGT TTCTACAGTG 1860 TTGGCCAAAA CAATAACTGT GGTCATGGCT TTCAAGCTCA CTACTCCAGG AAGAAGAATG 1920 AGAGAGATGT TGGTAACAGG GGCACCTAAG TTGGTCATTC CCATTTGTAC CCTAATCCAA 1980 TTTGTTCTCT GTGGAATCTG GTTGATAACA TCTCCTCCAT TTATTGACAG AGATATACAA 2040 TCTGAGCATG GGAAGATTGT CATTCTTTGC AATAAAGGCT CTGTCATTGC CTTCCATGTT 2100 GTCCTGGGAT ACTTGGGCTC CTTGGCTCTG GGGAGCTTCA CTTTGGCTTT CTTGGCTAGG 2160 AACCTTCCTG ACACATTCAA TGAAGCCAAA TTCCTGACTT TCAGCATGCT GGTGTTCTGC 2220 AGTGTCTGGA TCACCTTTCT CCCTGTCTAC CATAGCACCA GGGGGAAGGT CATGGTGGTT 2280 GTGGAGGTTT TCTCAATCTT GGCTTCTAGT GCAGGGTTGC TAATGTGTAT CTTTGTCCCA 2340 AAGTGTTATG TTATTTTAGT TAGACCAGAT TCAAATTTTA TACGGAAGTA CAAAGATAAA 2400 TTTCGTTAT 2409 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2556 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: ATGTTCATTT TCATGGGAGT CTTCTTCCTA CTTAATATTA CACTTCTCAT GGCCAATTTC 60 ATTGATCCCA GGTGCTTTTG GAGAATAAAT TTGGATGAAA TAACGGATGA ATATTTGGGA 120 TTATCTTGTG CTTTCATCCT GGCAGCTGTT CAGACACCCA TTGAAAAAGA TTATTTCAAC 180 ACGACTCTTA ATTTTCTAAA AACTACTAAA AACCACAAAT ATGCTTTGGC ATTGGTGTTT 240 GCAATGGATG AAATCAACAG ATATCCTGAT CTTTTACCAA ATATGTCTTT GATTATCAGA 300 TACTCTTTGG GCCATTGTGA TGGAAAAACT GTAACACCTA CACCATATTT ATTTCATAGA 360 AAAAAGCAAA GCCCTATTCC TAATTATTTC TGTAATGAAG AGAGTATGTG TTCATTTCTG 420 CTTTCAGGAC CCAATTGGGA TGAATCTTTA AGTTTCTGGA AGTACCTGGA CAGCTTCTTA 480 TCTCCACGTA TCCTTCAGCT TTCCTATGGA TCTTTCAGTT CCATCTTCAG TGATGATGAA 540 CAATATCCCT ATCTCTATCA GATGGCCCCA AAAGACACAT CTCTAGCATT GGCAATGGTC 600 TCCTTCATAC TTTATTTGAA ATGGAATTGG ATTGGCCTTG TCATCCCAGA TGATGATCAA 660 GGAAACCAAT TTCTTTTAGA GTTGAAGAAA CAGAGTGAAA ACAAAGAAAT TTGCTTTGCC 720 TTTGTGAAAA TGATCTCTGT TGATGAAGTT TCATTTCCAC AAAAAACTGA AATAAACTAC 780 AAACAAATTG TGAAGTCACT AACAAATGTT ATTATCATTT ATGGAGAAAC ATATAATTTC 840 ATTGATTTGA TCTTCAGAAT GTGGGAACCT CCCATTTTAC AGAGAATATG GATCACCACA 900 AAACAATTGA ATTTCCCTAC CAGTAAGACA GACATAAGTC ATGACACATT CTATGGATCA 960 CTTACTTTTC TACCCCACCA TGGTGAGATT TCTGGCTTTA AAAATTTTGT ACAGACATGG 1020 TTCCATCTCA GAAACACAGA TTTATGTCTA GTAATGCCAG AGTGGAAATA TATTAACTCT 1080 GAAGACTCAG CATCTAATTG TAAAATACTT AAGAACAGTT CATCTGATGC CTCATTTGAT 1140 TGGCTAATGG AAGAGAAGCT TGACATGGCC TTTAGTGAGA ATAGTCATAA CATATATAAT 1200 GCTGTGCATG CCATAGCCCA TGCCCTCCAT GAGATGAATC TGCAACAGGC TGATAATCAG 1260 GCAATAGATA ATGGAAAAGG AGCCAGTTCT CACTGCTTGA AGGTAAACTC CTTTCTAAGA 1320 AGGACCTACT TCACTAATCC TCTTGGGGAC AAAGTGTTTA TGAAGCAAAG AGTAATAATG 1380 CAGGATGAAT ATGACATTGT TCACTTTGCG AATCTCTCAC AACACCTTGG GATTAAGATG 1440 AAGTTAGGAA AGTTCAGCCC ATATTTACCA CATGGTCGAC ACTCTCACTT ATACGTAGAC 1500 ATGATTGAGT TGGCCACAGG AAGAAGAAAG ATGCCATCCT CTGTGTGCAG TGCAGATTGT 1560 AGTCCTGGAT TCAGAAGATT ATGGAAGGAG GGAATGGCAG CCTGCTGTTT TGTTTGCAGC 1620 CCCTGCCCTG AAAATGAAAT TTCTAATGAG ACAAATATGG ATCAATGCGT GAATTGTCCA 1680 GAATACCAAT ATGCCAACAC AGAACAGAAC AAATGTATTC AGAAAGGTGT CACCTTCCTA 1740 AGCTATGAAG ACCCCTTGGG GATGGCACTT GCCTTAATGG CCTTCTGCTT CTCTGCATTC 1800 ACAGCTGTGG TACTTTGTGT CTTTGTGAAG CACCATGACA CTCCTATTGT GAAGGCCAAT 1860 AACAGAAGCC TCAGCTATCT ATTACTCATG TCACTCATGT TCTGTTTTCT GTGCTCCTTT 1920 TTCTTCATTG GCCTTCCAAA CAAAGTCATC TGTGTCTTAC AGCAAATCAC ATTTGGAATT 1980 GTATTCACTG TGGCTGTTTC CACAGTTCTG GCCAAAACAG TCACTGTGGT TCTAGCTTTC 2040 AAAGTCACAG TCCCAGGAAG AAGATTGAGA TACTTCCTTG TATCAGGGAC ACTAAACTAC 2100 ATTATTCCTA TATGTTCCCT ACTCCAATGT GTTCTGTGTG CAATCTGGCT AGCAGTCTCT 2160 CCTCCCTTTG TTGATATTGA TGAACACTCT CAGCATGGCC ACATCATCAT TGTGTGCAAC 2220 AAGGGCTCAG TTACTGCATT CTACTGTGTC CTTGGATACT TGGCCTGCCT GGCACTGGGA 2280 AGCTTCACTT TGGCTTTCTT GGCCAAGAAT CTGCCTGATG CATTCAATGA AGCCAAGTTC 2340 TTGACCTTCA GCATGCTAGT GTTCTGCAGT GTCTGGGTCA CCTTCCTCCC TGTGTACCAT 2400 AGCACAAAGG GCAAACACAT GGTTGCTGTG GAGATCTTCT CTATCTTGGC ATCCAGTGCA 2460 GGGATGCTTG GATGTATTTT TGTACCCAAG ATTTATATCA TTTTAATGAG ACCAGAGAGA 2520 AATTCTACCC AAAAGATCAG AGAAAAATCA TATTTT 2556 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2169 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: ATCTGTAATG AAGAGAGTAT GTGTTCATTT CTGCTTTCAG GACCCAATTG GGATGAATCT 60 TTAAGTTTCT GGAAGTACCT GGACAGCTTC TTATCTCCAC ATATCCTTCA GCTTTCCTAT 120 GGATCTTTCA GTTCCATCTT CAGTGATGAT GAACAATATC CCTATCTCTA TCAGATGGCC 180 CCAAAGGACA CATCTCTAGC ATTGGCAATG GTCTCCTTCA TACTTTATTT GAAATGGAAT 240 TGGATTGGCC TTGTCATCCC AGATGACGAT CAAGGAAACC AATTTCTTTT AGAGTTGAAG 300 AAACAGAGTG AAAACAAAGA AATTTGCTTT GCCTTTGTGA AAATGATATC TGTTGATGAA 360 GTTTCATTTC CACAAAAAAC TGAAATATAC TACAAACAAA TTGTGAAGTC ATTAACAAAT 420 GTTATTATCA TTTATGGAGA AACATATAAT TTCATTGATT TGATCTTCAG AATGTGGGAA 480 CCTCCCATTT TACAGAGAAT ATGGATCACC ACAAAACAAT TGAATTTCCC TACCAGTAAG 540 ACAGACATAA GTCATGACAC ATTCTATGGA TCACTTACTT TTCTACCCCA CCATGGTGAG 600 ATTTCTGGCT TTAAAAATTT TGTACAGACA TGGTTCCATC TCAGAAACAC AGATTTATAT 660 CTAGTAATGC CAGAGTGGAA ATATATTAAC TCTGAAGACT CAGCATCTAA TTGTAAAATA 720 CTGAAGAACA GTTCATCTGA TGCCTCATTT GATTGGCTAA TGGAACAGAA GCTTGACATG 780 GCCTTTAGTG ATAATAGTCA TAACATATAT AATGTTGTGC ATGCCATAGC CCATGCCCTC 840 CATGAGATGA ATCTGCAACA GGCTGATAAT CAGGCAATAG ATAATGGAAA AGGAGCCAGT 900 TCTCACTGCT TGAAGGTAAA CTCCTTTCTA AGAAGGACCT ACTTCACTAA TCCTCTTGGG 960 GACAAAGTGT TTATGAAGCA AAGAGTAATA ATGCAGGATG AATATGACAT TGTTCACTTT 1020 GCGAATCTCT CACAACACCT TGGGATTAAG ATGAAGTTAG GAAAGTTCAG CCCATATTTA 1080 CCACATGGTC GACACTCTCA CTTATACGTA GACATGATTG AGTTGGCCAC AGGAAGAAGA 1140 AAGATGCCAT CCTCTGTGTG CAGTGCAGAT TGTAGTCCTG GATTCAGAAG ATTATGGAAG 1200 GAGGGAATGG CAGCCTGCTG TTTTGTTTGC AGCCCCTGCC CTGAAAATGA AATTTCTAAT 1260 GAGACAAATA TGGATCAATG CGTGAATTGT CCAGAATACC AATATGCCAA CACAGAACAG 1320 AACAAATGTA TTCAGAAAGG TGTCACCTTC CTAAGCTATG AAGACCCCTT GGGGATGGCA 1380 CTTGCCTTAA TGGCCTTCTG CTTCTCTGCA TTCACAGCTG TGGTACTTTG TGTCTTTGTG 1440 AAGCACCATG ACACTCCTAT TGTGAAGGCC AATAACAGAA GCCTCAGCTA TCTATTACTC 1500 ATGTCACTCA TGTTCTGTTT TCTGTGCTCC TTTTTCTTCA TTGGCCTTCC AAACAAAGTC 1560 ATCTGTGTCT TACAGCAGAT CACATTTGGA ATTGTATTTA CTGTAGCTGT TTCCACAGTT 1620 CTGGCCAAAA CAGTCACTGT GGTTCTAGCT TTCAAAGTCA CAGACCCAGG AAGAAGATTG 1680 AGATACTTCC TTGTATCAGG GACACTAAAC TACATTATTC CTATATGTTC CCTACTCCAA 1740 TGTGTTCTGT GTGCAATCTG GCTAGCAGTC TCTCCTCCCT TTGTTGATAT TGATGAACAC 1800 TCTCAGCATG GCCACATCAT CATTGTGTGC AACAAGGGCT CAGTTACTGC ATTCTACTGT 1860 GTCCTTGGAT ACTTGGCCTG CCTGGCACTG GGAAGCTTCA CTTTGGCTTT CTTGGCCAAG 1920 AATCTGCCTG ATGCATTCAA TGAAGCCAAG TTCTTGACCT TCAGCATGCT AGTGTTCTGC 1980 AGTGTCTGGG TCACCTTCCT CCCTGTGTAC CATAGCACAA AGGGCAAACA CATGGTTGCT 2040 GTGGAGATCT TCTCCATCTT GGCATCCAGT GCAGGGATGC TTGAATGTAT TTTTGTACCC 2100 AAGATTTATA TCATTTTAAT GAGACCAGAG AGAAATTCTA CCCAAAAGAT CAGGGAAAAA 2160 TCATATTTC 2169 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1889 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: GAATTCGGCT TCTGCACCAA ATGGCGACGA AAGACACATC TCTTTCACTT GCCATTGTTT 60 CTTTGATGGT TCATTTTAGG TGGTCTTGGG TTGGTCTAAT TCTCCCAGAT GACCACAAAG 120 GAAATAAAAT ACTATCAGAT TTTAGAAAGG AGATGGAAAG AAAAAGAATC TGTACGGCTT 180 TTGTAAAAAT GATTCCTGCC ACATGGACTT CATCTTTTGT CAAATTCTGG GAAAATATGG 240 ATGACACCAA CATAATAATT ATTTATGGTG ACATTGATTC TCTAGAAGGT CTAATGCGAA 300 ATATTGGGCA AAGGTTATTG ACATGGCATG TCTGGGTCAT GAACATTGAA CCCCATATTA 360 TTGAATATGA TAATTATTTC ATGTTAGATT CATTCCATGG AAGTTTAATT TTTAAGCACA 420 ATTATAGAGA GAATTTTGAG TTTACCAAAT TTATTCGAAC AGTTAATCCT AAAAAATACC 480 CAGAAGACAT TTATCTCCCT AAGATGTGGT ATTTGTTCTT CATGTGCTCA TTTTCTGATA 540 TTAATTGTCA AGTTTTGGAC AGCTGTCAAA CAAATGCTTC TTTGGATATG TTACCTAGTC 600 AGATATTTGA TGTGGTCATG AGTGAAGAGA GCACAAGTAT TTACAATGCT GTGTACGCTG 660 TGGCTCACAG CCTCCATGAG ATGAGACTTC AGCAACTTCA AACACAACCG TGTGAAAATG 720 AAGAAGGGAT GGAGTTCTTT CCATGGCAGC TTAATACTTT CCTGAAGGAT ATTGAGGTGA 780 GAGTCAACAG TTTAGACTGG AGACAGAGAA TAGATGCTGA ATATGACATT CTTAACCTCT 840 GGAATTTACC AAAGGGTCTT GGACTAAAAG TGAAAATAGG AAACTTTTAT GCAAATGCTC 900 CCCAGGGTCA ACAATTGTCT TTATCTGAAC AGATGATTCA ATGGCCAGAA ATATTTTCAG 960 AGATCCCTCA GTCGGTGTGC AGTGAGAGTT GTGGGCCTGG ATTCAGGAAA GTAACCCTGG 1020 AGAATAAGGC TATCTGCTGC TACAATTGTA CTCCCTGTGC AGACAATGAG ATTTCTAATG 1080 AGACAGATGT AGACCAGTGT GTGAAGTGTC CAGAGAGTCA TTATGCAAAT ACAGAGAAGA 1140 GCAACTGCTA TCAAAAGTCT GTGAGCTTTC TGGGCTATGA AGACCCTTTG GGGATGGCTC 1200 TAGCCAGCAT AGCTTTGTGC TTGTCTGCAC TAACTGCCTT TGTTATTGGC ATATTTGTGA 1260 AACACAAAGA CACTCCTATT GTTAAGGCCA ATAATCAAGC TCTGAGTTAC ACTTTGCTCA 1320 TCACACTCAA ATTCTGTTTC CTATGTTCTT TGAACTTCAT TGGTCAGCCC AACACAGTTG 1380 CCTGCATCCT TCAGCAGACC ACCTTTGCAG TTGCTTTCAC TATGGCTCTT GCCACTGTGT 1440 TGGCCAAAGC TATCACTGTG GTTCTTGCCT TTAAGGTCAG TTTTCCAGGG AGAATGGTAA 1500 GATGGCTAAT GATATCAAGG GGTCCAAACT ATATCATTCC TATCTGCACC CTGATCCAAC 1560 TTCTTCTTTG TGGAATATGG ATGGCAATAT CTCCACCATA CATTGACCAA GATGCTCATA 1620 TTGAACATGG TCACATCATC ATTTTGTGCA ACAAGGGCTC AGCTGTTGCC TTCCACTCTG 1680 TCCTGGGATA CCTCTGCTTC TTGGCCCTTG GGAGTTATAC CATGGCCTTC TTGTCAAGAA 1740 ATTTGCCTGA TACATTCAAC GAATCCAAAT TTATCTCACT AAGTATGCTG GTATTCTTCT 1800 GTGTCTGGAT CACCTTTCTT CCTGTCTACC ACAGCACTAA AGGGAAGGTC ATGGTCGCCG 1860 TCGAGGTCTT TTGCATCCAA GCCGAATTC 1889 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1889 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: GAATTCGGCT TCTGCATCAA ATGGCGACGA AGGACACATC TCTTTCACTT GCCATTGTTT 60 CTTTGATGGT TCATTTTAGG TGGTCTTGGG TTGGTCTAAT TCTCCCAGAT GACCACAAAG 120 GAAATAAAAT ACTATCAGAT TTTAGAAAGG AGATGGAGAG AAAAAGAATC TGTACGGCTT 180 TTGTAAAAAT GATTCCTGCC ACATGGACTT CATCTTTTGT CAAATTCTGG GAAAATATGG 240 ATGACACCAA CATAATAATT ATTTATGGTG ACATTGATTC TCTAGAAGGT CCAATGCGAA 300 ATATTGGGCA AAGGTTATTG ACATGGCATG TCTGGGTCAT GAACATTGAA CCCCATATTA 360 TTGAATATGA TAATTATTTC ATGTTAGATT CATTCCATGG AAGTTTAATT TTTAAGCACA 420 ATTATAGAGA GAATTTTGAG TTTACCAAAT TTATTCGAAC AGTTAATCCT AAAAAATACC 480 CAGAAGACAT TTATCTCCCT AAGATGTGGT ATTTGTTCTT CATGTGCTCA TTTTCTGATA 540 TTAATTGTCA AGTTTTGGAC AGCTGTCAAA CAAATGCTTC TTTGGATATG TTACCTAGTC 600 AGATATTTGA TGTGGTCATG AGTGAAGAGA GCACAAGTAT TTACAATGCT GTGTACGCTG 660 TGGCTCACAG CCTCCATGAG ATGAGACTTC AGCAACTTCA AACACAACCG TGTGAAAATG 720 AAGAAGGGAT GGAGTTCTTT CCATGGCAGC TTAATACTTT CCTGAAGGAT ATTGAGGTGA 780 GAGTCAACAG TTTGGACTGG AGACAGAGAA TAGATGCTGA ATATGACATT CTTAACCTCT 840 GGAATTTACC AAAGGGTCTT GGACTAAAAG TGAAAATAGG AAACTTTTAT GCAAATGCTC 900 CCCAGGGTCA ACAATTGTCT TTATCTGAAC AGATGATTCA ATGGCCAGAA ATATTTTCAG 960 AAGTCCCTCA GTCTGTGTGC AGTGAGAGTT GTAGGCCTGG ATTCAGGAAA GTATCCCTGG 1020 ATGATAAGGC CATCTGCTGC TACAAGTGCA CTCCTTGTGC CGACAATGAG ATATCTAATG 1080 AGACAGATGT AGACCAGTGT GTGAAGTGTC CAGAGAGTCA TTATGCAAAT ACAGAGAAGA 1140 GCAACTGCTT CCCAAAATCT GTGAGCTTTC TGGCCTATGA AGACCCCTTG GGGATGGCTC 1200 TAGCCAGCAT AGCTTTGTGC TTATCTGCAC TCACTGTCTT TGTTATTGGC ATCTTTGTGA 1260 AAAACAGAGA CACTCCTATT GTCAAGGCCA ATAATCGGAC TCTAAGTTAC ATTTTGCTCA 1320 TCACACTCAC CTTTTGTTTC TTATGTTCTT TGAACTTCAT TGGTCAGCCC AACACAGCTG 1380 CCTGCATCCT TCAGCAGACC ACCTTTGCAG TTGCTTTCAC TATGGCTCTT GCCACTGTGT 1440 TGGCCAAAGC TATTACTGTA GTCCTTGCCT TTAAGATCAG TTTTCCAGGG AGAATGTTAA 1500 GGTGGCTAAT GATATCAAGG GGTCCAAGAT ACATCATTCC TATCTGCACA CTGATCCAGC 1560 TTCTTCTTTG TGGAATATGG ATGGCAACTT CTCCACCATT CATTGACCAA GATGTTAATA 1620 CTGAAGATGG ATACATCATC CTTTTGTGCA ACAAGGGCTC AGCTGTTGCC TTCCATTCAG 1680 TCCTGGGATA CCTCTGTTTC TTGGCCCTTG GGAGTTATAC CATGGCCTTC TTGTCTAGAA 1740 ATTTGCCTGA TACATTCAAT GAATCCAAAT TTCTGTCATT CAGTATGCTG GTGTTCTTCT 1800 GTGTCTGGGT CACCTTTCTT CCTGTCTACC ACAGCACTAA AGGGAAAGTT ATGGTCGTCG 1860 TCGAAGTCTT CTGCATCCAA GCCGAATTC 1889 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: ATGAAGAAGC TCTGTGCTTT CACGATTTCA TTGTTGTTTC TGAAGTTTTC TCTCATCTTG 60 TGCTGTTGGA GTGAACCAAG TTGCTTTTGG AGGATAAAGA ATAGTGATGA TAATGACGGA 120 GATTTGCAAA GGGAATGTCA TTTTTACCTT GGGGCAGCTG ATACACCAGT TGAAGATAAT 180 TTTTATAGTT CACTTTTAAA ATTTAGGTTT TCTTTGGACC ATTTAATCCT AACCTACGCG 240 ACCATGACCG GCTGCCCCAT GTCCATCAGG 270 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1308 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: ATGAAGAAGC TCTGTGCTTT CACGATTTCA TTGTTGTTTC TGAAGTTTTC TCTCATCTTG 60 TGCTGTTGGA GTGAACCAAG TTGCTTTTGG AGGATAAAGA ATAGTGATGA TAATGACGGA 120 GATTTGCAAA GGGAATGTCA TTTTTACCTT GGGGCAGCTG ATACACCAGT TGAAGATAAT 180 TTTTATAGTT CACTTTTAAA ATTTAGAATT GCAGCAAGTG AATATGAGTT TCTTCTCGTA 240 ATGTTTTTTG CTATCGATGA GATCAACAGG AATCCTTATC TTTTACCCAA CATAACTTTG 300 ATGTTCTCCT TCATTGGTGG AAACTGTCAG GATTTATTGA GAGTTATGGA CCAAGCATAT 360 ACACAAATAA ATGGACATAT GAATTTTGTT AATTATTTCT GTTATTTAGA TGATTCATGT 420 GCCATAGGTC TTACAGGACC ATCATGGAAA ACTTCCTTAA AACTGGCAAT GCACTCTTCG 480 ATGCCACTGG TTTTCTTTGG ACCATTTAAT CCTAACCTAC GCGACCATGA CCGGCTGCCC 540 CATGTCCATC AGGTAGCCCC CAAGGACACA CATTTGTCCC ATGGCATGGT CTCCTTGATG 600 TTTCACTTTA GATGGACTTG GATAGGAATG GTCATCTCAG ATGATGACCA GGGTATTCAG 660 TTTCTCTCAG ATTTAAGAGA AGAAAGCCAA AGGCATGGGA TCTGTTTAGC TTTTGTTAAT 720 ATGATCCCAG AAAACATGCA GATATACATG ACAAGGGCTA CAATATATGA TCAACAAATT 780 ATGACATCTT CAGCAAAGGT TGTTATCATT TATGGTGAAA TGAACTCTAC TCTAGAAGTA 840 AGCTTTAGAA GATGGGAAGA GTTAGGTGCT CGGAGAATCT GGATCACAAC CTCACAATGG 900 GATGTCATCA CAAATAAAAA AGACTTCACC CTTAATCTCT TCCATGGGAC TATCACTTTT 960 GCACACCACA GAGTTGAGAT TCCTAAATTA AATAAATTCA TGCAAACAAT GAACACTGCC 1020 AAATACCCAG TAGATATTTC TCATACTATA TTGGAGTGGA ATTATTTTAA TTGTTCAATA 1080 TCTAAGAACA GCATTAGAAT GCATCATATT ACATTCAACA ACACCTTGGA ATGGACATCA 1140 CTGCACAACT ATGATATGGC GATGAGTGAT GAAGGTTACA GTTTATATAA TGCTGTTTAT 1200 GCTGTGGCCC ACACCTACCA TGAATACATT TTTCAACAAG TAGAGTCTCA GAAAAAGGCA 1260 AAACCCAAAA GATATTTCAC TGCTTGTCAG CAGATATGGA ACAGTGTG 1308 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1296 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77: ATGAAGAAGC TCTGTGCTTT CACTATTTCA TTTTTGTCTC TGAAGTTTTC TCTCATCTTG 60 TGCTGTTTGA CTGAAGCAAG TTGCTTTTGG AGGATAAAGA ATAGTGAAGA TAGTGATGGA 120 GATTTGCAAA GAGAATGTCA TTTTTACCTT TGGGTAATTG ATAAACCTAT TGAAGATAAT 180 TTTTATAATT CAGTTTTAAA TTTTAGAATA TCAGCAAGTG AATATGAGTT TCTTCTGGTA 240 ATGTTTTTTG CTACTGATGA GATCAACAAG AATCCTTATC TTTTACCCAA CATAACTTTG 300 ATATTCAGCA TCGTTGGTGG TCACTGTCAT GATTTATTGA GAGGTCTGGA TCAATCATAT 360 ACACAAATAA ATGGACGTGT GAATTTTGTT AATTATTTCT GTTATTTAGA TGATTCATGT 420 AACATAGGCC TTACAGGACC ATCATGGAAA AAATCCTTAA AACTGGCAAT GGATTCTTCA 480 ATACCAATGG TTTTCTTTGG ACCATTTAAT CCTAACCTAC GCGACCATGA CCGGCTGCCC 540 CATGTCCATC AGGTAGCCCC CAAGGACACA CATTTATCCC ATGGCATGGT CTCCTTGATG 600 TTTCATTTTA GATGGACTTG GATAGGACTG GTCATCTCAG ATGATGACCA GGGTATTCAG 660 TTTCTCTCAG ATTTAAGAGA AGAAAGCCAA AGGCATGGGA TCTGTTTAGC TTTTGTTAAT 720 ATGATCCCAG AAAACATGCA GATATACATG ACAAGGGCTA CAATATATGA TAAACAAATT 780 ATGACATCTT CAGCAAAGGT TGTTATCATT TATGGTGAAA TGAACTCTAC TCTAGAAGTA 840 AGCTTCAGAA GATGGGAAGA TTTAGGTGCT CGGAGAATCT GGATCACAAC CTCACAATGG 900 GATATCATAT TAAATAAAAA AGAATTCACT CTTAATCTCT TCCATGGCCC TATCACTTTT 960 GCACACCACA AAGTTGAGAT TCCTAAATTA AGGAATTTTA TGCAAACAAT GAACACTGCC 1020 AAATACCCAG TAGATATTTC TCATACTATA CTGGAGTGGA ATTATTTTAA TTGTTCAATC 1080 TCTAAGAACA GCAGTAAAAT GGATCTTTTT ACATCCAACA ACACATTGGA ATGGACAGCA 1140 CTGCACAACT ATGATATGGC GATGAGTGAT GAAGGTTACA ATTTGTATAA TGCTGTTTAT 1200 GTTGCGGCCC ACACCTACCA TGAACACATT CTTCAACAAG TAGAGTCTCA GAAAAAGGTA 1260 GAACACAACA GATATTTCAC TGTTTGTCAG CAGATA 1296 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1521 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78: ATGAAGAAGC TCTGTGCTTT CACTATTTCA TTTTTGTCTC TGAAGTTTTC TCTCATCTTG 60 TGCTGTTTGA CTGAAGCAAG TTGCTTTTGG AGGATAAAGA ATAGTGAAGA TAGTGATGGA 120 GATTTGCAAA GAGAATGTCA TTTTTACCTT TGGGTAATTG ATAAACCTAT TGAAGATAAT 180 TTTTATAATT CAGTTTTAAA TTTTAGAATA TCAGCAAGTG AATATGAGTT TCTTCTGGTA 240 ATGTTTTTTG CTACTGATGA GATCAACAAG AATCCTTATC TTTTACCCAA CATAACTTTG 300 ATATTCAGCA TCGTTGGTGG TCACTGTCAT GATTTATTGA GAGGTCTGGA TCAATCATAT 360 ACACAAATAA ATGGACGTGT GAATTTTGTT AATTATTTCT GTTATTTAGA TGATTCATGT 420 AACATAGGCC TTACAGGACC ATCATGGAAA AAATCCTTAA AACTGGCAAT GGATTCTTCA 480 ATACCAATGG TTTTCTTTGG ACCATTTAAT CCTAACCTAC GCGACCATGA CCGGCTGCCC 540 CATGTCCATC AGGTAGCCCC CAAGGACACA CATTTATCCC ATGGCATGGT CTCCTTGATG 600 TTTCATTTTA GATGGACTTG GATAGGACTG GTCATCTCAG ATGATGACCA GGGTATTCAG 660 TTTCTCTCAG ATTTAAGAGA AGAAAGCCAA AGGCATGGGA TCTGTTTAGC TTTTGTTAAT 720 ATGATCCCAG AAAACATGCA GATATACATG ACAAGGGCTA CAATATATGA TAAACAAATT 780 ATGACATCTT CAGCAAAGGT TGTTATCATT TATGGTGAAA TGAACTCTAC TCTAGAAGTA 840 AGCTTCAGAA GATGGGAAGA TTTAGGTGCT CGGAGAATCT GGATCACAAC CTCACAATGG 900 GATATCATAT TAAATAAAAA AGAATTCACT CTTAATCTCT TCCATGGCCC TATCACTTTT 960 GCACACCACA AAGTTGAGAT TCCTAAATTA AGGAATTTTA TGCAAACAAT GAACACTGCC 1020 AAATACCCAG TAGATATTTC TCATACTATA CTGGAGTGGA ATTATTTTAA TTGTTCAATC 1080 TCTAAGAACA GCAGTAAAAT GGATCTTTTT ACATCCAACA ACACATTGGA ATGGACAGCA 1140 CTGCACAACT ATGATATGGC CATGAGTGAT GAAGGTTACA ATTTGTATAA TGCTGTTTAT 1200 GTTGCGGCCC ACACCTACCA TGAACACATT CTTCAACAAG TAGAGTCTCA GAAAAAGGTA 1260 GAACACAACA GATATTTCAC TGTTTGTCAG CAGGTATCTT CCTTGATGAA AACCAGGGTA 1320 TTTACGAACC CGGTTGGAGA ACTGGTGAAC ATGAAGCATA GGGAAAATCA GTGTACAGAG 1380 TATGATATTT TCATCATTTG GAATTTTCCA CAAGGCCTTG GATTAAAATT GAAAATAGGA 1440 AGCTATATAC CTTGTTTTCC AAAGAGTCAA CAACTTCATA TATCTGATGA TTTGGAATGG 1500 GCCATGGGAG GAACATCAAT A 1521 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 933 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79: ATGAAGCAGC TCTGCACTTT CACTATTTCA TTGTTGTTTC TGAAGTTTTC TCTCATCTTG 60 TGCTGTTGGA GTGAACCAAG CTGCTTTTGG AGGATAAAGA AGAGTGAAGA TAATGATGGA 120 GATTTACAAA GGGAGTGTCA TTTTTACCTT TGGAAAACTG ATGAACCTAT TGAAGATAGT 180 TTTTATAATT ATGATTTAAG TTTTAGAATT GCAGGAAGTG AATATGAGCT TCTTCTGGTA 240 ATGTTTTTTG CTACTGATGA GATCAACAAG AATCCTTATC TTTTACCCAA CATGAGTTTG 300 ATGTTCTCCA TCATTGGTGG AAACTGTCAT GATTTATTGA GAAGTCTGGA TCAAGAATAT 360 GCACAAATAG ATGGACATAT GAATTTTGTT AATTATTTCT GTTATTTAGA TGATTCATGT 420 GCCACAGGCC TTACAGGACC ATCATGGAAA ACATCCTTAA AACTGGCAAT GCATTCTTCA 480 ATGCCACTGG TTTTCTTTGG ACCATTTAAT CCTAACCTAC GCGACCATGA CCGGCTGCCC 540 CATGTCCATC AGGTAGCCCC CAAGGACACA CATTTGTCCC ATGGCATGGT CTCCTTGATG 600 TTTCATTTTA GGTGGACTTG GATAGGACTG GTCATCTCAG ATGATGATCA GGGTATTCAG 660 TTTCTCTCAG ATTTAAGAGA AGAAAGCCAA AGGCATGGGA TCTGTTTGGC TTTTGTTAAT 720 ATGATCCCAG AAAACATGCA GATATACATG ACAAGGGCTA CAATATATGA TACACAAATT 780 ATGACATCTT CAGCAAAGGT TGTTATCATT TATGGTGACA TGAACTCTAC TCTAGAAGCA 840 AGCTTTAGAA GATGGGAAGA GTTAGGTGCT CGGAGAATCT GGATCACAAC CACACAATGG 900 GATGTCATCA CAAATAAAAA AAGACTTCAC CCT 933 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: GCAAGTTGCT TTTGGCGGAT AAAGAATAGT GAAGATAATG ATGGAGATTT GCAAAGGGAA 60 TGTCATTTTT ACCTTGGGGC AGTTGATAAA CCAATTGAAG ATAATTTTTA TAATTCACTT 120 TTAAAGTTTA GAATTGCAGC AAGTGAATAT GAGTTTCTTC TGGTAATGTT TTTTGCTACT 180 GATGAGATCA ACAAGAATCC TTATCTTTTA CCCAACATAA CTTTGATGTT CTCCATCATT 240 GGTGGAAACT GTCATGATTT ATTGAGAGGT TTGGATCAAG CATATACACA AATAAATGGA 300 CATATGAATT TTGTTAATTA TTTCTGTTAT TTAGATGATT CATGTGCCAT AGGTCTTACA 360 GGACCATCAT GGAAAACATC CTTAAAACTG GCAATGCATT CTTCAATGCC ACTGGTTTTC 420 TTTGGATCAT TTAATCCTAA CCTACATGAC CATGACCGGC TGCACCATGT CCATCAAGTA 480 GCCACCAAGG ACACACATTT GTCCCATGGC ATTGTCTCCT TGATGTTTCA TTTTAGATGG 540 ACTTGGATAG GACTGGTCAT CTCAGATGAT GACAAGGGTA TTCAGTTTCT CTCAGATTTA 600 AGAGAAGAAA GCCAAAGGCA TGGGATCTGT TTAGCTTTTG TTAATATGAT CCCAGAAAAC 660 ATGCAGATAT ACATGACAAG GGCTACAATA TATGATAAAC AAATTATGAC GTCTTTAGCA 720 AAAGTTGTTA TCATTTATGG TGAAATGAAC TCTACACTAG AAGTAAGCTT TAGAAGATGG 780 GAAAATTTAG GTGCTCGGAG AATCTGGATC ACAACCTCAC AATGGGATGT CATCACAAAT 840 AAAAAAGAAT TCACCCTTAA TCTCTTCCAT GGGACTATTA CTTTTGCACA CCGCAGATTT 900 GAGATTCCTA AATTTAAAAA ATTTATGCAA ACAATGAACA CTGCCAAATA CCCAGTAGAT 960 ATTTCTCATA CTATATTGGA GTGGAATTAT TTTAATTGTT CAATCTCTAA GAACAGCAGT 1020 AAAATGGATC ATATTACATT CAACAACACA TTGGAATGGA CAGCACTGCA CAACTATGAT 1080 ATGGTGATGA GTGATGAAGG TTACAATTTG TATAATGCTG TTTATGCTGT GGCCCACACC 1140 TACCATGAAC ATATTTTTCA ACAAGTAGAG TCTCAGAAAA AGGCAAAACC CAAAAGATTT 1200 TTCACTGTTT GTCAGCAGCA GATATGGAAC AGTGTG 1236 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2412 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: ATGTTCATTT TCATGGAAGT CTTCTTCCTC CTTAATATTA CACTTCTCAT GGCCAATTTC 60 ATTGATCCCA GGTGCTTTTG GAGAATAAAT TTGGATGAAA TAATGGATGA ATATTTGGGA 120 TTATCTTGTG CTTTCATCCT GGCAGCAGTT CAGACACCCA TTGAAAATGA TTATTTCAAC 180 AAGACTCTTA ATGTTCTAAA AACAACTAAA AACCACAAAT ATGCTTTGGC ATTGGTGTTT 240 GCAATGGATG AAATCAACAG AAATCCTGAT CTTTTACCAA ATATGTCTTT GATTATAAGA 300 TACACTTTGG GCCGTTGTGA TGGAAAAACT GTAATACCTA CACCATATTT ATTTCGTAAA 360 AAAAAAGAAA GCCCTATCCC TAATTATTTC TGTAATGAAG AGACTATGTG TTCCTATCTG 420 CTTACAGGAC CCCATTGGGA GGTATCTTTA GGTTTCTGGA AGCACATGAA CAGCTTCTTA 480 TCTCCACGTA TCCTTCAGCT TACCTATGGA CCTTTCCACT CCATCTTCAG TGATGATGAA 540 CAATATCCCT ATCTCTATCA GATGGCCCCA AAGGACACAT CTCTAGCATT GGCAATGGTC 600 TCCTTCATAC TTTACTTTAG CTGGAACTGG ATTGGCCTTG TCATTCCAGA TGATGACCAA 660 GGAAACCAAT TTCTTTTAGA GTTGAAGAAA CAGAGTGAAA ACAAGGAAAT TTGCTTTGCC 720 TTTGTGAAAA TGATCTCTGT TGATGATGTT TCATTTCCAC AAAATACTGA AATGTACTAC 780 AACCAAATTG TGATGTCATC CACAAATGTT ATTATCATTT ATGGAGAAAC ATACAATTTC 840 ATTGATTTGA TCTTCAGAAT GTGGGAACCT CCCATTTTAC AGAGAATATG GATCACCACA 900 AAACAATTGA ATTTCCCTAC CAGGAAAAAA GACATAAGTC ATGGCACATT CTATGGATCA 960 CTTACTTTTC TACCCCACCA TGGTGTGATT TCTGGTTTTA AAAATTTTGT ACAGACATGG 1020 TTCCATCTCA GAAACACAGA TTTATATCTA GTAATGCAAG AGTGGAAATA CTTTAACTAT 1080 GAAGACTCAG CATCTACCTG TAAAATACTG AAGAACAATT CATCTAATGC CTCATTTGAT 1140 TGGCTAATGG AACAGAAGTT TGACATGACC TTTAGTGAGA ATAGTCATAA CATATACAAT 1200 GCTGTGCATG CCATAGCCCA TGCCCTCCAT GAGATGAATC TGCAACAGGC TGATAATCAG 1260 GCAATAGACA ATGGGAAAAA GGAGCCCAGT TCCTCCCACT GCTTGAAGGT AAACTCCTTT 1320 CTAAGAAGGA TTTACTTCAC TAATCCTCCT GGGGACAAAG TGTTTATGAA GCAAAGAGTA 1380 ATAATGCACG ATGAATATGA CATTGTTCAC TTTGTGAATC TCTCACAACA CCTTGGGATT 1440 AAGATGAAGT TAGGAAAGTT CAGCCCATAT TTACCACATG GTCGACACTC TCACTTATAT 1500 GTAGACAGGA TTGAGTTGGC CACAGGAAGA AGAAAGATGC CATCCTCTGT GTGCAGTGCT 1560 GATTGTAGTC CTGGATTCAG AAGATTATGG AAGGAGGGAA TGGCAGCCTG CTGTTTTGTT 1620 TGCAGCCCCT GCCCTGAAAA TGAAATTTCT AATGAGACAA CTGTGGTACT TTGTGTCTTT 1680 GTGAAGCATC ATGACACTCC TATTGTGAAG GCCAATAACA GAAGCCTCAG CTACCTATTA 1740 CTCATGTCAC TCATGTCCTG TTTTCTGTGC TCCTTTTTCT TCATTGGCCT TCCAAACAGA 1800 GCCATCTGTG TCTTACAGCA AATCACATTT GGAATTGTAT TCACTATGGC TGTTTCCACA 1860 GTTCTGGCCA AAACAGTCAC TGTGGTTCTG GCTTTCAAAG TCACAGACCC AGGAAGAAGA 1920 TTGAGAAACT TCCTGGTATC AGGAACACCC AACTACATTA TTCCCATATG TTCCCTACTC 1980 CAATGTGTTC TGTGTGCAAT CTGGCTAGCA GTTTCTCCTC CCTTTGTTGA TATTGATGAA 2040 CACACTCTCC ATGGCCACAT CATCATTGTG TGCAACAAGG GCTCAGTTAC TGCATTCTAC 2100 TGTATCCTAG GATACTTGGC CTGCCTGGCA CTTGGAAACT TCTCTGTGGC TTTCTTGGCC 2160 AAGAATCTGC CTGACACATT CAATGAAGCC AAGTTCTTGA CCTTCAGCAT GCTAGTGTTC 2220 TGTAGTGTCT GGGTCACCTT CCTCCCTGTC TACCATAGCA CCAAGGGCAA ACACATGGTT 2280 GCTGTGGAGA TCTTCTCCAT CTTGGCATCC AGTGCTGGGA TCCTTGGATG TATATTTGTA 2340 CCCAAGATTT ATATCATTTT AATGAGACCA GAGAGAAATT CGACCCAAAA GATCAGGGAA 2400 AAATCATATT TC 2412 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82: ATGTTCATTT TCATGGGAGT CTTCTTCCTC CTTAATATTA CACTTCTCAT GGCCAATTTC 60 ATTAATCCCA GGTGCTTTTG GAGAATAAAT TTGGATGAAA TAACGGATGA ATATTTGGGA 120 TTATCTTGTA CTTTCATCCT GGCGGCAGTT CAGACACCCA CTGAAAAAGA TTATTTCAAC 180 AAGACTCTTA ATGTTCTAAA AACAACTAAA AACCACAAAT ATGCTTTGGC ATTGGTGTTT 240 GCAATGGATG AAATCAACAG AAATCCTGAT CTTTTACCAA ATATGTCTTT GATTATAAGA 300 TACACTTTGG GCCTTTGTGA TGGAAAAACT GTAACACCTA CACCATATTT ATTTCATAAA 360 AAAAAAACAA AGCCCTATCC C 381 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 228 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83: ATGAAAAACC TGTGTGTTTT CACTCTTTCC TTTTTCCTCC TGGAGTTTTC TCTGATCTTG 60 TGCCATTTGA CTGAACCCAT TTGCTTTTGG AGGATAAATA ATAATGAAGA TAATGATGGA 120 GATTTGAGAA GTGACTGTGG TTTTTTCCTT GCAGCAGTTG AGGGACCTAC TGACGACTCT 180 TATAATATCT CTGATCTTAG GTTTTCTTTG GACCATTTAA TCCTAAGC 228 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1644 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84: ATGTTAGAAT TGGCCCATGG CACTCTGACT TTCTCACCCC ATCATGGGGA GATTTCTGAT 60 TTCACAAATT TTATGCAGGA AGTCACCCCT ATCAAGTACC CAGAAGACAT TTTTCTTCAC 120 ATCTTGTGGA ACCAGTATTT CAATTGTCCA CTTTTGCATT CTGAGTGTAA AATCTTTGAA 180 AACTGTATAC CCAATGCCTC TTTGGAATTG TTGCCAGGGG GTGTTTTTGA GCTGGTCATG 240 ACTGAAGAGA GTTACAATGT GTACAATGCT GTGTATGCAG TGGCCCACAG TCTCCATGAG 300 AAGGCTCTCC ATCAAGTAGA AATTCAACCA CAGGATAATA AAGATAGGAC TATATTATTT 360 CCTTGGCAGC TTCACCCTTT TCTGAAGAAC ATTCAGCTGA TAAATTCTGT TGGTGATCGT 420 GTGATTCTGG ACTGGAAAAA GAAGACGGAT ACAGAGTATG ATATTTCCAA TATTTGGAAT 480 TTCCCAACAG GTCTTTCCTT ATTAGTGAAA GTGGGTACAT TTGCTCCAAG TGCTCCCAAG 540 GGGGAACAAC TTTCGATATC TGAACACACA ATTAACTGGC CCATAGGATT TACAGAGATT 600 CCAAAGTCTG TATGCAGTGA GAGCTGCAGT CCTGGACACA GGAAAGTCAT CCTGGAGAGC 660 AAGCCTGCCT GTTGCTTTGA CTGCACTCCT TGCCCAGATA AAGAGATTTC CAACGAGACA 720 GATGTGGGTC AGTGTGTGAA GTGTCCTGAA TCTCATTATG CAAATACAGA GAAGAGTCAC 780 TGCCTGAAGA AGACTATGAC CTTTCTGGAT TATAATGATT CCTTGGGGAC GGGACTCACA 840 CTCATGTCTC TGGGATTCTT TGTTGTCACA GGTCTTGTTA TTGGGGTTTT TATAATCCAC 900 AGAAACACTC CAATTGTGAA GGCCAATAAT AGATCTCTCA GTTATATCCT GCTCATCACT 960 CTCACTCTCT GTTTCCTTTG TCCCTTGCTC TTCATTGGGC TTCCAAACAC AGCCACATGT 1020 ATCCTACAGC AGAACTTGTT TGGACTTCTC TTCACTGTGG CTCTATCCAC AGTGTTGGCC 1080 AAAACTATCA CTGTAGTTAT GGCATTCAAG ATTACTGCTC CAGGAAGAAA GACAAGATGG 1140 TTGCTGATAT TAAGAGCCCC TCAGTTCATC ATTCCACTTT GTGCCCTGAT GCAAATCCTT 1200 TTCTCTGGGA TATGGCTGGG AACATCTCCT CCATTTGTTG ACATGGATGC TCACTCTGAA 1260 CATGGGCACA TCATCATTCT ATGCAACAAG GGCTCAGCTA TTGGCTTCTA CTGTACTCTG 1320 GCCTACCTGG GAGTCATGGC CTTTGGTAGT TACCTCTTGG CTTTCATGTC CAGGAATCTT 1380 CCTGACACAT TTAATGAATC CAAGGCCCTG GCTTTCAGCA TGCTGATGTT CTGCAGTGTC 1440 TGGGTCACAT TCCTCCCTGT CTACCACAGC ACCACTGGGA AGGTCAGGGT GGCTATGGAA 1500 ATGTTTTCTA TCTTGGCTTC CAGTGCAAGC ATTCTAACCC TAATCTTTGT CCCTAAGTGC 1560 TACATTGTTT TGTTCAGACC AGAGAGGAAC ATACTTCCTC TAAACAGAGA AAAAAGACAG 1620 CATAGGAGTA AAAATTCTGA AACA 1644 (2) INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2304 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85: ATGGAGGAAA TCAACAGGAA CCCTGATCTT TTACCAAATA TGTCTTTGGT TATAAAACAT 60 ACTTTGAGCT ATTGTGATGG AAATACTGCA GACCATATAT TTAAAGAAAA ATTTTATAAG 120 CCTTTACCTA ATTATGTCTG TAATGAAGAG ACTATGTGTT CATTTATGCT TATAGGGCTG 180 AATTGGGTAT TGTCTCTAAC ACTTTTTAAA GACTTGGACA TCTTCTCATT TCCACGTTTC 240 CTTCAAATTT CCTATGGACC TTTCCATTCC ATCTTCAGTG ATAATGAACA ATTTCCATAT 300 CTCTATCAGA TGACCCCAAA GGACACATCA CTAGCATTGG CAATTGTCTC CTTCTTACTT 360 TACTTCAATT GGAACTGGGT TGGGCTTGTC ATCTCTGATA ATGATGAAGG CAATCAATTT 420 CTCTCAGAGT TGAAAAAAGA GACCCAAAAC AAGGAAATTT GCTTTGCCTT TGTTAACATG 480 ATGTCAATCC ATGAGCATTC ATCTTATCAA AAAACTGAAA TGTACTACAA TCAAATAGTG 540 ATGTCATCAA CAAATATTAT TATCATTTAT GGGAAAACAA ACAGTATCAT TGAATTGAGC 600 TTCAGAATGT GGGTATCTCC AGTTATACAG AGGATTTGGG TCACAAACTC AGAGTTGGAT 660 TTCCCGACAA GTATGAGAGA CTTCACTCAT GGCACATTCT ATGGGACTCT GACATTTCTA 720 CACCACCATG GTGAGATTTC TGGATTTACA AATTTTTTCG AGACATGGGA CCATCTCAGA 780 AGCAGAGATT TAAATCTATT AATACCAGAG TGGAAGTACT TTAGCTATGA TGCCTCAGGA 840 TCTAACTGTA AAATATTGAG GAACTATTCA TCCAATGCCT CATTGGAATG GATAACAGAA 900 CAGAAGTTTC ACATGGCCTT TAATGATTAT AGTCATAGTA TATATAATGC TGTGTATGCC 960 ATGGCCCATG CCCTCCATGA GACTAATCTG CAAGAGGTTG ATAATAAGGA AATAAGAAAT 1020 GGGAAAGGAG CAAGTACTCA CTGCTTGAAG GTAAACTCAT TTCTCAGAAA GACCCACTTT 1080 ACTAATTCTC ATGGAGAGAG AGTGATTATG AAACAGAGAG TGAGAGTACA GGAAGACTAT 1140 GACATTGTTC ACATTCAGAA TTTCTCACAA CACCTTCGGA TTAAGATGAA GATAGGAAAG 1200 TTCAGCCCAT ATTTTACACA TGGTGGACCC TTTCACTTAT ATGAAGACAT GATTCAGTTG 1260 GCCACAGGAA GTAGAAAGAT GCCGTCCTCT GTGTGCAGTG CAGATTGTAG TCCTGGATTC 1320 AGAAAATCCT GGAAGGAGGG AATGGCCCCC TGCTGTTTTA TTTGCAGCCT GTGCCCTGAA 1380 AATGAAATTT CTAATGAGAC AAATATGGAT CAATGTGTGA ATTGTCCAGA ATACCAATAT 1440 GCCAACACAG AAAAGAACAA ATGCATTCAG AAAGACGTGA TTTTTCTAAG CTATGAAGAC 1500 CCCTTGGGAA TGGCTCTTGC CTTAATTGCC TTCTGTTTGT CTGCATTCAC AGCTGTGGTA 1560 CTTTGGGTCT TTGTGAAGCA CCATGACACT CCTATTGTGA AGGCCAATAA CAGAATCCTC 1620 AGCTACATAT TAATCATGTC ACTAATGTTC TGTTTTCTCT GCTCCTTTTT CTTCATTGGC 1680 CATCCTAACA GAGGTACCTG TATCTTACAG CAAATCACAT TTGGCATTGT ATTCACTGTG 1740 GCTGTTTCCA CAGTTCTGGC CAAAACAATC ACTGTCATTC TTGCTTTCAA ACTCAGAGAC 1800 CCAGGGAGAA GTTTAAGAAA CTTCCTGGTA TCTGGTGCAC CCAACTACAT TATTCCTATA 1860 TGTTCCTTAT TGCAATGTAT TCTGTGTGCA ATTTGGCTAG CAGTTTCTCC TCCTTTTGTT 1920 GATATTGATG AACATTCTGA GCATGGCCAC ATCATGATTG TGTGCAACAA GGGCTCCATT 1980 ATGGCATTCT ACTGTGTCCT AGGATACTTG GCCTGCCTGG CGCTTGGAAG CTTCACTACA 2040 GCTTTCTTGG CAAAGAATCT GCCAGACACA TTCAACGAAG CCAAGTTCTT GACCTTCAGC 2100 ATGCTAGTGT TCTGCAGTGT CTGGGTCACC TTTCTCCCTG TGTACCATAG CACAAGGGGC 2160 AGGGTCATGG TTGCTGTTGA GATCTTCTCT ATCTTGGCAT CCAGTGCAGG GATGTTTGGA 2220 TGCATCTTTG CACCCAAAAT CTACATCATA TTAATGAAAC CAGAAAGAAA TTCTATACAA 2280 AAGTTCAGGG AGAAATCATA TTTC 2304 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2001 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: ATGGCTCCTA AGGACACATC TCTGGCACTG GCCATGGTTT CTTTGTTTGT CCATTTCAGC 60 TGGAACTGGG TAGGAGCTGT TGTTTCAGAT GATGACCCAG GTTATGAATT TATCTTGGAA 120 TTGAGAAGAG AAATGCAAAG GAACAATTTT TGTTTAGCAT TTGTGAGTAT CATTGTTAGT 180 GATGACAATT TATTTCTGAA AAGGTATAAT ATCTATTACA ACCAGATCAA GATGTCATCA 240 GCAAAAGTTG TTATCATTTA TGGAGACAAA GACTCTCCTC TACAGGTGAA CTTTAGACTA 300 TGGAATTTAT TTGATATCCA AAGAATCTGG GTCACTACTT CACAGTGGGA TATGATCATA 360 AATAATGGAA AATTCCTCCT TAATTCCTTC TATGGGACTC TCAGTTTTTC ACATCACTAT 420 TCTGAATTAT CTGGTTTTAA AACATTTATC CAGACAGCAT ACCCTTCAAA CTACAGTGAT 480 GACTTTTCTC TTGGTATATT ATGGTGGGTG TATTTTAATT GTTCTTTGTC ATTATCTGAA 540 TGTAAGAATC TGCAAAATTG TCCAAAGGAA AACATATTTA GATGGTTATA CAGGCACCAT 600 TTTGAAATGT CTTTGAGTGA TACTACTTAT GACCTATATA ATTCTATGTA TGCTGTGGCT 660 TACACACTCC AACAGATGCT TCTGAAACAA GCAGATACAT GGCAAATAGA TGATGGAAAA 720 GAACCAGAAT TTGACTCTTG GCAGATGCTC TCTTTCCTGA GAAATATCCA ATTTATAAAC 780 CCTGTTGGTG ACAAAGTGAA CCTGAATCAT GAAGAAAAAC TGGATACAAA GTATGAGATT 840 CACCAGACTT TGACTTTTTT GCCAAATCCT GTATTTAAGC TGAAAATAGG AACATTTTCC 900 CAAAACTTAT CACATGGTCG ACAATTATAT ATGTTGAAAG AAATGATAGA GTGGAACACA 960 GGCCACCAAC AGTCTCCAAC CTCAGTTTGC AGTATTCCTT GTAGTCCAGG ATTCAGAAAA 1020 TCCCCTCAGC TGGGAAAGCC TGTTTGCTGT TTTGATTGTA CACCCTGCCC AGAAAATGAA 1080 ATTTCCAACA TGACAAACAT GAATCAATGT ATCAAGTGTC TAAATGATCA GTATGCCAAT 1140 CCTGGAGGAA CTCGCTGCCT CAAAAAAGTT ATTGTATTCC TGGGTTATGA AGATCCATTG 1200 GGAATGTCTC TGGCTATCTT GGCTCTGTGC TTCTCTGCTC TCACAGCTTT TGTACTTAGT 1260 ATCTTTTTGA AGCACCAAGA AACACCCACT GTCAAGGCCA ATAATAGAAC TCTCAGCTAT 1320 GTTCTACTCA TCTCCCTCAT CTCTTGTTTT CTCTGCTCCT TGCTCTTCAT TGGTCATCCC 1380 AGCTTTACCA CATGTATCAT GCAGCAGACC ACATTTGCTG TTGTGTTCAC TGTAGCTGCA 1440 TCTACTGTCT TGGCCAAAAC AATTATTGTA ATATTGGCCT TCAAGGTTAC TAATACAAGT 1500 AGAAAAATGA GGTGGCTGCT GGTATCAGGG GCACCTAAAT TCATCATTCC AATTTGCACA 1560 ATGATTCAAC TGATTCTCTG TGGAATTTGG CTGGGTACTT CTCCTCCATT TGTTGATGCT 1620 GATGGACATG TTGAAAAAGG CCACATTTTG ATTTTCTGTA ACAAAGGTTC AATTCTTGCT 1680 TTCTATTGTG TCCTGGGATA CTTAGTCTCC ATTGCCATTG CAAGTTTCAC CCTTGCATTC 1740 TTCGCCAGAA ATCTGCCCGA CACATTCAAT GAAGCCAAGT TCCTAACATT CAGTATGCTA 1800 GTATTTTGCA GTGTCTGGGT CACCTTTCTT CCTGTCTATC ATAGCACCAA GGGCAAGTCT 1860 ATGGTGGCTG TGGAAGTTTT CTGTATATTG GCCTCTAGTG CAGGGCTGCT TTTTTGCATC 1920 TTTGCACCAA AGTGCTTCAT TATTTTGTTA AGACCTGAGA AAAAATCTTT TCAGAAGTTT 1980 CAGAATATAC ATTCTAAAAT T 2001 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2598 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: ATGTCCAGGC TCAGAGCAGG AAAAAATATG CTCACCTTCA TTTTACTCTT CTTTCTCCTG 60 AACATTCCAC TTTTTGTGCC TAGTTTTATT TATCCCAGGT GCTTTTGGAG TATGAAGAAG 120 AATGAATATC AGGATAGAAA CCTGGGAACA GGTTGTATGT TCTTTATTCT AGCAGTGCAA 180 CAGCCTATGG AAAAAGAGTA TTTCAGTCAT ATTTCGAATA TACAAACACC TACTGAAAAC 240 CAAAAGTATC CTCTCACCTT GGCTTTTTCC ATGAATGAAA TCAACAACAA CCCTGATCTT 300 TTGCCAAATA TGTCTTTAGC ATTTACATTC TCAGAATATA GTTGTTATTT GGAATCCCAC 360 CACAAAAGAT TATTTAATTT TTCTTTAAAA AATCATGAAA TTCTCCCTAA TTTTATCTGT 420 ACAAAAGACA TCAAGTGTGG AGTGGTACTT ACCGGACTTA GTTTGGTAAC AACTGTGACA 480 CTTCATATAA TCCTAAACAA TTTCATATTT CAGCAGTTCC GTCAGCTTAC TTATGGACAC 540 TTTCATCCTG CTCTGTGTGA TCATGAAAAT TTTCCTCATC TATATCAGAT GGCCTCTGAT 600 GATACATCTC TAGCCCTTGC TCTCGTCTCC TTCATAATTC ATTTCAGTTG GAACTGGATA 660 GGGTTGGCCA TCTCAGACAA TGATCAAGGC ATACATTTTC TCTCTTATTT GAGAAGAGAG 720 ATGGAAAAAA ATACAGTCTG CTTTGCCTTT GTCAACATTA TTCCAGTCAA TATGAATTTA 780 TACATGTCAA GAGCTGAAGT GTATTACAGC CAAGTTATGA CATCATCCGC AAATGTTGTT 840 ATCATTTATG GTGATACAGG GAATACGTTA GCTGTGAGCT TTAGAATGTG GGACTCTCTA 900 GGTATACAGA GACTATGGGT CACCACCTCA CAGTGGGATG TCACTCCTTT TAAGAAAGAC 960 TTCACATTTG ATAATGGATA TGGAACTTTT GGTTTTGGAC ACCGCCACAG TGAGATTTCT 1020 GGTTTTAAAT ATTTTGTTCA GACATTGAAC CCTTTCAAAT ACTCAGATGA ATATTTGGTA 1080 AAGCTGGAAT GGATGTATGT TAATTGTAAA ATCTTAGAAT ATAACTGTAA GTCACTGAAG 1140 AACTGCTCCT TTAATCACTC ATTGGAATGG CTAATGACAC ATACTTTTGA CATGGCCATT 1200 ATTGAAGGGA GTTATGAAAT ATACAATGCT GTGTATGCTT TTGCCCATGC ACTCCATGAG 1260 ATGACTCTTC AAAATGTTGA TAATGTTCTC CTTCCCAATT ATGAAGAACA AAATTATAAT 1320 TGCAAGATGG TTTATTCCTT TCTGAGCAAG ACTCAATTCA CAAATCCTGT TGGAGACACT 1380 GTGAATATGA ATCAAAGAAA CAAACTGAAG GAAGAGTACG ACATTTTCTA CAATTGGAAT 1440 TTTCCACAGG GACTTGGATT TAAAGTGAAA ATAGGAATAT TTAGTCCATA TTTTCCAAAA 1500 GGTCAACAGC TTCATTTATC TGAAAATCTG ATAGAGTGGT CCACAGGACG TATACAGATG 1560 CCAACCTCTG TGTGCAGTGC CGATTGTGGT CCTGGATTTA GGAAAGTCTG GAAGAATGGA 1620 ATGCCAGCCT GTTGTTTTGA CTGCAGTCCC TGCCCAGAAA ATGAAATTTC TAATGAGACA 1680 AATGTGGAAT TGTGTGTCCA GTGTCCAGAG GACCAATATG CTAACCAAGA GCAGAATCAC 1740 TGCATTCACA AAGCTCGTAT CTTTCTCTCT TATGATGAAC CCTTGGGGAT GGCTCTTTCC 1800 TTAATGGCCT TATGCCTCGC TGCACTCACA GTTGTGGTTC TTGGAGTCTT TGTGAAACAT 1860 CACAGAACTC CCATAGTTAA GGCCAATAAC TGCACTCTCA CCTACATCTT GCTCATCGCA 1920 CTCATCTTTT GTTTCCTCTG CCCCTTGTTC TTCATTGGCC ATCCAAACTC AGCTACCTGC 1980 ATCCTTCAGC AAATCACATT TGGAGTTGTG TTCACTGTGG CTATTTCCAC TGTGTTGGCC 2040 AAAACAACCA CTGTCATTCT GGCTTTCAGA GTCACAGCCC CTCATAGAAT GATGAAGTAC 2100 TTTCTTGTTT CAAGGGCATC TAACTACATC ATTCCCATTT GTACTCTCAT TCAAATTATT 2160 GTATGTGCCA TCTGGCTAGG AGCTTCTCCT CCTTCTGTTG ATATTGATGC ACAGTCTGAG 2220 CATGGTCACA TCATCATTGC TTGCAACAAG GGTTCAGTCA CTGCTTTTTA CTGTGTCCTG 2280 GGATATCTGG CCTGCCTGGC CTTTGTGAGC TTCACCCTGG CTTTCCTTTC CAGAAACCTG 2340 CCTGTCACCT TCAATGAAGC CAAGTCCATG ACATTCAGCA TGCTGGTGTT CTGCAGTGTC 2400 TGGGTCACTT TCCTACCTGT TTACCATGGC ACCAAAGGCA AGGTTATGGT GGCTGTTGAG 2460 ATCTTTTCCA CCTTGGCTTC TAGTGCAGGA ATGTTGGGAT GCATTTTTGC TCCAAAATGC 2520 TACACAATAC TGTTTAGACC AGACAGAAAT TCTCTTCAAA TGATCAGGGA GAAGTCATCT 2580 TCTCATACTC ACATTTTA 2598 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88: ATGAGGTTTG CCATTGAGGA AATCAACAGC AATCCCCATC TTTTACCAAA CACATCCCTG 60 GGATTTGAGA TCAATAATGT CCCACACGGT CAGAGGTACA CTCTGGTCAA ACTTTTTAGC 120 TCACTTTCAG GGTCTAATTA TGACATTCCT AACTACATAA GTGCAAGTGA GAGCAATTCT 180 GCTGCTGTAC TTACAGGACC ATCGTGGACA ATATCTGAAT GCGTAGGGAC ACTCCTGGAT 240 CTTTACAAAT TTCCACAGCT TACTTTTGGG CCTTTTGATA GTCTCCTGAG TGAACAAAGA 300 CGGTTTTCTT CTCTGTACCA AGTGGCCCCC AAAGATACAT TTCTGACGCC TGGCATTGTA 360 TCTTTGATGC TTCATTTCCA CTGGAACTGG GTGGGGTTAT TCATCATAGA TGATGACAAA 420 GGTGCCCAGA CACTGTCAGA CTTGAGAAAT GAGATGGATA AAAATGGAGT CTGCACAGCA 480 TTTGTAGAAA TGATCCCAGT CATCAAGGGT TCATTTTTTA CCAAATCCTG GAAAAATCAT 540 GTGCAGATCC TGGAATCATC ATCAAATGTG ATTATTATTT ATGGGGACTC TGATTCTCTA 600 TTAAGCTTAA TAGTAAATAT TAAGCAGAAG TTGCTCACAT GGAAAGTGTG GGTACTGATC 660 TCACAGTGGG ATGTTTCTAA ATTTGATGAT TATTTCATGG TAGACTCATT GCATGGAGCT 720 CTTATTTTTT CACACCATCG TGAGGAGATT CCTAATTTTA CAGATTTTAT GCAGAAGTAC 780 AACCCTTCCA AGTACCCGGA AGACACTTAT CTTCATGTAT TGTGGCACAT GTACTTCAAT 840 TGCTCATTTG TTAAGAAAGA TTGTAAAATT GTGCACAACT GTTTGCCTAA TGCCTCCCTG 900 GGGTTCTTGC CTGGGAACAT ATTTGACATG GCCATGAGTG AAGAGAGTTA CAATGTATAC 960 AATGCTGTGT ATGCTGTGGC CCACAGTCTG CATGAGATGA TTCTCAACCA AGTACAATTT 1020 CAAACTCATG AAAAAGGAAA AAAGATGGTA TTCTTTCCTT GGCAGCTTCA CCCCTTTCTA 1080 AGGGAAAGAC AACTCATCAA TCAGAATGGA GCGAATGAAG ATCTGGATTG TACCAGGAAG 1140 TCACATGTAG AGTATGACAT TCTCAACTTT TGGAATTTCC CAAAAGGTCT TGGGCTAAAT 1200 GTGAAAGTAG GAACGTTTTC TCCAAGTGCT CCAAAGGAAC AGAAACTGTC CATATCTTCT 1260 AACATGATAC AGTGGGCCAC AGGGTCGACA GAGATTCCAC AGTCTGTATG CAGTGAGAGC 1320 TGTCATCCTG GATTCAGGAA AACCCACCAG GAAGGCAGGG TTGCCTGTTG CTTTGACTGC 1380 ATTCCTTGTC CAGAAAATGA GATCTCCAAT GAGACAGATG TGGATCAGTG TGTGAAGTGT 1440 CCAGAAACTC ACTATGCAAA CATAGAGAAG ATCCACTGCC TACAGAAAAC TGTGACATTT 1500 CTGTACTATG ATGACCCATT GGGGAAGACA CTTTGCTTCA TGTCCCTGGG TTTCTCCTCA 1560 CTCACAGCTG CTGTTCTTGT GGTGTTTCTG AAGAACAGGG ACACCCCCAT TGTCAAGGCC 1620 AATAACCTGG CTCTCAGTTA CACCCTGCTC ATCACTTTGA TGCTCTGTTT TCTCTGTCCC 1680 TTGCTCTTCA TTGGCCGTCC CAGCACAGCC TCCTGTATCC TGCAGCAAAA CATTTTTGGG 1740 CTTCTGTTCA CTGTGGCTCT TTCCACTGTG TTGGCCAAAA CTATCACTGT GGTTATAGCC 1800 TTCAAGATCA CTTCTCCAGG AAGAATTAGA AGATGGCTGC TGATATCAAG GGCCCCTAAT 1860 TTCATTATTC CCTTATGCAC CCTGCTCCAA GTTTTTCTAT CTGGAATTTG GCTGACAACC 1920 TCTCCTCCAT TTATTGATAA AGATGCTCAC TCAGAACATG GACACATCAT CATCATTTGC 1980 AATAAAGGCT CAGCTGTTGC TTTCCATTGC AACCTTGGAT ACCTGGGAGC ACTAGCCCTA 2040 GTGAGCTACT TTATGGCTTT CTTGTCCAGA AACCTACCTG ACACATTCAA TGAAGCCAAG 2100 TTCCTGGCTT TCAGCATGCT GGTGTTCTGC AGTGTCTGGG TCACCTTCCT CCCTGTCTAC 2160 CACAGCACCA AGGGGAAGAA CATGGTGGCT ATGGAAGTCT TCTCTATCTT GGCTTCCAGT 2220 ACATCTCTCC TAGGCATCAT CTTTGCCCCC AAGTGCTACC TCATATTATT AAGACCAGAA 2280 AGGAATTCAC TTAGCTATAT CAGGGACAAA ACATATGCTA AAAGCATAAA ACCTTCT 2337 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: ATGAAGTTAA GGGATAAAGA CTTGAGCATA ACTTGTTCCT TCATCCTTGA AGCAGTTCAG 60 ATGCCTACGG AAAACGATTA TTTCAACCAG ACTCTGAATA TCCTAAAAAC AACAAAAAAC 120 CACAAATATG CTTTGGCATT GGCCTTTTCA ATTGATGAAA TCAACAGGAA TCCTGATCTT 180 TTACCAAATA TGTCTTTGAT CATAAAATAC CCTTTGGGCC TTTGCGATGG ACAAACTACA 240 TTACCTACAC CCTATTTATT TAATGAAATA TATTTTAGGC CTATCCCTAA TTATTTCTGT 300 AATGAAGAGA CTATGTGTAC ATTTCTACTT ACAGGACCGC ATTGGATAAC ATCTTATAGT 360 TTCTGGATAC ACTTGAACAT CTTCTTATCT CCTAGTATGA ACCCAAAGGA CACATCCCTA 420 GCTTTGGCAA TGGTCTCCTT CTTACTTTAT TTCAAGTGGA ACTGGGTCGG CCTTGTCATC 480 TCAGATGATG ATCAAGGCAA TCAATTTCTC TCTGAGTTGA AAAAAGAGAG CAAAATCAAG 540 GAAATTTGCT TTGCATTTGT GAGCATGCTG GCAATCGATG AGATTTCATT TTATCATAAA 600 ACTGAAATGT ACTACAACCA AATTGTGATG TCATCCACAA ACGTTATTAT CATTTATGGG 660 AAAACAGAGA GTATTATTGA GTTGAGCTTC AGAATGTGGG AATCTCCAGT TATCCAGAGA 720 ATATGGGTCA CCACAAAAGA AATGAATTTC CCTACCAGTA AGAGAGATTT AACTCATGAC 780 ACATTCTATG GGACTCTTAC TTTTCTACAC AGCCATGGGG AGATTTCAGG CTTTAAAAAT 840 TTTGTACAGA CATGGTACCA TCTTAGAATC ACTGATTTGC ATCTAGTAAT GCCAGAGTGG 900 AAATATTTTA ACTATGAAGC CTCAGCATCT AACTGTAAAA TATTGAAGAA CTATTCATCC 960 AGTGCCTCAT TGGAATGGTT AATGGAGCAG ACATTTGACA TGGTCTTTAG TGATGGAAGT 1020 CGGGATATAT ATAATGCTGT AAATGCCATG GCCCATGCAC TCCATGAGAT GAATCTGCAC 1080 CTGGTTGATA ATCAGGCAAT AGACAATGGG AAAGGAGCCA GTTCTCACTG CTTTAAGATA 1140 AACTCCTTTC TCAGAAAGAC CCACTTCACT AATCCTCTTG GGGACAGAGT GATTATGAAA 1200 GAGAGAGAAA TACTGCAAGA AGACTATAAC ATTTTTCACA CTTGGAATTT TTCTCAGCAC 1260 ATTGGTTTTA AGGTGAAGAT AGGAAAGTTC AGCCCATATT TTCCACATGG CAGGCACTTT 1320 CACCTATATG TAGACATGAT TGAGTTGGCT ACAGGAAGTA GAAAGATGCC ATCCTCTGTG 1380 TGCACTGAAG ATTGTAGTCC TGGATACAGA AGATTCTGGA AGGAGGGAAT GGCAGCCTGC 1440 TGTTTTGTTT GCAGTCCCTG CCCTGAAAAT GCAATTTCTA ATGAGACAAA TATGGATCAG 1500 TGTGTGAATT GTCCAGAATA CCAATATGCC AATACAAAGC GGGACAAATG CATTCAGAAA 1560 AATGTGATGT TTCTAAGCTA CAAAGACCCC CTTGGGGATG ACTCTTGCCT TCATAGCCTT 1620 CTTTTTCTCT GCATTAACAG CTGTTGTACT 1650 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2379 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: ATGATAGTAT TCTTTCTCCT CAACATTCCA CTTCTCATGG CAAATTCCGT TGATCCCAGG 60 TGCTTTTGGA AAATAAATTT GAATGAAGTC AAGGATATAG ATTTAGATAC AAGTTGTTAC 120 TTCATCCTTG AGGCAGTTCA GTTGCCTATG GAGAAAGATT ATTTCAACCA GACTCTGAAT 180 GTCCTAAAAA CAACCAAATA CAACAGATAT GCATTGGCAT TAGCCTTTAC AATGGATGAA 240 ATAAACAGGA ATCCTCATAT TTTACCAAAC ATGTCTTTGA TTATAAAACA TACATTGGGC 300 CACTGTGATG GAAATATCCC ACTCCGCTTA CTTAATCAAA TATTTTATAT GCCTTTTCCT 360 AATTATGGCT GTAATGAAGA GACTATGTGT TCATTTATGC TTATGGGACC GAATTTGTGG 420 CCATCTGTAG ATTTTTTCAT TCACTTGAAC ATCTTATTTC CTCATTTCCT TCAGATTTCC 480 TTCGGACCTT TCCATTCCAT TTTCAGTGAT AATGAACAAT TTCCTTATAT CTATCAGATG 540 ACCCCAAAGG ATACATCACT AGCATTGGCA ATGGTCTCTT TCATACTTTA CTTCAACTGG 600 AACTGGGTTG GTCTTGTCCT CTCAGATAAT GATGAAGGCA ATCAATTTCT CACAGAGTTG 660 AAAAAAGAGA CCCACAACAC GGAAATATGC TTTGCCTTTG TGAACATGAT GGCAATCAAT 720 GAGAATTCAT CCATGAAAAA AACTGACATG TACTACAACC AAATTGTGAT GTCAACCGCA 780 AATGTTATTA TCATTTATGG GGAACGACCC AGTATTATTG AACTGTGTTT CAGAACATGG 840 ACATCTCCAG TCATACAGAG GATATGGGTT ACCAAATCAG AGTTGTATTT CCCAACAAGT 900 AAGAGAGACT TAAGTCATGG AACATTCTAT GGAACTCTAG CATTTCAACA ACACCATGAT 960 GTGATTTCTG GATTTAAAAA TTTTGTACAG ACATGGTACC ATCTCAAAAG CATGGATTTA 1020 TATTTATTAA AGCCAGAGTG GGGTTTCTTT GAATATGAAA CCTCAGCATC TTACTGTAAA 1080 ATACTGATGA GTAATTCATC GAATGTCTCA TTGGAATGGC TAATGGAACA GAAGTTTGAC 1140 ATAGCCTTTA ATGACAATAG TCATAGTATA TACAATGCTG TGTACGCCAT GGCCCATGCT 1200 CTCCATGAAA AGAATCTGAA ACAAATTGAT AATCAGGAAA TCAGCTATGG CAAAGGAGCA 1260 AGTACTCACT GCTTGAAGTT ACACTCATTT TTGAGAACGA TCCACTTCAC CAATCCTTTT 1320 GGGGAGAGAG TGATTATGAA AGAGAGAGTA AGAGTGCAGG AAGACTATGA CATTGTTCAC 1380 CTGCAGAACT GCTCACAACA CCTTAGGATT AAGGTGAAGA TAGGGCAGTT CAGCCCATAT 1440 TTTCCACATG GTGGACAATT TCACTTATAT GAAGACATGA TTGATTTGGC CACAGGAAGT 1500 AGAAAGATGC CTTTATCTAT GTGTAGTGCA GATTGTCGTC CTGGATACAG AAAATTCTGG 1560 AAGGAGGGAA TGGCAGCCTG CTGTTTTGTT TGCAGTCCCT GTCCAGACAA TGAAATTTCT 1620 AATGAAACAA CTGTGGTACT TTGGGTCTTT GTGAAGCACC ATGACACTCC TATTGTGAAG 1680 GCCAATAACA GAATCCTCAG CTACATATTA ATCATGTCAC TCATGTTCTG CTTTCTGTGC 1740 TCCTTTTTCT TCATTGGCCA TCCTAACAGA GGTACCTGTA TCTTACAGCA AATCACATTT 1800 GGAATTGTAT TCACTGTGGC TGTTTCCACA GTTCTGGCCA AAACAATCAC TGTGCTTCTG 1860 GCTTTTCAAG TCACAGACAC AGGAAGAAAG TTAAGAAACT TCCTGGTATC GGGGACACCC 1920 AACTACATTA TTCCCATATG TTCCCTGTTG CAATGCACTC TGTGTGCAAT TTGGCTAGCA 1980 GTTTCTCCAC CATTTGTTGA TATCGATGAA CATTCTGAGC ATGGTCACAT CATAATTGTG 2040 TGCAACAAGG GATCTGTTAT GGCATTCTAC TGTGTCCTGG GATATTTGGC CTTCCTGGCC 2100 CTTGGAAGTT TCACGATGGC TTTCTTGGCA AAGAATCTGC CTGACACATT CAATGAAGCC 2160 AAGTTCTTGA CCTTCAGCAT GCTAGTGTTC TGCAGTGTCT GGATCACGTT CCTTCCTGTC 2220 TACCATAGCA CCAAGGGCAG AGTCATGGTT GCTGTTGAAA TTTTCTCCAT TTTGACATCC 2280 AGTGCAGGGA TGCTTGGATG CGTCTTTGCA CCCAAAATTT ACATCATTTT AATGAAACCA 2340 GAGAGAATTC TATCCAAAAG ACAGGAGAAA TCACGTTTC 2379 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2394 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91: ATGGTAATAT TCTTCCTTCT CAACATTCCA TTTCTCCTGG CAAATTTCAT GGATCCCAGA 60 TGCTTTTGGA AAATAAATTT GAATGAAATC AAGGATGAAG TCCTTGGGAT GACTTGTTCC 120 TTCATCCTTG AAACAGTTCA GAAGACTATG GACAAAGATT ATTTCAACCA GACTCTGAAT 180 GTCCTAAATA CAACTACAAA CCACAAATAT GCCTTGGCAT TGGCCTTTAC AGTGGATGAA 240 ATCAACAGGA ATCCTGATCT TTTACCAAAT ATGTCTCTGA TTATAAAATA CAATTTGGGT 300 CATTGTGATG GAAAAACTGT AACAACTCTA TCCGATTTAT TTAATCCAAA TAATCATCTC 360 CATTTCCCCA ATTATTTATG TAATGAAGGG ATTATGTGTT TGGTTCTGCT TACAGGACCA 420 CATTGGAGAG CATCTTTATA TCTCTGGATA TCCGTGTATG TCTACCTGTC TCCACATTTC 480 CTTCAGCTTT CCTATGGACC TTTCTACTCC ATCTTCAGTG ATAATGAACA ATATCCTTAT 540 CTCTATCAGA TGGGCCCAAA GGACTCATCA CTAGCATTGG CAATGGTCTC CTTCATAATT 600 TACTTCAAGT GGAACTGGGT TGGGCTATTT ATCTCAGATG ATGATCAAGG CAATCAATTT 660 CTCTCAGAGT TGAAAAAAGA GAGCCAAACC AAGGATATTT GCTTTGCCTT TGTGAACATG 720 ATATCAGTCA GTGATGTTTC ATACTATCAT AAAACTGAAA TGTACTACAA CCAAATTGTG 780 ATGTCATCCA CAAAGGTTAT TATCATTTAT GGGGAAACAA ACAGTATTAT TGAATTGAGC 840 TTCAGAATGT GGTCATCTCC AGTTAAACAG AGAATATGGG TCACCACAAA ACAATTTGAT 900 TGCCCTACCA GTAAGAGAGA CTTAACTCAT GGCACATTCT ATGGGACCCT TACATTTCTA 960 CACCACTATG GTGAGATTTC TGGCTTTAAA AATTTTGTAC AGACACGGTA CAATCTCAGA 1020 AGCACAGATT TATATCTAGT AATGCCAGAG TGGAAATATT TTAACTATGA AGCCTCAGCA 1080 TCTAACTGTA AAATACTGAG AAACTATTTA TCCAATATCT CACTGGAATG GCTAATGGAA 1140 CAGAAATTTG ACATGTCATT TAGTGATTAT AGTCACAACA TATACAATGC TGTATATGCC 1200 ATTGCTCATG CACTCCATGA GAAGAATCTG CAAGAAGTTG AAAATCAGGC AATAAACAAT 1260 GCGAAAGGAG AAAATACTCA CTGCTTGAAG CTAAACTCAT TTCTGAGAAA GACCCACTTC 1320 ACTAATTCTC TTGGGAACAG AGTAATTATG AAACAGAGAG AAGTAGTGCA TGGAGACTAT 1380 AATATTGTTC ACATGTGGAA TTTCTCACAA CGCCTTGGGA TTAAGGTGAA GATAGGACAA 1440 TTCAGCCCAC ATTTTCCACA GGGTCAACAG TTACACTTAT ATGTAGACAT GACTGAGTTG 1500 GCTACAGGAA GTAGAAAGAT GCCATCCTCA GTGTGCAGTG CAGATTGCCA TCCTGGATTC 1560 AGAAGAATCT GGAAGGAGGA AATGGCAGCC TGCTGTTTTG TTTGCAACCC CTGCCCTGAA 1620 AATGAAATTT CTAATGAGAC GATGGTGGTA TTTTGGGTCT TCGTGAAGCA CCATGACACT 1680 CCTATTGTGA AGGCCAATAA CAGAATCCTC AGCTACCTAT TAATCGTGTC ACTCATGTTC 1740 TGTTTTCTGT GCTCCTTTTT CTTCATTGGC TATCCTAACA GAGCAACCTG TATCTTACAG 1800 CAAATCACAT TTGGAATCTT CTTTACTGTG GCTATTTCCA CAGTTCTGGC CAAAACAATC 1860 ACTGTGGTTC TGGCTTTCAA AGTCACAGAC CCAGGAAGAC AATTAAGAAT CTTTTTGGTA 1920 TCGGGGACAC CCAACTACAT TATTCCCATA TGTTCCCTAT TGCAATGTAT TCTGTGTGCA 1980 ATCTGGCTAG CAGTTTCTCC TCCCTTTGTT GATATTGATG AACACTCTGA GCATGGCCAC 2040 ATCATCATTG TGTGCAACAA GGGCTCCATT ACTGCATTCT ACTGTGTCCT GGGATACTTG 2100 GCCTGCCTGG CCTTTGGAAG CTTCACTATA GCTTTCTTGG CAAAGAACCT GCCTGACACA 2160 TTCAACGAAG CCAAGTTCTT GACCTTCAGC ATGCTAGTGT TCTGCGCTGT CTGGGTCACC 2220 TTCCTCCCTG TCTACCATAG CACCAAGGGC AAGGTCATGG TTGCTGTGGA GATCTTCTCC 2280 ATCTTGGCAT CTAGTGCAGG GATGCTGGGA TGCATCTTTG CACCCAAAGT TTACATCATT 2340 TTAATGAGAC CAGACAGAAA TTCGATCCAC AAAATCAGGG AGAAATCATA TTTC 2394 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2085 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: GTCTACCTGT CTCCACATTT CCTTCAGCTT TCCTATGGAC CTTTCTACTC CATCTTCAGT 60 GATAATGAAC AATATCCTTA TCTCTATCAG ATGGGCCCAA AGGACTCATC ACTAGCATTG 120 GCAATGGTCT CCTTCATAAT TTACTTCAAG TGGAACTGGG TTGGGCTATT TATCTCAGAT 180 GATGATCAAG GCAATCAATT TCTCTCAGAG TTGAAAAAAG AGAGCCAAAC CAAGGATATT 240 TGCTTTGCCT TTGTGAACAT GATATCAGTC AGTGATGTTT CATACTATCA TAAAACTGAA 300 ATGTACTACA ACCAAATTGT GATGTCATCC ACAAAGGTTA TTATCATTTA TGGGGAAACA 360 AACAGTATTA TTGAATTGAG CTTCAGAATG TGGTCATCTC CAGTTAAACA GAGAATATGG 420 GTCACCACAA AACAATTTGA TTGCCCTACC AGTAAGAGAG ACTTAACTCA TGGCACATTC 480 TATGGGACCC TTACATTTCT ACACCACTAT GGTGAGATTT CTGGCTTTAA AAATTTTGTA 540 CAGACACGGT ACAATCTCAG AAGCACAGAT TTATATCTAG TAATGCCAGA GTGGAAATAT 600 TTTAACTATG AAGCCTCAGC ATCTAACTGT AAAATACTGA GAAACTATTT ATCCAATATC 660 TCACTGGAAT GGCTAATGGA ACAGAAATTT GACATGTCAT TTAGTGATTA TAGTCACAAC 720 ATATACAATG CTGTATATGC CATTGCTCAT GCACTCCATG AGAAAGATCT GCAAGAATTT 780 GAAAATCAGG CAATAAACAA TGCGAAAGGA GAAAATACTC ACTGCTTGAA GCTAAACTCA 840 TTTCTGAGAA AGACCCACTT CACTAATTCT CTTGGGAACA GAGTAATTAT GAAACAGAGA 900 GAAGTAGTGC ATGGAGACTA TAATATTGTT CACATGTGGA ATTTCTCACA ACGCCTTGGG 960 ATTAAGGTGA AGATAGGACA ATTCAGCCCA CATTTTCCAC AGGGTCAACA GTTACACTTA 1020 TATGTAGACA TGACTGAGTT GGCTACAGGA AGTAGAAAGA TGCCATCCTC AGTGTGCAGT 1080 GCAGATTGCC ATCCTGGATT CAGAAGAATC TGGAAGGAGG AAATGGCAGC CTGCTGTTTT 1140 GTTTGCAACC CCTGCCCTGA AAATGAAATT TCTAATGAGA CGAATATGGA TCAGTGTGCG 1200 AATTGTCCAG AATACCAGTA TGCCAACACA GAAAAGAACA AATGCATCCA GAAAGGTGTG 1260 ATTGTTCTAA GCTATGAAGA CCCCTTGGGG ATGGCTCTTG CCTTAATAGC ATTCTGTTTC 1320 TCTGCATTCA CAGTGGTGGT ATTTTGGGTC TTCGTGAAGC ACCATGACAC TCCTATTGTG 1380 AAGGCCAATA ACAGAATCCT CAGCTACCTA TTAATCGTGT CACTCATGTT CTGTTTTCTG 1440 TGCTCCTTTT TCTTCATTGG CTATCCTAAC AGAGCAACCT GTATCTTACA GCAAATCACA 1500 TTTGGAATCT TCTTTACTGT GGCTATTTCC ACAGTTCTGG CCAAAACAAT CACTGTGGTT 1560 CTGGCTTTCA AAGTCACAGA CCCAGGAAGA CAATTAAGAA TCTTTTTGGT ATCGGGGACA 1620 CCCAACTACA TTATTCCCAT ATGTTCCCTA TTGCAATGTA TTCTGTGTGC AATCTGGCTA 1680 GCAGTTTCTC CTCCCTTTGT TGATATTGAT GAACACTCTG AGCATGGCCA CATCATCATT 1740 GTGTGCAACA AGGGCTCCAT TACTGCATTC TACTGTGTCC TGGGATACTT GGCCTGCCTG 1800 GCCTTTGGAA GCTTCACTAT AGCTTTCTTG GCAAAGAACC TGCCTGACAC ATTCAACGAA 1860 GCCAAGTTCT TGACCTTCAG CATGCTAGTG TTCTGCGCTG TCTGGGTCAC CTTCCTCCCT 1920 GTCTACCATA GCACCAAGGG CAAGGTCATG GTTGCTGTGG AGATCTTCTC CATCTTGGCA 1980 TCTAGTGCAG GGATGCTGGG ATGCATCTTT GCACCCAAAG TTTACATCAT TTTAATGAGA 2040 CCAGACAGAA ATTCGATCCA CAAAATCAGG GAGAAATCAT ATTTC 2085 We claim:

Claims: Claims 1. A family of pheromone receptor polypeptides, each of said polypeptides comprising from amino terminus to carboxyl terminus: (a) an amino-terminal extracellular domain containing from 30 to 600 amino acids; (b) a transmembrane region comprising: (i) seven non-contiguous transmembrane domains designated TMl, TM2, TM3, TM4, TM5, TM6 and TM7 (ii) three non-contiguous extracellular domains designated EC2, EC3 and EC4, and (iii) three non-contiguous intracellular domains designated ICl, IC2, and IC3, wherein the transmembrane domains, the extracellular domains and the intracellular domains are attached to one another from amino terminus to carboxyl terminus in the order TM1- IC1-TM2-EC2-TM3- IC2-TM4-EC3-TM5-IC3-TM6-EC4-TM7, and wherein the transmembrane region has at least about 35% homology and a length approximately equal to a transmembrane region of a polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50; and (c) a carboxyl-terminal intracellular domain containing from 5 to 200 amino acids; wherein the pheromone receptor polypeptides are expressed in a Gα 0 protein-expressing vomeronasal organ neuron or are expressed in another olfactory organ neuron in an animal which does not possess a vomeronasal organ. 2. The polypeptides of claim 1, wherein the transmembrane region of each of said polypeptides has at least between about 60% and about 90% homology to the transdomain region of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50. 3. The polypeptides of claims 1 or 2 , wherein the non-contiguous intracellular domains of each of said polypeptides has at least between about 60% and about 90% homology to the noncontiguous intracellular domains of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 34, 36, 38, 40, 42, 44, 46, 48, and 50. 4. The polypeptides of claim 1, wherein the extracellular domain of each of said polypeptides has at least between about 50% and about 90% homology to the extracellular domain ofa pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 50. 5. The polypeptides of claim 2, wherein the extracellular domain of each of said polypeptides has at least between about 50% and about 90% homology to the extracellular domain ofa pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 50. 6. The polypeptides of claim 3, wherein the extracellular domain of each of said polypeptides has at least between about 50% and about 90% homology to the extracellular domain of a pheromone receptor polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 50 . 7. The polypeptides of claims 1 or 2, wherein the extracellular domain contains at least between about 50 and about 500 amino acids. 8. The polypeptides of claim 3, wherein the extracellular domain contains at least between about 50 and about 500 amino acids. 9. The polypeptides of claims 4, 5 or 6, further comprising a signal sequence attached to the amino terminus of the extracellular domain. 10. The polypeptides of claim 9, wherein the signal sequence is selected from the group of signal sequences of a pheromone receptor polypeptide of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. 11. A method for identifying a nucleic acid encoding a pheromone receptor polypeptide, comprising: (1) contacting a mixture of nucleic acid molecules with at least one nucleic acid probe of a nucleic acid selected from the group consisting of: (a) a nucleic acid molecule selected from the group consisting of SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55 that encodes a pheromone receptor polypeptide; (b) a unique fragment of (a); (c) a human homolog of (a) or (b); and (d) a set of degenerate primers of any of (a), (b) or (c); and (2) identifying the sequences within the mixture that hybridize to the probe. 12. The method of claim 11 , wherein the mixture is a genomic library. 13. The method of claim 11 , wherein the mixture is a cDNA library. 14. The method of claim 11 , wherein the nucleic acid probe contains a detectable label. 15. The method of claim 11, wherein the at least one nucleic acid probe is a pair of degenerate polymerase chain reaction primers that amplify a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55, the method further comprising the step of subjecting the mixture to a polymerase chain reaction amplification reaction prior to selecting a member of the mixture which hybridizes to the nucleic acid probe. 16. The method of claim 15, wherein the pair of degenerate polymerase chain reaction primers is selected from the group consisting of SEQ ID NOs. 60 and 61, SEQ ID NOs. 62 and 63, SEQ ID NOs. 64 and 63, SEQ ID NOs. 64 and 65, and SEQ ID NOs. 66 and 67. 17. The method of claim 16, wherein the pair of polymerase chain reaction primers is selected from the group consisting of SEQ ID NOs. 60 and 61, SEQ ID NOs. 62 and 63, SEQ ID and NOs. 64 and 63. 18. An isolated nucleic acid molecule (a) which hybridizes under high or low stringency conditions to a molecule consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO. 1 , 3 , 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 54, and 55, and which codes for a pheromone receptor, (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and (c) complements of (a) and (b). 19. The nucleic acid molecule of claim 18, wherein the pheromone receptor is expressed in the vomeronasal organ or is expressed in another olfactory organ in an animal which does not possess a vomeronasal organ. 20. The nucleic acid molecule of claim 18, wherein the pheromone receptor is expressed in a Gα 0 protein-expressing vomeronasal organ neuron. 21. The nucleic acid molecule of claim 18, wherein the pheromone receptor is a G-protein coupled receptor. 22. The isolated nucleic acid molecule of claim 18, wherein the pheromone receptor has an amino acid sequence selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. 23. The isolated nucleic acid molecule of claim 18, wherein the isolated nucleic acid molecule is selected from the group consisting of SEQ ID NO. 51, 53, 54, 55, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92, that encodes a pheromone receptor polypeptide. 24. The isolated nucleic acid molecule of claim 18, wherein the isolated molecule comprises a molecule having a sequence which encodes a pheromone receptor unique fragment, wherein said unique fragment is selected from the group consisting ofa pheromone receptor extracellular domain, a pheromone receptor transmembrane domain, a pheromone receptor intracellular domain, a pheromone receptor extracellular domain coupled to at least one transmembrane domain, and at least one pheromone receptor transmembrane domain coupled to a pheromone receptor intracellular domain. 25. The isolated nucleic acid molecule of claim 18, wherein the pheromone receptor extracellular domain, the pheromone receptor transmembrane domain and the pheromone receptor intracellular domain have amino acid sequences selected from the group of sequences identified as these domains in SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. 26. The isolated nucleic acid molecule of claim 18, wherein the unique fragment is selected from the group consisting of between 12 and 4000, between 12 and 2000, between 12 and 1000, between 12 and 500, between 12 and 250, between 12 and 100, between 12 and 50, and between 12 and 25, nucleotides in length. 27. An isolated nucleic acid molecule, comprising (a) a molecule having a sequence selected from the group consisting of SEQ ID NO. 51 , 53, 54, 55, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92, and which codes for a pheromone receptor; (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and (c) complements of (a) and (b). 28. An expression vector comprising the isolated nucleic acid molecule of claims 18-27 operably linked to a promoter. 29. A host cell transformed or transfected with the isolated nucleic acid molecule of claims 18-27. 30. A host cell transformed or transfected with the isolated nucleic acid molecule of the expression vector of claim 28. 31. An isolated polypeptide encoded by the isolated nucleic acid molecule of claims 18-27. 32. The isolated polypeptide of claim 31, wherein the isolated polypeptide has a pheromone receptor activity. 33. The isolated polypeptide of claim 31 , wherein the isolated polypeptide comprises a polypeptide selected from group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. 34. The isolated polypeptide of claim 33, wherein the isolated polypeptide is a fragment of a peptide selected from the group consisting of an extracellular domain, a transmembrane domain and an intracellular domain, wherein the foregoing domains have amino acid sequences selected from the group of sequences identified as these domains of a pheromone receptor polypeptide selected from group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. 35. A vaccine containing an isolated polypeptide selected from the group consisting of the isolated polypeptides of claim 31, 32, 33, and 34. 36. A method for controlling fertility in an animal, comprising: administering to an animal in need of such treatment, an effective amount of the vaccine of claim 35 to elicit an immune response to the isolated polypeptide. 37. An isolated binding polypeptide which binds selectively to a polypeptide of claim 1 , 2, 4, 5, 6, 8, 10, 31, 32, 33, and 34, provided that the isolated binding polypeptide does not bind to a G-protein coupled receptor other than a Gα 0 + -coupled pheromone receptor. 38. The isolated binding polypeptide of claim 37, wherein the binding polypeptide binds to a polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52. 39. The isolated binding polypeptide of claim 37, wherein the binding polypeptide is an antibody fragment selected from the group consisting of a Fab fragment, a F(ab) 2 fragment or a fragment including a CDR3 region selective for a pheromone receptor polypeptide. 40. The isolated binding polypeptide of claim 38, wherein the binding polypeptide is an antibody fragment selected from the group consisting of a Fab fragment, a F(ab) 2 fragment or a fragment including a CDR3 region selective for a pheromone receptor polypeptide. 41. An affinity matrix comprising: a solid support to which is coupled an isolated binding polypeptide selected from the group consisting of the binding polypeptides of any of claims 37-40. 42. A method for isolating a pheromone receptor, comprising: contacting a composition containing a putative pheromone receptor with the affinity matrix of claim 41 under conditions to permit the pheromone receptor to selectively bind to the binding polypeptides coupled to the solid support; and isolating the polypeptides that bind to the affinity matrix. 43. A composition comprising : the polypeptide of claim 1, 2, 4, 5, 6, 8, 10, 31, 32, 33, or 34; and a pharmaceutically acceptable carrier. 44. A composition comprising: the nucleic acid molecule of any of claims 18-28; and a pharmaceutically acceptable carrier. 45. A composition comprising: the binding polypeptide of claim 37; and a pharmaceutically acceptable carrier. 46. A composition comprising: the binding polypeptide of claims 38, 39 or 40; and a pharmaceutically acceptable carrier. 47. A method for modulating a pheromone receptor activity in a cell, comprising: administering to the cell an amount of the isolated binding polypeptide of claim 37 effective to modulate pheromone receptor activity in the cell. 48. A method for modulating a pheromone receptor activity in a cell, comprising: adiriinistering to the cell an amount of the isolated binding polypeptide of claim 38, 39, or 40 effective to modulate pheromone receptor activity in the cell. 49. The method of claim 47, wherein modulating a pheromone receptor activity comprises reducing the pheromone receptor activity. 50. The method of claim 48, wherein modulating a pheromone receptor activity comprises reducing the pheromone receptor activity. 51. The method of claim 47, wherein the pheromone receptor activity is selected from the group consisting of a signal transduction activity and a ligand binding activity. 52. The method of claim 48, wherein the pheromone receptor activity is selected from the group consisting ofa signal transduction activity and a ligand binding activity. 53. The method of claim 47, wherein the cell is a vertebrate cell, preferably a mammalian cell. 54. The method of claim 48, wherein the cell is a vertebrate cell, preferably a mammalian cell. 55. The method of claim 47, wherein the cell is an invertebrate cell, preferably an insect cell. 56. The method of claim 48, wherein the cell is an invertebrate cell, preferably an insect cell. 57. A method for reducing the binding of a pheromone having a binding domain to a pheromone receptor having a ligand binding site that selectively binds to the binding domain of the pheromone, comprising: contacting the pheromone receptor with an agent which binds to the binding domain for a time effective to reduce binding of the pheromone to the ligand binding site of the pheromone receptor. 58. The method of claim 57, wherein the agent is an antibody which binds to the binding domain. 59. A method for decreasing pheromone receptor mediated signal transduction activity in a subject comprising: administering to a subject in need of such treatment an agent that selectively binds to an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to decrease pheromone receptor mediated signal transduction activity in the subject. 60. The method of claim 59, wherein the agent is selected from the group consisting of an antisense nucleic acid and a binding polypeptide. 61. A method for identifying lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated with pheromone binding to a pheromone receptor polypeptide containing a ligand binding site that selectively binds to a binding domain of the pheromone, comprising forming a mixture comprising a pheromone receptor polypeptide or unique fragment thereof containing a ligand binding site, a molecule protein containing a binding domain which selectively binds the pheromone receptor ligand binding site, and a candidate pharmacological agent, incubating the mixture under conditions which, in the absence of the candidate pharmacological agent, permit a first amount of selective binding of the molecule containing a ligand binding domain by the pheromone receptor ligand binding site, and detecting a test amount of selective binding of the molecule containing the binding domain by the pheromone receptor ligand binding site, wherein reduction of the test amount of selective binding relative to the first amount of selective binding indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which disrupts selective binding ofa molecule containing a binding domain by a pheromone receptor containing a ligand binding site and wherein increase of the test amount of selective binding relative to the first amount of selective binding indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which enhances selective binding of a molecule containing a binding domain by a pheromone receptor polypeptide containing a ligand binding site. AMENDED CLAIMS [received by the International Bureau on 11 December 1998 (11.12.98); original claim 1 amended; remaining claims unchanged (1 page)] 1. A family of isolated pheromone receptor polypeptides, each of said isolated polypeptides comprising from amino terminus to carboxyl terminus: 5 (a) an amino-teπninal extracellular domain containing from 30 to 600 amino acids; (b) a transmembrane region comprising: (i) seven non-contiguous transmembrane domains designated TM 1 , TM2, TM3 , TM4, TM5, TM6 and TM7 (ii) three non-contiguous extracellular domains designated EC2, EC3 and EC4, and I o (iϋ) three non-contiguous intracellular domains designated IC 1 , IC2, and IC3 , wherein the transmembrane domains, the extracellular domains and the intracellular domains are attached to one another from ammo terrninus to carboxyl terminus in the order TM1-IC1-TM2-EC2-TM3- IC2-TM4-EC3-TM5-IC3-TM6-EC4-TM7, and wherein the transmembrane region has at least about 35% homology and a length 15 approximately equal to a transmembrane region of a polypeptide selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50; and (c) a carboxyl-terminal intracellular domain containing from 5 to 200 amino acids; wherein the pheromone receptor polypeptides are expressed in a Gα g protein- expressing vomeronasal organ neuron or are expressed in another olfactory organ neuron in an 0 animal which does not possess a vomeronasal organ. 2. The polypeptides of claim 1 , wherein the transmembrane region of each of said polypeptides has at least between about 60% and about 90% homology to the transdomain region of a pheromone receptor polypeptide selected from the group consisting of SEQ ID 5 NO. 2, 4, 6, 8, 10, 12, 14, 34, 36, 38, 40, 42, 44, 46, 48, and 50. 3. The polypeptides of claims 1 or 2 , wherein the non-contiguous intracellular domains of each of said polypeptides has at least between about 60% and about 90% homology to the non-contiguous intracellular domains of a pheromone receptor polypeptide selected from the 0 group consisting of SEQ ID NO. 2, 4, 6, 8, 10, 34, 36, 38, 40, 42, 44, 46, 48, and 50.

Inventors: BUCK LINDA, DULAC CATHERINE, HERRADA GILLES, MATSUNAMI HIROAKI, BUCK, LINDA, DULAC, CATHERINE, HERRADA, GILLES, MATSUNAMI, HIROAKI
Applicants: HARVARD COLLEGE, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Application year: 1998
Main classification: C07K14
IPC codes: A61K38, A61K39, A61K45, A61K48, A61P15, C07K1, C07K14, C07K16, C12N5, C12N15, C12Q1, G01N33